/*Accordion Page Settings*/

149 Extend Fertility’s Lessons From The Market For Egg Freezing

Dr. Joshua Klein, REI,  Chief Clinical Officer, Medical Director, and Co-founder of Extend Fertility in NYC joins Griffin this week on Inside Reproductive Health to discuss the business of getting into business. Listen as they share perspectives on risk tolerance, people-management, financial backing, and the potential to lose -or gain- it all on the path to entrepreneurial leadership.  


Tune in to hear:

  •  Dr. Joshua Klein share how he successfully cornered an underdeveloped segment of the fertility market, and what steps he took to get there.

  • Griffin question Dr. Klein on how he knew when to time the change in his career path, and what others in the same position should consider before making a move.

  • Griffin question Dr. Klein when he says “people are the hardest part.”

  • How to not get way over your head in overhead before you even start.

Dr. Klein’s information:

LinkedIn https://www.linkedin.com/in/joshuakleinmd/

Website: www.extendfertility.com

Transcript

Griffin Jones  00:04

How many ways are there to start an REI practice? How many ways are there to start fertility business? Explore that today with my guest, Dr. Joshua Klein because a lot of younger REIs think about well, do I have to go partner with somebody? Do I get a salary right at an academic center? Do I go off on my own, and I risk everything, because I've got this stupid medical school debt. And I went to some very expensive undergraduate college and maybe my parents were wealthy enough to help me but maybe they weren't. And I've got that debt to some of you who are coming out with a lot of debt. And, and so starting a venture, your own entrepreneurial venture can seem pretty daunting. And so our guest today Dr. Klein talks about another possibility is finding other people with financial backing. And in starting your own endeavor, as a piece of that you won't necessarily be a majority owner and own everything. But that's one way to do it. So we talk about the massive learning curve that you're gonna go on, if you want to learn more about the business of fertility, whether you own it or not, that it's drinking from a firehose. So Dr. Klein talks about some of the things that he picked up and the challenges of managing people, a vision for an REI practice. To start the whole thing of looking at fertility preservation is something that was underserved in the market. And what Dr. Klein thinks is the right demographic, or the more appropriate demographics for fertility preservation, and why he saw that as a need in the marketplace, and other hard lessons learned, like cost per lead cost per new patient acquisition. And so we both we talked about those things, and Dr. Klein closes with thoughts of how younger dogs might approach making that choice. So I hope you enjoy today's episode, Dr. Klein originally was a he completed his fellowship at Columbia. And then he was an associate physician at RMA of New York. And now he is a partner at Extend Fertility. And I hope you enjoy this conversation with him. Josh, welcome to Inside reproductive health. 

.

Thank you so much for having me, Griffin. I am interested in the topic for today because we have had people to talk about egg freezing on in the past. And but I'm interesting because your group extend fertility was one of the first to make a brand around. Yes, you're a comprehensive IVF practice. But you did have a special focus in fertility preservation early on. And so I want to spend some time talking about that. Maybe we get to the business second, but you were where were you in your career, when you started to feel like, you know, fertility preservation was something that was clinically viable, because, you know, that wasn't the case. 20 years ago, maybe the people just getting on board now are late. So when was it for you? Yeah, that's a question that that I thought a lot about. When we first were putting this place together.


Dr. Joshua Klein  03:31

I came out of training in 2012. So I finished my fellowship at Columbia in 2012 and took my first job at RMA New York, which is as many listeners probably know, is affiliated with Mount Sinai. It's one of the big academically affiliated programs in New York City. And part of it is just history because ASRM? Well, I should say, the studies that demonstrated that egg freezing could be done through vitrification relatively reliably and reproducibly. And with relatively good success rates really came out in the late 2000s Going into the early 2010 2011. That sort of timeframe. And then actually was at the end of 2012, technically published, I believe, in January of 2013, when he ASRM sort of put their guideline out that said that egg freezing can be offered as a method of fertility preservation without the rubric of an IRB without an experimental protocol. There was a lot of buzz around that that didn't mean that ASRM was you know, endorsing egg freezing or something that everybody should be doing. But at the very least, it wasn't considered an experimental modality anymore. And so that that was 2012 2013 which was literally the first year I was out in practice and kind of getting my feet under me. And, you know, sitting in an office in New York City and Manhattan with that The culture around us, you know, certainly being the case that most women are not getting getting pregnant and building their families in their 20s People are, are sort of young if they're getting pregnant in their 30s. It felt like to me, egg freezing is something that might be super valuable to like, a lot of women, not just a select few, but to like, sort of in some way, the average educated professional 30 something year old Manhattanites, who isn't, you know, hasn't partnered up yet, or isn't ready to settle down yet is still building their career and not at that stage of their personal or professional life where they're ready to have kids. And so, you know, at that time, egg freezing was still very small, it was still new, most people didn't know about it, and this people weren't accessing it for one reason or another. And so even at a big program, like RMA, they were doing, I think, something like 120 Egg freezing cycles a year, which means, you know, maybe 10 a month and the entire practice. So I was seeing a small handful of patients of who are interested in egg freezing. And it just felt like it didn't match the demographics of what it should. So at some point, that kind of light bulb went off that there's a disconnect between the number of like single, professional educated women who might want to do this, and then people are actually doing it. And then of course, the question became like, what's the missing link here? How come? How come it's a mismatch. And so the things that I thought about and that kind of got parlayed into building extend fertility, where people don't know about it. So there was a lack of proactive education about fertility preservation, you know, IVF, clinics, are doing a really good job of keeping busy helping people build their families, people who are struggling to get pregnant with IVF. And so egg freezing was kind of not the center of their attention. So that's one was education and awareness. Two was sort of, I think, the environment, I think egg freezing was never really thought of as like an important piece of an IVF clinic. And so I always used to say that, like, you could pick out the egg freezers in the waiting room, because you know, they were the ones sitting by themselves younger, kind of looking awkward when most of the infertility IVF waiting room is couples who, you know, kind of sad and tortured a little bit in the egg freezers, or they don't have a problem, they just are wanting to be proactive about planning their, their their reproductive life. And then third is cost because egg freezing tends to be priced as sort of like the IVF pricing, but a tiny notch less, even though technically, it's a lot less work for the lab to do so. So it kind of was overpriced, I think at that time. And so those principles were the ones that we tried to harness when we created a Extend Fertility as a center that focused on egg freezing back in 2015 2016. To kind of build a brand and a culture around the idea of making egg freezing and fertility preservation more understandable, more accessible, making the experience a little bit less unpleasant, especially if it's a sort of a purpose built environment, and then bringing the price point down in a way that that could still allow us to have a viable business model. So that's kind of the threads that went into it.


Griffin Jones  08:11

So you saw the market. You saw the the the the flaw in the market when it came to pricing and availability. What about demographics? Because that is a point of maybe contention, but that I just I don't I don't hear a lot of consensus about is what is the ideal demographic, and there are both clinicians and egg freezers did say, the younger, the better. And it it should be something that, you know, 22 year olds parents gift to them for graduating college, I hear both clinicians and egg freezers say that I also hear clinicians and egg freezer say that no way, like it's a very narrow demographic, and it's for 3839 year olds, maybe who are right, right, just before the window of have a real DOI risk, I suppose. And so, where how do you? How do you come to what you think the proper demographic is? Yeah,


Dr. Joshua Klein  09:19

it's a that's a great question, because it is something that I think gets debated hotly, and we have patients every day that say, you know, can I wait a year? Can I wait two years and sometimes it gets a little silly, you know, how can I wait six months? It's like a negotiation. But I think what, what has to be recognized to sort of think through that intelligently is that it's in arguable that in general, if someone does egg freezing younger, they're going to get a more valuable end product meaning younger woman will get or any particular woman if she doesn't younger, will probably get more eggs and more healthy eggs and that same woman who in an alternative universe does it older So, by that rationale, it's, which is oversimplified, as I'll explain, everybody should do it, like you just said at 22. Like, it should be a universal thing, the younger, the better. And so there's not much to argue about. But the reality is that even even at a place like extendable, we tried to keep it on the more affordable side, it is a luxury good meaning between the cost of of the service and the cost of the medications, and then the cost of storage, it's a, it's a, it's a significant amount of money. It's not the easiest process, we try to make it as easy as possible. But it's not the easiest process, it does take a lot of wherewithal to kind of get through it. And so it's not, you know, if if it really was something that you can get come into the doctor's office, you know, get a procedure done for 10 minutes, and it costs $100, I probably wouldn't be singing that same song of everybody should just do it when they're 22. Because kind of why not. And it could, could really be an important thing in your life. But but it's a lot different than that. And so what I what I want to point out is that every year that passes that you don't do it is another year that you might not end up having to do it, right. Because if you're 25, and thinking about doing it, but you wait. And then by 28, you actually got married and then started your family naturally, then that you want that gamble, right? Because you didn't have to do it. And now you may never have to do it, because you're already getting getting your family started naturally. And so you kind of dodged that bullet and you save the money and you save the anxiety and the investment of time, energy and resources to do it. And so in a certain way waiting to do it longer makes sense. Because the younger you are, the more likely you're going to end up starting your family in an easier way than egg freezing, if you just give it some time. And that's why I don't think that the 22 year olds should be less, there's a special situation which I'll actually get to also in a moment. But for most average healthy women, 22 Doesn't make sense because you can afford to wait because if you do it when you're in your late 20s or early 30s, you'll still get a very good end product. And there's a large percentage of women who will in fact, the majority of women who are thinking about it 22 By the time they get to 30 they won't need it anymore. So I think we're overselling it if we're selling it to 20 year olds. So that's something I think isn't always articulated clearly. But that's a reason not to do it too early, even though it's true. If you do it at 22, we'll do it at 30, you'll get more out of it 20 at 22. But you might not need to do it at 30. And so a lot of times it makes sense to wait to sort of let your life unfold. And then but then you gotta be careful not to let that slippery slope slip. Right. So if you do it at 39, I certainly would think that that's a mistake, because that's already you're sort of reacting when egg freezing works best as a proactive maneuver, right? If you're freezing eggs that are mostly not healthy already, which is when you're getting close to 40. That's the reality, it might work. But it's certainly not a great situation. The other thing Oh, the other thing I wanted to emphasize is the fact that age is only half the story, which is to say age is the best marker of egg quality. But there's another issue which is quantity, right how many eggs a woman has and we've learned over the last 1020 years, especially through how Hmh testing has become very common. And actually a symbol of a test. That is , it's been a very important development, I think, in the last 1020 years of fertility, management and treatment. Because if you're a 28 year old with a very low Hmh, which there are a lot of healthy 20 year olds that are going to have a low AMI, it's something that's very highly individual variable, it will probably make a lot more sense than thinking about freezing eggs at that point. If you're 28 year old with a very great Hi imH. You could say okay, I've waited a year. And that's not such a terrible decision. So I think that's another thing that's often overlooked is it's not only about age, it's another dimension when it comes to egg freezing, which is your egg supplier ovarian reserve and Hmh testing is so easy to get it's almost a shame that, you know, I believe that that OB GYN should just be doing it routinely, they do a lot of other health maintenance stuff that may or may not be helpful. And this is something that could be really useful. And I think slowly they are doing it more and more. But I think that's another dimension of calculus that needs to be recognized. And that can help a woman who's trying to strategize to make that kind of decision is really useful to have.


Griffin Jones  14:16

I don't think that this question is gonna go away because it doesn't seem that it doesn't seem that we have hit the plateau for the age of first birth in this country. So I think everybody remembers that headlines from earlier this year hit the first average birth. For women in the US the median age hit 30. And if my records are right from the CDC, it was even just in 2014 it was a little over 26 years old. Yeah. So it went, it went up one and a half years from just shy of 25 and 2000 to 2026 in less than 26 and a half in 2014. And then in 2022, it's 30. So I suck at math, but I think most of the people listening can see the exponential growth. So I don't think that this is going away. What do you see in the marketplace? Do you see peaks and valleys? You know, what I wondered is when you started in 2015, in New York is like, okay, are we going to see this in Charlotte in three years? And then in Cleveland, two years after that, and talk to us about what you're seeing?


Dr. Joshua Klein  15:46

Well, I think you're right, first of all, that this is still a moving target, and the market is still maturing. The, it's interesting, because there were some well publicized predictions that were made 2014, let's say I think about what the expected size of the egg freezing market would be. And there's one quote that's out in the media that said something like 85,000, or 100,000 cycles of egg freezing by 2020. The truth is, it hasn't grown that explosively. And you could think about lots of different reasons why that might be the case. But I think that egg freezing has clearly grown a lot. I do think it's going to continue to grow, I actually think that some of the kind of spin off growth that we're seeing, and that others probably are seeing as well, is more and more married couples, or not just married, but I guess more and more couples are coming in to proactively plan their families, even as couples when they're not ready to have their children yet. And also, and this gets a little hazy, where the line gets drawn between fertility treatment and fertility preservation. And sometimes it's an issue with insurance coverage, and so forth. But lots of patients who, you know, come in in their late 30s, for fertility treatment, they do IVF, and they get an embryo. And they say, Well, wait a minute, we always wanted two kids, and we struggled to even get one good embryo. So what we want to do is we want to do another stimulation cycle to at least get one more before we go ahead and use this one. And that happens all the time, these days that people are trying to bank at least, you know, not bank inventory of embryos, in some unreasonable way. But to put away one or two good embryos for the second baby if they're having their first baby in their late 30s, or 40, which is actually very logical. And so the I think the fertility preservation concept is kind of growing and branching out into other in other ways that in some way, are still evolving, by the way, another, I think, idea that will come to fruition, but I don't think it's happened yet, is I've had a handful of patients who have read about and are interested in doing proactive couples who are interested in making embryos for PGPT, which is the polygenic testing, you know, looking at, particularly if let's say, a couple comes in, the guy says, you know, my, my dad has terrible Parkinson's disease. And I know there's no gene for a consensus disease that I can screen for, but it just scares me to death that that's something that I might have a kid and it's going to be at high risk for. And so what I want to do is do these kinds of polygenic testing, you know, involving multiple genes to say which embryos have a higher or lower risk for developing, whether it's Parkinson's or Alzheimer's or diabetes or heart disease and things like that. So that's something that's not common yet. But I think that it's coming, as this sort of feeling devolves into a lot of this proactive planning your family type of and then genetics is obviously evolving and improving as well.


Griffin Jones  19:02

So you made a brand that I think is pretty well positioned for that. The brand Extend Fertility really works for both sides of fertility preservation and fertility treatment, it is because it's the extension is very intentional. And so you, you started this in 2015 is when the was when the business started, right. So you completed a fellowship at Columbia in 2012. You go work for RMA for three years. This is the point that a lot of the listeners are at they're either just leaving fellowship or their associate docks and they're thinking about the next step. You are at a place where you're at a great practice. You could pursue partnership there, or you could go off and do something risky. What was your decisions? When did it start? to appear in your mind of I could go off and do a venture like how did that originate?


Dr. Joshua Klein  20:07

That's a great question. So, yeah, I mean, without getting, I guess, too personal, I have a lot of gratitude towards my years at RMA, I learned a lot. And it's a good place. I think that for me, I think that it well, it was a hard decision, let me just say that much. The truth is that when I started speaking to one of my associates, my business partners who was interested in investing money, putting together investors to build out Extend Fertility, my original expectations that I would sort of be some kind of consultant on the project and not actually do it myself. But as we kind of continue those conversations, and I got more enthusiastic and excited about the idea, and he got more enthusiastic about me actually getting in it, it took some time, to warm to the idea, but I kind of got more excited about about doing it myself. But it's scary, you know, especially first job out of training. And I was fortunate to have, you know, good training and at large academic centers at Ivy Ivy League institutions. And so I hadn't kind of been really out in the business world before before then. But I think that my mindset essentially was that I felt like a small fish in a big pond at RMA, which isn't necessarily passing a judgement, it just the way it is, when you're working for a large institution like that. It's a big pond, it's a big pond, and to their credit, it's a big pond. And so I felt like I was young enough at that point where if I was going to ever take a risk, you know, I didn't, I probably couldn't have done it the day after I finished fellowship. Or I certainly think it's very hard to do it. The day after you finished fellowship, there are those who do it, and I give them credit, too. But I felt like having gotten my feet under me at for a couple of years. If I if I stayed for another few years, it probably would have been that much harder to leave. Probably my income, presumably would rise slowly. And so that, you know, the better you're doing the more than make it attractive to stay. And so, you know, when you're young, you're just getting started, it's a little easier, because you're not giving up so much. And so, I don't know, I guess my thought process was basically I felt like this was a good idea. And at the end of the day, I felt like, before I started my before I finished fellowship, before I started my professional career, I felt like I questioned, like everybody has self doubt, I knew I was a bright kid. But like, it's hard to see yourself doing what your what your teachers and mentors and superiors are doing, like, Can I really handle it when when stuff gets, you know, kind of difficult when there's an unhappy patient? And how do you? How do you deal with that, or when you have some issue with like an inspection and there's regulatory stuff, and hiring and firing and all that it's very intimidating as a young, you know, kind of medical trainee. But I think that what I started to realize was that the hard stuff is still hard when you get older, and everybody does their best to handle it. And so and everybody's just human, I think that's what I what I really kind of it became clear to me that everybody's doing this is doing their best and no one knows all the answers in advance and kind of everyday brings another challenge with it. But if you know if the other guy can handle it, probably so can you and you just have to kind of have that courage and have that confidence in yourself. And so that was what I think allowed me to take that leap is sort of getting out in the world seeing that nothing's perfect. Even behind the curtain, every practice, every lab has its own questions and issues and, you know, uncertainties and every practice has its own issues that come up and like that's life and you kind of do your best to keep people happy and to do to keep the patients happy and go home, you know, doing the right thing and hopefully sleeping well at night. And you know, so it kind of lost that in that side of the intimidation. And then I felt like you know what, I'm going to take the leap. And by the way, if you take the leap and you kind of just fall on the floor. So you still have your training and you're kind of embarrassed probably but you can get up and go get a job and so you know, I felt like it's it's not if you if you let that opportunity go when you're young doc it may not come back to you. But if you take it and you swing and miss Well, no one's gonna fault you for taking the swing I think and and your career isn't ruined just because you tried something it didn't work so


Griffin Jones  24:40

and if you fall flat on your face and you're humble and self aware enough, it will make you a better partner somewhere else absolutely Well, as long as you are and those are two big as. Those are two big conditions. Not everybody is onboard and self-aware. But but if you are falling flat on your face can give can can make you do that much more valuable as a as a partner somewhere else is if the gays and then you know, if you are successful, then that's then you have you've done it long before most other people have. So in your view, what's harder? owning a business or residency


Dr. Joshua Klein  25:21

apples and oranges I guess I mean, I think I think Well, the obvious answer residency is harder, because it's physically so demanding. And then you also have to kind of keep your mind sharp while you're literally exhausted. To be clear, and for the record, I don't, I'm a very small part owner of extent, but I wouldn't call myself the owner of extent, because there's a lot of investor money that went into building this place out, and that and by the way, too, for, for the, for the, for the record for the listenership here also. So I'm talking like a big shot, oh, yeah, I'm gonna, you know, go off my own and start something new. And I in some ways, that's true. But I wasn't in a position to put up tons of my own capital, because I didn't have it. And so I did start off with investor money. And I guess I had to earn their their respect and their confidence to get that investor money, but I didn't, I didn't find $5 million in my own pocket to put down and build out a lab and build out a program. So I didn't have that much courage, or I guess, wherewithal at that point. But having said that, there's no doubt that running a program is hard. And I think that the reason that that's true is because literally you feel stressed and responsible for like 1000 different things that can come up and everyday, something does come up. A lot of it's the people, the people is the hardest thing. You know, they say hiring and firing. And that's, that's the most blatant example. But, you know, people who are thinking of leaving, and people are unhappy for X, Y, or Z and people who don't get along with each other. And they're both important pieces of your, of your of your of your team, and you gotta help them get along somehow. And, you know, the day to day, team, building, Team preserving is is is is complicated, and there's no playbook and you just got to do your best to sort of read people's emotions and feelings and instincts. And that's obviously not easy. Also, the fact that you feel responsible for everything, and maybe I that's one of the things I have to continue to mature to learn, let go. But like a silly little example, there was a, someone who dropped off a gift bag for a patient letter retrieval. Was it yesterday morning or two days ago. And somehow that gift bag disappeared. And it never got to the patient in their post op, it was supposed to be like some snack. It was nothing. It was like some snacks. And some, I don't know what, maybe a heating pad or something. And the person who dropped it off was obviously not happy because the patient was was was heard about and they were expecting and and I don't even know what happened. Somehow it never, never, never made the way and so then I'm was approached by the person who dropped it off. Because of course, like, you know, I'm kind of considered responsible for everything and like, Where can we figure it out? And then I'm asking you at the security cameras and the security camera wasn't focused, it wasn't working. And then I'm asking the lab and it's just like, this is the last thing I want to be you know, working on is finding the snack bag. Like Who else am I gonna you know, I did get help and and still not figure it out. But the point is, like, from the littlest to the biggest things, you worry about it because you feel responsible for everything that happens under the under the four walls or under the roof. And so that's that's not an easy way to live. And my hair's a lot grayer than it was five years ago, that's for sure. But well good news,


Griffin Jones  28:36

Josh. That means you're not a sociopath. So you it's, it's like it to be a business owner is one I it's so hard and I'm not running a medical practice but just you know, even running a client services are it is so hard for the reasons that you describe balancing, delivery and sales and, and the people that the to do all of those things and and you have to be so you have to be receptive to people. You have to listen and then there are other times where you have to forge ahead and say okay, we're moving on and and so you have to be agreeable enough to listen to not be a sociopath AND and OR a narcissist and but also not so agreeable, that you're just Oh, okay. Yeah, I guess I guess that is too much work for you to do. Yeah, I guess. I guess the patient doesn't really need that. You know, it's you have to you have to walk a line that can be pretty heavy.


Dr. Joshua Klein  29:48

It's funny the way you frame that because I also think it sort of tangentially but it connects to, in my opinion, how to be a doctor with a good manner in terms of how you manage patients and patient make patient recommendations. In the sense that, especially with infertility, where most of our patients are, you know, relatively young, relatively educated, lots of them are doing lots of Google research. And they're on the message boards, and they're talking to their friends and their and their sisters and whoever else that that their doctor said, you have to do this or that doctor said that never should be doing them like that, or Google, you know, says X, Y, and Z. So I think it's a really hard balance to strike, you always want to be open to hearing your patients feedback, or thoughts or questions or suggestions. If you're perceived as as dismissive of their input, that's going to be the kiss of death, patients hate bad. But at the same time, and this is something that I've also learned and continue to learn is that it's not healthy to just say, Oh, you read about that, you want to try that, or your friend did this, I'm sure we'll do that. Like, I think you not only is it not good practice, but it also you lose respect. And it's not a healthy dynamic for the patient, if you're just willing to do whatever. And so, you know, you have to really strike that balance of being being open minded, willing to discuss but also firm when you know, sort of what's right and what's wrong, and make sure that you express your opinions, so that people know that you kind of have something that you kind of believe in and that you're willing to draw boundaries and give firm recommendation. So anyway, tangential to the managing a practice. But I think it's the same skill set in a certain way to be able to read people and allow them to see that you're willing to listen to them, but not kind of just they're


Griffin Jones  31:43

both examples of leadership. So the idea of partly being is that you're meant to lead me as the patient Yeah, you have to listen to me in order to be able to lead me effectively. But at the end, you you are not the pharmacist and I am not the physician, you are the physician, I am the patient. And you have to be able to lead me in the same as drew in a business and for not just fertility practice owners and other business owners in the fertility field who listen to this show. But all of us business owners across the market think the last year and a half, two years have gotten unbalanced advice from it's all been about the employee, just go on LinkedIn. And see I haven't seen one post on frickin LinkedIn sticking up for a business owner in two darn years. Everything is and we deserve this too. And we also should have that and we're finally making what we're worth. It's like, really, that's what your worth is, is right now in the most unprecedented inflated economy of all time, like, is that house really worth a million and a half dollars? Okay, but then does that mean that that's what you're worth when there's a recession or or the pendulum swings the other way. And for business owners, the advice has been do whatever you can to retain, show that you care show that. Listen, give them what what they're asking for. And in many cases, you do have to do that. It also has to be balanced with leadership and saying this is where we're going and holding people accountable. And many people, the last few years, many of us have been afraid to hold people accountable, have been afraid to, to really, you know, leverage leadership. Because it's like, well, if I lose that person, you know, we're already down three people. And, but, but it sure makes things worse. Because then it becomes a cancer in the organization. And and then nothing you do is good enough, when you are listening when you are if you don't have the other side to balance and say this is where the organization is going. And we're all accountable to it.


Dr. Joshua Klein  33:56

Right, right. Yep. And it's not easy. You know, it's and it's, I think it's probably as hard as it's ever been for the reasons that you're talking about it. We all do appreciate our employees and our colleagues and genuinely, and they do deserve what they deserve. But yes, it can get out of hand pretty quickly if you don't set sort of some framework for what's reasonable. And that's not an easy thing to do. So


Griffin Jones  34:25

other than like principles like that, about people just even like function? What are things about business that you knew nothing about when you started? Like, I think now, good advice for most people, unless they're 100 on this on the entrepreneurial spectrum, and by 100, I mean, Mark Zuckerberg, I mean, Elon Musk, I mean, that type of but you know, your average business owner might be like a 70 on that spectrum. And, and so I think for most people, unless they're the most extreme on the entrepreneurial spectrum are better off I'm going to work for someone first learning as much as they possibly can, and then starting their own business, if they still think that's a good idea. And I say that and I believe that at the same time, though, I know things like I wouldn't even Effingham County what to look for, in many cases. So what are some of those things where you're like, I didn't even know, to look for that. Before I was, before I managed to practice.


Dr. Joshua Klein  35:30

I think I mean, in a very fundamental way, I think one of the things that has become clear to me is that so much of business relies on assumptions that are necessarily loose. You know, one of the things we struggled with and as they struggled with, but but that we, that we learned along the way was, I mentioned earlier that when we started extended, we wanted to push down the price point and egg freezing to help make it more accessible. And this has been an ongoing debate that's still ongoing, you know, what's a reasonable price for for an egg freezing cycle? And even more, it might sound crazy, but what does it cost for us to deliver an egg freezing cycle, because it's not simple math. You know, there's fixed costs and variable costs. And so I think when I when I agreed to join in San fertility, and I had some really accomplished smart business, people who joined as well, and we started, you know, kind of making decisions about how we're going to set things up in the framework. I was, I think, expecting that these business business people with their MBAs, Ivy League MBAs would have some magic formula, they're going to pull out some Excel spreadsheet, and they're going to just have it all figured out. And like this is, you know, it should cost x. And as it turns out, they don't know, at best, they say, well, let's assume that this year, we're going to do this number of cycles. And let's assume we're gonna have to do X number of embryologist, doctors and obviously, you all the different things you have to put on paper. And then yes, there is some smart math you can do to sort of make a smart, smart decision and a smart assumption. But I think that it was sort of a little bit disturbing about how much of a business is done in a way that you just have to like, make thoughtful decisions based on as much available data and often there isn't a lot of available data, and kind of just try it and see what happens and then adjust along along the way. So I think that, you know, it definitely I've learned a lot about business over the last number of years. And I've learned to respect people enormously for their successes in business. At the same time, I think the my perception that there's like this business secret book that like you only get if you're a business person, and that doctors aren't privy to that, I think misconception has been, or I've been abused of that notion. So you kind of just have to get comfortable with saying, Well, this is like the best guess we're gonna make. And let's, let's go with it. So that's something I think that you only learn when you're on the other side and really see the books and know how the some of those decisions are made with regards to the dollars dollars and cents. That's one, I'd say another sort of big learning item for me was, I think, when you're on the outside and thinking about a business, from a financial perspective, in a relatively unsophisticated way, are you tend to think mostly about revenue and not about overhead, and he's out while they're doing 1000 cycles of IVF. And every cycle is, you know, they're getting 10,000 bucks. And so that's like, well, whatever that is $10 million of revenue. And so like, it's 10 million bucks, like that must be rolling in the dough, except that you don't realize that, like, your annual rent, if you're in Manhattan can be easily a million dollars or more. And then you've got, you know, four or $5 million of payroll for all of your people. And then you've got all of your equipment, and then we got like, etc, malpractice insurance. Yeah, and the insurance and not just malpractice and liability and the cyber insurance and like, and all of a sudden 10 million bucks is not exactly a ton of money anymore, you know? So I think that the to the to the uninitiated, it's easy to see a business as as a revenue entity, but it's not it's it's a it's a P&L entity. And so and there's so many more overhead items that you never dream of before you're kind of in it. And so I think that's something that I would definitely caution people to think about if they haven't gotten on the other side of the curtain yet is just you got to realize that that delivering a product and certainly a high quality product and certainly a you know, a high touch service. highly regulated product, like health care in America, for fertility patients is a very expensive thing to deliver. And it's not so easy to cut out a lot of these major major expenses and so, you know, it's for full transparency, you know, I kind of imagined we'd be able to push price points down a lot more than than is realistic before I knew what goes into it. And so you know what we charge for our server He says now is more than I thought we'd have to charge but the reality is, it's it's it's very expensive to deliver good quality care or even mediocre quality care, let alone good call quality care. And so, so don't forget the overhead it's it's it's an important other


Griffin Jones  40:14

how I remember the first time you did a budget, the first time we tried doing a budget was like, it's like, I don't know how much that's gonna like before we launch the podcast, but I don't know how much it is to podcast, like, I don't know how much we're going to end. So it does take some, like some expense tracking, which is different from budgeting that helps that informs but you know, it's a lot easier for us to do a budget and forecasting, because like, How the heck are we going to sales forecasts in the beginning? I don't know, how many clients am I going to sell this year? How many. And so that's that's two areas that I really would recommend that if somebody's thinking about starting their own business, their own practice and their their in an organization, I would I would try to do two things. And the first, well, maybe three. First is is see as much of the financials as you can some people do like that our firm is moving towards open book management, where we share that with our team. And maybe some places you can only see a piece of it. But David sable recommended a book to me last year called how to read a financial report. That's exactly what it sounds like. It's as interesting as reading New York state tax code. But it is it's the basics. And it would be great if you could do that for your own practice, or even your own Rei division if you're at an academic center, and to see what that is to have some education that the second is to know what to know, the sales and marketing pipeline, how are people coming in? That is extremely important to know, as deeply as you can. And the third is the Human Resources pipeline. How are we getting in retaining people? And like those are three areas where I think it makes sense to really delve in May, maybe even more than operations and delivery, I might even put those three areas ahead of operations and delivery. In terms of priority of learning, what do you think?


Dr. Joshua Klein  42:15

I think you're right, because that's kind of how you get to have a team that can do the things you want to do. And if you have that, then you figure out how to do you know, if you have the right team, you're gonna do the things you want to do the operations and delivery, but you can't, you can't get there without sort of getting your Human Resources figured out without getting your sales and marketing figured out. So you have you know, a customer and that you get your finances straight. So yeah, I think that's probably right. And by the way, the sales and marketing piece is also another thing. And I can reflect with our own experience that extend you know, we came in to be open and came into the market heavy on the increasing, increasing is more so than, you know, infertility treatment, an elective service line, it has less insurance coverage than IVF does. Even today, you know, even with progeny and Karen and when fertility, there's still only a very small percentage of of women will have coverage for fertility preservation, and only a minority percentage of our patients have coverage. And we were very aggressive with our marketing and our marketing spend early on. And we grew very fast. And so it was clear to us from the first couple years of doing it that marketing works when it comes to egg freezing. The problem is that that only actually works. Ultimately, in the long run, if you can spend money to get customers in a way that allows you to still have a profit margin on what you're charging for your service. Meaning if you got to spend $5,000 on marketing for every customer that you're going to convert every patient you're going to convert, that may not be a viable business model, because you're not charging enough to justify it. And so you know, how you're gonna get your patients the best way, of course, is when they show up, you know, they word of mouth, it's free. But the reality of fertility in the US right now, certainly in any major metropolitan area for sure, is that there's lots of competition, and everybody's got an angle. And most practices, even the academic practices are doing something on the sales and marketing. And so it's important to be realistic about the fact that that stuff has to be done carefully, thoughtfully, and it costs money and you have to keep track of how much money you're spending and what you're getting for that for those dollars. And once again, like maybe I was way too naive, but this isn't stuff that I thought about, you know, figuring okay, just buy some Google ads and there's your marketing and like it, you know, it's a lot more complicated than that, obviously. So that's definitely another area that that I've learned a lot about over the last number of years.


Griffin Jones  44:55

We're talking about lessons learned, you know, owning a practice or owning a business in the future. silletti field and things that you may want to learn how to do or learn about before you go and start your own venture. Another thing is some of the systems that are used, and oh people that can give really good recommendations on the different EMRs. They've shopped and the depth and scope of functions. But I would ask someone that you know, that uses engaged MD, if you're not already, if you don't use engage them D in your system, you're thinking, I want to open my own office within my own group, or I want to open my own practice, I want to go join somebody else, and I want to be able to add something to it, engage them D is one of the surest bets that you can do, but you don't take my word for it. Ask someone that you know, because more than half of your colleagues are using EngagedMD and more than half of your colleagues are extremely delighted with EngagedMD because they got real informed consent. They don't have stacks of papers that people have to sign and then account for and then keep an eye out file cabinet somewhere. They have true informed consent from patients that have a module at their convenience, so that the staff isn't overburdened with questions that they don't need to be getting that they can help the patient with the attention that needs to be devoted to that patient's case. Because the elementary the rudimentary is covered, and now it's just what that patient is stuck on or what's unique to their case that the care team can focus their care on. That's what personalized care is. And more than half of your colleagues have seen the benefit from engaged MD that way, so just reach out to any of them. Hey, guys, do you use EngagedMDin the people you want to fellowship with people that you see it ASRM? Hey, do you use engage MD? What do you think I hear Griff, talk about it. But he doesn't want to practice? What do you guys think, and see what they say. But if you want that free workflow assessment, want to see what other practices are doing, you want those insights that engagedMD has, and you want to see how your practice stacks against that ideal workflow, then you go to engage them the.com/griffin. And you mentioned that you heard them on the show, you mentioned that you heard them from me, and then you're going to get that free workflow assessment. So ask somebody else, don't take my word for it, but go to engage them db.com/griffin Or say, or an on the show. So you heard from me, so you can get that free work assessment for you. That's one of the biggest system wins that you can have right off the bat. And you can verify that just by asking people you already know, I hope you enjoy the rest of this episode about things you need to know for the fertility business, you might start, I'm gonna let you conclude on whatever topic you want to but before that, because we have so many younger Doc's that listen. And they're thinking about like, how do I choose who I'm going to work with you were you chose your your business partners, and, and they chose you. And so talk about how you did that? Well,


Dr. Joshua Klein  48:21

I'd say I was probably luckier than I realized, the main person, the main business person that I that I partnered with, is a wonderful guy named Michael Kohn, whose private equity hedge fund guy, the truth is looking back, I got lucky that he is of as high integrity as he is, because I probably could have gotten really treated much more poorly or gotten abused more if I wasn't so lucky to find someone. So I think that the advice would be, you definitely have to choose we get into bed with very, very carefully, especially when it comes to business people because I think that they're not all going to be the most high integrity people. And to be fair, like business people are, their profession is to use business to make money. And that's true for doctors too, obviously, with our professionals, how we pay our bills and make a living. But I think the mindset of young doctors is a little bit more idealistic than the mindset of probably mid career fitness people is and you got to be very careful not to be too trusting or too idealistic in that sense, you know, for young blacks are coming out and looking at job opportunities. So it's, it's complicated, because I think that, you know, the people that you're going to work with day to day are the clinical team, you're going to have obviously Doctor colleagues, and then other clinical colleagues and embryology colleagues and so forth, but these days, a lot of practices are either owned or part owned or managed by business entities that you may or may not have much direct interaction with. And it's it's a very, very seen I think that I Have the level of involvement and exposure to the business behind the practice is going to be very different from one place to another. And I think that that's those are important questions to try to really investigate while you're looking at different practice opportunities, you know, if there are going to be places that are looking at the conversion metrics, you know, how many consults did you do, and how many of those turned into IVF patients, and if you're below a certain bar, maybe they're gonna get dinged, or you're not going to get your bonus. And, you know, to some degree, that's not crazy. But if that's gonna bother you, like you better you should be aware of it. And in other places, certainly in more academic environments, the culture, maybe more sleepy, but, but that might be more comfortable, to not have to sort of think about numbers like that. And so I think that I'm not sure that I have much brilliant insight other than to say, it's a very, very playing field out there. And so you really want to ask as many questions as you can and talk to as many people as you can, looking at to what degree is that practice run like a business or like a medical practice that has a business behind it, because the culture of the place and look, business is not terrible. And there are some very successful, very busy places out there that run like a business and that patients are happy, and the doctors are happy. And you know, that's not necessarily always the worst thing. But I think different doctors have very different priorities of how they want to practice medicine, and what kind of lifestyle they're looking for. And it's going to be pretty different from one practice environment to another. And so just Just do as much investigation and homework as you can. Because it is going to be very different from one opportunity to another.


Griffin Jones  51:45

So that's for the homework, let's conclude with the introspection thing, because a lot of people listening are in the position of the 2012, Josh or Jean Klein. And maybe there's a couple different routes for that type of person, but some of them should stay at Columbia or wherever their academic center is, wherever they're doing fellowship, because they're going to be happy, they're at another one, some of them should go on to be should should just gobble and gobbling, gobbling till they're a bigger fish in the bigger pond that they end up with it someplace like an RMA or or an RMA or wherever they end up, some should go off on their own. And then there's other people still that it's like, oh, there's somebody that just started their own thing couple years ago, I don't totally want to start my own thing that I don't feel like starting from zero. But there's also a lot of opportunity for me to help make this bigger, I want to go join the Josh Klein's out there. So there's a couple of different options introspectively. And then this will this will be your final thought for the program? What How should people decide what's best for them?


Dr. Joshua Klein  52:58

That's a great question. I think that you can't have everything, I think that it's important to be realistic about the fact that if you're someone who is going to prioritize, you know, maximizing income, then you're probably not going to get that at a pure academic program. Because you're going to be salaried. And usually, that's not the culture. If you're someone who enjoys teaching who enjoys having some abstract today's stream every year going to conferences, then you're going to get that at a more academic program, it's gonna be much harder, you're gonna be sort of swimming upstream at at a pure private practice. If you're someone who has, you know, family, or hobbies or outside interests that are very important to them, that that, you know, you want to be out of the office by 5pm every every evening and not work weekends, you know, that that's going to be something that you want to take into account. And I think the bottom line is that there's no job, probably, that's gonna let you be like the division chief, and academically active going to conferences every couple of months. And you know, making a seven figure income, and not working weekends, and being out of the office by 5pm, every month, and every week, every day. So, so I think it's just a matter of, and again, no brilliant insight here, but you really just have to think about what are the things that are most important to you and your lifestyle and money is important, but it really is not necessarily the most important. And so, you know, make your list and then try to get as many of those things as as you can, because you're just it's like buying a house you're just not going to get everything unless unless something's you know, your I guess our unlimited budget, but most people are going to have to pick and choose. And so just think seriously about what's going to make you happy in five years and 10 years and then chase after those things. And maybe some of it will come along with it. You know, you can be in a private practice and still be the research person who does put together some research abstracts every year and like that's fantastic. But as long as you you know, are are comfortable the fact that that's kind of if you can, you'll do it but it may not happen then you're being being smart. So I think it's it's really a matter of triaging what what is going to be highest priority for you and your career and, you know, being honest with yourself about what's going to make you happy. And if you do that you should be landing in a good place. And there's lots of good places. That's another comment is that there's not like one right job, I think there's a lot of ways to be happy. So we're in a good time, there's a lot of good going on.


Griffin Jones  55:27

Well, if if one of those routes makes sense to talk to you, as you say, talk to everybody is that an offer you would extend are there that you would extend to the younger dogs that they can reach out to you on LinkedIn. So we will include that in the


Dr. Joshua Klein  55:45

video, I think my journey has been an interesting one and not the most common, you know, working and big place academic place, and then in New York, kind of CO founding my own place, and it's been a journey and it's been a learning journey. And so I do think that I can give people guidance, or at least my, my personal, you know, perspective, so I'd be happy to be available.


Griffin Jones  56:05

Dr. Josh Klein, thank you for coming on inside reproductive health.


Dr. Joshua Klein  56:09

Thank you for having me. It's been my pleasure.


56:12

You've been listening to the inside reproductive health podcast with Griffin Jones. If you're ready to take action to make sure that your practice thrives beyond the revolutionary changes that are happening in our field and in society. Visit fertility bridge.com To begin the first piece of the fertility marketing system, the goal and competitive diagnostic. Thank you for listening to inside reproductive health



153 Elizabeth Carr: What is U.S. IVF’s First Born Working For and What Is She Doing Now?

 This week on Inside Reproductive Health, Elizabeth Carr shares her experience from birth to where she is today, at TMRW, and everywhere in between. Born quite literally into the industry and its spotlight, Elizabeth has chosen to be an advocate for IVF, working to change public education, and further ‘industry’ advancements. 

Tune in to hear:

  • What Elizabeth Carr is doing to give back to the community that made her existence possible.

  • How her relationship with Dr. Jones and his family contributed to her life and ultimate career path.

  • What she wishes people in the industry would push harder for. 

Elizabeth’s information:

LinkedIn:https://www.linkedin.com/in/elizabethc

Twitter: @ejordancarr

Website: www.ejordancarr.com


Transcript

Elizabeth Carr  00:04

My speaking up and out has always been kind of my love letter to the industry as a thank you and to all the patients. As a thank you for saying thanks for not giving up and making sure that I got here.

Griffin Jones  00:17

unlimited human potential Do you ever think about the line of work that you're in, in those terms, unlimited human potential. That's what I think about when I think about the in finite or at least in depth finite number of IVF babies that can be born or babies born from art in general, my guest is Elizabeth Carr, you know who she is because she was the first baby born from in vitro fertilization in the United States, through Dr. Howard Jones and his Institute. And we talk about what that was like to always be in the limelight. But I think the reason why you'll get an interest in or you'll take an interest in this episode is because partly the relationship that she talks about with her family and Dr. Jones and, and then what the other IVF babies that she knows from the institute, what their relationship was like, and their fondness and even the way she thinks of Dr. Jones's colleagues, and that weren't there at the institute, but But everywhere. And so I think as you think about what kind of legacy that you're having, maybe we take a little break from the private equity and the hiring and the marketing and the business development and all of the this stuff, the important stuff that we do have to do we take a break for a second, so that you all can reflect on the legacy that you're leaving from someone who had one is very good about speaking about it, but to at least in this country, has been living it for the longest. So now she's with TMRW Life Sciences. And I get to talk a little bit about that, and a little bit about advocacy and an opening up. But think about this episode with regard to your legacy. And enjoy this interview with Elizabeth Carr. Ms. Carr. Elizabeth, welcome to Inside reproductive health.

Elizabeth Carr  02:23

Thank you so much for having me. It's great to be here.

Griffin Jones  02:26

You are the United States of America's first baby to be born through in vitro fertilization. So does Louise Brown, like ever? Just Does she ever throw some nationalistic crap at you that the UK beat us to it? Or does the stet you know, does that Steptoe Jones legacy does it? Does it manifest itself as a rivalry decades later, or was it the whole world collaborating to? To try to do the right thing?

Elizabeth Carr  02:57

Yeah, no, no shade, definitely no shade from Louise. And yeah, my doctors Jones actually worked with Steptoe and Edwards to kind of understand what they had success with, and then tried to replicate. In the US, of course, my distinction versus Louise, where maybe I'm throwing a little shade is that I'm really the first IVF baby, that, you know, when we think of modern IVF, I'm it so Louise was a natural cycle, whereas I was the first baby born using all of the, like, hormone protocols that we're also familiar with now.

Griffin Jones  03:35

Wow. So well, that's another reason why whenever somebody says, and normally there's playing around, but our country did this first or our team, our university, whatever did this versus like, but yeah, they did that one step first. And then because you did that one step and you help somebody out, they figured out another step. And then the other guys and gals over here figured out another step and as much better to think collegially Exactly. So. So when did that start to become a part of your life? Because it was always a part of your parents life, but But for you, it definitely wasn't, you know, in the first couple years of your life, in terms of like you knowing that, you know, at least age two and three

Elizabeth Carr  04:25

you Well, I mean, yes and no. So I let me put it this way. My first press conference ever was at three days old. So while I may not have had the cognitive realization of what was going on, I have always known that I was not like all of my other peers, you know, other kindergarteners weren't going on Good Morning America, but I was, you know, think things like that. So I may not have realized until I was older. What this meant: But, but I knew that my parents went through something different in order to get me here. That was kind of like my understanding when I was very young.

Griffin Jones  05:10

My assumption was no, it would have taken a few years before some of the to be able to explain it to you. But you were just never out of the limelight is what you're saying.

Elizabeth Carr  05:19

Correct? No. I mean, it was a media firestorm from the day that it was announced that there was a pregnancy even before I was born, just even a pregnancy there and woman impregnated was the headline that my father recalls reading. And he was like, yep, that's my wife. So yeah, it's always been a subject of media spotlight and scrutiny.

Griffin Jones  05:45

And so how long did that last for? You said you went to? You went to kindergarten, and then

Elizabeth Carr  05:54

I made its last my whole life. Yeah, it still happens. It's lasted my whole life. Basically, every reproductive milestone, somebody will want to talk to me about what this means, or you want to check in and make sure I was developmentally just like everybody else, because this was, you know, had never posted, by the way. Yeah, I mean, you know, mostly abnormal, I

Griffin Jones  06:19

think, crazy as everybody else.

Elizabeth Carr  06:22

Exactly. I don't think there's any real normal out there. But yeah, so I mean, it's been a constant. limelight. I mean, I had a camera crew here last week at my house, and I'm, you know, I'm just living my life. So

Griffin Jones  06:37

were there. Were there points in your life where people were less aware the media was less interested, like, oh, 13 year olds are gross. Let's bother again, when she's old enough to vote? Like, Were there ever lows in? Were there? And, or maybe at least lows compared to the peaks?

Elizabeth Carr  06:58

Yeah, I think, yeah, the ages that were less exciting, right. So like, nine was not a big deal. But 10 was a huge deal. Because it had been a decade since I had been born. You know, when I turned 16, it was like sweet 16. Right? When I turned 20, when I got married, when I had my son, when, you know, it's like, all of these kinds of life milestones that people go through. Mine had an additional level of media interest that I don't think many people realize until we start talking about it.

Griffin Jones  07:29

Hey, are you gunning for centenarian status? triple digits, because

Elizabeth Carr  07:35

I know that the running joke is, you know, this year, I turned 40. And I was like, you know, I can't lie about my age. Everybody knows when my birthday is exactly how old I am forever. Never. That's, you know, that's what I'm stuck with. So yeah, it's, it's crazy.

Griffin Jones  07:52

So when did this notoriety start to get you involved with the fertility field, like the fertility field had always known about you? The doctors knew who you were, and they certainly knew our Jones was. But at what point? Did it start to get you involved with them?

Elizabeth Carr  08:22

Yeah, so I mean, aside from the media attention, and all the interviews that I've had, over the course of my life growing up, I, I've always had an interest in science, I'm not good at math. But I've always liked to explain the science. So I've always, and I always, I think I was probably 10, when I started really paying attention to the industry and seeing what was going on and developing. So I've always paid attention to the reproductive field. But I also started realizing that because I had this weird platform in life, that I could use my voice for good and for change. And so I've really, from a pretty young age, started speaking up about different reproductive options out there, and became kind of like a junior advocate, you know, Junior age, probably 1011, I really started paying attention to what was going on with insurance. And I'm still actively fighting those insurance battles and testifying in front of various committees and on state by state basis and paying attention to all the laws and, you know, looking into just helping people understand their options. So I started really paying attention to that stuff, probably when I was 10. And then I went on to be a journalist and wrote, not surprising to many I don't think primarily about health and science and again, stayed up on everything going on. And then I've worked for a few fertility startups and done a bunch of free then to writing and social media for various companies. And now I'm at TMRW Life Sciences as director of marketing.

Griffin Jones  10:07

So you started off as a journalist, were you ever kind of covering just a regular beat? Or was it always Health and Science?

Elizabeth Carr  10:16

Yeah, so I did a range of things. When that you, when I started out, I worked from age 18, at the Boston Globe. And I actually started out as an obituary writer, because you can't label a dead person, believe it or not, so they let you start there. And then I did a lot of general assignment. And then I went into health and wellness was a writer, then I became a health and wellness editor. And so I've done you name that you name it, it runs the gamut in terms of journalism,

Griffin Jones  10:47

what made the switch or the transition from journalism to marketing.

Elizabeth Carr  10:53

So I spent 15 years of my career at the Boston Globe. And I actually jumped from the editorial side of the business to the marketing side of the business, because I wanted to learn, you know, the dirty little secret of newspapers is that you don't make money selling a newspaper, you make it doing events, and marketing, and in house advertising, and all these other kinds of modalities that a newspaper has available to them. So I just wanted to learn soup to nuts, the business. And so that's why I jumped to the marketing side. And then I figured out that, you know, this was an important skill in the fertility world for, you know, anyone looking to grow their practice or understand the business of infertility services or reproductive technologies as well. And, you know, it's hard, it's, it's complicated, right? If you don't understand the reproductive field, it's hard to translate it into plain English for people sometimes. And I that's, that's a skill that I wanted to learn and adopt very early, that I wanted to be able to explain something very complex in a way that people could understand it.

Griffin Jones  12:05

So what areas of marketing did you experience both at the Boston Globe and then afterward?

Elizabeth Carr  12:12

So I was one of the first digital reporters, you know, back before anybody knew what a blogger was, I was blogging, doing social media, tweeting, you know, doing kind of the early days of podcasting, where, you know, we did audio over stills, it wasn't really movies back then. But audio over stills kind of storytelling. You know, things like that, basically anything I could get my hands on and play around with I was experimenting with.

Griffin Jones  12:46

And then and then what happens after the Boston Globe.

Elizabeth Carr  12:51

Let me see, after the Boston Globe, I actually went to work for Runner's World Magazine, I was an editor there because in my free time, I am an endurance runner, and I run marathons. And so again, kind of still in that health and wellness bent, was a was a writer and editor there. Then I went to work for over science for a very short period of time, I then I worked for genomic prediction, I've done nonprofit fundraising, and leads kind of all the way up to today, TMRW.

Griffin Jones  13:27

All the while that you're doing like that you're at the globe that you're Runner's World. Are you? Are you involved in the advocacy? You said? Yeah, surance passion never left you. So what were you doing during that time?

Elizabeth Carr  13:42

Yeah. So it's all the stuff that nobody sees, right? It's all the stuff behind the scenes that we all know, hopefully we all know is going on, of, you know, fighting to get insurance mandates in various states where there aren't mandates and coverage, as well as making sure that bills that are being proposed have language that is protective of all, not just some seeking reproductive options. So all of the nitty gritty stuff that's behind the scenes that nobody really, you know, it's not visible, but it's critical work. So I've kind of always been doing that, since I was very young. It's just not something that people see.

Griffin Jones  14:23

So then how did you when did the logical or now seemingly logical conclusion of starting to work with startups in the IVF space? When did that happen? And how did it happen?

Elizabeth Carr  14:38

Probably. I don't I'm trying to think how many years ago probably 10 years ago, I think is when I started. Sorry, my dog is drinking water loudly off camera. Miracle. Thank you. So probably about 10 years ago, is when I started working in the infertility slash startup space in a in a professional capacity as opposed to just in a patient advocacy capacity? And how did it happen? You know, I'm not really sure I've just always kind of known a lot of people in the space. And I happen to have this like weird digital tool set to or skill set in my tool belt of various things I was good at. And I understood the needs of patients as well as the needs of clinics or providers as well. And so it was kind of marrying all of these various skills from journalism, marketing, patient advocacy, kind of all into one. You know, one multi tool, I guess you would call it,

Griffin Jones  15:47

as you've established, we all know how old you are. This took place about 30. Why not? Until then was was it? Was it just because you were just another person doing other things in your career? Or was it because there weren't as many startups in the fertility space at that? I think,

Elizabeth Carr  16:05

yeah, I think it was both to be honest with you, I think I was just kind of still, I felt like I still had a lot of growth to go at when i i left the globe, and I was 33. So I still kind of had this mini city of people to learn from and that was, I was really grateful that I spent a majority of my career there because I have learned so many different skills from so many different people. And then yeah, I think also, yes, we have seen more and more fertility startups survive those early days, to be honest with you. I think it's there's there's many, many out there, but not many of them become known until after they survived that first few bumpy like six months to a year. Right. And so that's kind of when I feel like people rise to bubble up to the surface.

Griffin Jones  17:02

What was it? What were people working on at that time that you found interesting in the fertility space?

Elizabeth Carr  17:09

I mean, back then, you know, it was a lot of the early days of pre Implantation Genetic testing, which is fascinating to me, because it was not even in the realm of possibility. And when I was born, I mean, this is really dating me, but they had a statement written, or my doctors had a statement written in their pocket about how it was a sad day for infertility that they had on backup, just because ultrasound was showing that I was really, really small and they were worried I was going to come out with birth defects because I was only five pounds 12 ounces. And ultrasound was so bad back then. Right. So people forget that, like the things that we take for granted now. vitrification I remember when vitrification became possible, and that was like, the catalyst and game changer in the field. You know, egg freezing was I remember being probably my late teens and touring a facility that had done the first egg freezing for fertility preservation for cancer patients, because that was it was very niche back then. And it was like groundbreaking that they figured out that, you know, we can freeze eggs and and they can still go on to become viable pregnancies. People didn't know that that was possible. So it's kind of like all of these milestone moments that I remember growing up with industry really in, in my view.

Griffin Jones  18:37

And then what, what landed you TMRW, and how long have you been there for?

Elizabeth Carr  18:44

So I'm trying to think I think I've been here six months now. I saw TMW at ASRM, actually. And I just thought, wow, this is the kind of safety and transparency that I hear from a daily basis that patients really are kind of clamoring for that they want, you know, they want more information. I know that we we all think it can be information overload because it can be right we didn't my my mother always jokes that she was kind of grateful that there was no Dr. Google back then when she was going through IVF. Because it is so overwhelming the amount of options and information out there. But I hear from people you know, I really wish there was a way I could just stay up to date on all of my eggs, embryos, health information, everything I needed to know and not wonder where things are or what the status of them is, in in the moment really, to know that everything is safe and I've worked so hard to you know, get these eggs or embryos that I want to protect them at all costs. And I think that you know, TMRW unique digital chain of custody and patented technology is just It's just, you know, so interesting in kind of leveling up that transparency and peace of mind for patients.

Griffin Jones  20:08

I don't know exactly when a startup becomes not a startup is.

Elizabeth Carr  20:13

I don't either.

Griffin Jones  20:16

Do we still call TMRW a startup?

Elizabeth Carr  20:18

I mean, I don't know. That's a very good question.

Griffin Jones  20:22

A lot of money, a lot of people.

Elizabeth Carr  20:25

We're all working very hard roster

Griffin Jones  20:27

at this point. So yeah. So in your director of marketing,

Elizabeth Carr  20:34

that's your director of product and clinic marketing,

Griffin Jones  20:37

clinic market? So do they pull you out like a dog and pony show? Yours? Which is, which is partly the role of marketing director anyway. But given your status, how was that used?

Elizabeth Carr  20:55

No, I mean, it's really kind of, I'm always the one saying like, Oh, I know them, or or, you know, like, let me I want to help or, you know, I'm really the one who kind of said, I want to help move the needle in whatever way I can for the industry. That is kind of my that is my, like, personal stake in the ground aside from TMRW, or any other company I've ever worked with? It's really how can I personally move the needle? For the better in the industry at for patients? That is, that is my end game. And so everything I do is kind of with that mindset, you know, moving forward? And no, it's really my job to kind of, again, translate all of the complex things about the about this technology that we have, and explain it to people in a way that makes sense. And let people know, you know, why it matters.

Griffin Jones  21:50

So our director of clinic and Product Marketing means of what TMRW is marketing to clinics, yeah, helping

Elizabeth Carr  21:59

helping clinics so that they can level up their practices in terms of having our cutting edge technology at their practice. And then as well as explaining the product itself, like soup to nuts, nuts and bolts in a very, you know, non technical way to understand.

Griffin Jones  22:16

So what are you doing to, to talk to practices now?

Elizabeth Carr  22:22

Yeah, so essentially, you know, my job now is to interface with all of our current partners, and help them explain to their patients, you know, this is the TMRW platform, this is why we're using it, this is what it means, you know, that kind of stuff. So I help them explain to their own patient populations, why this is important, and it matters as well. And then again, explaining the product to the clinic so that the clinic can then explain the product to their patients as well.

Griffin Jones  22:49

We're talking about lessons learned in owning a practice or owning a business in the fertility field and things that you may want to learn how to do or learn about before you go and start your own venture. Another thing is some of the systems that are used, and oh, people that can give really good recommendations on the different EMRs. They've shopped in the depth and scope of functions. But I would ask someone that you know, that uses engaged MD, if you're not already, if you don't use engage MD, and you're CISM, you're thinking I want to open my own office within my own group, or I want to open my own practice, I want to go join somebody else, and I want to be able to add something to it, engage them D is one of the surest bets that you can do, but you don't take my word for it. Ask someone that you know, because more than half of your colleagues are using engaged MD and more than half of your colleagues are extremely delighted with engaged and be because they got real informed consent. They don't have stacks of papers that people have to sign in then account for and then keep an eye out file cabinet somewhere. They have true informed consent from patients that have a module at their convenience, so that the staff isn't overburdened with questions that they don't need to be getting that they can help the patient with the attention that needs to be devoted to that patient's case. Because the elementary the rudimentary is covered, and now it's just what that patient is stuck on or what's unique to their case that the care team can focus their care on. That's what personalized care is. And more than half of your colleagues have seen the benefit from engaged MD that way so just reach out to any of them Hey, guys do use engage in the people you want to fellowship with people that you see it ASRM Hey, do you use engage them D What do you think I hear Griff talk about it. But he doesn't want to practice. What do you guys think? And see what they say but if you want At every workflow assessment want to see what other practices are doing, you want those insights that engage them D has, and you want to see how your practice stacks against that ideal workflow, then you go to engage them. the.com/griffin. And you mentioned that you heard them on the show, you mentioned that you heard them from me, and then you're gonna get that free workflow assessment. So ask somebody else, don't take my word for it, but go to engage md.com/griffin Or say you're on the show. So you heard from me, so that you can get that free work assessment for you. That's one of the biggest system wins that you could have right off the bat. And you can verify that just by asking people you already know, I hope you enjoy the rest of this episode about things you need to know for the fertility business you might start. When you're at SRM, especially like if you're either talking or you're involved with a session, or somebody invites you to be the guest. They're the guest of honor at their party, and you meet fertility doctors, what do they say to you?

Elizabeth Carr  26:05

Oh, it runs the gamut.

Griffin Jones  26:08

I want to hear the game I want to hear all the time, I want to hear

Elizabeth Carr  26:12

all of the games. I mean, I've heard everything from the very young embryologist who are like you're in all my textbooks, which makes me feel really old and weird, but in a good way. versus you know, some of the older physicians who remember by doctors, Dr. Howard and Dr. Georgiana Jones, and comparing notes to like, what it was like back then versus what it's like now. I've had people ask me really odd questions such as, Do I have a belly button? Spoiler? Yes, I do. I was born just like everybody else.

Griffin Jones  26:48

Doctors are asking that question. And doctors and patients have asked

Elizabeth Carr  26:51

me that question. I kid you not which it's always shocking when a clinician asks me that question. Mostly OBGYN so I have to be honest.

Griffin Jones  27:02

I wonder if there's what the reason that they're asking that question because

Elizabeth Carr  27:05

there's because in the early days of IVF, the slang term was test tube baby, right. And so the, the image in everybody's head was that I was grown in a test tube, which is just wildly inaccurate. Also, fertilization happened in a petri dish. And there were no test tubes involved in any way, shape, or form. So I always found that very amusing. And I've always hated that nickname.

Griffin Jones  27:30

But I thought there might have been like, but they didn't know that you that you went through gestation in utero, they didn't know that. They are a lot of people. A lot of people vitro fertilization also means grown

Elizabeth Carr  27:43

in a lab, like literally. Yeah. And I have to, I often have to remind people that that, honestly, the only difference was that fertilization happened in in a petri dish. And then I was placed back in my mother's womb. And nine months later, I came out just like everybody else does.

Griffin Jones  28:01

I mean, a lot of people think that, you know, like, Alaska is a country or that. Queen Elizabeth lives in Brazil. So like, it could, it could be, you know, I could see a lot of people thinking anything about that. But it surprise surprises me that OBGYN ins have

Elizabeth Carr  28:23

not awesome just to fit. You know, I'm just not I'm not saying everybody. But yeah, I mean, it's I think that's the one thing that surprises me still to this day, is that I have to do so much still basic education on what IVF? You know, I only primarily speak about IVF, because it's what what got me here, so I know it intimately well. But in terms of education on what exactly IVF is, there's still a lot of baseline education that needs to happen on a on a general level for a lot of people, many people have maybe heard about it, and think they understand what it is. But a lot of people there are still misconceptions about it. Yeah.

Griffin Jones  29:05

Unfortunately, it doesn't happen to me as much now that that generation is mostly gone. But I used to meet people that that knew my grandparents, I would meet older people that knew my grandparents, and they would talk about how they, how they knew my grandpa's. I guess that happens with my parents generation, too. But I guess I know more about my parents generation. So I'm just Yeah, a couple years ago, my brother and I were at a neighborhood bar in the neighborhood that were for the working class outside of Buffalo neighborhood for generation two, and we're at a neighborhood bar where like, all of the Irish working class stereotypes are coming together like our second cousin is our attending that we don't know that was oh, yeah, I know. And then there's this older couple there and that oh, and I know who your who your family where they were the Burns is and they were like telling me about my grant. parents and their family and great grandparents. I wonder, do you ever get that vibe from from older physicians like, who were maybe just behind the Steptoe Jones generation? And, like, do they want to tell you about Dr. Jones or duck, maybe even Dr. Steptoe, even though he wasn't in this country, like do they want to tell you about them in the same way that your grandparents friends would want to tell you about your grandparents?

Elizabeth Carr  30:33

Absolutely. And the grandparent analogy actually is a very good one, because that's how I've always referred to the Jones is my second set of grandparents. Our relationship for my whole life until they died was very, very close. Phone calls, emails, writing all sorts of correspondence. When I had my son, Dr. Howard wanted to make sure that I was going to a hospital with a level two NICU just in case, you know, all these kinds of things. So, yeah, people definitely want to share their stories with me of Oh, I was a fellow I was a Jones fellow or I went through the program, or, you know, I learned from so and so who was on the original team, or, you know, all those kinds of things, I actually really appreciate when people share those stories with me, because, you know, those were, those were kind of the Wild West days back then. Right? They were trying to figure out what was going to work, I don't think people realize that my parents you know, they didn't realize they were going to be the first until my mother got pregnant. And then the Jones were like, by the way, you're the first. And my parents, I think, naively assumed that there had been success, like it didn't dawn on them that there wasn't success. beforehand. And they weren't the only couple going through this. There were a group of other people going through this process at the same time, my parents were, but all the couples had a different protocol. And so none of the couples knew like, are we going to be the ones that the protocol works? Or is it going to be somebody else? And they weren't really allowed to share notes or talk about, you know, how their protocols were different. So it was kind of like, you'd pass in the hallway and wave and but you didn't know like, are they? Are they pregnant? Are we pregnant? What's going on? So yeah, it as I said, it was a wild west. So it's always interesting to hear those stories from from the very early group.

Griffin Jones  32:33

And so Dr. Jones passed away, like when I got into the fertility business, I started working with that, our first fertility client in 2014, but moved back to the US in June of 2015. And he passed away that summer. And how much correspondence did you have with Dr. Jones throughout your life?

Elizabeth Carr  33:00

Oh, as I said, so much correspondence. I mean, when I was little, we had a Mother's Day reunion every year at the Jones Institute in Norfolk, for the first 100 Babies essentially. And when it got to be 1000, and 1001 babies, that was our last reunion, because it just got to be too many people. And that was just from the one, you know, clinic. So throughout my life, you know, he would come to the airport and pick us up, or he would you know, I've got Birthday, birthday cards and phone calls every Christmas and on my birthday from them. I when I interned as a writer at The Virginian pilot newspaper, Dr. Howard actually helped me figure out my housing and I stayed with one of his fellows. And he and I had a standing lunch date every Wednesday. Well, I was there for the entire summer. He was one of the first people I told when I was pregnant with my son. He was invited to my wedding, you know, they were invited to my wedding. You know, anytime I had a newspaper article that made the front page or something like that, he would send me a note. So if people I think don't realize that we had such a close relationship, and they really were like a second set of grandparents, as I said,

Griffin Jones  34:23

so I just had a client asked me today, they were like, because we're doing a photo shoot for them. And we have a part of that where we we have just like an open period where people can come in and they can take their pick, they can bring their kids and they can take a picture and and they asked me what's the age limit because we just had someone in their early 20s who reached out to Dr. Toe and toe and said that they're now beginning medical school and as like there's no age like Yeah, that's great. That's incredible lady Yeah, like, that's it's not just a cute chubby cheeks that that is the whole story like, and you could argue that that's like, that's the story like, you know this, more broadly speaking this unlimited human potential you don't know what the human potential is, but we know that it wouldn't have existed if not for. Right. And so you like you were a part of of of that growing up. So I want to ask this question that has to do with the infertility community. If you think it's personal to me, I'll edit it out. I think it's, I think it's germane to the conversation. So sure. Did you go through infertility treatment

Elizabeth Carr  35:44

for everybody asks me that, no. So that was the other the other interesting thing about my mother's fertility journey to have me, she actually didn't have traditional infertility. She like where it was unexplained, or, you know, something was going on like that. It was scar tissue from a botched appendix surgery when she was in her teens. And she actually had three ectopic pregnancies before having me and so her fallopian tubes were removed, which, then that's where her fertility issues really came in. Because you, you know, back then you couldn't have a child unless you had fallopian tubes. So ironically, my mother could get could always get pregnant, she couldn't stay pregnant, the reason she couldn't stay pregnant was because of that scar tissue. So she was kind of the ideal candidate for this IVF program. And then No, I had no fertility issues at all. And I had my son at the same age actually, that my mother had me I was 28 when I had my son.

Griffin Jones  36:46

The reason why I asked is because I wonder what that's like the fertility community is such a tribe in many, in many cases, partly because they have at least some, some similar roots to draw upon. Like, even though the journeys are different, there's, there's some common threads, and sometimes those common threads are so distinct from the rest of society, that's where they form their bond. And, and you don't have that with them, you have a different kind of bond with them. It's like it's, it's as though they're, it's like their kids, you know, the the ones that have gone through treatment and been successful, are gone through time. Fast forward to be a grown up and now are with them in that community. So what what is that like, like to be to be not one of them at all, in one sense, and to them? And to be like, the most proud I know, there's so yeah, right, and product and and others? What's that? Like?

Elizabeth Carr  37:49

Yeah, so I mean, that's where, to me, I've always been very cognizant of that. There's like, I cannot speak to what it is like to exactly experience infertile infertility or trouble with your family building, right? I'm very aware of that. So I never speak to what that is like, what I can say is I can relate to what my, my parents went through, in their very unique situation. And that is where it has become my goal, that I am very humbled and privileged to be here. And I realized that I am very humbled and privileged to be here. And so my work as a patient advocate, or, as somebody who can be a resource or connector for somebody else going through this, my goal has always been for people to know what their options are before they need them. Because my parents really, you know, we're kind of given this option in a moment of crisis of like, Oh, my God, what do we do we have, we can have a child of her own, what are we going to do, and I never want anyone to feel like they don't know where to turn. And so my speaking up and out has always been kind of my love letter to the industry as a thank you and to all the patients. As a as a thank you for saying like, Thanks for not giving up and making sure that I got here. Because it took everybody it took all of my parents willpower of fighting. It took all of the scientists and lab technicians and embryologist and nurses, and even receptionists answering the phone and all the billing folks, it took so many people just for me to be here talking to you today. And so that's where I'm going to keep keep using my unique platform and voice to keep moving the needle ahead in this industry. And it's it's just it's it's honestly my only way of saying thank you because the words thank you seem wildly inadequate.

Griffin Jones  39:48

How old were you when you started meeting other adults that well, maybe now I won't even ask the question adults. How often How old were you? You when other people started introducing them to themselves, do you say I'm an IVF? Baby, too?

Elizabeth Carr  40:08

I mean, I think I'm a bad person to ask that question only because I have a magnet right at the end. And, you know, we had those reunions from from when I was very little with a Mother's Day stuff. So, so I always had other IVF babies around me, always. The only difference was, you know, when I was little, we would all introduce ourselves using our numbers. And so, you know, a friend of mine would be like, I'm never 10 and be like, I'm number one. You know, so nice to meet you. Where's number five? We don't know, like. So but then, you know, to have friends of mine. Now my age saying, Oh, I'm going through IVF or I'm having an IVF. Baby, myself. And they often say thank you. And I'm like, you know, I appreciate that sentiment so much. But like, honestly, I my, my joke is that I didn't really do anything I just showed up. It was really everybody else did the hard work, you know, I had no control. And whether I was here or not, it was everybody else.

Griffin Jones  41:06

Because you've got this passion, because you got this unique perspective. Are you ever asked to? Or do you take it upon yourself to be a public relations force when something bad happens, like when there is the the rare tank leak or embryo mix up? Or some sociopath in some, like OB GYN clinic from 30 years ago that fathers, how many embryos like when that stuff happens, and people are looking at the fertility field? Like, wait, what like, is that witchcraft? What's going on over there? And we know how rare that is, we know how much of a sliver it is to, in comparison to the good in the hundreds of 1000s of lives now over a million IVF babies that have been born from the treatment. But like, do you see yourself in in a unique position? Like do you feel an obligation to to be a counter voice when that stuff starts to get a larger share of voice in the public sphere?

Elizabeth Carr  42:23

I mean, yes and no. So obviously, especially with with my role TMRW, we're always trying to move the needle ahead for safety and you know, best practices and upping the standard of care, right? And so on, on that kind of mission level, I'm always saying like, this is why this technology is so desperately needed, so that in the rare circumstance or whatever that it happens, this is this is not a possibility, or the risk is mitigated to, you know, such a degree. On the other hand, I also know, because I grew up in this industry, how deeply IVF clinicians and lab techs and embryologist and everybody care about what they're doing. And, you know, I come at it from a very different lens of like, nobody would ever do anything on purpose, right? Like this is, as you said, like, these are catastrophic mix ups that I don't think anybody obviously ever wants to have happen. And so therefore, like, let's come together, link arms, let's talk about best practices, let's make sure that we're all doing everything in our power to make sure that this never happens, right, that this this is, this is the one thing we all collectively have agreed that we want to avoid from happening. So let's figure out how to do that together. And it is not from a place of, you know, fear mongering, it's, you know, we had a practice in place that was the best at the time. Now there's a new option, you know, let's let's go forward with the new option. Because it's new, it's a new standard. And it's just like, you know, kind of same thing with how the industry itself has grown up, right? We used to use certain hormones in the early days of IVF that now we don't really like my mom was on personnel, they don't make personnel anymore. There's now a new version out there. That's the next best, latest, greatest right? So we're always iterating we're always moving the needle. Again, even vitrification wasn't it was a moment in time where they were we were moving the needle, right? We went from fresh transfer to now we know we can vitrify and we can flash free. So what does that mean for moving the needle? And so that's where I always am kind of coming from like, what do we have to do now to move the needle? From an advocacy standpoint, from a safety and technology standpoint? What can we do together?

Griffin Jones  44:53

I'm curious a little bit while we're talking about that, I do want to conclude with you sharing what you think the field should be paying attention to. But I want to ask with regard to the extent that you're able to talk about what, what is TMRW’s vision or potential outside of just the IVF space? Like, I got to believe that this company is, is also going to do other things with this technology. So what's on the horizon?

Elizabeth Carr  45:25

Yeah. So I mean, I'm actually a terrible person to ask. Because I am so ingrained in this in this particular field and this particular dish that I'm like only, like a horse with blinders on that this is our goal right now, this is our mission, this is our drive. I'm, I'm the wrong person to talk about future looking, because at this point, it's we just want everybody to understand what we have going on. Right now. That's in the marketplace for patients and clinics to move forward. But I am excited about where where the potential of this could go. Although I don't necessarily I'm not the person that's necessarily involved in those discussions. But I am excited about yours, knowing about the person perceived benefits of this technology in, you know, potentially other fields. Who knows?

Griffin Jones  46:20

Well, let's talk then about what you think that the field should be paying attention to. And so let's maybe start this conclusion with what do you think that people aren't paying attention to enough of that, that you see, from your vantage point from having worked for all these different startups from our comfort mile from having talked to so many doctors and been involved in the institutional structure? What do you think that people just aren't paying attention to enough of right now?

Elizabeth Carr  46:55

I mean, that is such a hard question. For me, I think it's always the coverage and insurance landscape. We have known for many, many years that, you know, in many ways, reproductive technologies are cost prohibitive for so many people. And that continues to be a really tough nut to crack to make it more accessible to more people, and, and that is something that I know, we're all striving to change, but it's so hard, and it's so slow, that I think that that, you know, in this Roe v Wade overturned landscape, it's really come to the forefront even more, you know, as as a, as a worry that, you know, it will become less accessible, as opposed to more accessible. So I think, for me, personally, that's always one that I'm like, you know, if everybody can really pay attention, not just to the technology and best practices going on in the world, because we know that's going to continue to march forward. But really the landscape itself and, and making sure that everybody has access, and, and that is so key, and I don't think we can ever stop paying attention to it. Truthfully, like, if we take our eyes off that ball for one minute. I think it can be really harmful in the long run.

Griffin Jones  48:32

Well, then I'll let you conclude, however you want to clean our audience of practice owners and Doc's and fertility execs. Maybe it's it's a call for how you'd like them to get involved with that. But how would you like to conclude?

Elizabeth Carr  48:46

Yeah, I mean, I think, you know, for me, it's always, it always comes down to what do we think we need? And how do we think we need to get there. And I grew up in an industry where everything was highly collaborative, right? That was what everybody that talks about the Jones remarks how collegial and academic and collaborative they were, back then, that they, you know, wanted to share the latest and greatest research, they wanted to share best practices. And I think we all still need to kind of especially in this current landscape, continue to link arms and and kind of look around and say like, Yes, I know, we're competing, maybe for customer acquisition and those kinds of things. But let's make sure that we all agree that we want to provide the best care that we can to our ability, period, full stop, and whatever that looks like in the current day, landscape, technology, whatever it is, if we can all say that we're all driving towards the utmost best patient care. That's really all that matters to me. And I think that that's really all that matters to patients as well as they all want to know that we are marching in the same direction, you know, towards the best care and I think wholesale, you know, all of the practitioners that I've come into contact with, you know, embody that, which is a lovely thing. And it's very rare to have a whole industry care so deeply about, you know, their patients on it on a very human level. So I just hope that we continue that, and that we don't let any political landscapes or law changes kind of derail us from from really providing the best that we can.

Griffin Jones  50:34

And then we'll have a few more million Elizabeth cars. Oh, God. I'll be guests on the show. Maybe not me. But we'll, we'll do like every every million dollars or maybe 100,000. That can can be a guest.

Elizabeth Carr  50:50

That's that's the running joke of why my parents never had another they were like we were good with you. We decided to stop after you,

Griffin Jones  50:58

Elizabeth. Karen, thank you very much for coming on inside reproductive health.

Elizabeth Carr  51:02

Thanks so much for having me.

51:03

You've been listening to the inside reproductive health podcast with Griffin Jones. If you're ready to take action to make sure that your practice thrives beyond the revolutionary changes that are happening in our field and in society. Visit fertility bridge.com To begin the first piece of the fertility marketing system, the goal and competitive diagnostic. Thank you for listening to inside reproductive health

152 Pinnacle Fertility: Where’d They Come From?!

Inside Reproductive Health guest, Andrew Mintz, shares the evolution of Pinnacle Fertility on this week’s podcast episode with Griffin Jones. The fertility network which now owns ORM (Oregon Reproductive Medicine), SRM (Seattle Reproductive Medicine) and others, seemingly came out of nowhere. Is their model scalable? Will it stand the test of time?

Tune in to hear:

  • Andrew Mintz detail the Pinnacle Fertility model, including how they constructed their Medical Director and Lab Director Councils, and how they contribute to the overarching success and development of their network.

  • Griffin press Andrew on the efficacy of Pinnacle Fertility’s physician buy-in program, and how it could potentially implode.

  • Griffin question whether or not Pinnacle Fertility’s private equity backing equally beneficial to physicians across the board, or only those stepping into retirement.

  • Griffin ask how Andrew Mintz and his team approached the selection of the ever-challenging EMR system, and how they decided on just one. 

Andrew’s information:

LinkedIn: https://www.linkedin.com/in/andrew-mintz-712a999/

Instagram: https://www.instagram.com/pinnaclefertility

Facebook: https://www.facebook.com/PinnacleFertility

Website: https://www.pinnaclefertility.com/


Transcript



Griffin Jones  00:04

Nobody says we put the patient last, Andrew, and nobody says we're a bunch of dishonest dirtbags that are going to stab you later. So how were you able to actually demonstrate that almost every Fertility Center in North America is going to be owned by one of two companies in the coming years. It's one of the things that I talk about with our guest, Andrew Mintz. He's the CEO of Pinnacle fertility. If you're like me, you didn't know about Pinnacle fertility last year until he was ASRM last year, maybe even PSP CRS this year that that name really took off, they acquired six groups at the end of 2021. They have acquired more since including Seattle reproductive medicine. So they're quickly becoming a big group. And we talk about their model for making protocols uniform, raising the standard of care in their view, including having a council of lab directors, a council of medical directors, which I think that concept is interesting for you to listen to. I push Andrew on the criticisms that people have of private equity is it really just for the benefit of the retiring Doc's? I asked him that question of do we think that this is going to become a two horse race in the future? I talked about brands, that Kindbody style of brand versus this network style of brand and tell him which side I think is better, and ask him for his opinion. I also asked him to talk about choosing an EMR what goes into that process and should go into any that process and why they chose the EMR that they did. I asked about the model of doctors buying into the parent company and not into not not the equity coming from the at the practice local level. So we get some good answers in there. If you feel that I can go deeper on a specific set of questions, email me, let me know and our next guest will be the victim for that. In the meantime, enjoy this interview with the CEO of Pinnacle fertility, Andrew Mintz. Mr. Mintz, Andrew, welcome to Inside reproductive health.

Andrew Mintz  02:21

Thank you, nice to finally meet you in person.

Griffin Jones  02:25

I had never heard of Pinnacle fertility before the winter of 2022. And then by the time I got to PCRs, it was all the buzz, it was blue Pinnacle liquid pinnacle is doing now. And it's and so here's a company that, as far as I know, didn't exist a year ago, or a year and a half ago, maybe you'll correct me on the timeline. But then, in short order, started making a splash in the field. So why don't we start with the timeline of Pinnacle. And the the opening or need that you all saw in the marketplace to to state your own existence?

Andrew Mintz  03:05

Sure. So we actually started in December of 2019, with the acquisition of Santa Monica, fertility out in California, and then you know, COVID, hit kind of right away, and there wasn't a lot done for the year 2020. But come 2021 We started to reengage in the market. And we closed six practices in 2021. In the second half of 2021. We didn't actually create our name of Pinnacle fertility until like October, which is why no one's ever heard of Pinnacle before. But we brought on first RGA of Ohio, which is out of Akron and Westerville. And brought on a Dominion fertility and Virginia ihr. In Chicago. We brought on advanced Fertility Centers in Arizona, California fertility partners in in California, and ORM in Portland, so a really good group. And I think, you know, there were a couple of things that we saw as an opportunity to partner with groups, and that was that I had this conversation with Richard Morris, who runs our medical director Council, which I'll tell you about in a minute. But years ago, the way the fertility industry used to work is that doctors were very collaborative with each other not competitive. So they would go to their meetings, and they'd really start sharing all kinds of information about what they did in the lab, what their clinical protocols were, what they were seeing in terms of outcomes, how they're trying to improve outcomes. It was a very collaborative approach. I think that over time, as more clinics were created, especially as those that were created in the same markets, it became more competitive and The willingness to share the secret sauce started to whittle away. And so I think we had lots of people who were doing their own thing, and seeing what their outcomes were and, you know, comparing themselves against national benchmarks, as they saw in SART or the CDC database, we really wanted to bring back the concept of doctors working together, sharing what they're doing in the lab, reducing the variation in care, and to really improve the outcome. And we saw that as an opportunity that we didn't see happening in this marketplace as much as it could have.

Griffin Jones  05:42

Well, what do you feel that you can do to facilitate that happening that many of the existing networks aren't or can't?

Andrew Mintz  05:50

Yeah, so I mean, we've done a several things. So one, we started a couple of councils, which have real teeth behind them. So we have a medical director, Council and a lab director Council. And those councils have a representative from each one of our clinics. And more as we brought in this year, we brought on another few practices this year. And what we do is we talk about in the lab, for example, we talk about making sure embryologist are using same techniques and protocols, the media that we're using in the lab are the same, that the equipment that we're using are the same. And really just starting to compare the outcomes and talking about what people are doing. So we actually have lab directors that are going from one lab to the other, to look at what others are doing and then sharing that in in a forum under which they're making decisions about how to reduce that variation and improve the outcome. And I don't know that we see that in a lot of other clinics, I think there's a lot of talk about it. But we've done a lot of that and, and the other piece that we've had to do is come out of the lab director councils, the fact that as we continue to expand, some of the problems that we're facing in the lab have to do with just what you can fit through the lab from a volume perspective. And there just aren't enough embryologist. And so our lab director console, for example, started our own embryology school. We're looking now at a certification for the students in terms of how they become certified which doesn't really exist outside of ASHRAE. And really trying to get a lot more embryologist out into the marketplace. So we can they started the school, we do it in two places. One in Arizona, one in Ohio. We have four students at any one time, we get them trained in about 100 days. And we can train about 30 embryologists a year. And so we're really dedicated to one being able to have more embryologists available for the industry, and also specifically about making sure that we are teaching them the kinds of processes that we think lead to the best outcomes, and to ensure that in fact, we see that across our network.

Griffin Jones  08:18

Are you doing the same thing on the clinic side with a council of medical directors or practice directors?

Andrew Mintz  08:26

We are so we do have a medical director console as well. They making decisions in terms of you know, what kinds of genetic testing are we doing? Where do we send it? Who do we do it on? What kind of Mosaic embryos are we going to transfer? Which ones are we not? They're looking at safety protocols. They're looking at recruitment and retention issues. So there's a whole set of initiatives that our medical directors looking at as well, including clinical stimulation. So, you know, what are we doing to, you know, really reduce that variation, make sure that, in fact, we're doing the right thing for the patients and being able to maximize the, you know, their outcomes. And so there's a lot of sort of deep dive data that we pull and start sharing and discussing in those consults about the ways under which we're going to be practicing medicine within within pinnacle.

Griffin Jones  09:25

Is each practice represented by one medical director in the council?

Andrew Mintz  09:31

Yes. So we have one medical director regardless of size, so we brought on Seattle reproductive medicine just a few weeks ago. They have 14 rei physicians, but they only have one representative on the council, and then we've got Dominion fertility, which only has two physicians. And so they have one representative as well. It's a little bit like the Senate having two representative from each state. But But yeah, I mean, because the reality is, is that regardless of whether they're just talking to one other doctor or 12, they really need to make sure that that information is brought forward. It's discussed locally, and they are able to provide feedback in terms of what those what those protocols are.

Griffin Jones  10:12

Do they offer an equal vote and how the protocol comes to be?

Andrew Mintz  10:16

Yeah, so I think it's more of, you know, I think it's more of a discussion. And they come to consensus as opposed to voting things up or down. So you know, everyone recognizes that you can adopt a guideline that you think is going to be best for the organization, and then look at those outcomes. And if those outcomes aren't what you want, then you need to adapt your, your guidelines. So I'm not sure that we've actually taken a vote as much as there's been conversation and debate about the right thing to do. And, but everyone is dedicated to following the guidelines as they're created within the organization. So I don't think it's a majority rules type of, of atmosphere.

Griffin Jones  10:59

So that's my second question is, is how is the council governed, then, who makes the final decision who who releases the document, who drafts the document after, after the consensus is reached?

Andrew Mintz  11:16

Yeah, so we have the head of our medical director Council is Richard Mars, out of CFP. And he's the one that helps set the agenda. Um, he's collecting information from the clinics, and then coming up with recommendations to be discussed at the meetings. And so he is really kind of the driving force behind helping us prioritize what's important to the outcome, and the kinds of things that we're going to be addressing first, and how we're going to get there. So that's really how that's kind of organized, it's, it's a very, it's a free flowing set of conversation. So there's not a it's not a I wouldn't call it real formal, but they do come to decisions. And they do decide, you know which direction they want to go to. And we're just starting to scratch the surface. I mean, we're a new organizations, so they're addressing a handful of items, and they've got a handful or a long list of items that they really want to address going forward as well. You are

Griffin Jones  12:15

just scratching the surface, because now you've got a couple you your congratulations on that SRM acquisition, by the way, now you have a couple of dozen doctors across the, the the group thus far across the organization. Now, and, and, and people can come to consensus, but inevitably, people do not come to consensus every time in any organization. And we work with five Doctor clinics, and Dr. Nixon and I, I hear them not on the same page as each other. And very often, one doctor will be practicing a protocol in in office a and Dr. B is practicing a different protocol in office B. And and so when you inevitably run into, okay, there isn't a there isn't a complete consensus, maybe 70 or 80% are really on board and really feel strongly inevitably there's going to be a couple of people that feel strongly the other way. What do you do when you have established that protocol based on what the majority of the council sees it as best given the evidence? But there are a couple of people involved that don't want to practice that way.

Andrew Mintz  13:27

Yeah, so I mean, the first step is to create the protocol, the second step is to measure who's following it and who's not. And that's what we're in the process. So one of the things that we've also done is we've converted everybody to the same electronic record. So it makes it easier for us to be able to set things up within the system and for us to measure whether people are following the process as it's been decided. And so, you know, those are conversations, doctor to doctor, look, it's not a matter of whether they follow the protocol 100% of the time, there's no such thing as someone following the protocol 100% of the time, the issue is, are they documenting why they are not following the protocol, and there's going to be good reasons for it. So if there's a specific way under which we want to be stimulating a patient with a certain condition, and a doctor does not follow that protocol and does something else, if they're documenting why they're doing it, that allows us to be looking at that to understand how we need to expand our protocols to take care of different variables. So, again, being new, we have not yet I mean, we've created a handful of protocols and working on more. But really, these are long term studies for us to really determine whether in fact, they're giving us the outcomes we need, and who's following them. But we're really at the first step here of just making sure we create those protocols and and then we're going to start looking at who's following them and who's not and why.

Griffin Jones  14:50

And he talked about getting that measuring that as part of the EMR. You got everyone on the same EMR which is also not easy to do, which EMR did you choose? Did you make your own

Andrew Mintz  15:00

No, I mean, we don't start from scratch. So I mean, you know, there are, you know, everyone talks about using evidence based medicine. But the reality is that there's more than one protocol that's considered evidence based medicine. So I think there's not a lot of variation to begin with. And so I think

Griffin Jones  15:17

we're now referring to the protocol referring to the EMR that you chose your own proprietary, did you create your own proprietary EMR you chose another,

Andrew Mintz  15:26

we did not know, we, we moved to an assistant called Enable. And so we put everyone on enable, which we felt was has, right now the best capabilities to help us really connected with other technologies. So we've been really working hard on trying to use all the components of that system, to allow us to automate processes, and to really enhance the patient experience. So I've been talking a lot about, you know, creating and improving the clinical outcome. But the other piece of this is that we also really need to focus on the patient experience. And I think by having everyone on that same system and using technology to help us and the patient get through the process, I think that we're going to we're laser focused on that piece as well. So we need to make sure that patients are able to communicate to us effectively on time, we can be responsive to them, and there are the right people available to them. And the technologies are there to be able to interact with them appropriately get the information together and be able to present that to the patient, as well as recommendations and next steps. So we have not, at this point create our own electronic health record.

Griffin Jones  16:45

Well, let's talk about that shopping process. Because I think it'll be interesting to people. I'm not plugging one EMR over another. I am not I'm not qualified to do that we our clients use a number of them some of our clients use enable. But I think some people will be interested in to how you made that decision. I imagine there was a bit of a shopping or vetting process.

Andrew Mintz  17:06

Talk to us about that. Yeah, so we did that through all the IVF specific EHR systems out there. So we eliminated the ones that are more general electronic health records are used in the healthcare industry. And so there's a handful of ones in there. And we've actually done a review last year, and we recently did another one and just felt like it would meet our needs the best, especially in the way again, that it can integrate with technology, how some of the security issues that are, I think, available to it. And so really, we have a specific operational model that we have been employing in our practices. And we felt that this was just the best fit for that. And it's so far, it's, you know, it's worked for us because we're able to really collect the data. So at the end of the day, it's about how you use the electronic record system, as opposed to necessarily which ones you pick, this had features that we liked better that we think worked for us. And so that's how we made that decision. And that's what we're have moved are moving everyone onto that platform, what were those features that you liked? Oh, again, it was, you know, they have like two way texting with patients that gets embedded in the medical record and interfaces with the phone system, certainly in the way that it is built for the cloud. So it's not a server based system that was put in the cloud. It's a true cloud based system. So it has, we think some good security pieces in there. We felt that it was able to interface with vendors and and equipment more easily, giving us some good information, allowing us to bring it in and present it to the patient or want to, we'd like the patient portal, and the way that we could communicate to the patient. So there's just a bunch of things in there that sort of check the boxes for us. And, again, for the kind of operational model we use, I think that it just was a better fit. And so you know, the other ones have their I'm sure it have their advantages. We just felt like all the ability to use technology, all the think all of the capabilities that are built into the system that we are trying to take advantage of. We're just, you know, slightly ahead of, of where I think the other sports are there.

Griffin Jones  19:41

You mentioned wanting to improve the patient experience at a process level. What are some of the points in the process that you see is in need of fundamental repair?

Andrew Mintz  19:57

So there's there's a A fair amount, I think one is, you know, a number one has access. So, you know, being able to get patients in and get them through a IVF cycle that's efficient, that can make it efficient for the providers as well as the staff, I think is, is keep. So the biggest, I think hurdle in this industry for any practice is the fact that we still have a significant greater demand for services and supply of physicians and other providers to provide those services to them. And I believe that there is a room for innovation within practices that can allow for us to be able to service more patients in a very friendly way to get them through the system. And we can really sort of maximize the ability for patients to get in. So we still have clinics that have appointment, wait times that are three and four months out. It's too long, it's really unacceptable. And we need to solve that problem. So we think that the system will help us with automating processes and communicating to patients in a way that will make them more efficient. And so that's the first thing that I think needs to happen. The second thing is, is that I think we also need to meet the patients to where they are. So, you know, obviously, since COVID, you know, telemedicine has really caught on and it's here to stay. And I think patients like the convenience, I think a lot of them like the convenience, I think that they want to be communicated in a way other than a phone call, especially for the patients that we serve and the age group they're in. And so having the technologist that's allowed that we can text them to weigh that we can make sure that they're getting the information they need, we can embed the, the the videos that we have the educational materials that we have, and make sure they're getting through the process without someone having to call them and check in and we can sort of look at electronically will also help with that. So a lot of patients get lost through the process, they get lost at the beginning, because it's so overwhelming. And then they get lost through the process. And so to the extent that we can create processes, and have technologies that support getting these patients to understand what they're entering, and to help them get through the system efficiently, without being confused without being you know, without anyone falling through the cracks without missing something. Those are the things that I think are really key. And there's you know, story after story that I have seen where you know, patients, they get, you know, they get lost in this and they end up dropping out when they really need to continue through their IVF process or whatever fertility process. And

Griffin Jones  22:59

I have to say that I have to disclose that they're a sponsor before I ask the question, so it doesn't sound like a shameless plug, what are you using EngagedMD and all of your centers?

Andrew Mintz  23:10

Yeah. So I mean, we are rolling all these out and all of our practices. So they will all B have, they will have similar ways under which they are going to be processing patients. Obviously, there are differences from clinic to clinic, but we will be you know, we are continuing to roll out and refine our processes to make this efficient.

Griffin Jones  23:35

For those clients that are there, excuse me, those clinics that are three, four month out booking waitlist, and it's usually it's a couple physicians that are booking, it's often not the whole clinic unless it's a really small clinic in a really busy place. But for those that are booking out 12 plus weeks, is making that process more efficient include bringing some some of the testing that normally would happen after the first visit, and between the first visit and the follow up before the first visit.

Andrew Mintz  24:08

Yeah, so we are looking at the total process of care. And some of that is also, you know, some of the testing that we maybe can do in house to make that efficient as well. But we are looking at, you know, what's involved in a new patient visit what's involved in a follow up consult. And what information do they get between the first and the second and then before they start their cycle? What information do they get? And when do they get their medications and, and on and on. So we are looking at the whole process of care. We have mapped this out. And so we have a sort of a very specific philosophy about what should be happening at each step through the process. And the more consistent we can make that the better job we're going to do, of making sure that the patients aren't getting caught in the middle, you know, or Last,

Griffin Jones  25:00

can that also include some places the nurse does the follow up visit and the Ri does the initial visit, sometimes the REI does both. But some places the nurse does the first visit. And and so is that also part of this solution is a we? Well, maybe we used to do testing after the first visit. But now with this, with with booking this far out, that would mean that people can't get into the care system until that point. So we can we can do our testing before they come in for their visit we can we we can maybe have them meet with a nurse earlier so that that 12 week isn't isn't the first time they're seen. But it's the follow up with the RBI does does having either a nurse or an AP do the first visit is that in the playbook?

Andrew Mintz  25:50

Yeah. So I mean, we are invoking a type of license model. So we do not want physicians doing things that really only physicians can do we want advanced practice nurses to be able to do the things that they can do, we want RNs to do the things that they can do. And so we do have a general, a core set of services that we want each level to be to be doing. It depends on each mark, and, you know, each clinic. So in some clinics, we employ OB GYN who are doing some of that work as well. Some are have a really used nurse practitioners a lot others less so. But we do have a, a top a license philosophy. And so as we continue to integrate the practices, we will continue to be working on making sure that, you know, we're able to get doctors to do what doctors can do, which will help with the access issue. So if they're doing for example, you know, every single ultrasound, you know, that's not necessarily the most efficient use of physicians time.

Griffin Jones  26:57

I want to ask about the the inherent financing models of private equity, I'll let you know, Andrew, that I've been chewed out more than once by each side of being accused of being shill for private equity, that, you know, I'm in bed with these new private equity companies coming in and just using them to help buy clinics, which I'm not. And I've also been accused of being anti private equity and that, you know, I'm anti network and which I'm also not, I just I'm not qualified to evaluate the business models at that level, yet, I'm not strong enough in the finance piece of business in order to be able to say that maybe 510 plus years from now we'll be but right now, I'm very strong in the sales and marketing side. And I still feel like I have some pieces to shore up on that. And I and we are as a firm and so that's what I feel comfortable evaluating people on and I just ask people questions and I try to get them to respond to the counterpoints and, and so but I do hear a lot of the the model is inherently flawed, partly because of the debt that they have to service. And partly because I was stacked in favor of retiring doctors, and one of these folks that that mentioned, these boys is Dr. Ben White, he's a radiologist. And he's not in in Rei, but he writes about this a lot. And he says that the only doctors who can reliably benefit in private equity, are those senior partners close to retirement who can take their money and retire. So I'd like you to respond to that point.

Andrew Mintz  28:36

Yeah, I mean, to toe the truth grip, and I think it depends on who the private equity sponsor is, and what they are, you know, what are they trying to achieve? And what are they allowing the company to do? And so, so on one hand, I think there's two pieces to this one is, you know, and we see the stories is private equity, you know, destroying healthcare. And I can say that, in my experience working with Webster, which is the private equity, that company that controls, Pinnacle, is that they are very supportive of the strategies that that have been created. And that have been, you know, rolled out to the practices. And so we find a very, we have a board that is really pushing towards the successes of clinical outcomes, and patient experience, and caught and trying to find cost efficiencies for the patient. And I think that it creates a company that is sustainable strategy that's sustainable, that goes beyond who the private equity firm is. And so depending upon who it is, and I've worked with some that I think are very geared towards what's my return And I've quickly come to get it. And there are some that are really geared towards how can we build a great company? And what is it that we need to do to make that happen? I think we're gonna see more advances in healthcare is in fertility, particular, because of the investments being made. So I actually am very much in favor of allowing for investment in the industry, which I think it needs, when it comes to who does it benefit. I think it depends on how you define the benefit. But if you're talking about creating a company with with longevity, that is going to be competitive in the marketplace that has, you know, the latest technologies and equipment and provide the best outcome to the patient, I think that's a benefit to all physicians, whether they are near retirement age or not. And, in fact, those people who are younger will benefit from the investments that are being made now, that others may not in terms of the buyout that's going it goes out, you know, the buy up those towards the partners who own the clinic at the time. And so there is a one time, you know, financial gain to those positions. But I think if it's structured, right, you ensure that there, everyone's incentives are aligned. And that really, everyone's going to benefit from that. So we give, for example, we give equity to physicians that are, that did not own the practice, at the time of the sale, who have either we're either employed at the time or even employed after the transaction, we actually grant equity towards those associates. So they're tied into the whole value and, and the strategy, because the more successful the company, we want them to benefit from that as well. So

Griffin Jones  31:49

I think Woody in the private industry, me equity in the practice, or in the parent company, the parent company, for every associate or just for some associates that look like those are the ones that you want to stay on,

Andrew Mintz  32:02

for every Rei. So we give it to every REI has, is either been granted or is in the process of being granted equity in the parent company. And so they will own, you know, shares in the company, as does the private equity firm, as does the physicians who, you know, who bought who sold, you know, we're partnered with Pinnacle on that. So we find that an important aspect of tying everyone in. And for us, I think it helps with some of the some of the issues with turnover. So you know, the last thing that clinics can stand in this industry is to have physicians who are coming and going, it's disruptive, they're hard to find, access is already at a premium. So the better you can tie them into the success of the company, I think, the better chance you have of them staying and, and if you also create processes, and given technologies that make it easy for them to do their job, and they enjoy that and you create a culture of collaboration. And then they get to create a peer network of other physicians within pinnacle in this in this instance, I think it creates a winning strategy for doctors,

Griffin Jones  33:19

the investments that you talked about making it even if they all work, at the end of the day, it's about those investments are in service of getting our eyes to see more patients to be able to do more procedures. How much is there left to squeeze? Do you suppose before you're actually just squeezing?

Andrew Mintz  33:45

Yeah, it's not necessarily about the doctors working harder. Remember, we really want to move to a top a license model. So we really want them doing things that only physicians can do. So if they're working a 10 hour day, and, you know, they're doing, you know, consults for a few hours and and ultrasounds for another couple hours and then procedures for another couple of hours. The question is, what's the best use of their day? And how can that work? As opposed to how can we make you work harder, so that our support systems, more staff, more nurse practitioners, they may be able to assist and alleviate the work that are done by the doctors. And so the problem is still this imbalance between supply and demand. So the more that we can get people through the system, and the smarter we can work, the better we're going to be servicing the patient population.

Griffin Jones  34:41

I know a lot of doctors are seeing by 30 new patients a month it depends on how many partners they have and what kind of systems they have. But if we weren't to add hours into their week, and we were to do it with efficient processes, investment what What do you do? What do we suspect that that number is? Is it 50 new patients per month? Is it 60 new patients per month that we can, that we can get them to with pure efficiency and not hitting them with a, with a stick and dangling a carrot in front of their face?

Andrew Mintz  35:17

Yeah. First of all, I think that differs by doctor. So you know, they each process, you know, differently. I think we also need to be thinking about, you know, other ways to bring patients into the system. So, we talk about top of license, but the question is, can we train OBGYN is to do things that we aren't allowing OBGYN to generally do? Can we train nurse practitioners to do things like new patient intake, or to handle patients for cryopreservation, or for egg banking or some of those other things? So, again, I think we need to continue to innovate to make sure that people who want the service that they need can get it. But I'm not sure that that necessarily means that doctors have to see more patients in their day in order for us to significantly increase the ability for people to access and get through the process.

Griffin Jones  36:13

I want to shift gears for a second. Because I've had two different guests on with with different views on this. And I think it was back in episode 100. I had Mark Segal asked about he was asking about my opinion on what do I think about a network brand or partnership brand versus individual practice brands? And then I also had Gina bar tz on from kind body to talk about her brand, the global brand, that kind bodies building? In my opinion, Andrew is that I think that you all meaning that groups that have different brands from the parents organization and individual markets SRM in Seattle, or, or I'm in, in Portland. And I think that that I think that you all are at a disadvantage. It's like the IGA true value model where it's hard to scale brand to become a consumer brand. That is the pretty green lady from Starbucks that I think kind body has that advantage. Some people disagree with me, they think that it's better to have the local identity. Ultimately, I don't I don't think so in the in the longer run, I think you still have local reputation. Reputation is different from brand. But the whole point of brand is, is to be able to scale and identify. So you might think differently than I do. So I'd love to hear your side.

Andrew Mintz  37:44

Yeah, I mean, I think the branding strategy is to us not necessarily top of mind, in terms of some of the things that we're trying to accomplish. The reality is that these practices have local reputations, and the doctors themselves have local reputation. So there are some of our doctors who I think are known more so than for the name of the practice that they're in, let alone the national network that they're part of, I think that we will see over time that we'll be putting in some kind of tagline to our practices, such as, you know, a member of the pinnacle family, or something along those lines and create that, but I don't see the need for you know, the Starbucks of fertility, I just don't know that, that we need to create that kind of patient experience where they feel they can get the same thing when they go one to the other. If they're in Seattle, and they're going to go to LA and they want to go to Starbucks, they want they want to, they want to know that they're getting the same coffee made the same way. With the same process. I don't think that that's necessarily holds true in fertility, that what we do in Chicago, and what we do in Phoenix has to be exactly the same because we're not really servicing the same patient population, I think we will eliminate variations, but I'm not sure that that's going to be important to patients who are going to be accessing those services.

Griffin Jones  39:03

That's a good point from the repeat, you know, from the the repeat visitor, the repeat patient or in other fields, repeat customer side, it's not as necessary, which is part of what you want in a brand. You want people to just know what they're going to expect next, and they and they keep coming back. But in some areas like social media, especially, lots of people have lots of friends and they follow people in different markets. So to just being able to say I went to this place in New York, it was great. I went to this place in Chicago, and oh, there is one by me here in LA that that is useful. But also I think one thing that's just tremendously underused on the clinic side in our field is influencer marketing. We've seen the tip of it, but part of the reason why we haven't seen more is because up until very recently, there hasn't been somebody with one name that justifies a there a big price tag or a big Campaign for, you know these influencers to say, Yeah, we use x company.

Andrew Mintz  40:08

I just think that if we can provide the patient with the best possible outcome better than our competitors, and we can provide them with a good experience, I don't think that name is going to make a difference. And I think we're just going to stay focused on really those two aspects of the business and worry about the branding as time goes on. But at the end of the day, I'm on a much more sort of focused in on, how can we improve our outcomes? How can we improve our live birth rates? How can we make sure that patients are feeling like they were cared for through the process? And if that feels the same from clinic to clinic over time? That's great. If they're not called the same thing? I it, frankly, not that important to us.

Griffin Jones  40:51

You're doing something right, because you move very quickly, you said October of 2021 is I think, is when you decided on the pinnacle name, and it was in the second half of the 2021 that you closed on? Is it six practices. And and some of those are are ones that all of the other groups would have loved to have closed down. And so talk to us about your courtship process. Why was it successful in that short amount of time?

Andrew Mintz  41:22

I think that they buy into our strategy and our value. So our core values that we have around, you know, putting the patient first collaboration, integrity. These are I think, what speak to them. So we have

Griffin Jones  41:38

nobody says we put the patient last Andrew and nobody says we're a bunch of dishonest dirtbags that are gonna stab you later. So how were you able to actually demonstrate that?

Andrew Mintz  41:47

Yeah, I think that when we talk about not just that we have values, but that we live our values. So the creation of our lab director Council, and our medical director Council, for example, is a tangible thing that they can see that we're actually living our values. And so I think that's important when we go and have conversations with them about, we have these values, and this is how we live them. Here's our strategy, here's specifically how we are achieving these goals that we set up for themselves in terms of outcomes in terms of, you know, patient care, in terms of, you know, the patient experience in terms of all kinds of things. So we have some very specific goals for ourself. And, and we tell them specifically how we're going to get there, and what their and what their role is. And I think they get excited about it. Frankly, there's a there's more than one several practices that we had conversations that either we didn't think that they would fit well into our strategy in terms of them really participating it or they didn't like our strategy. And so from our perspective, that's okay, too. In that we think that we are partnering with those that are really dedicated to making that happen. And they have to take actions to make that happen. So the fact that they are participating on these committees, that they're adopting our protocols that they are, you know, we announced a partnership with genomics for our, our PGT testing, and everyone's now going to be sending to a genomic so that we can get consistency in terms of results. I mean, these are things that we are doing tangibly to make sure that we're getting the best outcomes. And I think that they see in the early days, they saw the vision and they bought into the vision. In the more recent days, they're seeing that we're actually executing on our strategy. And I think that speaking to who are partners in?

Griffin Jones  43:41

Yeah, so how did you how did you paint the vision? Because you, you did it before you even had a company name in many cases? So did you did you like bring a handful of people with you? Did you have Did you have some kind of storyboard? How did you you're successful in bringing some pretty big groups in before you even had like a cohesive exterior identity. So how did you How were you able to articulate the vision without that,

Andrew Mintz  44:12

so we set our we set a strategy and our strategy has some very specific goals. And so we were able to bring that out with us in terms of what we were going to do and how we were going to get there. Some of it is definitely leap of faith. So they looked at this and maybe they just saw something different than what others were doing. I can't speak to what the other networks are doing or what their strategies are other than what they share on your podcast or or on LinkedIn or something else. But I think that they really liked the concept and you know, selling the, you know, the whole collaboration piece you're going to work with other clinics are going to have peers, you're going to be sharing information and you're going to be making changes and making improvements and those be Pull to recognize that, in fact, that needs to happen. Even though some of our clinics have some of the best outcomes, I think in the country, the reality is that they all know that they can do better. And so the those that are more entrepreneurial, and spirit, those that are really understanding that, you know, change is not going to be avoided, that they have to embrace it. I think those are the ones that are really sort of gravitated to our strategy and our and our values, our mission, in terms of, you know, the thing that the steps that we're going to do to take to make some change now, you know, some of that is also, you know, comes with changes in process and changes and in partnerships and those kinds of things. And everyone recognizes that all that has to be reevaluated. So I think the clinics that we've been able to partner with have that same mindset, and those that have decided that we're not the best partner, maybe just have a different view or, or buying into, you know, the, you know, the mission of, you know, a competing platform, which is fine, too, there's plenty of that to go.

Griffin Jones  46:14

So you mentioned sometimes that it isn't a good fit, either. They don't think you're good for you don't think they're a good fit, what are some of the things that that tell you fairly early on or not even early on, at some point in the process, that it's not going to be a good fit.

Andrew Mintz  46:31

So two things are real red flags for us. One is, when they're only discussing money, then we know what the motivation is. And I'm not saying that money is not an important part of the conversation, but when they're fixated on the money and only the money, then then we know that they're really in it for the money. And that's not really the partner that we're looking for. The second thing is that we have a specific business model, you know, we when we ask them to roll equity, they roll it into the parent, not into the local. And so when they start when they start having conversations with you about changing the way and your philosophy about how you're approaching your partnership, then we recognize that maybe that's not there, too. And then, you know, we also do our own reviews of that as well. So, you know, we are looking at operations in the lab before we, you know, before we sign, you know, our definitive agreements, and we really need to make sure that, you know, they have a basis that we can build from, and not all clinics that we saw necessarily.

Griffin Jones  47:43

So they're getting equity in the new so part of you taking equity in their group is that they are doing that in exchange for equity, some partly, your cash is involved, too, but equity in the in the parent company, is that what you're

Andrew Mintz  47:59

talking about? Correct? That's correct.

Griffin Jones  48:03

What's the advantage of doing it that way?

Andrew Mintz  48:06

I think, you know, it allows them to buy into the full strategy of the organization. So if we are going to be building their own egg bank, for example, then they're going to be interested in figuring out how to make that as good as possible. And for them to be participating in the building and the use of an egg bank, as opposed to well, that's a separate financial, it doesn't really hit me. And therefore I'm sort of less invested in the outcome of how some of these, you know ventures are doing. So from our perspective, we like them to be supporting the strategy as a whole and them to be, again, part of that collaboration is that for all on the same page, so if it's good for, you know, if it's good for the organization, it's good for them, as well, as opposed to maybe advantage, one group over another for whatever reason. And, you know, we certainly don't want there to be competition within the organization, regarding who's getting more profits, we really want that ball to come into pinnacle. And for them to be incentivized to the pinnacle level.

Griffin Jones  49:19

I can see the upside of that. And sometimes there's a downside if people don't buy into the parent organization, and then it's just, it's just flipping the current. It's just flipping that the current practice, it's like, well, how much efficiency was really added and how much did we miss out on by not being a part of the network? So I can see the advantage of that does that put them at more of a risk for an Integra mat situation if my equity is here in this parent company now and then this parent company just took? Yeah, just bit the dust and, and now I don't have anything over there.

Andrew Mintz  49:53

Well, I think there's a lot of learnings from Integra med that I think everyone has taken with them Whether they were part of that network or not work, I mean, I think that because we have so many physicians involved at so many levels in the organization. So it's not just the medical director and the lab director concept, but we got someone who, you know, one of our physicians acts as a part time cmo for us. One of our physicians is leading a, our, our efforts on research and clinical trials, we have a physician who's leading our efforts on international marketing and other kinds of activities that sort of get them engaged and how it's going to work for the network as a whole, the more they participate in that, the more excited they are for it, and the more they're sort of willing to, to make it work. You know, I can see on the downside, which is, you know, what I do individually doesn't have as big of an impact to the whole organization as if it was just my clinic, but really don't have people thinking that way, at this time, at least. And so for us, it's been nothing but exciting to see the growth and the engagement that we're getting from our physicians and our practices to help Pinnacle be successful. And, and there were, they're starting to refer themselves as Pinnacle clinics, you know, over the name of their local brand. And, and, you know, internally, I mean, we don't clinical is not a patient facing brand, but it certainly is speaking to them in terms of what we're trying to do. So we're just loving the engagement that we're getting. And we're finding new ways to engage more and more physicians in the process.

Griffin Jones  51:45

For the audience that doesn't know Al Ries and Jack trout were two of the the like marketing thinkers of probably 80s, early 90s. I think Donny Deutsch, David Ogilvy, nowadays, Gary Vaynerchuk, they have that many books, they have a book called The 22 Immutable Laws of marketing, which I don't think is as relevant, I don't, I don't think they're I no longer think they're immutable, or at least many of them. I think some of them are mutable, but one of the rules that they have is the law of the category. And, and in that if you can't be the leader of a category, you create a new category of think of, well, you know, I'm not going to be the top personal injury attorney in my marketplace, but I can be the top personal injury attorney maybe for workplace accidents, and I'm going to own that category. And so, as long as we're speaking of just IVF centers, Fertility Centers is one category that hasn't fragmented in that way. Another one of their laws is that every in the end, every category becomes a two horse race. There's no RC Cola anymore. It's Coke and Pepsi. And, and I think there's, I don't know that that's true in every category. But do is that what we're going to see in the fertility field, is it so we've got pinnacle, we've got inception, Prelude we have. We've got us fertility, we've got the fertility partners, we've got IV somebody's gonna be really pissed at me for forgetting, you know, first facility, Boston, IVF, you know, somebody's gonna be mad at me. I'm going to forget somebody. But we have, you know, 678 network groups now. And is it inevitable that there's two of them and a number of years?

Andrew Mintz  53:33

Yeah, I mean, I think we'll see that we saw that with EDR. Ma. Right. So that was there an international play, and more so than, than local, but I would think that over time. The network's you know, there's only there's only 450 Some clinics in the United States. And, you know, some of them just are, you know, maybe investable. And so I think at some time, there will be conversations, if they're not already happening among the platforms to be combining their efforts into, you know, a single play, it would really, really have to show the advantages to making that happen. And I think that there, there is an could be. And so I would expect over the next few years, we may see that we may see platforms starting to come together. So if that's

Griffin Jones  54:25

the case, then it seems to me like some platforms would be incentivized to get gobbled up rather quickly. They they acquire a number of clinics, all of a sudden they are a company with a healthy balance sheets, they can get a multiple of the multiple that they purchased on which returns what their obligation to their limited partners. And so I could see some companies that may be where they were in business as a network partnership for a year or two. Become acquired by another one and And if that's the case, our practice owners not missing out on something because it's like, well, should, I should I could have just tried to build that multiple, that we ended up selling for more by myself.

Andrew Mintz  55:18

Welcoming, hindsight. 2020 So the reality is though, the woulda, coulda conversations I'm sure people have with themselves all the time, I think that we are going to see that. I think that in this industry, what we're going to find is that strategy, and and I think culture are going to win out. You know, we're, we're working in a very niche healthcare environment, right. And so certain, there are certain things that we don't see in fertility that you see in many other areas like, like burnout. Burnout is not nearly as prevalent in fertility as it is, let's say, an OB GYN. And so I think that we're going to find that people will continue to engage and stay engaged. And I think that these as these platforms come together, you'll find that you'll find a lot of interest from the partners to make it that much more successful. So if they have rolled equity or granted equity, I think that they will continue to want to have a stake in the game, and make sure that the kinds of collaboration and strategic initiatives that need to happen will happen. And I think we're going to continue to see that, at least in my lifetime.

Griffin Jones  56:46

I've, I've grilled Jaya, and you've been a great sport and and showed people what what they can consider with Pinnacle the our audiences, almost all practice owners, fertility execs, peers of yours, how would you want to younger Doc's? How would you want to conclude with them? Andrew?

Andrew Mintz  57:06

Well, I think what we really want is we want physicians to step up. So we are plagued infertility with a whole set of physicians that are called in or close to retirement. And what we need is we need future leaders. And I think the time is better now than ever. And so being able to go into a platform, such as pinnacle, or any of the others that you mentioned, and and be able to create opportunity for themselves in terms of leadership is never been stronger. And so I would really encourage physicians who are already in or about to enter the rd by field to really think about how to make it better. What can they do that their predecessors haven't? Haven't done? What kinds of ways can they take advantage of new technologies and investment that can take it to a whole different level, and I'm eager to see what some of these new strategies and some of these new adopters are going to come forward with and, and then see what happens. So I'm excited for the future and I can't wait for you know, seeing what's next, what new competitor comes in and what our existing competitors are doing to raise the bar.

Griffin Jones  58:33

We will link to Pentacles website in the show notes and as well to your LinkedIn profile for those that want to get in touch with you. Andrew Mintz, CEO of Pinnacle fertility, thank you very much for coming on inside reproductive health.

Andrew Mintz  58:48

Thank you, Griffin. Appreciate it.

58:50

You've been listening to the inside reproductive health podcast with Griffin Jones. If you're ready to take action to make sure that your practice thrives beyond the revolutionary changes that are happening in our field and in society. Visit fertility bridge.com To begin the first piece of the fertility marketing system, the goal and competitive diagnostic. Thank you for listening to inside reproductive health

151 3 REI Fellows Walk Into A Podcast…

What They Really Want Out of Their Future Permanent Position

This week on Inside Reproductive Health, Griffin Jones hashes out the goals, aspirations, and challenges of three prominent REI Fellows in their search for the right permanent placement.  Dr. Megan Sax, Dr. Victoria Jiang, and Dr. Zoran Pavlovic share their experiences on recruitment, what factors weigh in on their decisions on job selection, and how much they’re willing to put at stake for their professional (and personal) success. 

Tune in to hear:

  • What they are looking for in a partnership and/or position.

  • How factors such as location and politics have a huge impact on the appeal of job offers.

  • Griffin press all three and question how much accountability they are willing to take on in exchange for the autonomy they crave.

  • What you might say to a recruit to catch their interest.

Dr. Megan Sax Information:

Dr. Sax is a 2nd-year REI fellow at the University of Cincinnati. She has engaged in leadership roles as a women’s health advocate and medical educator. She previously served as the ACOG Junior Fellow Chair of Ohio and currently sits on the CREOG Council as the Junior Fellow liaison to ACOG. She has received recognition for exceptional teaching and humanism and intends to continue a career in medical education after her fellowship.

Twitter: @saxmeg8 



Dr. Zoran Pavlovic Information:

Dr. Zoran Pavlovic: Zoran Pavlovic is a second-year fellow at the University of South Florida Morsani College of Medicine and splits his fellowship training time between Shady Grove Fertility and Tampa General Hospital. His areas of interest include reproductive surgery, fertility preservation, third-party gestation, genetics, and IVF. Zoran loves meeting and conversing with great minds, innovators, and creators within the field of REI and is excited about the future of fertility care. He hopes to one day be an active contributor in the field of REI and a mentor to the next generation of physicians.

LinkedIn: https://www.linkedin.com/in/zoranpavlovic27/

Dr. Victoria Jiang Information:

Victoria S. Jiang, MD is an REI fellow at Massachusetts General Hospital. She is board eligible in Obstetrics and Gynecology and is currently completing her second year of fellowship in Reproductive Endocrinology and Infertility. She graduated from Emory University with a double major in Chemistry and Biology, with a focus in Organic Chemistry. She received her MD from Wake Forest School of Medicine in 2017 and completed her residency in OB/GYN at Emory University School of Medicine. She has received numerous awards for her teaching, research, and wellness efforts. Her interests include the integration of AI in medicine, genetic testing, and the ethical expansion of PGT, and PCOS.

Instagram handle: @vsjiangmd 



Transcript

Dr. Victoria Jiang  00:04

For people who want to have a seat at the table and make those decisions, I think for me that's at least where I'm seeing myself now. I want to be able to sit at that table and have a little bit more of a say in how these practices are developed. Because I think the biggest frustrations that I see in kind of these big, you know, corporates, like scenarios is that loss of autonomy

Griffin Jones  00:28

already everybody's trying to learn, you're probably trying to hire them. Everybody wants to get an associate doc or someone out of fellowship, and they're in short supply. So I talked to three of them today, and they're already in conversations with potential employers there. They've just started their second year. They come from different parts of the country. I'm gonna let them introduce themselves in terms of where they've studied. It's Dr. Victoria Jiang, Dr. Zoran Pavlovic, and Dr. Megan Sax. And we talk about how important being active as a fellow is and how important being active as a recruiting physician is, in order to tap into this person. We talked about how important partnership is to them or not, as long as we talk about how important academics are to them, or not as much as political advocacy, the things that they're paying attention to, when they are interested in partnership, I pressed them about okay, what are you expect you to put forth? What are you expecting to be accountable for in order to have that level of autonomy, and that level of share of the product, the company in the practice? So this is not meant to be confused with data. These are anecdotes, but I'm introducing you to three sharp fellows who are active who are plugged in. And knowing people like this helps you get in touch with more folks like them and knowing what they're paying attention to can give you a recruiting advantage. So hope you take advantage of that. And I hope you enjoy this conversation with three Rei fellows about what they want out of the practice that they ended up joining and what they want out of their careers in terms of partnering with other companies in the facility. To talk doctors Sax, Pavlovic, Jiang welcome all of you to the inside reproductive health show. Meg Zoran Victoria, it's good to have you. Thanks for having me. Great. So I did I just mess up your last name even though you told me right before we started recording is it Pavlovic?

Dr. Zoran Pavlovic  02:47

No of Pavlovich. Close you know

Griffin Jones  02:51

that that's a tough that's starting to make a little bit of a name for yourself, which is interesting. Meg was just mentioned in a podcast that I recorded earlier today. I'm on the board for the Association of reproductive managers a subgroup with in ASRM and there was some sort of programming that we're talking about for younger Doctor fellows. And the three of you were mentioned because of the role that you had at ASRM. So. But no, I mean, Rei fellows are coveted. And I don't like to do man on the street interviews meaning like I don't like to have anecdotes be representative of population, I don't have a ton of data necessarily, but it is kind of useful to at least it's at least somewhat, if taken with a grain of salt to go through some of your experiences and maybe your aspirations and what you want to accomplish because people want to recruit you, not just the three of you, but the 100 and however many 120 or so 130 140 fellows that are out there, and and that all listen to this show religiously. So we're going to do that. So each of you just want to give a little bit of background of where you are, what year you are, what were your fellowship and let's just start with that.

Dr. Victoria Jiang  04:33

Sure I can. I can go ahead. My name is Victoria Jiang. I am originally from Atlanta, Georgia. I went to Emory undergrad and majored in chemistry and biology with a focus on organic bio organic chemistry. Then I went to Wake Forest for medical school and marine for residency and now I am a second year Fellow at Massachusetts General Hospital.

Dr. Megan Sax  04:58

Meg Sounds good and happy to be here. Thanks for having us again Griffin classic 2024 coming around the bend. My name is Meg sacks. I grew up in Michigan, huge Michigan Wolverine fan went there for undergrad and yet somehow married a Buckeye against all of my family's wishes. That's gross. It is gross. Let me tell you. I studied neuroscience and then went to rush Medical College in Chicago for med school and then match at University of Cincinnati for OB GYN residency where I stayed on as an REI fellow and I'm currently a second year. I'm very interested in patient advocacy, Uncle fertility and education. I work both via different initiatives that ACOG and Korea ag and I'm hoping to continue a career in medical education.

Dr. Victoria Jiang  05:51

Yeah, Meg is our advocacy queen.

Dr. Megan Sax  05:54

You gotta be when you live in Ohio. Gotta be oh, we're

Griffin Jones  05:57

gonna have to talk about some of that. Then what about us on?

Dr. Zoran Pavlovic  06:01

Yeah, happy to be here, Griffin. Thanks for having me on the show as well. My name is Zoran Pavlovich. I'm a second year fellow at the University of South Florida in Tampa, where I split my training between surgery at Tampa General and also Shady Grove fertility for the IVF part. I'm originally from Chicago, and I went to residency in Chicago. And then college was at Creighton in Omaha, Nebraska. So kind of been a little bit of everywhere. And I came back here to Florida because I also did my medical school here at UCF. So you see up to USF enjoying the weather, and it's it's, you know, 90 degrees and super hot right now, but I'm glad to be here. And our focuses are down. Oh, sorry. Go ahead.

Griffin Jones  06:41

You all just started second year.

Dr. Zoran Pavlovic  06:43

I'll just start a second year.

Griffin Jones  06:46

Have any of you looked at employment agreements yet? Have any of you been in conversations with people about you know, I should say later conversations with people about where you're going to end up after fellowship?

Dr. Victoria Jiang  07:02

Well, I will say, Oh, go ahead.

Dr. Zoran Pavlovic  07:04

You go ahead. We go first.

Dr. Victoria Jiang  07:06

Oh, well, I guess I will say, you know, I think one thing that's been really terrifying is that the employment kind of timeline has very much moved so early in our fellowship. So as you're trying to grasp, like, how do I be a human? How do I be a physician? How do I be an REI, you're suddenly faced with finding this would be my first job since I was literally a waitress in high school. And so there's definitely been a bunch of really great like, podcast people to be able to lean on. I actually came back from an interview yesterday. And so this was definitely the first very early foray into the employment kind of piece. But it's exciting that the idea of gainful employment that our future.

Griffin Jones  07:44

Yeah. Yeah, like, Do you know any medical students? Let's interview them, because it's starting early. And earlier. Sorry, I interrupted us.

Dr. Zoran Pavlovic  07:55

Oh, no probs can see I agree with Victoria. And that I think I started having my first conversations back in the SRA retreat in Park City, which was November of my first year, just a few months in still trying to figure out my research project and already talking about places for to visit them to interview to send emails and have zooms and that's it started way earlier. So as Victoria said, when you're a resident, you're just thinking about how to be a doctor. Now, as a fellow, you're already thinking about, Oh, what's my career gonna look like? What job do I want? What environment do I want to be in? And that's definitely different. And I think, something tough to tackle for everyone.

Griffin Jones  08:30

What about you, Meg? Are you having these conversations yet? Or?

Dr. Megan Sax  08:33

Yeah, it's just wild. We had heard last fall at Esrei that they're going to start come in and you know, prepare yourselves, get in mind what kind of practice you're interested in what location and other kind of aspects of that. And I think historically, it was really the ASRM conference that people had their first interviews. And now that timeline has really scooched up. So we're having places reach out to us as soon as at the end of the first year, just like Soren and Victoria had said, and I'll be honest, these two have been my gurus in terms of what I'm looking for, and practices and things like that, and even what questions to ask from these employers.

Griffin Jones  09:17

I don't think that was the case a couple years ago, I think it was like, you know, you get towards the end of your third year and you start talking about it or that was before every last place was looking for an REI. I'm not saying that every practice is hiring for an REI, but I don't think any of them are not not hiring at the very least they're like, Yeah, we would hire somebody if, if if it was the right fit at the least. And then of course, many are really actively searching. So at this point, until we see a major reversal in supply and demand, at least which isn't on the immediate horizon. I think that at this point, first year, like once you're in fellowship, you're going to be an RA I therefore you are fair game for recruitment. It's like we might as well just try to beat everybody. Because if it's like college football, right, like it used to be, yeah, you just sign the people after they had a stellar senior year, then then the big sec, schools are recruiting for the most competitive players, and they start signing up, and then their junior year, and then sophomore year, etc. So, same thing has happened here. So I want to I want to go into some of these questions that you have, which by the way, when I have podcast, guests, I asked them for three to five questions ahead. And I would say, at least a quarter of them, give me nothing ahead of time. And by producers, bugging them for quiet, you guys gave me 30 questions. So we're not gonna get to all of your 30 classes a day. But I love that that that continuing education mind frame that three of you are still in, you're very welcome, way more prepared than the vast majority of podcast guests ever do. So let's talk about what are some of the key elements in your job search. And I'd want to just start with, like, I want to do a little bit of I mean, you can go into detail if you want to, but I want to do a little bit of a lightning round. Let's start with location. And Victoria, let's start with you. Do you have a location or a number of locations that you would like to be in? Yeah,

Dr. Victoria Jiang  11:24

great question. I originally was trying to go back down to the southeast because that's where my family was. And that's where I'm interested. Interestingly enough, with the dogs were stocks in rolling that has really put a wrench kind of in that big planning picture. My husband's a dermatologist, so we're looking at big cities with reproductive rights.

Griffin Jones  11:41

So you're now more flexible than you were? Is that what you're?

Dr. Victoria Jiang  11:46

Yeah, definitely more flexible than we were, I think there are gonna be big limitations as far as certain geographical regions, as far as just density of population need for an REI in that case, and, you know, competition and whatever those pieces are. But yeah, big kind of big cities kind of all around the US are kind of looking very broadly, and kind of seeing where we land.

Griffin Jones  12:09

So how, like, is it still? Is it a shortlist of cities that are on there? Or are you in on a scale of, of one being we're going to this exact city 10 being where we're open to Fairbanks, Alaska, we're open to anywhere? Where are you?

Dr. Victoria Jiang  12:26

You know, I have Fairbanks, Alaska is great for freezing eggs. Constantly. I would say on a scale of one to 10 we have definitely our top five favorite picks. And I'm definitely looking in those kind of top five cities. So like looking at places that have opportunities like the space for potentially my husband's a dermatologist, so he wants to open up a hair practice. So if you guys need any hair advice, I got the man for you.

Griffin Jones  12:52

Those all like top 20 cities, are they all more or less coastal? Like Are we more or less talking about? Is Boston New York's or Chicago LA? Like? Is that what we're talking about?

Dr. Victoria Jiang  13:03

Yeah, so I think we're looking at, you know, big cities. And so we had looked at like, you know, Nashville, Tennessee, we were looking at Northern Virginia, we're looking at, you know, Denver, Colorado, parts of Montana, and like, kind of that Montana, Wyoming area. And so a slightly, you know, second, like, we're not like top 10 biggest cities, but maybe areas that have a need that we can fill that kind of give us a nice, kind of I think one thing that's actually really interesting that we've been thinking about more than like the, the go getter academic, like you have to go from place to place to place is really starting to value quality of life, and seeing where we can raise a family. And so kind of see where that kind of falls into that has been a really interesting transition of goals for me, which I think isn't the most natural thing for really anybody in medicine, because that's not what we're used to.

Griffin Jones  13:49

No, I want to see more of that. Let's ask the go getter, academic mag, where do you want to end up location for Yeah, well,

Dr. Megan Sax  13:55

I love what Victoria is saying about transition into this new mentality. You know, our whole career thus far has been get into the next program match into the specialty match into the sub specialty, with a little less freedom of selecting your location or ideal city. For me, I'm also kind of that Doctor, Doctor couple, my husband's Arad ONC. So we'd be centering more along the bigger cities where we have opportunities for both of us. We are definitely born and raised Midwesterners, but just like Victoria said, you definitely need to consider this political climate change. But I will say you can be surprised by the institution you join by the kind of coalition network you can form again, I I love a cog staying involved in advocacy, you form your network and you you fight and stick it to the man the best that you can, but you also need to look at the long term and your future. So I would say for us, I'm very interested at staying at a academic institution or a practice that works closely with residents and fellows which can restrict the field a little better where you're applying to but I'm very open minded in terms of cities across the Midwest cities where we have family We're also very interested in Denver with most of my my big brothers are all moving out that way. So kind of keeping that eye on family where you're going to have that network where there's some academic opportunities.

Griffin Jones  15:23

Would you also do the Wyoming thing like Victoria is thinking about and have that focus on the quality of life? Are you looking for a big city partly because your spouse is also a specialist and you have to Yeah, you have to needs to fill

Dr. Megan Sax  15:38

right Victoria is way cooler than than I am I'm not sure I would do as well in Wyoming if

Griffin Jones  15:44

you want to be in a major city you want to be a bit more city

Dr. Megan Sax  15:47

I think having lived in places to me Ann Arbor, you know, the Midwest is a city so I think something like Ann Arbor, Chicago, Cincinnati, Denver would be more like ours. You

Griffin Jones  15:58

want you want to stay generally in the Midwest, though. Yeah. Are you like what about New York? What about LA? What?

Dr. Megan Sax  16:05

Yeah, that's a great question. I think with the right practice, if you find a good fit, that I'd be open opened anywhere I need to need to kind of keep the whole family in mind though, for sure.

Griffin Jones  16:15

What about us on?

Dr. Zoran Pavlovic  16:17

Like, yes, I'm also in a doctor, Doctor relationships. There's all three of us here. Well, my wife my wife's maternal fetal medicine fellow, second year Fellow at University of Cincinnati. So you know, her making friends, which is nice. For my situation is actually a little different. And that's because she or her father's private practice is in the Boca Raton Delray area. And so she's going to go join him after fellowship. And so I have to follow her, you know, we're going to stay together. So I got a winter follow her and down to Florida. And we're going to be in the southeast. So I'm looking basically between Jupiter to Miami, that south eastern seaboard of Florida. And so my practice locations were much more specific. I wasn't looking at different cities or even regions, but much more specific. And I think that's kind of one of the reasons why I may have started my job search earlier by asking questions, networking, asking some 30 year fellows if they knew anybody, or had any connections, because I knew where I wanted to go. So I didn't want to wait till the end of second year, beginning of third year where maybe the spots where I needed to go have to go, we're already filled up and taken by somebody else. So that's why I started my job search earlier. But I also was looking for not straight academics, but not small one to two person private practice, something in the middle, kind of private academic model, which REI has a great field for. We have a big enough practice, you can still do clinical research, or mentor residents and fellows, but not have to be part of an academic center or be too small to do anything like that.

Griffin Jones  17:48

This is also where the marketplace for REIs can be beneficial for someone like us. So you like Boca is not the biggest market, but you're kind of looking between Miami and Jupiter. And this is a time where a lot of those Miami groups, they'll be like, oh, yeah, yeah, yeah, we need a bulk office. We're just kind of sure, like you. And so that may not have been the case a few years back. But for the fellows listening, I think that, you know, like, a lot of Detroit people do have an office like or, you know, like might have offices elsewhere in Michigan and or like, so you want to be in Toledo, Ohio, you don't actually want to be in Detroit. Well talk to the Detroit people, talk to the Chicago people, even talk to the Cleveland people, like you want to be in you want to be in Bar Harbor, Maine, like, maybe there's not a big enough area for that, but talk to the people in Boston. And so that's something that I don't think was as feasible a couple years ago. I think that you'll have options talking to some of those groups. So how about so it's a May you straight up want to be in, in academics? How hard are we on that?

Dr. Megan Sax  19:05

Oh, yeah, no, that's a great question. I think just like Zoran said, that Rei is a really unique field and that these private practices still work with residents, do a lot of research, do data analysis within their own clinic and database. And honestly, some of the best data that we have in the field comes from those large private practices because they do so much more, so many more IVF cycles and other HRT. And so, again, I'm pretty open minded. I think as long as there are those opportunities to work with learners and continue research

Griffin Jones  19:44

are either a view or are either view really wanting to be in academics for Victorians are on or Do either of you really not want to be in academics?

Dr. Victoria Jiang  19:55

I will say one thing that really drew me to the field I sound like I'm about to interview for fellowship. Uh, I will say one thing that I do think is really unique about Rei, that is really special. It's kind of playing on what Baggins Warren was kind of saying, is that a lot of practices are still participating and have really robust research infrastructures. And I think being an academic for me means a lot of different things. It's not just working with learners. But it's also like staying up to date having Journal Club, like being able to stay involved with the most recent evidence that is being published and staying up to practice with X y&z And so I think for me, we're joining a kind of middle sized practice where I can get mentorship and making sure that I get like, you know, library access and have like a continual journal club or team review, like those kinds of academic pieces, I think, carry over to a lot of different types of private, domestic and private jobs. And I think that with a lot of the local hospital affiliations, you can a lot of the time still work within a private practice structure, and still have residents and fellows that you can mentor and kind of work with, which I think is really special. I know that one of my uncles, like my in law, is an REI in Chattanooga. And his practice partner is, for example, one of the MCS faculty at a local hospital and is able to work with all of the fellows in that capacity. Shout out to Tennessee reproductive medicine. And I think that's what's really great is because you can have a lot of opportunity, but not have to fit that like cookie cutter academics, because a lot of the challenges that I've seen with the academic programs is, is they're all being bought out by a lot of private equity firms. And so even if you join what is under the academic affiliation of you know, one program or another, you may not actually be buying into that true academic structure. And so I think finding the right program for me, is more important than really like whatever the definition of academic or private or private MX really is.

Griffin Jones  21:44

I think that's why you have answered that same questions. I want to talk about that point, Victoria, I think it's worth every fellow considering. This is, this is an actual data, this is just what I think it could be that the chance, whatever, of practicing ownership, you end up signing up for the chances of it actually being that ownership in three years time is less than 50%. Maybe it's 50%. Or no, it's fine. It's probably somewhere around there. And that's actually something to consider as you sign earlier and earlier, right? Because if you sign in at the end of your third year, then you can have a little bit more of a conversation with the ownership of what kind of direction you plan to go in. If you sign early on in the first year, a whole lot can happen in two years. And I've, I've I've seen this a bunch of times as far as like, and I'm going to join this practice right now can't wait to join this independent brand owned by Sierra. I'm gonna be an academic Sierra going to the Cleveland Clinic man, and they're owned by the Maven click. So zone, what about you? How hard or not hard? Are you wanting to be in the academic sphere?

Dr. Zoran Pavlovic  23:06

Pretty hard on not wanting to be at a straight University, academic situation more. So I think for me, I found that to be a little more, I guess the freedom of the clinical practice that I wanted to do in the private academic setting. I'm not a big person for grant writing, which I think there's a lot of that in academics. And I think there's people that do that and do it really well. And I'm really happy that they're in our field. And I respect them and love them a lot. But for me personally, that would be very difficult. And when I look at the clinical research that I would rather do you see all these biggest groups around the country, the CRMs, RMA, shady groves, US fertility is all that they have these huge clinical databases where you can have up to 100,000 patients and your sample sizes. And you can be really great robust clinical data. And like Megan said, you can drive the conversation, you can change practice patterns, you can help create committee opinions based off of that. And so that's why for me, I felt like I could find an impact within research and still be involved in that academic capacity without being an academic setting. And I personally also have more of an entrepreneurial business sites and one of my minors in college was was business. And so I do want to go to a place where there's that opportunity for either equity or partnership or growth or some kind of opportunity where I can help create and build something together with the practice that I'm at. And that would be hard to do at other other facilities in an academic centers would be more so moving up a professorship and becoming tenured. Whereas in a private practice, it's it's a kind of a different situation that just more so appeals to me. Well, I can still remain Tane some of that academic rigor.

Griffin Jones  24:44

So I'm just hearing that more from people in general, they still want a bit of the involvement with either research or teaching and this is probably something that some private practices need to figure out a lot of this a lot of the larger ones are already involved with at academic centers, but many of the smaller ones are not. So they have to figure out some way of scratching that itch, whether it's, you know, whether it's teaching the residents or whether it's sponsoring some type of research or going in and research with someone else or allowing time for their Doc's to submit an abstract answer. I think that that's something that private practices that aren't that don't have an academic relationship probably need to consider, because what the three of you just said, seems to be a recurring pattern from what I'm hearing from fellas. But now let's talk about partnership, which you started to talk about. so on. So I'll go back to you, which is on a scale of one to 10. How much do you want to be a partner meaning someone that owns a piece of the practice that they're working at?

Dr. Zoran Pavlovic  25:53

That's a tough question. I think it's anywhere from eight out of 10 to 10, out of 10. And the partnership can mean different things that can be either owning a piece of the practice and of the laboratory, or being able to bind to equity of the overall practice. So all of those options to me are appealing and things that I asked questions about and looked into. But some of the practices that have been talking to you to offer these more structured partnership tracks, and that have defined milestones of how you get there. And what that means. That appeals to me a lot, because then I know what I can do to work to get there. What that means when I get there, what does it mean to be a voting member of the facility to be able to help to drive the practice to improve the laboratory outcomes, and work with my colleagues and where we can actually be kind of a almost like a family unit in in making our practice as best as possible. Rather than either being a number in an Excel spreadsheet, or just like one person in a huge conglomerate, or even just in a one to two to three person practice where you make a partnership and that, but how much clinical decision making can an impactful decision making can you make when you're not involved as much in research or academics or mentoring others. So for me, it's an important I think the three things I would say, that I look for when I'm talking to all these practices are the culture, they really want to be surrounded by great people and great mentors that I can actually get along with and vibe with and feel like they're my friends and family, not just someone at work with the ability for opportunity for advancement, which is either partnership or equity or some kind of situation like that. And the ability to pursue some of the endeavors and passions that I have within the field of Rei. So I personally would like to have a day a week to do reproductive surgery, fibroids, endometriosis, laparoscopy robotics, and to be at a practice that will allow me to do that and schedule that into my clinic time instead of just making me do IVF all the time is really important to me as well. So those are kind of three categories that I look at when I talk to practices,

Griffin Jones  27:53

the millennial that wants it all right, well, let's, let's just talk about that, that that passion, and we're in regard to the criteria for advancement as you were talking about. So because what I see happening is a lot of associate Doc's getting to a point where they've been, it's almost always at the two year mark, it's somewhere around there, maybe a little bit shy, sometimes it goes up to three years, but it's almost always around a two year mark, where they feel like they can buy into the practice that they should be allowed to. And the partners don't see it that way. They don't think they're in a position to buy. And it's very often because it wasn't spelled out black and white, this is the volume we expect from you. This is the revenue we expect you to bring in. And or maybe here's some of the other business responsibilities that we expect you to take on. So I think it's a problem because people are hearing I can have my cake, I can do my reproductive surgery this time. And I want this partnership track and what they're telling me and that they're telling me I can buy into the partnership track, but that means that I do have to do as much IVF as possible. So let's talk about what first seconds are on of what like when they're giving you when when you're talking about a clear partnership track, like I they showing this is these are the volumes that you like these are this is the number of procedures that you'd have or the number, the amount of revenue that you would have to bring in. And is that commensurate with what you can do while still having a day for your passions.

Dr. Zoran Pavlovic  29:30

Yeah, some practices are more specific than others. And I think that that's something that every fellow if I have a bit of advice to give is to get really specific and what those details mean. And also have the contract lawyer review that with you and go over all those details. And don't be afraid to ask those questions. Because for some practices, they say it's a four year track mark, you meet the milestone of being board certified or board eligible and then board certified and that your volume is at least this much per year, you're reaching this productivity bonus. And then you become eligible to be considered for that partnership track. And then you can buy in for that. And this is what the buy in typically is, or this is what it was these past couple of years for our partners. And so they tell you this defined ways to do it and that I think I really appreciate so you can actually have a goal you can build a game plan in your mind going forward, as opposed to be more vague, saying, well, after the three to five year mark, we'll see where you're at or or or if the partners agreed, then yes, you can become eligible to maybe buy into something those the vague language I think is something that we should always look at and try to define as best as possible. Because the ones that are more structured I think are better for fellows and allows you to really kind of plan your time there. What

Griffin Jones  30:45

better for the practice so there's nothing to be gained from mutual mystification. It's why I sometimes think I'm a dick, my sales process because it's so specific, I create so much content about the sales process itself, and then the delivery process? Because it's like, no, no, like if we if I don't have partners, agreeing on what we're doing here and what it takes to do that. I'm not letting you engage in anything. I'm not letting you just create what my company does in your mind, and then still hold me accountable to that same result. I don't think the mutual mystification benefits everyone, that's what results in in the in the discrepancy, you can always still have discrepancy no matter how specific URL but the more specific you are, the less likely you are to have to enforce something later on or have to dispute something later on. Back. What about you for partnership one at a time?

Dr. Megan Sax  31:44

Yeah, that's a good question. For me, it's really more about the fit, I would say. And I love how Zoran kind of prioritized his 123 I think, honestly, it's so important to be transparent when on those interviews with that and vice versa, kind of turn the tables to what are you expecting out of me or out of a new hire? What role do you guys really need to be filled? And am I going to be the best fit for that because you both want this to be a relationship you might be moving across the country for and to make sure that this is going to be a long term sort of, you know, beautiful relationship here. So I would say for me having an opportunity to become a partner would be in more of a private Demick setting would be important and to have that outlined and have those goals set up. But I would say overall, you know, I'm kind of open to various models here, I can see. My note is not a deal breaker for you. Right, I think the most important thing is, you know that longevity, I want the security of having a job that I love. And if that means every day I go to work thinking you know, I get energy from teaching, I get energy from doing research, having colleagues who want to write papers, which Zorah and I know is so sick of fun. But I think being able to have that energy is the most important thing and really loving where you work. Having a partner opportunity, I think is only only a good thing and in the way that I view entering this process.

Griffin Jones  33:20

Fair. So you're, you're you're lower on the spectrum, then John, John is not going to work for anybody where he can end up owning a piece of it. And you're open to others, you're you're you're interested in it, but you're also weighing in other factors. Victoria, where do you fall on that spectrum?

Dr. Victoria Jiang  33:37

You know, I've thought about this a lot. And I would say I'm probably closer to where Zoran is like the seven to nine, eight to 10 kind of range. As far as partnership partnership means something that isn't just like, you know, buying into the company, it's like for me partnership is really more of like, do I have the autonomy to be able to do the things that I want to do? Can I contribute meaningfully to the way that this clinic is operated in practice? And can I be able to have a say in the really important decisions that are being made? And I think at the end of the day, I mean, you touched upon it like practices are being bought out so quickly, like the landscape of a lot of different areas are really changing very rapidly. And to be in a situation where you're an associate provider in like a scenario where you know, your value, you bring a lot of value to the clinic say it's reproductive surgery, and you're otherwise referring out all those cases, I think being really kind of straightforward about that and asking for it's going to be important, but I also don't want you know, the rug pulled from under me saying that like oh, by the way, surprise, you're we're actually getting bought out by XYZ company in the next six months. We're transitioning all of our leadership and we're all suddenly like an employee model. And I think that's what's really challenging for me is that you'll build a life you'll build a home, and you'll live somewhere for three to five years and if you don't have a clear plan of where that next step is going to mean for you. I think that's going to be really challenging for career longevity because I think a lot of the burnout that we see He is that, you know, KPI metrics, like you have to meet these certain, like UVF conversion criteria, and you have to do X amount retrievals a year, and it very much feels like the industrial IVF machine. And, you know, I think we, as physicians, should see that we bring a lot of value and being able to negotiate that earlier on, if that means less compensation, to be able to do the surgery that you want to do. If that means carving out like a stake in your contract to say, you know, I'm really interested in artificial intelligence. So I want to be able to have the opportunity to develop that kind of technology freely, and you know, thoughtfully, being able to negotiate that at the beginning is kind of like being able to have like a good practice partner is it's kind of like the philosophical idea, but then also like that whole legal idea. And I really just want to work with a group of people that understand where my mission is, we have a combined vision that we want to bring forward. And we want to be able to expand our influence in a more meaningful way. And I think that can be negotiated in a very unique manner, and whatever kind of job that you're going to be looking at,

Griffin Jones  36:04

might be worth examining autonomy and flexibility. Because they're not totally the same thing. Some of the things that you mentioned seemed to me like it would be more advantageous as an associate employee, like if, if, if I don't want to be a production machine, I feel like okay, this is what I'm willing to, like, this is what I'm willing to work, this is the scope that I also want to be able to do those things. And in, sign me up for that salary. Whereas if it's like, if you're, if you want to be a partner, somewhere, you're gonna be a production machine for a little bit. It's like it's better if it's something worth buying into. There's a reason why that is.

Dr. Victoria Jiang  36:42

Yeah, no, totally. And I think that, you know, it's all about I think, what I learned in residency, the most valuable lesson that I learned in residency is if you have a problem, being able to propose a solution to the person that needs to solve your problem is a much easier way of getting something done than to just like, be like, Oh, I don't like this structure, but I don't have an alternative, right. And so like, for example, if you're like about to start a start working for a practice and say, they're worried about your productivity, you want to start doing reproductive surgery, you go say to them, you know, I, you know, really love doing reproductive surgery, I know that as my clinic volume revs up, that may not be something that I can do once a week, but in the interim, could you just refer all of your patients, as I'm filling my schedule, we can kind of get that money back for our clinic, we can reclaim some of those reimbursements from the surgery that we otherwise would be referring out. And then we could come back and say, you know, as my clinic starts filling up, you're gonna get referrals, you're gonna get friends, you're gonna get all these different, you're gonna be drumming up more business, that I think that they weren't necessarily having seeing as an avenue of revenue, and being able to sell that value that is very uniquely you, I think it's not just being a fellow that can do IVF. But it's also like, I can, you know, represent us at local, you know, marketing events, I can do all of these little pieces that kind of build into that practice that I think also builds rapport with your practice partners. And I think part of the whole practice partner piece is is that your partner is trust you and do your partners, think of you as somebody that they can lean on to make decisions. And I think I want to be able to build that trust with my partners.

Griffin Jones  38:12

Boom, that's bringing a solution that's coming proactively to make that selling your case for what you want to do. You also made another point that I think we should talk about, which is because I think it can go either way, it's something for people to consider and that has to do with future risk. Are you better? Are you in a better position to to mitigate that as a partner as an associate, meaning like all the people that are selling their practices? And it's like, Wait, this isn't? This isn't what I signed up for? I could see it going either way, if you're a partner, you potentially have more you potentially have a lot more to benefit from. If they're flipping that and and the partners are, are part of who gets to make that and they're not always that's one of the things that they can get screwed over on they did they get to make that decision, they get to vote on that decision to begin with. You could also be, you could also straight up get screwed ie Integra mat, like the people that were partners that those practices got screwed there. They had to find new payroll company money they had to the people that had paid ahead of time that year, they had to make that up. And if you're associate that's not really like that's not coming out of your overall bank, and God forbid if it doesn't work out overall, you just go get a different job somewhere else. So I could see I could see that. Like you mitigating risk. Are you taking more risk on? I think it could be either one? Well, I think

Dr. Victoria Jiang  39:46

it's like what do you think is like risk first benefit, right? Like I think the associate model like if you're able to say you have a side hustle, something that you're into, like say you have a really popular fertility podcast, and you really want to like figure out How to really lean more into that like that may be better for you to be an associate more like an associate partner in that capacity because you can work on side hustles, you can have things carved out, have a little bit more time in that capacity. But I'm a strong believer that without risk, there is no reward. And it may be that you take on a big risk, and it doesn't necessarily play out and what you want it to be. But the alternative is that you're going to be putting in just as hard of work on a day to day clinical level. And whether or not you're going to be able to be the person that's at the, you know, helm of the ship. I think that's the phrase, I think that's going to be per person, I think that's going to be what people deciding, you know, I've met people who are saying, this second phase of my life, I'm done with training, I want to focus on my family, I want to pass my boards, I want to buy a house and I want to like, you know, snuggle at home, I think that's fantastic. And just as important as any of these other aspects of your job. But you know, for people who want to have a seat at the table and make those decisions. I think for me, that's at least where I'm seeing myself now is I want to be able to sit at that table and have a little bit more of a say in how these practices are developed. Because I think the biggest frustrations that I see in these big, you know, corporates, like scenarios is that loss of autonomy, you know.

Dr. Zoran Pavlovic  41:21

That's a return. I've talked about this so many times via text message and phone calls. And we talked about how being at that table being able to participate in that decision making is so much more, it's better than not being there at all. And I think that can even carry over into advocacy, which may you can speak about if you're not at the table making those decisions, and other people will be making those decisions for you. And that's doesn't work out well in politics and advocacy in medicine. I don't think it works out well. And the business aspect, either. And if we're physicians, and this is our field, we should be participating in this situation, not everyone will want to which is totally okay, as victorious. There are some of us that do. And I think that that's we may be some of the people that want to hear in this conversation. And I think that's important because I would rather be there and at least try to put my two cents or help make a decision or put a vote in versus not having that decision taken. For me, I would almost regret that saying like, Oh, I didn't actually do my utmost or my best to try to change this outcome or influence it in any way. And that's why that kind of decision making capacity is important to me.

Dr. Victoria Jiang  42:28

He is in fact, a millennial who wants it all.

Griffin Jones  42:31

So that's this is what I'm trying to think about. Because it's like, okay, there has to be something in exchange for the decision making authority. I've had, I had, I had a real struggle with my employees at one point in the past year, which is because one of the things that I do promise them is autonomy, they get to make decisions for their seat. That doesn't mean they get to make every decision about everything. And, and so I also learned that I need to be specific about what that means, like, No, I own this company 100%. And I am ultimately accountable for everything I am accountable for if I have to make payroll every single time I have, I have mouths to feed, lots of them. And I have an accountability to our clients that nobody has that level of accountability in our organization. And the more accountability you have, the more the more autonomy you have. So it's like, okay, we want to make these decisions. So what are you taking on? What are you being accountable for, you know, in a partnership agreement that that gives you that seat at the table?

Dr. Zoran Pavlovic  43:47

Yeah, absolutely. I don't think you can want to be involved or be a partner or in a decision making position or seat without taking on some of the responsibility and accountability and look into those details of that practice and diving into your your functions, your operations, how that could be better, where things could change, dealing with issues at the with, with employees, or between patients or bad reviews, I think you have to you do have to take on some of that administrative work. And I'm not much not a big fan of administrative work, but I know I would have to have it, it's going to be part of my life. If those are the kinds of decisions, if that's the kind of position I want to be in one day, and you're right, you have to it's going to be some it's going to be additional responsibility. And so you decide for yourself, is that a responsibility that's worth it to you to have that partnership or decision making process or is it not? I think that can change throughout your life as well.

Griffin Jones  44:38

We're talking about lessons learned in owning a practice or owning a business in the fertility field and things that you may want to learn how to do or learn about before you go and start your own venture. Another thing is some of the systems that are used and help people that can give really good recommendations on the different EMRs they've shopped in that depth and scope. Both functions. But I would ask someone that you know, that uses engaged MD, if you're not already, if you don't use engage them D in your system, you're thinking, I want to open my own office within my own group or I want to open my own practice, I want to go join somebody else, and I want to be able to add something to it, engage them D is one of the surest bets that you can do. But you don't take my word for it. Ask someone that, you know, because more than half of your colleagues are using EngagedMD and more than half of your colleagues are extremely delighted with EngagedMD, because they've got real informed consent. They don't have stacks of papers that people have to sign and then account for and then keep an eye out for a file cabinet somewhere. They have true informed consent from patients that have a module at their convenience, so that the staff isn't overburdened with questions that they don't need to be getting that they can help the patient with the attention that needs to be devoted to that patient's case. Because the elementary the rudimentary is covered, and now it's just what that patient is stuck on or what's unique to their case that the care team can focus their care on. That's what personalized care is. And more than half of your colleagues have seen the benefit from engaged MD that way, so just reach out to any of them. Hey, guys, do you use EngagedMD in the people you want to fellowship with people that you see it ASRM? Hey, do you use EngagedMD? What do you think I hear Griff, talk about it. But he doesn't own a practice. What do you guys think, and see what they say. But if you want that free workflow assessment, you want to see what other practices are doing, you want those insights that EngagedMD has, and you want to see how your practice stacks against that ideal workflow, then you go to engage them the.com/griffin. And he mentioned that you heard them on the show, you mentioned that you heard them for me, and then you're gonna get that free workflow assessment. So ask somebody else, don't take my word for it, but go to engagedmd.com/griffin, or say you're on the show. So you heard from me, so you can get that free work assessment for you. That's one of the biggest system wins that you can have right off the bat. And you can verify that just by asking people you already know, I hope you enjoy the rest of this episode about things you need to know for the fertility business, you might start, I think there's there's a couple of different ways that you all can look at your careers, which is everybody talks about being an entrepreneur, like it's the greatest thing, it's not the greatest thing, there are advantages to it, one of the advantages is leveraging systems and capital so that you're not just trading time for money, and that so you potentially have the freedom to do a lot of other things. But it comes with a ton of risk, a ton of spotlight, a lot of obligation. And then another way of looking at your career is is you're a craftsman and and craftsmen can also have really great lives because they have a trade that is so in demand that they can call a lot of shots, then they don't have to have a whole system to they don't have to leverage a whole system. They can say this is what I charge like I'm this good at it. And make it seems a little bit more interested in I mean that you're still interested in the entrepreneurial route too. But but you're also open to this this craftsman, right? So what like, what is it that you also want to be able to do and advocacy is one of those things. So why is that important?

Dr. Megan Sax  48:44

Yeah, for me, it was really just being in medical school in Chicago, I did a lot of work with a program called the Midwest access project that did some elective termination training. We spent a lot of time at Planned Parenthood. And then coming to Ohio for residency was almost like a culture shock for women's health. But I will say in Cincinnati, it was really incredible place to do residency because it's, for those of you who don't know, the Ohio geography, it's on the river, and the other side is Kentucky. So it's really the first safe haven for most women seeking abortions from the south. So you got this incredible training at Planned Parenthood, which was five minutes from our hospital. And you just heard all of the stories saw incredible experiences and women going through just about everything to get there. And I can we have this Fetal Care Center and all these other you know, everything that you hear about in terms of fetal anomalies, medically indicated abortions. And so the dog's decision has just been tragic for the woman of Ohio. We overnight really went from 20 weeks, six days elective termination now down to six weeks. And like I said, this was the first is a place for a lot of the South to come to. And so I think not only do you have to Did it teach me coming here that you need to be familiar with the legislation in your state surrounding women's health, but you also have to be a fighter and you have to be vocal on behalf of your patients and share those stories with legislators, obviously, in a HIPAA compliant fashion. Because nobody else is going to speak the scientific truth if you don't. And so to me, you know, hearing Victoria mention this risk benefit and, and that I'm really thinking of it more from a perspective of, I want to be in a leadership position, I do want to make these decisions for my practice, whether I'm at an academic institution, but whether that's as a medical school clerkship director or fellowship program director, or division director, you know, to be in the room, where it happens, is definitely very important to me. But whether I take that risk financially to have that possible financial gain, I would say, you know, it's definitely very appealing and interesting, but I would be seeking, you know, consult from these two on that, as I typically do with with anything business oriented.

Dr. Victoria Jiang  51:15

I mean, for what it's worth, I think Meg is a great testament to the whole idea of finding that passion and learn, like feeling that spark for something and then chasing right after it like she has, we always say she's our advocacy queen, because she always has like, gonna sign this petition and like, we have this thing going on, like, oh, my gosh, we're trying to fly it in protests and do all these things. But I think that for me is like, that's the autonomy, right? It's like finding that passion, doing that passion, and then making something out of it. And I think that's the true spirit of entrepreneurship, right? It's like, finding something that you can have like a very specific niche and focus and being the best in that field and doing that. And I think if you bring those skills in that focus, then you can really like one of the biggest things I learned in fellowship is that you can't say yes to everything, and you shouldn't say yes to everything. And it's okay to not have your like eggs and every baskets, even though we like a lot of eggs hashtag. But it's like, you know, you can't say yes, everything, you can't do everything, you've got to focus what you're gonna do and market yourself from that perspective. And, you know, being partner for Meg, maybe being clerkship director or fellowship director, and that in and of itself would bring value and joy in that long, like career longevity. And I think for us, as at least for me, up to this point in training, it's been blinders on just clinical practice patients above everything, you know, you're in this hyper competitive academic environment is all about publishing papers. And then realizing and this last year doing research, there's so much more to the field that you can bring, that isn't necessarily the most traditional medical aspect, because the traditional medical aspect is becoming something so much more different than what it was 15 years ago, and being able to navigate that in stock to job search, but also like, life goal searching, I think, is been the most kind of interesting revelations, at least for me when thinking about that philosophical kind of partnership role, like what do you want out of your job? What do you want the freedom to be able to do?

Dr. Zoran Pavlovic  53:13

And other career I would say, the more the more philosophical, global aspect medicine, I think if you become complacent, right, medicine becomes run by someone or something else. And as physician burnout increases, I think a lot of that burnout comes from just us becoming complacent or being forced to be complacent. And so other people are making decisions for us. Other people are dictating our time, where we do anything from reimbursements to how much advocacy to do to what the laws are. And if we want to make medicine, you know, health care oriented, you know, physician and provider run system, we got to be a little bit less complacent at the least, that's what I feel like I want to be involved and that's what drives me. And I get the passion from that to be part of it. To help make it our own again, instead of just letting either businesses or politics or other other outside forces drive health care and medicine, if we can make any

Griffin Jones  54:09

change. Well, that can quickly become that can quickly become perverted, though candidate like corrupted that because like, it's like, then the business person really could just like the doctor can become the business person like and it's, it's, it's not immediately obvious where it's like, okay, that's the clinician, that's the business person over there. And, and especially when you can also as we see in marketing all the damn time, you can use ethics, you can even use or what's perceived as ethics to drive a marketing message. It reminds me of the Simpsons episode where Mr. Burns. He gets involved in recycling for some reason and like he's just using it to dry up the oceans or something and Lisa says, Eat you You're so evil and when you're trying not to be evil, you're even more evil. I saw this all over the place in business. Some of them the marketing messaging is, it is like just totally dishonored. It's perverse. And I don't think we're immune to that in the REI field. So I want to go down that rabbit hole, I want to ask you like, one other question, going back to the basket is Victoria talked about the basket, and maybe that will bring us back to this, of like, like this mission and message? Because I've asked you one question out of your 30 questions. And looking at this sheet, it's not just 30 questions, because each of them are like five quiz all like, all the things that we talked about were from one question, although we probably we did cover a lot that we covered what I wanted. But I want to ask you, well, there is another question that I'm glad you all put on here, which is do your do you see yourself in any role outside of medicine? So maybe that ties back to what we were talking about, like of keeping the mission Hall. And Meg was talking about advocacy. But that can really mean anything? Like what roles? It can mean anything? I mean, sitting on a board that has nothing to do with reproductive medicine? I could it could be not actually practicing medicine, but sitting on advisory forum for for a Silicon Valley company. What roles do you all see yourselves outside of medicine?

Dr. Victoria Jiang  56:30

Meg Sax for President 2036 Go.

Dr. Megan Sax  56:36

up right here. You got it.

Dr. Victoria Jiang  56:38

I'll be revised. I mean, all jokes aside, I guess for me, oh, gosh, I think that for me, I've always had this this is like totally. So like thinking totally outside of medicine, I've always wanted to learn how to bake like really fancy French pastries. So I feel like in the second life that I'll have, I'll probably go to like chef school and learn how to be like a patisserie, like person like pastry chef. And like the more realistic kind of like logical, field oriented way, I kind of imagined myself pivoting into more of a data science space, I think that one of the biggest untapped, you know, really untapped and truly understood like power of big datasets and clinical processing is going to be thoughtful developments of artificial intelligence and data processing, to be able to better diagnostics to be able to better die, like better, like genetic information processing. And I think it's going to be revolutionary towards the ability for us to have image processing. And so I imagined myself either doing my own kind of startup in that capacity, or potentially like joining a advisory board or serving in that capacity, kind of feeling how I can disrupt the field in a different way that is going to be bigger than me seeing patients myself, I think that is what I imagined my long term legacy to be and what I hope it to be because I think we have this one short life on the world, and I want to be able to make the biggest impact and get the most people pregnant as I can.

Dr. Zoran Pavlovic  58:06

Yeah, I agree with Victoria in the sense that there was a question on there that I think we pull it what do you think was the biggest things coming up in infertility and REO the next biggest innovation or what that and I think artificial intelligence and genetics are those two sectors that are really booming in our field, ai ai being closer to and like genetic engineering, all that being a little further away. But both of those are have such powerful capacities to make a lot of change in people's lives. But also, like you were saying, Griffin, there could be a double edged sword, you know, things different technologies may not be may be marketed as being great, but they may not actually be as great. Or we may be talking about when we get to the point of actually AI dictating care or genetics being able to be modified and embryo like what does that mean ethically? And I think there's these crazy ethical questions and business questions and medical questions that need answering. And I see myself as hopefully one day becoming knowledgeable enough and enough of an expert in my field, that someone would trust me to be part of a consulting group or a CMO of our company, or an advisory board or somebody people to sit down to help make these difficult decisions and have these difficult discussions. And I would like to train myself and gain my knowledge to get to that point one day, that would be really amazing, because I do feel like we have these epic situations and questions that we need to answer coming up. And if I can be a part of that and at least contribute in a positive way that I would look back at my life when I'm retired or just sitting on a beach somewhere in Bali, hopefully, like I did something, you know, beyond just like tutorial was saying, being in my clinic and taking care of patients, which is extremely important and the utmost importance of medicine, but that's how I would want to try to see if I can add to the field.

Griffin Jones  59:54

Yeah, I want to maybe just remark on that because it's amazing how It subspecialist physicians you're so you're so educated, you're so trained, you're so freakin smart. And, and, and truly are exceptional in many extra ordinary in many senses. And then in other senses, it's like, just as human as everybody else. And it's amazing. When I'm in a room of a very eyes, it's, it's a natural human tendency that likely comes from evolutionary biology that when you see someone getting more, you really want more, and because so much is coming into our field right now. It's, it's, it's very easy for me to say like, I want that, and I would just caution people a little bit yet you've worked really hard, where you're gonna be okay, no matter what you do, you're gonna, you're gonna be all right. Remember that the vast majority of human life up to this point throughout history, and even in great many parts of the world today is extreme poverty. And, and even by the standards of our country, you're going to be you're going to be doing well, no matter what. So I think it's just something to keep in in mind. As for all the the, for all the artists was for all of us, that it is our tendency to look at people and be like, they gave him what he's getting what for being on that board. He sold his practice for what? And it's like, you know, focus on some of the other things as well. And maybe you compare yourself to your ancestors, as opposed to the other colleague all of the time. I know, and just your competitive rate, especially REIs. So you're going to do it some of the time. But

Dr. Megan Sax  1:01:48

Matt, towards our patients for a second, too. Yeah. Yeah. I mean, you're so right. I think, unfortunately, that is kind of the human nature. But we feel that for our patients, too. And I know I've talked to these two about it. And one of the most frustrating things about our field is the accessibility and really lack thereof for such a huge proportion of the population. And I mentioned earlier onco fertility, huge passion of mine, as well as just fertility preservation for transgender population among other kind of medically induced infertility. Right. eugenic infertility. And so I mean, to kind of swing together the two questions of what's your passion outside of your clinical practice? And Zoran bringing in the where's this field going in the next decade or so I would say increasing access, I'm gonna make it back to advocacy for a second just say, you know, currently, we have 12 states that have fertility preservation laws, or in other words, mandating insurance coverage for that I intragenic. Infertility. And to me, this is this is not enough. And I can tell you, Ohio is not one of them. But, you know, we're seeing the state mandates increase now with 20 states, and we're seeing IVF coverage in 14 of those states. And I think that's going to go up. And I think in the next decade or two, maybe even sooner, we'll see a much larger patient population, I think that's part of the reason why they're coming for the REI fellows earlier in earlier is anticipating this huge increase, but I know the three of us will, will be fighting for our patients and increasing that accessibility and, and that's going to be hopefully part of something that I do outside of my clinical practice,

Dr. Victoria Jiang  1:03:35

I think that's really important to always like think of is that as you accumulate more resources, you also get to be the person who delegates the utilization of those resources. And I think what's what, you know, Meg was really thoughtful about kind of touching upon is even being able to practice right now, as a fellow in a mandated state, you know, even the state mandates aren't perfect, and there's a lot of insurance hoops, you have to jump through each case, you're you're spending a lot of time with patient, you know, authorizations and pieces like that. And so there's a lot of work to be done in the field that, you know, disrupting the field isn't just like, you know, the big bucks and making millions of dollars, it's like, allowing, it's like starting a genetics company and allowing people to have cheaper, more affordable carrier screening, so that they can actually know what carrier screening is, and being able to offer that at a price point that they can afford, instead of $1,000 a panel, it's increasing access to patients who otherwise would be afflicted with genetic diseases and offering genetic testing from that capacity and like being able to really utilize the resources information in the best, most thoughtful way. And I think that, you know, any physician that I have ever met always, you know, is thinking, what about my patient? How can I get the best care for this person? How can I get around these hurdles? And I think that that's something that uniquely positions, you know, physicians to be leaders and ethical development of the fields because we're always having that patient in mind and that may not necessarily be as easy to see, for, you know, politicians. I know, it's been a huge challenge with being able to bridge that gap of politicians being able to see like, what does it actually mean to have a six week abortion ban? And how is that going to actually impact the patients that you're seeing on a daily basis. And so I think having a bigger voice, and being able to be at that position is going to be hard work, you know, it's going to be seeing 1000s of patients and having good reporting good outcomes and doing the best for them. Because at the end of the day, that's what we do. We are craftsman, a craftsman with an idea for bigger.

Dr. Zoran Pavlovic  1:05:33

It's our job to kind of sift through all these things to these different technologies. You know, you go to ASRM every year and there's all these new booths or this brand new technology coming out. But how much of it is actually helping patients? How much is more marketing and a marketing gimmick? And what does it actually mean? And sometimes it's years of using that device or that idea before people are looking at the outcomes and say, this actually didn't help anybody. And so that's where we need physicians that are patient, mind and patient focus to be there at these advisory boards at these tables and to discuss these things to see what will actually be beneficial, what won't be beneficial, what is the research back what's evidence base, what might not be evidence based, but we don't have any other treatments for it. So maybe we should go down that avenue, and be able to make those decisions for patients so they get the best possible care and the best possible access is big in Victoria, we're staying.

Dr. Victoria Jiang  1:06:20

Clearly I've been doing these conferences wrong, I thought the best technologies were the ones that gave out the best sperm pens,

Griffin Jones  1:06:26

are getting the swag is something to be said for that. Well, one of the things I say frequently is that it's hard to provide, it's hard to to have a valuable business mean, it is hard to have something so valuable, that it is worth getting more money than then what you're what you're giving away, it's so hard to be able to do are you meaning actually, the opposite, I think I'm trying to say is that you have to give away so much value that it's it's worth more than the money being received for it. And in order to to actually like deliver something so high in value, all of the systems and people that need to be it's hard to do. And, and I take that obligation so seriously, as a business owner that when we're not doing our best, as a firm, we're just taking people's money, we're just I hear I say they all say they're going to add to the pie, but we just feel like, they're they're just taking away a piece of our pie. And when you fail a business, that's what you're doing, you're just taking away a piece of the pie. When you succeed a business you are adding to the pie. And it's so much harder to do than to say. But I want to conclude with let's just say each of you have interviewed at this point, each of you are talking to people, names, specifics. And I know you're not going to give those but give us some insights or just what are you paying attention to like as you're we've talked about the like what's important to you, but I'm talking about when you're interviewing with people, like what are the impressions that you're getting from interactions? What is it that you're paying attention to? Let's conclude with that? Dr. Sachs? We'll start with you.

Dr. Megan Sax  1:08:10

Sure, I think something that has really stood out to me and kind of gives you that that nice feeling like oh, wow, this could be a really good fit, is when they say we want to make sure that this is where you're going to be happy. You know, when you start to get into well, which clinics would it be? Or which you know, other kinds of details? Like Zoran would say, really that importance of the details. They'd say, you know, this is we want you to be happy. And that really stood out because I feel like as as a resident as a fellow, maybe it was more like No, no, I want you to want me What can I do? And it's really nice to kind of have this table flipped this time. And I think it feels a lot more comfortable than those kinds of stage we did. We were the first rate I think we were the first COVID interviews for fellowships. And we were so used to the zooms on zooms and those kind of, you know which answer which story am I am I tell him for this question, which just feels silly after a while. But these interviews, it's like, Who do I want to be my partner? This could be for 2030 years. So I think that's important. And I did also want to include that. I don't want any fellows out there feeling like Why haven't I heard anything yet? I think the three of us have, you know, gone to conferences,

Griffin Jones  1:09:28

I'd be thinking that I would think of that. You're gonna suck you suck if nobody's called. Nobody's college by the end of the second is something to be said for that make which is Be active. The more active you are, the more opportunities you have. And that isn't just there. It's not just for fellows to i, there's been a couple of people that I know are trying to hire fellows, and I've invited them on this show. And, and there's like they just don't It's like this, this fellows are listening to the show you're trying to I'm giving you free advertising to talk about whatever. I, the people that are really good at recruiting fellows, I'll just make up I don't want to say any doctor. So I'll just make one up Dr. Angeline. bolsos is so good at recruiting fella is because she's all over the place. And she's super generous. And, and there are other people like that. And it's tougher for some of the smaller people to do that. But the more active they can be, the more likely they are to be able to be connected with people like you. And and the same thing is true for you guys that opportunity begets opportunity. You are active at Mrs. Ai, you ended up on this show that's going to result in a couple of phone call or an email from somebody here there. Yeah, it was you met somebody from the armed group, which is going to lead to another opportunity. So no, I wouldn't be a little concerned. Like if you haven't gotten a call. Maybe I should start being a little bit more active.

Dr. Victoria Jiang  1:10:59

I will say I think a lot of people wait until ASRM of their second year. And I think that's a really great touchdown point for a lot of people because it's really easy to connect with people. So if any fellows out there I knew for me, like thinking of ASRM as like kind of a deadline or kind of like a touch base point of like putting out feelers and networking, I think was a good place to start. And I definitely think that we're really early in kind of looking at the field. But soon, you know, time flies, and you're going to be graduating sooner than we I mean, hopefully,

Griffin Jones  1:11:33

you're early and this is the least busy time of your lives for the at least the five years on either side of it. Right? Like you were busy as hell and residency and yeah, this is a brief window, you're gonna be busy as hell again. And so yeah, it's not like you're it's not like you're behind the eight ball if you are if you haven't talked to anybody by by second year, but but the more you put yourself out there, the more opportunities you get. There's one: What are you paying attention to?

Dr. Zoran Pavlovic  1:12:05

Yeah, pay attention again, but big for me is culture, how the different partners talk to you know, interact with one another, how they say the practice runs together, how they say the console. It's a big deal for me, when I talk to someone at the actual practice, and they say things like, Oh, I'm gonna have an issue, I just walked down the hall and my partner, I call this person or if I have a tough surgical case, this person is there to help and backing me up just just shows me that strong culture of collegiality and togetherness and collaboration, which collaboration is a big word for me, Megan will here has heard me say it a million times. And back when we met in the NIH, that's like all we did was collaborate on a bunch of things, and now Victorian and also doing some stuff. So that's that collaborative togetherness environment is big for me, because I think as a team of physicians, we can do so much more as a team of physicians and of course, other practice providers together, we can do so much more than an individual. And so it's important for me to be part of a great team. And so I pay attention to that team environment, how are they within one another? How did it happen? How does the practice run together? How cohesive are they to help each other out? And I get that from actually having personal conversations, not just from the interview? But I'll find people at the practice and email say, Hey, do you have time for a phone call half an hour here? Half an hour there and just speak to me one on one so that I can get them one on one? And really hear from them? What they think, what are their thoughts? What are some of the pros, what are some of the cons and that goes back to what you said Griffin about being active. If I had advice for residents, incoming fellows, new fellows or current fellows, now it's that don't be afraid to just kind of put yourself out there to network to have conversations with everybody around you even even if you're introverted, which may be harder to do that. Just put yourself out there, we have such a great field of so many people that want to help and there'll be excited if you're excited about the field and passionate. So walk up to that person after the presentation or go to the poster presentations or when some guy that you recognize from podcast walks up to you to pull up PCRs, you know, talk to that person. I think that was huge. When I met you for the first time, I was like, wait, I know your podcast. And that's our first conversation started, but just be active in those conversations, because that will continuously lead to more and more connections and doors and situations. And we can help each other that way. I mean, that's what makes them united. She asked me for some help with connections in Chicago people that I did research with, and I was just like, yes, let me text that person right now about you how awesome you are. And that's how it worked out. And so keep having those conversations and just be active. We're here to help.

Griffin Jones  1:14:33

Victoria, did I ask you what you're paying attention to or to interrupt you with calling people losers?

Dr. Victoria Jiang  1:14:39

Maybe a little bit of both. I will say the things that I'm looking out for definitely the same layer of collegiality. I definitely want to be practicing with people that I just love working with. But I think for me, it's going to be the little details of clinical care that I think are going to be the make or break it or you know, I want to be in like a medium sized practice. I don't want to be by myself. I want to have a little bit of mentorship. I don't want to be driving to 55 Different satellite clinics, you know. And I think what's really important for me is Journal Club and team review and being able to like lean on my practice partners to learn and get better. Because I think the great thing is, is that you're going to pull together people that have been trained in all different places in different times. And I think that you can learn a lot and make your practice like your own. And I think for me staying ahead on the literature on the new findings, the new technology is going to be something that's going to be more challenging as we get into the nitty gritty and I want to be in a like environment that pushes me forward and allows me for like professional development in whatever capacity that they may mean and being able to be around the right people to do that. And be able to have good mentors in that capacity I think is going to be what's the most important

Griffin Jones  1:15:52

if you go to Montana or Wyoming you're absolutely driving to six different satellite your your driving hours to go to the gym. Doctors Jiang Pavlovic, Sachs, Megan, zone, Victoria in reverse order. Thank you so much for coming on inside reproductive health. It's been a pleasure talking with you all. Yeah, thanks so much.

1:16:16

You've been listening to the inside reproductive health podcast with Griffin Jones. If you're ready to take action to make sure that your practice thrives beyond the revolutionary changes that are happening in our field and in society. Visit fertility bridge.com To begin the first piece of the fertility marketing system, the goal and competitive diagnostic. Thank you for listening to inside reproductive health

150 EngagedMD’s Prescription For Reducing Fertility Center Pain Points, Featuring Co-Founder Jeff Issner

In this sponsored episode, Griffin Jones and co-founder of EngagedMD Jeff Issner discuss the unique ways the company provides added value for practice owners, employees, and their patients. How informed is your informed consent? Does your practice unknowingly carry added risk? EngagedMD’s education and informed consent solutions help to increase provable informed consent, reduce practice risk, increase and personalize provider-to-patient face time, increase patient education, save time, add to practices’ bottom lines, and ultimately increase access to care.

Tune in to hear:

  •  Jeff and Griffin discuss ever-present nurse burnout, and what EngagedMD does to take some of the weight off of nurses’ shoulders.

  • Griffin question how EngagedMD’s program roll-out can be successful with varying practice size and demographics.

  • Griffin question how business advantage and patient standard of care can both be bolstered by partnering with EngagedMD.

  • Staggering statistics on the EngagedMD analysis of ROI on just a two-practitioner clinic, and how these results increase patient access to care.

Jeff’s information:

LinkedIn profile: https://www.linkedin.com/in/jeff-issner-0620a912/

Website:  https://engaged-md.com/

Facebook: https://www.facebook.com/engagedmd


Jeff Issner  00:04

If somebody blindly signs off on something, and then an issue happens, if you can't demonstrate that the informed part of informed consent occurred, it's not helpful. It's not very valid. So all of these things are, of course, litigated through the courts. And but it's very clear that just signing a piece of paper is not informed consent, you need to ensure that patients are informed and actually understand before consenting, fertility, nursing, burnout, Rei, productivity, fertility, patient satisfaction, the standard of care, revenue, these are just a couple of things that I talked about with my guest, Jeff Fisher, he's the co founder of  EngagedMD, and you've heard of them, because they're a sponsor of this show. And you've heard of them. This happens, all fertility clinics in North America are using them. And you've heard of them, because so many people have come on the show and at conferences and other places and been talking about how amazing they are. It is a sponsored episode. And so you'll hear me sing their praises, because I legitimately don't. I don't have anything to counter with, it's been the most lopsidedly Positive reported company that I know of, in the fertility field. And

Griffin Jones  01:14

but I still tried to make it more about things than EngagedMD in the scene. So that's what Jeff talks about. On the show, he talks about areas of nursing burnout, and what clinics are doing to solve that. He talks about areas where physician productivity is limiting or, or the hindrances to it are limiting access to care what they did to improve access to care, we talked about what the bridge is between business, like a business advantage versus now is integral for the patient experience and for the standard of care that patients receive. And we talk about the risk that practices face in informed consents, and the hindrances, that that can lead to people moving on to treatment and practices being liable. So all of these things we cover in this episode today. And if you want to engage MD to take a look at your workflows, if the examples that Jeff talks about in this episode are interesting to you, he is somebody who will look at your work and they'll do a free assessment. If you go to engage them d.com/grip. And they'll do that assessment for you for free. They'll point some of these things out to you. It's a free eye opener for you from a third party that works with more than 200 fertility clinics. And if for no other reason, it is nice to say that you heard about them on the show that you heard about them from me, because that helps us create more free content for you. So I really enjoyed this conversation with Jeff, I liked hearing about what  EngagedMD is going to do next. And the case studies that Jeff refers to and the problems that clinics are facing, I think will be of interest to you too. So please enjoy this episode with Jeff Isner, co-founder of engaging Mr. Listener. Jeff, Welcome back to Inside reproductive health. Yeah, thanks, Griff. Glad to be here. You're the first person to ever do a sponsored episode of  EngagedMD and I get a lot of messages from companies, what can we sponsor the show? Can we be a sponsor? And I'm gonna work it out, you know, we're gonna work out inside reproductive health, eventually to where I would say eventually, because I'm still working on this, you know, fertility bridge Client Services stuff. But inside reproductive health is getting big enough to the point where we can start to work out things that aren't an endorsement, but because right now, it's been the podcast, it's been my voice. It's almost like there's no way there hasn't been a way for me to do a sponsorship, that isn't an endorsement. And I have to be really careful about what that is, like when people say, You're a shill for this company or a show for that. It's like, the only sponsor that I have is EngagedMD and I tell all of you that and it's because I've known Jeff and Taylor since 2015. And more than half of our clients have used it and all of the things that people tell me about EnagedMD so I've only even had the sponsorship conversation like the opportunity to be a sponsor with like three companies. And ultimately, so far you are only the only one there was a good fit for at this like endorsement type level. And it is because you hear me on the show Jeff puts out a challenge every week where I'm like, Okay, if if you're the person that's gonna tell me the for There's a bad thing about EngagedMD, send me the email. I'm not saying the email will never come. I suspect that one day it has to write like one day it has to come where somebody's like EngagedMD do. No one ever has no one ever has up to this point. It's all been like glowing reviews. And so I just like for the three people that are living under a rock, what is the  EngagedMD from the owners perspective? And what's the value that you sought to bring in the marketplace to begin with? 

Jeff Issner  05:31

Sure, sure. First of all, thanks again, for having me. We appreciate what you do, in terms of the podcasts and all this amazing information that you share with this community. And we're not perfect, enga EgagedMD is not perfect, but we work really hard to create amazing experiences for our users and ultimately for patients. 

Griffin Jones  05:47


Jeff Issner  05:48

So to answer your question, now, the way I like to explain engaged MD is through the story of how we actually got started. And about in 2015, when we met, our medical director really felt this problem day in and day out and his practice. And he was explaining the same things over and over and over and over again to patients and their partners. And making sure people understood what the process looks like for fertility, treatment, the risks, the alternatives, and medications, all these really important things that patients need to understand in order to make good informed decisions. And he realized, well, I'm repeating myself over and over again, and I'm probably only covering maybe 60, or 70%, of what I ideally like to and I've got all these kind of external factors that are pressuring what I can cover, whether it's the time I have for the appointments, or what else is going on in my life, or in my day. And he realized, well, I'm doing it this way. And every provider in my clinic is doing it a little bit differently. And ultimately, the patients are on the other side of my desk trying to just drink from the fire hose and absorb all of this very complex medical information for the first time. And so when patients go home, they try and remember everything that they had just been told, whether it be from their doctor or their nurse, or medical assistants or any other staff, it's too much. It's just too much. It's a ton of information that we're jamming into these appointments. And so they go online, they look for answers, they end up calling their nurses and their medical teams to try and get those answers. The nurses are picking up the brunt of this. They're doing IVF classes, med teach classes, really trying to fill in the gaps again, so that patients can make those good informed decisions. And they make those decisions historically on pen and paper. So documents are being printed, they're being given to patients, they've got to take them home, they're getting notarized, they're getting filled out incorrectly, and they're getting lost before, hopefully they get scanned back. And so we looked at this problem and said, Wow, it's so much time and energy that everybody is putting into this. And it's a suboptimal patient experience, clinic experience. There are all sorts of risks that are introduced. And so there's just got to be a better way to go about what we viewed originally as just informed consent, making sure that people are educated and consent to the right things in the way that aligns with their behaviors and what they want to do with their treatment and their goals. So we EnagedMD. And that was kind of the impetus for the platform and the company. And we have two primary product lines. The first one is Elon, so a library of educational modules that we've developed, that cover everything from COVID-19 protocols and fertility one on one, all the way through all the different types of treatment that patients may be pursuing, through the very end of the patient journey, what to do with extra gametes or embryos that you may have that OurCrowd preserved that. And these modules can be pushed to patients so that they can watch this content on their own time. They can rewatch it as many times as they want answer questions, demonstrating that they actually understood everything and then come back into their next appointment, and have a much more effective, much more efficient discussion with their medical team that's focused on the nuances of their care. Let's talk a little bit about that informed consent part for a little bit. Because anytime you talk about informed consent, you have to say, I'm not a lawyer, talk to a lawyer, get legal advice. Don't get it from me, because I'm not giving it to you because I'm not qualified to give it to you. But when I ask attorneys in our field, and

Griffin Jones  09:18

I'm chairing this session that you're actually speaking at SRM and I asked people about like, just like, what's the standard for informed consent? They'll just engage them D A N, like, What do you mean by and so what do they mean by that?

Jeff Issner  09:36

 Yeah, well, ultimately, it's a non delegable duty for the provider to provide informed consent and it's making sure that patients understand everything that they need to know all of the process the risks, the alternatives, in order to and also they comprehend everything, not just or being told everything but they actually understand everything that they need to know in order to make a good decision a shared this vision with their medical team about their care.

Griffin Jones  10:03

So I didn't really think of it in this way until I was on one of Dr. Katz's webinars and the viewer, you may have also been speaking on it. And and, and this may have been in the beginning of the pandemic, when people like the people that hadn't figured it out already kind of like had to figure out their the E signature, and people were asking about informed consent. And it and Dr. Katz said, What what's, what's greater evidence of informed consent, a stack of papers, that it's that like, there's a signature and at the end, and a couple initials throughout that, like 10 point font of language that people have never heard before, or a series of videos where they have to sign off at where they have to complete each module where they have to take a quiz, demonstrating that they that they did and then a a trackable digital signature at the end. So Ken, like you talk about that level of informed consent.

Jeff Issner  11:16

Yeah. And it's the way that you're talking about it. It's kind of how we break up our product lines, I've always related the informed part to our elearning product line and the consent part to our esign product line. But consenting is much more than just signatures on paper, if somebody blindly signs off on something, and then an issue happens, if you can't demonstrate that the informed part of informed consent occurred, it's not helpful, it's not very valid. So all of these things are, of course, litigated through the courts. And but it's very clear that just signing a piece of paper is not informed consent, you need to ensure that patients are informed and actually understand before consenting,

Griffin Jones  11:55

and it's pretty easy to me, it happens a lot you can ask your turn, how often is somebody able to argue that they weren't informed and in cuts out just went through, you know, just got married not too long ago, and then, you know, talking about just family law and in figuring things out like that, and, and they don't even let people do pretty, you know, they don't even honor prenups that are within like, oh, let's say a week or two, because or I should say many courts, many courts will not honor that prenup set or within like a week or two because it's like, well, it can't really be informed consent, many courts will throw out prenups that don't have where the other person isn't represented by counsel. Many courts will throw out them where they were represented by counsel, but there isn't the documentation that they were properly informed. I think that's how Eduardo Saverne successfully sued Facebook to get back his stake. And that, I think it is because he signed everything. But he said that he wasn't properly informed. And I think he won't, and that's why his name is back on the Facebook mass that is co founder. So is that like,

Jeff Issner  13:09

it's all of these components. And Dr. Letteri from Seattle reproductive, wrote a great paper a few years back about the primary components of various litigation that has occurred over a certain period. And even if informed consent, isn't the primary reason for the case, is very often a supporting issue around the case

Griffin Jones  13:29

that it was that Was that intentional from the beginning? Or was that just kind of like a happy byproduct? Like originally, you're trying to inform patients to help with client workflow or just help with clinic workflow to help with the patient experience so that they're better informed? And oh, yeah, well, we'll include the e-signing. At the end was, was it a byproduct of this being used for informed consent in this way? Or like, like, which came first? Was it the patient experience focus, kind of workflow experience? Or was it the informed consent?

Jeff Issner  14:09

Yeah, so it was very purposeful about informed consent at the beginning. But that's not our primary value proposition anymore in terms of how we talk about the product. So when we originally developed EngagedMD, we started with the elearning modules, and really started with IVF and IUI. And it was all about ensuring that every single time people were consistently and comprehensively informed and understood what they were just being informed about. And we realized we had that informed part. And we needed the, what I'm calling the consent part, the digital signing part. So we built out our esign engine that helps digitize all of the consenting signature workflows. And it was only once we really started getting traction in the market. And one of our primary demos is to listen really closely to our customers to determine what we develop next. And what we're hearing is informed consent is super important. This is great. It's very helpful. Bye To the real benefits that we try and the real problems that we try and create benefits around our saving time, improving patient experience, reducing risk where we can, and going paperless. So it was only after we launched it, we realized, wow, this is much bigger than we originally thought. It's not just legal informed consent. This is creating these other benefits that are much bigger than what we had originally intended.

Griffin Jones  15:23

I want to talk about that, because I saw the benefit immediately, like as soon as I figured out what you guys did, and it probably took me a little bit to be fair that I probably don't know what half of the people in ASM do. But it didn't take me too long. Like as soon as I met you guys, and we talked and I was probably 2015. And I thought, Oh, these guys are nice. I kind of, you know, I have an idea of what they're doing. But it wasn't probably until I started people, I started hearing people say, this is what we're using. This is how we're using it. I'm like, oh, light bulb, I need to pay attention to what this is. And very early on, I saw the I saw the value and but I could also see what the potential objection would be. And I could almost immediately also know how to address that objection. And that objection was, well, you know, people expect personal care from us, they want to be able to talk to a nurse, and they want to be able to talk to a provider and you know, they're paying all this money for care, they shouldn't be at home and, and watch a video and and I just immediately thought like, yeah, they're paying all this money for care. And is this stressful to go through this process? They shouldn't, they shouldn't get the least amount of value out of their time with you that they can, they should be getting the most amount of value with you that they possibly can. And if they can only remember 30% of what you told them. If they're asking you questions that are completely generalized questions as opposed to specific to their case, then that is not the highest amount of value. So did you all have to work on that positioning it for? How do you help clinics position it the right way.

Jeff Issner  17:20

And it was my biggest concern, when we launched to, quite honestly, was this just going to be homework for patients when they're paying 10s of 1000s of dollars for care, and a few things to know. One is what you call about, we are trying to make that in person time more valuable, so that patients can come in with that baseline knowledge and actually have a good interaction. That's two ways that really focus to their personalized care, not the basics of how the menstrual cycle works. And what stimulation is, we want to focus on your specific issue when we've got that really valuable in time, that time together in person. So that's kind of like the core reason why this improves those interactions is you're giving that baseline info at home. But we study this obsessively. We are extremely data oriented at our company. And we measure every single step along the way, both from the patient experience and the clinical experience where I'm just wrapping up a case study right now with Seattle reproductive medicine. And this aligns with the rest of our data points where we surveyed patients and clinics but 98% of patients that the videos were helpful addition to their consultations with their medical team, and 89% agreed or strongly agreed that engage them D actually made them more satisfied with their care. So we've got to meet patients where they are, I know personally and patients who would agree based on our survey results, that people want to do things on their own time at their convenience, and they want to use that time together with their care team as effectively as possible.

Griffin Jones  18:55

That's, that's, that's huge buddy. If anybody had a nine or a close to a 10 on a net promoter score, that would be through the roof, you know, almost almost unheard of, and and SRM is not a little practice. I don't know how many Doc's they're up to now at least 12. Maybe they might even have more than that at this point. They at least two abs and they're really great group that serves a diverse patient population from all over the Northwest. So to have something like to have people say that I'm jealous of you. And and if I can go on a little tangent of why I'm jealous as a business owner of  EngagedMD. I was watching I was on LinkedIn and one of my favorite marketers was talking about he was making fun of a lot of b2b marketing companies and he was saying we make blank easy. And he's and then he's like this is this is the value prop that most b2b marketers put forth, he's like, how about you just take blank off my plate entirely. And there's so much that you guys are able to take off the plate that as a client services firm, it's like I am always trying to develop to develop further develop what we can take off people's plate, but you guys just you take off so much of people's plate that they can actually provide that level of care that the patient needs.

Jeff Issner  20:29

Yeah, we're, again, we're obsessive about the data. But we're really, really obsessive about listening to our market and listening to our customers. And every single new interaction that we have with a fertility clinic, we start with a needs analysis, we really want to listen, what is your current workflow? What is the current patient journey? Where are you spending time that is manual redundant, that you don't need to be spending so that you can operate at the top of your license. So we're just absolutely obsessive about finding those pain points and helping support clinics to get better about them and to improve on upon them, whether it's using engaging DEA or not, but we're trying to develop all of our products around those issues that we hear directly from our market and our customer base,

Griffin Jones  21:13

I want to talk about those pain points, because they're not getting less painful. There's a lot of things that people could or, or more might do to improve their business that would be beneficial for their best business. But it's not necessarily. It's not painful enough. It's the adage of the old man on the porch with the dog and the motorist stops by and he's visiting the old man. And while he's having the conversation with the old man, that dog keeps whining. And finally, he asks the old man, what what is he whining about? And the old man says he's sitting on a tech, is it? Why doesn't he just get out? Why isn't it quiet? Why isn't he get up, and he has heard some bad enough to whine it doesn't hurt him bad enough to get on. And, and, and in your space? I think that there's it with the pain that your company is addressing. There's a lot where it's the point where the dog has to get up and maybe even, you know, prior to two years ago, maybe they could have sat on the tack longer. But nurses are so burnt out and embryologists are burnt out if people can't get enough staff, but you can't get an even get enough people to answer the phone. And so you need to make what you have with people, the time that you have with people as productive as possible. So we've talked about a couple of these problems, like I want to talk about the nurse time savings. I know, like there's examples of people everywhere, but they just talked to me about you know, what nurses, you know, like the time savings, and and yet, otherwise having to deal with appointments, that has been a pain for them and and how you've helped to solve that.

Jeff Issner  23:01

Yeah, to your point, the pandemic definitely accelerated a lot of these problems. And the the nursing shortage that we're facing right now is certainly exacerbating the issues that we're trying to help support. So I think it's it's pretty well agreed upon that nurses take on a huge brands of patient education and patient support throughout the entire patient journey. And that forms in IVF consults or IUI costs, whatever treatment starts before that, honestly, even through diagnostic testing, and talking through all the different things that you may want to consider prior to starting treatment and determining your treatment plan. And then throughout treatment, as well. As you're getting ready, you've got your Med teach. So I think that's a great example of an area where we heard that things we actually partnered with SNP pharmacy on this. Together, we heard that this issue of really non personalized injection, teach classes where everyone is coming in sometimes one on one, spending an hour with a nurse learning how to inject themselves through with all these different types of medications. And you've got to go home and you've got you know, videos that you can find on YouTube that you can try and search down that aren't particular to how your clinic does it or particular to your plan. So we built med ready together, which is a very personalized approach to injection training. So together with SMP, we built all this content, it's all done through motion graphics so that we can keep it up to date. And we can keep on modifying it and customizing it so that it makes sense for the clinic's protocols and their approach and how they use their medications. And when you assign these modules, you're assigning a module that is specific to the medications that the patient will be using. And this really engaging 3d Motion Graphics manners, that patients can go back and watch it over and over again, and not only understand how to use the medications, but understand why they're using each medication as it relates to the protocol. So I'll use an example from our friends at RTI, Ohio. and they were having 45 to an hour minute or 45 to 60 minute long consultations with patients just for injection training, and those were with every single patient and couple. And they adopted our med Ready program. And you know, I think, as most people are a little bit hesitant to reduce the time with patients, but they realize that this was actually able to completely replace their injection training classes for the majority of their patients. So the patients who didn't need that extra time, again, very specific questions about their injections, the majority of things are answered through the module. So they're saving four to five hours per day of nursing time by just using one of our module components. So you can apply that kind of math and apply that logic to all these different stages where you have the redundant conversation happening again and again. So that you're focusing keep on saying this nursing time, physician time, and that's provider time, they're operating at the top of their license really focused on the personalized issues, not the general things that can be repeated through a video series.

Griffin Jones  26:05

I'm just picturing the nursing managers that listen to this show here that like four to five hours per day of nursing time. And if they're one of the few clinics that aren't working with engagement, busting into the practice owners door right now with their iPhone in their hand playing this piece of the podcast, we get what for? And a lot of people can think that are listening, but what would you do if you had four to five hours of nursing time? Back like, you know what, that four to five hours is being wasted on right now that you're not getting to where your where your nurses are burnt out where they're where they're saving calls for the next day, because they just can't get to any more else, they're never going to leave the office, and then the patient's pissed off about that, because they aren't getting the answer back that day that they they were hoping to because the nurse is answering some other question or doing something else. So I think that's it. I think that's incredibly useful, no matter what employment market we're in. But especially with people being so short on nurses, it's just like a necessity now.

Jeff Issner  27:22

Yeah. And you know, you're looking at that. And so we're, we're starting with this kind of base level, ensuring comprehensive, consistent education occurs. And then it builds on that and you're actually improving the patient experience and the clinical the nursing provider experience. But when you start taking that problem a level higher, from a business perspective, you have more time to see more patients. So ultimately, you're generating more revenue, you're helping more patients access better care, and you're able to generate more revenue as a business. So it's really a win win win. And that those layers of value proposition continue to build on each other.

Griffin Jones  28:00

Let's talk about maybe the consent side, too. And at some point, I want to talk about of just like, of like how this impacts of weightless or rather what you can do during long wait periods, because that I would say the average is eight weeks now and some are 1216. And so but let's talk about consent for a little bit like what of the the issues been for clinics pre gauge MD? What are they struggling with?

Jeff Issner  28:37

Yeah, so it goes back to just the issues of paper. And, you know, it's 2022, and things have gone completely digital. But in the fertility world, this paper is really important, you've got to make sure that the right person is signing the right thing at the right time, you're authentic, getting all of that in song, the right workflows. And with paper, you're not really fully sure what's going on outside of the office. So you give people this information, they have to read it. It's an incredibly complex medical legal format, they've got to make their decisions on it. Oftentimes, they need to go to a notary to get that authentication done. And then they have to bring it back in or ship it back in or scan it back in. And if anything goes wrong along the way, you got to redo that whole process, right. So if somebody fills out the wrong thing or signs in the wrong place, notaries aren't trained to fertility treatment and what people should be doing with their decisions. You've got to go back and do that whole process again. And then if it comes back and you actually do collect it correctly, it's got to get back into the medical record so it can get lost, they can get caught up on a doctor's desk or somebody's desk, ultimately needs to get scanned and to have that proof that you've got the official informed consent. And so there's a lot of costs and a lot of time and a lot of again, suboptimal experiences in corporate added in that workflow. So with our esign engine, we're really just trying to make sure that all of that can be handled through your inbox. So you can digitize all of your documents we'll work through with our customers, for anything, not just consent, anything from patient intake through financial documents to test requisition forms, we have the ability to create those workflows digitally. Ensure you can track all the education and all the documentation in one place. So things are never getting lost. They're following these digital workflows that make it really hard to choose the wrong thing or to make errors on the consent, you're never going to miss a signature and nobody's ever going to get skipped in the signature process. And you can always go back to engage them data, see that digital copy are never going to be searching for the paper version that might have gotten shuffled somewhere.

Griffin Jones  30:48

Which that in and of itself of how long that can take people and like the anxiety when you can't find it because it is in that one file that it's supposed to be in. Yeah, it's just amazing how people use paper for for anything, at this point,

Jeff Issner  31:07

nothing worse than somebody getting ready to start their cycle or even worse, somebody's getting ready for retrieval and say, Oh, no. Where's that consent? That's the that anxiety that we're trying to completely eliminate?

Griffin Jones  31:20

Well, it was. It's funny, you should say that, because when I did my talk at PCRs, it was originally supposed to be about like, like bizdev. And then they gave me the talk to the nurses, the nursing track, they gave me the the last talk of the of the week, it was like the 11am Saturday talk. And he gave it to it was to the nurses. I was like, great, like the people who couldn't give two craps about business development. And this is what I do. So how am I going to make my talk relevant to them. And it was it had to do with branding, it had to do with creative and I had to tailor it to how to get patients to want to engage with your practices, processes. And I was just asking nurses ahead of time. Like, like, what's the biggest thing that when you tell like, you could tell patients 100 times, but you still feel like you're struggling with this problem with them. And consent was at the top of the list, like having their consents ready having their paperwork done ready to go before it started protocol?

Jeff Issner  32:30

Yeah, it's, um, nobody likes paperwork, right? I think we can say unanimously, nobody likes chasing down paperwork. But it's critical. It's really important. And so what we're trying to do is build that into the workflow, throw that in as part of, you know, these engaging videos that you're watching, tie it into a bigger part of the journey, make it digital, make it engaging, exciting, make it so that people want to do it, at least more than they would want to do it. If it was just trying to go find a notary and sign some things on paper.

Griffin Jones  32:59

You guys are right at this junction point of something that I've wrestled with since I've been in the field, which is I could just tell it like that eventually, something that might be a business plus, it first, eventually becomes part of the standard of care or elevating the standard of care. And, you know, 10 years ago, probably having a digital module would have been a business plus, it would have been Yeah, a nice little advantage to have. But now, it's like, man, you're dealing with the biggest stress in your life as a patient and a top five, and you're usually spending a lot of money. And you're, you're doing this all at a time when you like, you have to keep track of all these different things that add all this different times. And you guys are kind of like almost a little. I'm not saying the same way. But like how when you sign up for Airbnb, like it's a lot to list a property on Airbnb like to go through everything, but they break it up. So you know, you're not filling out 100 question form. It's like, what kind of house do you have? And then next, and I'm not saying that everything that you do is like that is like that, but you break things up in a way for the patient that I do feel that it is the state like that's the standard of care that's necessary for improving the standard of care now, it's not just a business plus anymore.

Jeff Issner  34:38

Yeah, I think there's a few things that you just call out there. We'll start with the standard of care. You know, we're, we're operating with about 60% of the US fertility market. We've got a very large market share and Canada, UK and Europe as well. And so, I would say that it's becoming the standard of care, especially in terms of informed consent. We're really proud of how widely adopted, this has become, and it's really become the way to educate and to consent. So really proud of those statistics. But the the other thing that you called out is the way that we're breaking things up. And we're taking experts and adult learning and elearning. And we're taking all of the best practices that are constantly evolving. I mean, we're in the world of Instagram, and Tiktok, and video, education and video. You know, absorption is definitely the standard. And we're taking all those best practices, and applying them within our platform, so that people are getting the right information at the right time, that is unique to their journey. So we're really, really focused on making sure that that overall journey, we're pushing the right information and nice chunk size bits, so that people get the right amount at the right time to properly absorb it properly make the right next decision.

Griffin Jones  35:58

For the listener, just imagine, imagine going through something as legally intense, and as outside of your expertise that requires deep expertise that you can think of like you're going through a, you know, some some very detailed estate planning. Or even more, maybe you're going through, like the you're building your dream house, and you've never built a house before you just you've been a good Rei. And now you can afford it. Now you're building your dream house, do you want to get it all in one huge sum? Like, here's the dot, like, here's the here's this stack of papers, and you got this limited amount of time to talk to me? Or do you want to have an extremely thorough module that you can go through piece by piece on your time, go back and make sure that you understand, and then use your time with the expert to be able to ask any any question I, I think if people think about it, if if they had that same opportunity, in other realms, it becomes even more heir apparent of of how useful it is. Yeah, it's

Jeff Issner  37:12

hard. And you know, we're all biased because we live in this industry. And so some of it is it becomes second nature to us. But it's so hard learning about fertility. For the first time, I remember when I first started working in the industry, all the acronyms of the, you know, different ideologies of infertility, all the different treatments and medications, there's just so much to comprehend. So I think we take that for granted sometimes that this is second nature to us. And people who are exploring treatment for the first time, it's all completely brand new, down to the vocabulary,

Griffin Jones  37:49

we're talking about improving workflow, which means improving productivity, which means potentially improving revenue, and that is flush with the topic that we cover on the show a lot. It is a business show. And we talk about private equity, we talk about venture capital, and one of the one of the claims that private equity has, and one of the gripes against them has to do with increasing productivity. And so I say on every episode that I talk about private equity, I don't have a dog in that fight. I don't I don't know I don't feel qualified to analyze the standard of care that private equity either improves or, or worsens. I just bring people on and I try to challenge them. But the the argument for private equity is that they increase efficiencies. And the argument against private equity is that ultimately, whatever those efficiencies are just means like squeezing more cases out of the provider. And so it's like, okay, we could squeeze more cases out of the provider by making them work more by packing in patients by by taking away time that they actually need to see the patient. Or we could do things that legitimately improve the experience for the patient and allow the provider to not do things that are redundant or lost, because the patient is a deer in headlights. So can you talk about? I mean, have you done any kind of analysis for return on investment?

Jeff Issner  39:35

Yeah, definitely. And just to kind of address the goals of private equity. I mean, I think process optimization is clearly one of those in order to generate a more efficient business. And if you can do that, while creating better care, that's amazing. And if you can do that, creating better care and also improve access to care by creating more time and more efficiencies in that whole process, you're helping more people ultimately have a child. So I think that's a really positive thing I know there's many different angles to private equity and with all things, there's pros and cons. But to take it this on a much smaller scale of how we look at ROI, again, going back to that initial needs analysis and workflow analysis that we do with every clinic, every clinic has unique problems, they all kind of revolve around the value propositions that we talk about. But one example that I'll give them a needs analysis that we recently completed and completed the ROI analysis for this company, they were to provider clinic. And they had 45 minute new patient consults, and 45 minute IVF consults. And we did all the math with them in terms of how much time you had save, what you could be doing with that time, how many more patients you'd be able to see with that time your margins on that. And we came out with an ROI of over $100,000 per year just on a to provider clinic, saving those 15 minutes on each of those consults, where you're able to accomplish by just spending your time more effectively, more efficiently, ultimately helping more patients access care.

Griffin Jones  41:12

That, to me, seems huge for the places that just can't get another Rei. And in a two provider clinic, there's a lot of those in your smaller cities. And, and it's the smaller cities that really struggle to get new Docs, it seems to me like 80% of the docs go to 20 cities in the US. And it seems to me, I still don't have any data. But it just seems that every anecdote that I can think of supports that that the only time that you see someone from an REI go to a Buffalo, New York, where I'm from, or a Youngstown, Ohio or Lincoln, Nebraska, is when they are their spouse are from within a few hours of their it's just so hard to get Doc's and so the alternatives like what we're just not going to, we're just not going to provide care to these people that are here. And so I often think of like EngagedMD, like being useful for ROI for for for bigger groups, because you know, they're the ones that kind of have their their eye on the p&l, but more but is there's not really separating the Pro and revenue from the from the increase in access to care is there.

Jeff Issner  42:37

Yeah, I think so. I think so. And people who really embrace that are where we see the most success. And even with, you know, the smaller local clinics, you can still make this your own right. And I think the fear sometimes as well, I don't want to be like everybody else. The people that really embrace this and start customizing the video modules and produce their own content to have as part of the patient journey and make it branded and talk about their practice and talk about their locations. That's that just warms my heart to see because they're really taking this technology and making it their clinics and making it using all those kind of efficiencies of what's being built as a baseline, but really customizing it so that it meets their needs. It really does give that boutique feel to each of their patients that come through the door.

Griffin Jones  43:32

How have you seen engage them the influence patient behavior, have you?

Jeff Issner  43:39

Yeah, that's a great, really great question. We've been doing a lot of research on EngagedMD. So we've been very fortunate to have third parties say, Oh, this is interesting. Let me get a study going. And we've had a couple of papers published. And we've got a great one that Dr. Meg sacks from University of Cincinnati. She's an REI fellow there is presenting at ASRM. So this is an example of how we've seen patient behaviors and outcomes change. And we're just starting to explore this because I think, anecdotally, it makes sense, and it happens, but we want to prove it with data. So let me give the example that she's been studying. We've been really focused on carrier screening. So just to give some background on what carrier screening is and why it's so important, from my perspective, we can prevent genetic conditions from being passed down if patients do pursue carrier screening. And it's one of a bajillion different things that has to be explained to patients as part of that initial console diagnostic testing phase. So like everything else that can be kind of shortcut, and patients may not have the right information in order to make an informed decision about actually pursuing or declining carrier screening. And not only is that kind of a workflow issue, but it's also a risk issue. We've seen massive lawsuits in the space of a patient's who feel that they weren't properly informed and ultimately had a child and Fortunately, that was affected by a genetic condition, because they declined

Griffin Jones  45:03

carrier screening because they didn't. And they didn't feel they were informed

Jeff Issner  45:08

correctly, they didn't understand the impacts of not pursuing carrier screening, informed declination is what we would call it, and didn't realize that they could go through PG TM and prevent this genetic condition from being passed down. So that information is important from, you know, population health perspective, it's important from a risk mitigation perspective. And also, it's just one of the like I said, bajillion things that has to be covered with every patient. So we developed a module on carrier screening in a workflow to allow patients to learn about what carrier screening is at home, just like the rest of our elearning modules. And then they can flow directly into making their decision about either moving forward or not moving forward. And what we saw when comparing the patient cohort that went through the  EngagedMD workflow, versus the cohort that went through the traditional provider console, is nearly double the amount of patients who went through  EngagedMD in deep decided to pursue carrier screening, which is just gonna let that sit for a second, that's massive, that's a huge impact that we can create.

Griffin Jones  46:09

Do you know the sample size off the top of your head, I don't know

Jeff Issner  46:13

off the top of my head, but we replicated it at a completely different clinic with a completely different group and completely different researchers kind of creating the study and is nearly identical results. And that was at a very large group that we had a ton of volume going through, but Dr. Sacks will be presenting SRM quick plug for her. She's got the poster is gonna be

Griffin Jones  46:34

on this podcast. I'm actually recording recording that episode with her and two other Rei fellows later today. So I don't know if their episode will come out before yours or yours will come out before there's I don't know how we have it scheduled right now. But yeah, little little shout out to her.

Jeff Issner  46:50

Yeah. And I think this is just the tip of the iceberg. We're really motivated to figure out what drives these patient behaviors? And how can we create really positive outcomes and health outcomes, not just patient behaviors, like positive health outcomes from using this tool, and providing great education and great patient journey management? Every single step along the way?

Griffin Jones  47:12

So yeah, maybe people should let that there's a couple of things that need to sink in people's minds from from this conversation so far. One is four to five extra nursing hours per day, what would you do if you had four to five extra hours for your nurses per day? Another one is, what would the quality of care be like for your patients? If double the normal number were going through carrier screening? But how do you make sure that engagement is actually rolled out successfully, because people have asked me to build software before and the first reason I declined is because I'm not a build. It's just not my core competency. I'm a creative I'm a salesman and building out that is what I'm good at. And, and even a CRM is too far away from that, that core competency, but the other thing is just like until it until it talks to everything. In many cases of software, it's just one more damn thing for for staffs. And, and people very often aren't even using the same EMR for scheduling as they are for billing as they are for the actual medical records. And, and then much more like, yeah, there's some people that use HubSpot and and Salesforce, I've never seen somebody like really use it like really, really, at best. I've seen a sort of rudimentary use of, of CRMs. And that's true for Yeah, like project management software that I've seen workflow software, I've seen kind of shoes. So how the hell have you been able to be like, how do you actually get people to, to roll it out? Because it's obviously being rolled out? You're at least half of clinics are using it. Everybody's telling me they like it. And and you have these surveys from both patients and staff that give you the glowing reviews. But how do you actually make sure that the rollout gets you to that place?

Jeff Issner  49:18

Yeah, well, no one likes change, right. I think that's people humans in general don't like change so that the

Griffin Jones  49:25

it's because it comes at a cost, right? It's because there's Eduardo Harrington, Dr. Harrington sent me a book. Oh, and the name is escaping me. So I'll put it in the in the show notes. But he was a Harvard professor. And and he talked about this very dynamic of like, of why companies especially don't change because the cost to change can be so disruptive to what it is that they're working on that very often when there is a disruptor in the marketplace. It is the new To company because they don't have the current obligations that the established companies have to serve us. So it's hard to implement change.

Jeff Issner  50:12

Yeah. And I think it goes back to having a big enough pen, the problem has got to be big enough, and we have to understand it well enough. So the that needs analysis that we start with, that turns into a workflow analysis, and really understanding the problems that we are trying to solve together, that are big enough to introduce this change. That's where it all begins. So we are, while there's best practices that we've learned with the about 200 clinics that we've launched at, each one uses it slightly uniquely, to solve their specific problems. So we need to understand we need to really intimately understand those problems, so that we can introduce a workflow and associated training for staff that aligns to solve their problems so that they're able to feel those efficiencies. With this has been a, an area that I've focused on from day one in town, I've really made a priority. The first person we hired as a customer as a Customer Success lead, we want to make sure that people are supported through that onboarding, that implementation, so that they start to feel and see that value. And then on top of that, we going back to being obsessive about data, we create dashboards, we're monitoring every step along the way to make sure that people are being successful. And we provide that data and those dashboards back to our clinics so that they can see which of my staff members are being compliant, which are not being compliant. How are things being received by patients? Where can we tweak and modify the workflows. So a really great example that the customer success team shared with me SEMA over at SCRC, has created a dashboard that we provide all the data into, and she actually creates competitions about who can send the most modules and forms and who can follow these workflows, the best to really encourage that compliance. So I thought that was a fun way to kind of leverage that data to make sure you're creating that optimal outcome. So it starts with really understanding the problems we're trying to solve. It ends with really closely monitoring and supporting our clinics to ensure that that change curve is overcome so that people can really see and feel the value. Talk to me a little bit

Griffin Jones  52:19

more about what your customer success leads do, like how do they help people implement? Yeah, so

Jeff Issner  52:26

we've got a number of people who are focused on this, the customer journey, I'll call off the customer buying journey. So starting with our sales team, who's really kind of understanding the problems that we're trying to solve. We have a professional services team, who's doing all of the digitization, helping with the workflow analysis, and ensuring that the right training takes place. So really making sure that the the workflow and the needs that we understand are translated appropriately into solutions within  EngagedMD. And then as we launch, our customer success team is there on an ongoing basis to check in to make sure that things are going successfully to compare across benchmarks, and to listen to things that change because we all are clinics or businesses are going to evolve, whether it be through legislation or through growth, or whatever it might be. So we're here to listen and to introduce other ways that you can keep on tweaking your workflows, tweaking the platform, growing within introducing other modules, customizing your modules, changing your consent, workflows, whatever it might be to ensure that ongoing success.

Griffin Jones  53:31

What about at the financial piece of the journey in the fertility bridge, fertility patient marketing journey, it appears in the third column, there's four columns, the third is conversion from a pointment to treatment. So they become they be they've gone through their first konsult They have not yet gone on to treatment there's some drop off their finances one of those pieces so we we like to make videos about finance, we like to we like to create more content ahead of time we'd like to insert some of the content that people get before they meet with the financial counselor so that again, it's not a deer in the headlights thing and that they just it's not like their Sally down the hall go talk to her now like they they have a little bit of familiarity with with Sally there, if not looking forward to seeing Sally that they know who Sally is what they're going to talk about with her in a way that doesn't try to answer their questions that can't be answered before. It's actually one to one specific to that person. So what do you all do you all help with that? That part of the journey at all and how?

Jeff Issner  54:53

Yeah, we're really starting to make great headway just recently in this area of the patient journey and So the way that the majority of our products have been developed is by hearing our customers say, Yeah, we started using engaging D to do this. And it was like, Whoa, I hadn't even thought about that. How did we not? How do we not think of that, let's try and develop more of a productize solution for that issue. So Shady Grove, as a great example of the financial area, their financial counselor started using our esign engine to get financial documents squared away. And as we dug in a little bit deeper to that, we started learning about all the things that people are saying over and over again, very similar to a US an IVF patient as an example, the way that nurses and providers are explaining the medical process to financial counselors, we're explaining the same financial programs, how to navigate your insurance, what to be looking for what to be thinking about. And so we've just started building modules, that helps support that financial decision making just like the medical decision making. So this is allowed Shady Grove to help support their financial concepts, they've got a massive financial counseling team to help ensure that patients can make those good financial decisions. And this allows their team to not have to repeat things about their payment programs and their financial programs, instead have a much more impactful, much more efficient discussion with patients about what their options are and how to move forward. So we're starting to, you know, as  EngagedMD continues to grow and to look to other areas, we want to be exploring other places the patient journey, other places of the clinic journey, and other types of users within the clinic who are looking to save time looking to improve the patient experience looking to reduce risk, we're looking to go paperless, that's how we want to keep on growing is finding ways that we can help support them best those issues best, so that the practices can keep growing and seeing more patients and we can keep growing as business as well.

Griffin Jones  56:57

I think that people often just stop at the financial challenge and think like, well, either patients can afford it or not. It's like, that's that that's not as far too simplistic of a conclusion. There is a range within there. And sometimes that there's no financial option to where a patient could feasibly pay for treatment. And that's, that's very sad. There's often a range of people that if they could, if they understood what the options were for them, then that's what household budgeting is. It's all a calculus, and the things that win are the things that one seems higher priority, but to that you understand that you understand how you're going to, you're going to pay for something and it isn't just simply a question of, well, they can afford it or they can't.

Jeff Issner  57:51

Totally totally. And it's that kind of plethora of topics that need to be explained. And as a staff member at a clinic, you have to prioritize your time and what's going to help people the most to make decisions, and it's impossible to cover everything. As you know, a consumer of healthcare is I think all humans will be at some point, navigating insurance is super hard. It's really complicated. And I work in healthcare, and I understand the space very well. And it is so complex to navigate insurance. It is so complex to navigate out, taking out loans to look through these different types of shared risk type programs. There's a lot to comprehend there. So we're trying to serve hacking away at that. Everything down to what is the deductible and what does that mean? And what does it copay through loan terms? And how do you actually navigate these different financial programs many clinics offer,

Griffin Jones  58:48

I want to ask you about the future of EngagedMD, but I want you to give me something that I can like, talk crap on you at because yeah, it's a sponsored episode and you guys pay me but you don't pay me well enough that I wouldn't bring that I wouldn't jab you with a thorn. If I had it. I just kind of love doing that. And like I do it with every guy I tried to. But I also hate it when I watch the news. And I feel like they're trying to get somebody to a specific conclusion. I just like playing with each side of an argument. And I just don't have anything for the argument against you and I don't have anything. I appreciate

Jeff Issner  59:33

that. But we are not perfect and we are trying to become more and more perfect every day our team is growing. Our processes are growing. Our product is growing. It's evolving, because you have to keep on evolving. And we do run into issues with any technology as any business does. And we're really just trying to be the best selling cannon. Our ultimate mission is to make life easier for everybody so that we can improve patient access to care. And so we're trying to center on that. And we're trying to be really thoughtful about the solutions that we bring to market and the way that we support our customers. As with any company, there's growing pains that come along with that. But we're working really hard to add value to the industry to really be a positive light as an industry player who can help support clinicians, staff, members, embryologist, patients, their partners, really all the players that take part in an episode of care,

Griffin Jones  1:00:31

will tell me a little bit about some of those things like, give me some of the earnest struggle that you're having and one of ours has been in that, like that third phase of the patient, or because we're never going to be pure operations consultants, that's not us. But you get to a point where sales and marketing can say, well, it's out of our hands, now it's in it's in our hands. And to me, that just always seemed like a dereliction of responsibility. Like, at the end of the day, someone is hiring a marketer because they want more revenue, they're not, there are some other things that they hire that person for, but a marketer needs to be able to set up the sale. And, you also should be able to set up a sale, that is delighted. And so I've had challenges with my team. And if you've made some personnel changes in the last year, because we couldn't get on the same page of what that is. But an example is, you know, we're talking about reputation management, like we help with reputation management, like the online reviews, and, and we know how to get people more positive reviews to a point. And then we might reach a point where it's like, okay, they're still getting these types of complaints. And, and what I want to be able to do is give people clients, the procedure of this is exactly what's broken. This is how you fix or this is exactly how you implement this into your EMR, I don't want to just give people something that could have been written in a blog post. And because I agree with Rita Gruber, when she says marketing throws the ball, it's the practice's job to catch it. But the practice doesn't care if you're Tom Brady, and you throw the perfect spiral. If they can't catch it, I want to make the ball land into their hands. That's the idea. And so, and that takes a ton of work. It takes discipline. And you have to be able to say like we don't, we don't totally have this yet. Because every marketer just wants to say they're the, they're the cat's pajamas. And the only reason why other people suck is because they're not as good as it No, it's it, it is connecting all of these dots, that's what it is, you're supposed to connect all of the dots. And, and so that's what, you know, that Fertility Bridges are in a struggle, what's EngagedMD?

Jeff Issner  1:03:00

Yeah, you know, I kind of go back to all the ways that people have stretched the platform in ways that we didn't fully expect. And it's great. They've created these workarounds. And sometimes there's things that people want to stretch the platform and do things that intuitively make sense in the vein of education and documentation and patient journey management, that when they even on the expense, it's like, oh, yeah, I wish we could do that today. But we, you know, we're building out a platform that needs to be scalable, it needs to be secure, it needs to be well managed, it can't break down. So we were just constantly trying to build out things in a very thoughtful way to meet these kinds of workaround methods and workflows that people have put together on our platform. And I wish we could do it as fast as possible because what it ultimately creates is people might run into a bug or they might run into an issue where they can't complete the workflow. And that's not the experience that we want people to have and our support team has helped people through that come up with other workarounds. So we're constantly trying to build the platform out again, in that scalable, secure way. So that your data is safe, your patients are safe, you're safe. And we're working really hard on that we've got a give a little bit of teaser to the next generation of  EngagedMD they're getting ready to launch that will help ensure that scalability and more flexibility so that all those crazy use cases that our customers come up with will be able to better support them and continue to build upon at a faster clip to help make sure that we're supporting people even better so. It's not perfect, I think we're doing a really good job of creating as many workarounds as possible and supporting people but that would that would be the area that kind of keeps me hungry and keeps me you know, Taylor and me working really hard and growing the team and growing our resources so that we can support more of these things that really should feel fall within our wheelhouse education documentation patient journey manage met, we want to keep on growing the functionality so that there's nothing this will never be the case, of course, but we want it to be as close as nothing that we can't help solve for.

Griffin Jones  1:05:10

As the challenge with the business owner, right, you're, you're steering the ship. And it's either the iceberg that you want to avoid, or the part of the water that you want to turn towards. You can see it like you can see, it's like, can you turn fast enough for that is the challenge of a business owner. When Marc Andreessen says that software is going to eat the world? One, I believe him too. I think he's talking about  EngagedMD, as you're as you're just is, as you're competently absorbing each of these spheres as you expand. So let's conclude with what do you, what can you tell us about your your roadmap, where, where, as specific as you feel comfortable going on public record, what can you share with the audience?

Jeff Issner  1:05:58

Yeah, so I mentioned we have a new version of our platform coming out, that's going to continue to expand upon the ways that we help support patients through their ultimate journey. So while some aspects of our platform right now are very much like, here's where you are, here's what you get, we're trying to create a more cohesive patient journey that's easier to manage, from soup to nuts to create a very consistent, comprehensive experience for all of the different patient journeys that you can have, and then track and manage. We're also to that point, expanding into other areas of the patient journey. So like the financial counseling journey, we'll call it, we want to keep on building out products, content, things that can help support patients through all those different stages, and we don't currently do right now. And then the last thing is just introducing more industry partners and working with more industry partners that can benefit from having this interaction with both patients and clinics to help, you know, support through things like the medication management processes, or the genetic testing processes or whatever it might be, we want to make sure that we're plugging everybody together to create, again, a great patient journey. So software contents, the people to help support it. That's where we're growing so that we can keep on helping more and more people access that amazing care.

Griffin Jones  1:07:21

Yeah, fastener it has been a pleasure having you on we're going to link to engage MD obviously, in the show notes and tag you in social but people can actually go to engage md.com/grip, and they can get a workflow assessment where EngagedMD looks at a lot of the things that Jeff talked about today. So if you want to see how your clinic stacks up, they will look at that for you. And they'll do it for free if you go to engage md.com/griffin first sponsor I ever had, because of how many people have just been blown away by your company. And I know that my own company isn't at that same echelon. Yeah, I can, I can save that. And so I admire that you've been able to do that because I'm really really trying and I know how hard it is. So thanks for sharing that on the show.

Jeff Issner  1:08:18

I really appreciate the kind words, appreciate your support and really excited to continue growing with you and growing with the industry. And so thanks again for having me. Can't wait for the next one.

1:08:30

You've been listening to the inside reproductive health podcast with Griffin Jones. If you're ready to take action to make sure that your practice thrives beyond the revolutionary changes that are happening in our field and in society. Visit fertility bridge.com To begin the first piece of the fertility marketing system, the goal and competitive diagnostic. Thank you for listening to inside reproductive health

148 "Physicians Are Bad Business People" And The MedikalPreneur Author Who Says That’s A Lie

This week on Inside Reproductive Health, Griffin hosts MedikalPreneur author, board-certified REI and OBGYN, and Inside Reproductive Health fan-favorite, Dr. Francisco (Paco) Arredondo to discuss the misguided concepts of physicians as business owners and operators, and what it takes to make it as both a healthcare provider as well as a successful proprietor. https://medikalpreneur.com/product/medikalpreneur/

Listen to hear:

  • Dr. Arredondo’s 5 H’s for hiring success.

  • Griffin point out that doctors can get away with bad business techniques because their trade is so high in demand.

  • Griffin press on the tension between employee satisfaction and client retention, and question who really comes first, and why it matters.

  • How much culture influences business success, and what to ask yourself about your own clinic operations.

  • Dr. Arredondo’s crash course in business success as a practicing physician.

147 The Fertility Private Equity Playbook: The Players And The Payors. As Analyzed by David Stern, CEO of Boston IVF

Boston IVF CEO David Stern describes some of the challenges of private equity backed businesses. Griffin grills David on the models of Boston IVF and their parent companies.

Listen to the latest episode of Inside Reproductive Health to hear

  • David Stern talk about how little of their own money private equity firms typically use

  • Griffin press David Stern on whether business decisions and clinical decisions are always separated

  • David Stern and Griffin discuss the meaning of “trapped equity”

  • What happens when Private Equity doesn’t flip at the right time, who pays for claw back provisions, and what about those hidden fees?

  • David Stern talk about Boston IVF’s model for partnership

146 Held Over The Coals: Fertility Insurance Not Created Equal

This week on Inside Reproductive Health, Griffin gets to the root of the insurance debacle in the fertility industry with Holly Hutchison, managing partner of Reproductive Health Center in Tucson, Arizona. Are cash pay patients subsidizing insurance companies’ poor coverage? How can practice owners survive when insurance authorizations are exceedingly slow, reimbursements are laughable, time to pay is unpredictable, and patients don’t understand their own coverage- or lack thereof? Who is left holding the bag when insurance doesn’t cover what it claims to, and can anything be done about it?

Listen to hear:

  • The evolution of insurance in the fertility space: how it began, when it was successful for a hot second, and where it is today.

  • Griffin question which is more beneficial to the provider- employer benefit groups or insurance companies- and why.

  • Griffin question why fertility clinics haven’t cut out the insurance companies who are draining their bottom line.

  • Griffin discuss the cost-benefit analysis: (Reimbursement, time to authorization, time to payment, volume to practice, patient cost sharing) and how to bring more leverage back to the provider.

145 Two Founders Trying to Flip The Script in The Challenging Fertility Start-up Space: Abby Mercado and Kristyn Hodgdon

On Inside Reproductive Health this week, Griffin Jones chats with Rescripted founders, Abby Mercado and Kristyn Hodgdon about their business model, how it came to be, and what risks they have in this space. How has Rescripted’s capital been invested? How do they keep content fresh? Will they survive and thrive in this space, even though so many others before them have failed- despite having massive capital? Listen now and join the conversation, with Griffin Jones on Inside Reproductive Health.

Listen to hear:

  • Griffin point out that pharmacies missed the boat- they could’ve seized the direct to consumer route, but did not.

  • Abby and Kristyn break down their business model, why it works, and what they won’t allow in their space.

  • Griffin discuss raisers of capital who had the cash, but ultimately failed, and question whether or not Rescripted has what it takes to beat the odds.

  • Abby and Kristyn explain why, and how, Rescripted was founded, and where it hopes to go in the future.

144 More Dangerous Than Overturning Roe? The IVF Legislation You Really Need to Watch, According to Atty. Igor Brusil

Griffin hosts embryologist-turned-attorney, Igor Brusil, to discuss what he, as an attorney, believes is a bigger threat to the fertility space than the overturn of Roe v. Wade, and why. What implications could changing donor privacy laws have on your practice-even if you don’t practice in the state that overturns them? Could they extend beyond donor rights and result in an inspection of your business? Listen to hear one specialist’s opinion on Inside Reproductive Health with Griffin Jones.

Listen to hear:

  • Who is advocating for the release of donor information, including medical history.

  • What laws, changing in states like Colorado, could impact your practice (even if it is not in the same state).

  • Griffin press on whether Roe v. Wade has a larger potential to damage the fertility space than changing donor privacy laws.

  • Griffin question why no one is protecting the rights of the donors.

  • Igor’s opinion on what you, as a practitioner, can do to protect yourself and your business.

143 Tips and Tricks to Publishing Your Book: An Inside Perspective with author and IVF Doctor, Dorette Noorhasan

This week on Inside Reproductive Health, Griffin talks with Dr. Dorette Noorhasan, fertility doctor (and patient) as she shares her journey to publishing not one, but two books in the fertility field- with a newborn at home. Always considered writing a book? What is stopping you? Listen as Dr. Noorhasan shares her experience writing and publishing her self-authored books, and find out what she wishes she knew sooner.

Listen to hear:

  • How the book writing process truly takes place, and how you can expedite it.

  • What you need to do first to save yourself time and energy in the publishing process.

  • Who you need on your side, and how to find them, in the publishing world.

Ep. 142 When the pretty lady in green comes to the fertility field: 4 Competitive Disadvantages for Fertility Business Owners

This week on Inside Reproductive Health, Griffin Jones explains how reputation and brand overlap, how they are both born of positioning and culture, but are not equally synonymous. “Brand is about relevance and differentiation. Reputation is about legitimacy”.

In this week’s podcast, Griffin shares four competitive disadvantages for fertility business owners.

Listen to hear:

  • What four things brand can do that reputation cannot.

  • How impactful recognition is in your brand, and how to improve it.

  • How your brand can align with peoples’ individual expression of self.

141: The Fertility Website Ripoff: 6 Tips to Protect Doctors

141: The Fertility Website Ripoff: 6 Tips to Protect Doctors

This week on Inside Reproductive Health, Griffin and guest Shaina Vojtko, Senior Digital Strategist at Fertility Bridge, share how to determine whether or not you’re getting the right bang for your buck with your fertility practice website marketing company, how safe your website truly is from attacks, and what you can do to improve your overall digital marketing health.

Listen to hear:

  • What the markup truly is on website maintenance.

  • Whether or not you are paying expenses or investing with your marketing budget.

  • Why you shouldn’t hire a development agency to do your marketing.

  • How to keep your hosting costs the lowest

140: 9 Steps of IVF Center Lead Conversion

PICK UP THE PHONE and 8 Other Ways to Improve Patient Lead Retention

This week on Inside Reproductive Health, Griffin dishes on 9 effective ways to retain leads and turn them into patients- and they’re not what you might think. Listen to hear Griffin uncover the best ways to focus on, and correct, your patient lead process for increased profits and improved patient satisfaction. 

Listen to hear:

  •  What you can do today to increase lead retention, at no cost.

  • Griffin explain how to head-off no-call-back online reviews.

  • The importance of first point of contact, and how it impacts patient experience all the way down the line.

139: Two REIs Debate OB/GYNs’ IVF Capabilities with Dr. Brauer & Dr. Arredondo

Dr. Anate Brauer (REI, co-founder and IVF Director of Shady Grove Fertility’s New York Region) and Dr. Francisco (Paco) Arredondo (Chief Medical Officer and founder of Pozitivf and author of MedikalPreneur) hash out their agreements, and disagreements, on the upskilling of OBGYNs in the fertility space

Listen to the full episode to hear:.

  • Dr. Anate Brauer argue that years of training and experience as an REI do not equal OBGYN general practice upskilling, which compromises patient care and increases risk.

  • Dr. Francisco Arredondo state that it is taking place already, the need for providers far exceeds supply, and that OBGYNs are capable (and successful), if properly trained.

  • Dr. Brauer and Dr. Arredondo agree on where APPs can offload the burden of REIs. 

  • Griffin question whether upskilling OBGYNs to handle IVF will create another chasm in the healthcare system.

  • Griffin push back that a solution needs to be identified, (after years of overpromising and underdelivering on the increase of graduating REIs), as they are handcuffed by fellowships and educational institutions. 

Dr. Anate Brauer’s Information: 

Website: https://www.shadygrovefertility.com/locations/new-york/manhattan-fertility-center/

Dr. Francisco Arredondo ’s Information:

LinkedIN: linkedin.com/in/fertilitysanantoniotexas

Website: www.medikalpreneur.com


[00:00:52] Griffin Jones: Can OBGYN do IVF retrievals? Are you good with that? Are you okay with that? You disagree. You the inside reproductive health audience disagree on if non REI fellowship trained OB GYN can do IVF egg retrievals or not. This is one of the things that we talk about today with my guests, Dr. Anate Brauer and Dr. Francisco Arredondo. We try to get down to the exact point that they disagree on and really zoom in on what they think OB-GYNs, that are not REI fellowship training, can do and can't do. There's a whole bunch of things that pile into this access to care argument, and I try to piece them out and I try to elucidate.

Okay. What's the exact point that you disagree? And I think we found that as well as we talk about the duopoly, the duopoly of the pharmaceutical manufacturers, we talk about the shortage of embryologists is that need even greater of a bottle of the bottle neck. Then the shortage of REI is we talk about expanding fellowship programs, which is never gonna friggin happen from my vantage point.

Maybe I'm being cynical, but Dr. Brauer promises to get me somebody that can walk us through that in a podcast episode. And I think these are two of the people to do it. This is a bit of a continuation from the debate that I have with Dr. John Storment and Tracy Keen, the CEO of Mater Fertility, both Dr. Brauer and Dr. Arredondo had listened to that episode as well as some others and felt that they had something to offer. And I think they both did have something to offer Dr. Brauer's of course, with Shady Grove Fertility in New York, she's fellowship trained from Cornell, which a various med fellowship program.

And Dr. Arredondo is the Medikalpreneur is going to be on a different episode to talk about that there are initiatives that he was involved in, including the foundation that he talks about in this episode that I didn't even know at the time of booking. I also didn't know that he sits on the board for Mate Fertility.

And so I feel that should be disclosed. It wasn't disclosed in the conversation. And so I'm disclosing that here, but I feel that both parties really spoke what they truly belief and and they both make strong cases for what they believe in. The shout out for today's episode is going to go to Dr. Matt Retzloff.

I'm sorry, friend. I probably butchered the study that you were recommending that would give us better data on making decisions about the quality of care. So, Dr. Retzloff, if you want to come on the show and spend the entire time talking about what you recommend. I promise to let you to do justice for you there.

So I can't make this debate. I'm not a clinician. We have two good clinicians on here who disagree, you analyze their motives. You do all the psychological analysis that you want, but you tell me, who do you agree with? Who do you think is right in this context and what are we missing? If anything, enjoy this discussion with Dr. Anate Brauer and Dr. Francisco Arredondo.

Dr. Arredondo Francisco welcome back to Inside Reproductive Health, Dr. Brauer Anate welcome to inside reproductive health. 

[00:04:21] Dr. Anate Brauer: Thank you so much for having me. 

[00:04:23] Griffin Jones: Dr. Arredondo has been on twice before. And part of the reason why you have Dr. Brauer is because I have had probably four or five people from Shady Grove on, at this point, and I'm going to be accused of playing favorites, but now I'm going to be accused of playing favorites with Paco too, because this is his third time on the show.

He's going to come back on for a fourth because he's got a new book, medical preneur that once I get finished reading that he and I are gonna go over that, but you're both on, because you each had some points of view on an earlier episode, a couple earlier episodes that I've done. One started off with mate fertility and that got people talking.

Then we had the CEO of made fertility on to talk with Dr. John Storment even before that episode aired. And that you shared with me that you had concerns about what the REI about taking things out of the REI preview and what that means Paco, you had points after that came out where you felt like that there needed to be a physician arguing for the side of upskilling or training OB-GYNs outside of fellowship, but let's start with your concerns not. And just, what was the concern that you had when you listened to that first episode, or just in general about the issue? 

[00:05:43] Dr. Anate Brauer: Sure. So I think my background is I trained at Cornell, which I realize is in New York City, where there are 22 other IVF centers and there is a lot of access to care.

So I understand that we're coming at this from different perspectives, but my fellowship director always said to us when the time I was a first-year fellows. Our field of medicine, more than any other field of medicine has the potential to change society. As we know it right. For better or for worse. And I think that that comes with huge responsibility and liability.

And so it's a big undertaking. And one of the hardest things we'll talk about kind of bottlenecks to access because that's a big part of this discussion. But one of the hardest things I do is counsel patients not just do procedures, but also counsel patients on very complicated endocrine issues that have to do with competing, brokering failures and other things that we'll get into.

And I don't feel like I would be equipped. To treat the patient with the level that they should be treated. If I didn't have the training that I had. So it does concern me this idea of standardization of pair as a CEO of, of Mate stated that said that those words multiple times because each case is individual and all of the training that we've received and experience that we've had, I think helps us get that individual patient to their goal of competing safely.

And so that's my concern here in New York, by the way, what prompted my conversations about this and actually will prompted my interest in being on the start QA committee, which I'm now on, is seeing chart after chart of complications of IVF cycle overseen by general OB GYN who have not been properly trained, who are working for some of these companies that are looking now to scale very quickly.

And so that's what kind of prompted this concern in me. So there you have it. 

[00:07:53] Griffin Jones: Okay. I'm going to come back that I took a couple notes on two different points. You made one about fellows and then another about the complications that you seen, but Paco, when you reached out to me and just said, there needs to be a doctor arguing.

There needs to be an REI arguing for the case of training OB-GYNs outside of fellowship. What did you mean by that? And if I'm paraphrasing correctly. 

[00:08:14] Dr. Francisco Arredondo: Sure. No, no. Yes. I thank you once more for having us and thank you to, and not to be willing to do mental gymnastics here. So I would like to set three things straight before we enter into any debate in one of them is that debates in my view are not to be won or lost.

The baits are to be learned from that's the first thing I want to state. The second one is that if we agree in the context here, that we believe both sides, that human reproduction is a universal, right? That's the other thing that I want to set as a context, because everything else evolves from there.

And the third thing is that there is a difference between clinical medicine and health policy that we asked physicians at the clinical level. We use sometimes not always created at the same, and there are very different interests in individual care versus health policy. And when we have 90% of the needs of the fertility unmet in this country then is when I do argue that we have to think of different models of providing care and among them, we have to explore the possibility to utilize every one a was at the top of our licenses.

So that's basically what I meant. And I would start by saying that it is not my intention ever to replace REI's we don't be ever, but we have to learn from other places, even within our specialty, let's go to fetal maternal medicine, the fetal maternal medicine, which are high-risk deliveries and high-risk pregnancy.

Those guys do not do one single delivery. All of the deliveries are done by OB GYN. They basically handle themselves at the top of the license by managing different pregnancies, recommending guidelines, recommender, and course of actions, and are executed by OB GYNS. And it's the sociologist, the only way they run five or so at the same time is by having extensors like CRNAs radiologist.

They don't do every single x-ray. In fact, they just sit and read the x-rays that the technicians and other people run healthcare. Otherwise. If we have a potential market of 3 million IVF cycles in the United States, and we are currently doing 300 cycles. Even if you crank the production of REI, we will never have all the REI is doing every single egg retrieval that is out there.

So my argument is, and this is the argument of our nonprofit, which is called universities to train people, to do other tasks that physicians are doing, or nurses are doing that can be done by different people at the top of the license that is there. 

[00:11:54] Griffin Jones: I want to let Dr. Brauer and analyze that in a moment.

I want you to start though Paco with what is the limit of what the REI can do? So if you already, I needs to practice at the top of their license. What is the limit to what can be done outside of fellowship training? 

[00:12:12] Dr. Francisco Arredondo: Yeah, so I think I would approach it gradually. The other way it is, there is no question that an OB GYN and a nurse practitioner or a PA with good guidelines should be able to do every single diagnostic step of the fertility patients.

Number two. I think that doing an egg retrieval. For example, I would not give it to a nurse practitioner or physician assistant because they are not capable of resolving a complication bleeding, et cetera, but an OB GYN absolutely can do an accurate very well. There is no reason why an OB GYN can let's put it this way in the last week I spoke with probably 20 different fellows that our fellows out there that are coming out doing 10 egg retrievals in their whole fellowship that it's still to this day, they are reproductive endocrinologists that come out of fellowship without with zero embryo transfers, zero embryo transfers 

[00:13:36] Dr. Anate Brauer: This is an issue write that down Griffin, because that's something that should definitely be touched upon regarding fellowship program.

[00:13:43] Griffin Jones: So I am writing that down. I want you to continue Paco with so every step of the diagnostic process OB-GYNs can do egg retrievals.

What else?

[00:13:52] Dr. Francisco Arredondo: Currently we're doing IUI is playing IUIs in the OB GYN office. And I think that there's no reason why they will not be able to do IUI and again, all under the supervision of a fertility specialist. Now you will have control of, or a guide, several OB GYN and there is a difference between what we call improvement in quality and innovation, because the requirements for improving quality are exactly the opposite to innovation quality requires consistency, repetition, precision standardization, because quality, the enemy of quality is variability. So that is what is required for improving quality. However, for innovation, you actually required the opposite. You require failure variation and serendipity. So we have to be able to dance this delicate dance between improving quality and innovating in healthcare.

And yes, how I see the market right now, or fertility taking certain steps imply that we will take some breaths. But not taking a risk right now, you will imply that will never satisfy the demand. 

[00:15:37] Griffin Jones: So before we go improving the, before we go innovating, now, I want to see in this game of, of blackjack, let's call it and that where we're hitting you one after another, at first OB GYN is doing every step of the diagnostic process, then doing egg retrievals, then doing IUI.

Do you disagree with any of that? 

[00:15:55] Dr. Anate Brauer: I think in general, all of these access conversations are glossing over one major issue, right? The issue with access does not just come down to how many RAs are graduating every year. There are other major roadblocks to access. So the three issues that I see with access are costs and affordability.

Even more than our eyes embryologists. Okay. And then REI is for us at SGS our biggest issue as we're expanding in various markets is not necessarily finding doctors to put into the clinic. It's even more so finding embryologists right. Takes about two to three years to train a good embryologist, to do biopsies and egg set cetera.

So all of these conversations are revolving around how do we get more providers? Did you retrievals to get more new patients in the door? But there's also roadblocks on the other end of that. I'll talk about some of the ways that we are trying to address from those, some of those robots within our organization and why I wish other people would be doing the same work.

I'm happy to talk about that. But one of my that, for example, when you were interviewing the Mate CEO that you were talking about access and costs, they don't take insurance. I have a huge, huge issue with that. And so I think we can not only talk about providers, if you don't talk about whats our solution for costs and embryologist, and a lot of the solutions for cost is well higher general OBGNYs, or would you want it?

And then you don't have to pay them as much as you do an REI by the way, some of my best friends in life are general OB GYN who are unbelievable, amazing what they do. And so none of this discussion in any way, a ding on being a general OBGYN. I also think we should look at our other fields in our space.

So I know some amazing generalists that are unbelievable surgeons. That doesn't mean that they can become GYN, oncologists. And so I think we should have a very clear discussion on what we need to do to expand more trained REI in this country and not only to roll over OBGYN, but also the role of APP.

For example, I do most of my own scans which I know sounds a little archaic, but that's how I was trained. And I'm in New York and my patients want to see me and I liked him the ultrasounds, and I think the more ultrasounds is even better, your retrievals. But I do think there's a role for APPs is, are advanced practice providers to do ultrasound, to do IUI, even to manage IUI cycles.

It doesn't even necessarily have to be a general overview. And I personally do not feel comfortable with the general do and doing retrievals unless they've done thousands and thousands of retrievals or unless it's an REIs physically on site. The CEO has made with saying, oh, we have five REI's on the board who are there by telemedicine.

She also didn't mention who these people are, but I don't know what REI that I know would feel comfortable with the liability of being on a video, walking in GYN, through a complicated egg retrieval, and some that has fibroids, maybe someone that needs an abdominal retrieval, it SDF. We have a policy that if someone requires an abdominal retrieval because of body habitus or anatomy or fibroids, there has to be two MDs on site to do that together in the, or so yes, 99% of retrievals are easy, but when they're hard, they're really hard.

You can be one millimeter away from the illiac I mean, I will not feel comfortable with an OB GYN handling case like that unless I was in the room with them. 

[00:19:22] Griffin Jones: Okay. 

[00:19:23] Dr. Francisco Arredondo: You will know those hard retrievals in advance. Obviously you will not have scheduled them.

[00:19:28] Dr. Anate Brauer: Not if I'm not scanning them.

[00:19:30] Dr. Francisco Arredondo: Huh? 

[00:19:31] Dr. Anate Brauer: Not if I'm not doing the ultrasound.

Right. 

[00:19:34] Dr. Francisco Arredondo: Do you think that an OB GYN will not affect the note by an ultrasound? A fibroid? I mean, I think that the OB GYN are capable of doing that and much more surgery, sometimes more complicated than, than I realized, but that is a debate that we can have, but regarding the issue of REI and the access of costs, I think it is very clear that the lack of production of REI is related to the lack of decrease of cost of idea.

We actually have very high IVF costs because we don't have enough supply. And if you think about any other industry, even in healthcare. Braces, I remember when I grew up only the rich people have raised raises a lot of other plastic surgery, every single one of those procedures has been going down in price.

The microwave was $600. Now you buy for 30. The only thing that has going up is the IVF cost. And it's not only because of the physicians. It is because there is a duopoly on the pharmaceutical industry. There is other reasons that there is no competition, but if there is in now with the consolidation of private equity, it actually will have even less competition that will not be quizzed the price of access.

So my point is that the correlation of access to cost is directly correlated with the lack of providers. 

[00:21:13] Dr. Anate Brauer: Right. So how do we increase that? Right. So for example, we, so I'm part of Shady Grove Fertility, which is a part of a larger organization US fertility, we train, we graduate about six fellows a year. So we now run the NH fellowship program, the University of Colorado's program, and the University of South Florida.

[00:21:33] Griffin Jones: But how many of those are new fellowships? And not like the University of Colorado was acquired by us. Jeff Jones was acquired by us. Jeff, not how many of them are new? 

[00:21:42] Dr. Francisco Arredondo: We need hundreds.

[00:21:44] Dr. Anate Brauer: Right. But hold on a second. Let me just finish what I'm saying. Right? So we support those fellowship programs. We train those fellows, we fund those fellows.

Which I don't see any other non-academic program doing or offering to do. We would love to open more fellowships. For example, I'm here at STF, New York with my partner Tomer singer, who was the director of the residency director at Lenox hill for almost 15 years. Right. So we would love to do that. The problem is there are many hoops and ACG requirements. You're required you to be affiliated with an academic center, which for us in New York, everyone's already taken up. Everyone already has their own fellowship program and they don't want the competition, which is a whole other conversation. It's impossible as an REI and New York city to even get hospital privileges because they don't want to give you privileges because they don't want you competing with them, which is a whole other problem that you really be on the cover of the New York time.

But that's the problem we want to train fellows. We do. I can't speak for other organizations like CCRM or Kindbody or anybody else. We want to train fellows. We are training fellows. We are training embryologist since we took over the Jones' program, we're expanding that training program. But these are the things that we need to be focusing on rather than taking shortcuts and hiring OB GYN and train them to do, what would we do.

[00:23:04] Griffin Jones: But everybody's been saying that for years now, and it still hasn't happened. We're still not adding more of them. 

[00:23:10] Dr. Francisco Arredondo: I don't think that it's taking shortcuts. It's thinking out of the box to re think the model because the truth is being very realistic. If we are currently doing 300,000 IVF cycles with 1500 IVF doctors, and we have required 3 million cycles in the country, when are we going to produce another 10,000 REI?

 We want. We want. Period. I mean, we have to be realistic.

[00:23:45] Dr. Anate Brauer: Right. I think the main issue is that the fellowship programs are siloed within academic programs who have no interest in expanding or working with private practices to expand fellowships because they're perfectly comfortable. In the situation that they're in.

Right. And so that's a major discussion that needs to happen. And I'm still asking the embryology question because my main limit to increasing my cycle number is how many embryologists do I have in my lab? And to me, it's much harder finding embryologists than it is to find an REI. 

[00:24:19] Dr. Francisco Arredondo: And actually in that I would say Griffin to schedule a talk with Tony Anderson.

Who is our lab director and the main person. He has IVF Academy of IVF of USA and that he is going to be incorporated into our University. And basically he presented at the Pacific that after doing a two month training. The outcome is exactly the same as if somebody that has more than one year doing an exam.

He prove it. He has the data is not data that is just mentioned is data, solid data. So we are actually changing the way the training is happening. There is a hybrid training online, and then there is in-person with actual cases. And I think that the academy can produce very good embryologists in approximately four months with all the training.

Well, I'm not an embryologist and this is what my embryologists are saying. 

[00:25:27] Dr. Anate Brauer: You should ask Michael Tucker and Jim Brown, and maybe they can debate each other. 

[00:25:32] Griffin Jones: My job as moderators did keep this a little bit boring by preventing the 18 different topics from going, focusing on one. So I'm going to try and do that.

I do want to come back to Dr. Brauer's point about embryologists later because Dr. Storment afterwards texted me and said, I wish that I had brought that up to although now no, I'm going to save my tangential thought for when we come back to that, I want to, and the duopoly of pharmacies and the fellowship programs, I want to come back to still what you are comfortable with the OB GYN being trained to do not.

And it sounds like, okay, they can do retrievals if an REI is physically in the room and. 

[00:26:13] Dr. Anate Brauer: Yeah. And then that defeats the purpose, right? Because I'm still physically in the room. I still have to physically be in there. They will do the retrieval.

[00:26:23] Dr. Francisco Arredondo: I personally disagree that you don't require a REI to be pressing down the hall? Not even, I mean, not even there because an OB GYN in a simple case, which is what we want to select to give to them. They have the capacity to open that patient. They have the capacity to the tech. When the patient is bleeding, they have the capacity to suture a cervical artery probably better than us.

So now they have not done it. And as I mentioned, there are currently a lot of our REI colleagues when they started practicing, they have done less than 10 equity retrievals. That's what it is in. we are naive and we don't think that that is happening, that we were learning on the train. 

[00:27:09] Griffin Jones: Anate are you not satisfied that an OB GYN could address the complications?  

[00:27:15] Dr. Anate Brauer: I fully again, like many of my friends who were generalists are probably better surgeons than I am I guess I don't understand what the, the kind of, it's almost a perseveration of OB GYN, OB GYN, up-scaling OBGYN and why is that? 

[00:27:31] Dr. Francisco Arredondo: Because we have 90% of the market without cover. We have 90% of the market that is not covered. 

[00:27:38] Dr. Anate Brauer: Okay, so let's talk.

Why are they not covered? 

[00:27:41] Dr. Francisco Arredondo: Because A, lack of access financially, B lack of go live, go of competition because we don't produce and offer REIs and our boards have for 20 years spoke with both of them. Saying that they wouldn't increase access and they have not done it because we have not produced more REIs because there is access to care.

Like there are certain areas that are in rural areas that they want to solve right now. Their practice in private equity will not buy it because, oh, it doesn't provide a lot of revenue there. So those are in insurance coverage is another one and that it is not mandatory. So all those are reasons.

But the main reason, if you look at any healthcare issue is a supply driven market. The more suppliers you have, the bigger the market will be there and we are not supply-driven. 

[00:28:43] Dr. Anate Brauer: So I just want to take those points one at a time. Right? So. And put the, my argument aside for a second, because one let's, let's talk about cost, for example, that's the first thing you mentioned.

So the main issue with costs is lack of insurance coverage. Right? If everyone had insurance coverage, everyone would have access. Is that accurate?

Right? So that's that we should be focusing on. If the, 

[00:29:16] Dr. Francisco Arredondo: if the, if the, if the insurance is given to everybody, not only the ones that work, then it will be covered. So if they don't see universal health care coverage, yes. 

[00:29:25] Dr. Anate Brauer: Your premises I'm from Israel. Originally, everyone has coverage and everyone has IVF pilots.

But 

[00:29:30] Griffin Jones: how does that supply, how does that solve your supply and demand issue pocket? If, if, if, if we're, if, if we're only serving a quarter of the population are actually not a quarter, a fraction of the population and, and that's, that's covered and we still have eight and 10 week wait lists. How does, how does ensuring more people increase access?

[00:29:55] Dr. Francisco Arredondo: I don't think so because you have much more demand, but you don't have for supplies. 

[00:30:01] Dr. Anate Brauer: Okay, so then let's talk about why are there waitlist? So we have, we have, I don't know, 40 something offices now in all different regions, we follow our waitlist very closely. We're not in any, , we're in Colorado, Colorado spring.

We're not, , we're not in the Midwest. So I have friends in Nebraska. I think she has a wait list of two or three months or something like that, which they can get their initial workup done with her OB GYN. And by the time they get to her, , I think COVID has changed a lot. We can do a lot of virtual consults to me.

When, when I talk about access, someone's not going to open you to financially support IVF labs, to be able to argue, to put an embryologist that two minimum, two embryologists there could you need witnessing and all the staff that you need to staff a, an ASC, et cetera. You may have an ASC in a major city and you may have kind of satellite monitoring.

Stations, if you will. And if I train some on whether it's an ultrasonographer or a PA, it doesn't have to be a general OB GYN is my point. If I train a PA to do all the monitoring there, I think I have more than enough time to review those cycles. So that's why I don't know what, why specifically we're talking about the way to solve the access to care issue is trained more overdue in because if I had someone doing monitoring and then coming for me to do retrievals and my partners to do retrievals and I can sit there and do virtual consults all day long, I don't see why, why this is an issue.

I don't 

[00:31:27] Dr. Francisco Arredondo: think that we can, we can, we can not do 2.7 million ed retreat. We can't 1500 people cannot do 2.7 million egg retrievals it's on reasonable is up. It's not possible. I do agree with you a hundred percent. We open a satellite, a hundred percent run by a PA a hundred percent. She saw the patients she's monitored.

She sent them, we do the egg retrieval. We do the transfer could not agree with you more. And that I think that we can set it up here as the basis for agreement that we can develop satellites where everything else. And we can start as a point of view to start training those people, to do the satellites.

Now there's going to be a point that those satellites are going to saturate the egg retrieval bottleneck that will occur, and then we can discuss the next step. But I think that as a first step, we need to train people that. It's comfortable doing all the monitoring, all the counseling and tweaking the medication during the stimulation.

So we agreed that they can do the diagnosis. They can do some basic, 

[00:32:49] Dr. Anate Brauer: oh, I said, I set 

[00:32:50] Dr. Francisco Arredondo: a PA or nurse practitioner or a generalist. It's okay. It's cheaper. Or is less expensive if you use a RPA, but now for an country. I certainly will allow. In fact, there are plenty of OB GYN out there, general OB GYN that are doing that for, 

[00:33:08] Dr. Anate Brauer: with as we speak.

Yes. And I have managed their complications.

[00:33:16] Dr. Francisco Arredondo:

[00:33:16] Dr. Anate Brauer: have, I'm not saying there aren't out there and , we've all had complications. 

[00:33:21] Griffin Jones: Did they appear to be disproportionate to you or not? Did they do, does it appear anecdotally, do you, does it seem that you're seeing more complications from 

[00:33:31] Dr. Anate Brauer: hyperstimulation syndrome? Absolutely because they haven't been trained and.

Hundreds of thousands of simulation cycles. And by the way, I totally agree with you Paco. I was lucky enough to train at Cornell where by the time I graduated, I saw more simulation cycles and most attending feat in a year. Right. So I understand which is another issue. Like there's fellowship programs out there that do 200 cycles a year, that's it?

And they have two fellows. They should not have two fellows because those fellows aren't getting clinically trained. I mean, that's a whole other discussion even needs to be 

[00:34:05] Dr. Francisco Arredondo: had. And that would be the second point of agreement, which is we agree that we can train all those people. The second to try to find common ground is that somehow we need to revisit how the people is being trained in fellowships, because we're putting a lot of emphasis of 18 months or 20 months in research when 99% of the people come out and do IVF, maybe we need to track.

So REI. The researchers 

[00:34:36] Dr. Anate Brauer: and the IVF. So 

[00:34:39] Dr. Francisco Arredondo: you'll have now two different tracks and you can produce in one year a good REI fellow in a, that is going to do IVF because by that year, they can do easily a hundred retrievals, easily 50 transfers and seeing their sheriff complications and they can go on. So that's another compromise that I have no problem doing.

But I think in, in, in basically that's one of the ideas or just university that we really need to create. And that's what we've made it a nonprofit, because we don't want to, anybody to mention that we're doing this for profit thing. We are doing this for the firm belief that we think that the United States.

Do not have the healthcare that they deserve at the level of fertility, we have 90% and we need to change that and how we do it, we can obviously have the debate and this, but we need. 

[00:35:43] Dr. Anate Brauer: Griffin the fellowship question and the training. So at SGF, we require any one onboarding. I only have to do two weeks, but we require six weeks out of fellowship and spend it in Rockville.

You're doing hundreds of cycles. Minimum a hundred transfers before you can do anything in any of our labs. And so I, I, , unfortunately some fellows need a mini fellowship. We haven't made a business out of it, but maybe we should, but that's, , 

[00:36:11] Griffin Jones: and answer to your question of why this issue is I w I'm not qualified to argue that it's the most present maybe that maybe dogs are done to is, are arguing that this is the most important thing that we can do.

I'm simply observing that it is one thing that we can do out of many reasons. And the reason why we stalemate in politics very often, we're trying to improve education while the teachers need to, the teachers need to do this while we can't do that until the parents do well. And then you, when you. Go from one issue to another, just nothing ends up getting done.

So it's okay. We take the issues that we have in front of us and try to unpack each of them. I'm definitely not solving the duopoly of the, of the pharmaceutical companies here. And the embryologist, I do want to talk to more, but it's also another issue. Could it be more important than this one that's arguable, but this at least that the number of fellowship programs in the country is another issue, but I'm not a bog.

And and, and, and they still, nobody's still suggested in a bog person for me to talk, to, to do an entire episode soup, to nuts of what it would take to build find me, someone who, somebody listening, find me, that 

[00:37:22] Dr. Anate Brauer: person find the same answer, but 

[00:37:25] Griffin Jones: what's happening right now is that there are people training, OB GYN, generalist, OB GYN.

It sounds like. We have some agreement on what they can do. Some disagreement on the level of oversight needed and the, and the likelihood of complications that come from retrievers. What about the diagnostic piece? And what about OB-GYNs doing IUI? 

[00:37:51] Dr. Anate Brauer: So I think so I would, I would, the first one talks about the diagnostic.

So is it Mitchell? And again, I am in New York city where I treat a very different kind of patient population. I very rarely see a bread and butter facilitation. By the time the patient is sitting in front of me, they've cycled the four other centers. And show up with their like binder of medical records.

And so I don't see kind of the bread and butter. I have a lot of friends who are generalists, who want to send patients to me and in the interim, they're kind of doing a workup. So I do feel like one thing that would definitely help is training is first of all, increasing REI education in general and OB GYN residency, right?

OB residency, four years, I spent a ton of time in antepartum learning all the MFM stuff. Do you want oncology that I, Cornell is a very, I also did my residency at Cornell, very surgical program. I, I went into ODU and to do, do an oncology and then swung the other lines of spectrum. But I spent so much time in OBGY/Onc.

I wanted to do REI and I spent three weeks in REI and this is someone who actually wants to do it. So you can imagine the resident that doesn't care. So the OB GYN is graduating programs right now. Residency programs really know very, very little about REI. So we have residents here rotate with us in New York all the time.

From various hospitals and, and the first step is to just teach them the basic workup. What does it take to make a baby? How do you talk to a patient about it almost from, as in flipping in normal uterus to implant normal ovaries with normal numbers of eggs and genetically competent eggs, right.

Just be at the conversations that the ingredients doing the workup, right. That automatically takes so much off of my plate. And so by the time they're coming to me, they're already kind of packaged up of, okay, here's the basic workup, also doing the preconceptual genetic testing so that they're all kind of set up.

So I'm totally comfortable with an OB GYN doing those sorts of things, then even comfortable with an OB GYN, managing IUI cycles. For example, as long as they're monitoring cycles, I'd actually rather have an OB-GYN working under. Stimulating patients and actually monitoring them than just randomly giving them.

Clomid like, it's candy. Like we see all the time. Right. And you don't even know how many follicles are growing and even an GYN or a PA or an MP doing an IUI at Cornell, which is very tightly managed. I mean, fellows can't even stand follicles that are over 13 millimeters, right? When I was a fellow, unless you were a senior fellow and very experienced and ultra down, but the NPS and the PAs would be the ones doing IUI.

So that's, that's very low risk. I have no problem with that. It's really, when it gets more into the, it's very important for me to counsel a patient on what IVFis, the pros and cons of it, the risks and benefits, the possible outcomes and complications, right? Because it's all about setting expectations.

And I feel like we know all the possible outcomes, genetic testing, which is becoming more and more complex. The pros and cons that are constantly changing every few months, we're learning more and more. And specifically when there's failures talking and counseling patients through that, we know with our eyes, what happens in the lab, most fellowship programs, you do spend time in the lab.

And so those things that take it does take a fellowship for them to learn all of those things, thin lining, but current implantation failure, we're current present the wealth, all of the things that we're still well versus taking it. So those are the cases that I want to manage. I feel comfortable with an OB-GYN managing a simulation cycle, but I also feel comfortable with a PA running through that dosing with me, which takes, , five seconds for me to do.

And I'm even profitable the PA doing the IUI. So that's why I don't, I don't think it even requires training general. I would do am. I think an REI can handle it. Doing more cases. If we, if we're set up in a more efficient way. I also think one thing that we haven't brought up here, which is huge for efficiency is AI, right?

The, we, we at us fertility are, have, are investing a lot of time and money and research dollars into exploring various ways that artificial intelligence can be used. I think one of the best ways it can be used is, and this is for everything from doing an ultrasound, like you can have an MNA, take an ultrasound probe, put it in the vagina and you get a read out of every follicle and what sizes objectives.

Cause there's always subjectivity when you're talking about measurement. So something is a little of that to extrapolating it, to. Dosing a patient's right. And algorithms of looking at hundreds of thousands of cycles and predicting even based on fire cycles that, that patient's done when you should trigger how you should trigger, et cetera, and also into the lab of grading embryos, et cetera.

So I think, I think where the investments should be is training more REI, which is complicated because that involves a bag and ACG made all of those things. We've got to find a way to do it. Training more embryology. And artificial intelligence to make our lives more efficient to solve our problem.

[00:43:09] Griffin Jones: Darn it. He will, he will buy the, it'll start a new one by the end of this podcast 

[00:43:14] Dr. Francisco Arredondo: at 99% of the things. I agree because I agree that we only as a OB GYN rotate one month and the issue is when they pressure you to take vacations in our, in every I in just one month or two months in the whole 48 months of of training, I do agree that artificial intelligence is the future.

And obviously there are already companies out there, like we were just mentioning and all that. I think the key difference, and we agree that we need to train REI perhaps in a more expedite manner. Or in two different tracks, we agree that we can utilize nurse practitioners, physician assistants in order to increase efficiency in the system.

All that I think the only difference that we have is that I feel strongly that a OB GYN can handle equity tremble. And obviously she does not. But in order to dive into that particular question, let's think of other examples within our industry , that you have birthing centers and you have delivery centers and in the birthing center, you're not going to send a patient with a previous C-section preeclampsia and diabetes to be delivered there.

No, you want to send this straightforward case that will have. Very unlikely, a reason to have a complication. And if that thing arrives, you have a system in place to send it to the delivering hospital, which is rare. So it is the same thing in fertility where you can put the simpler cases, especially those that are in rural areas in markets B's.

And C's where a train OB can do the retrofit. And we don't know what is going to be in the future because now in the future, you might get. You send the act to a place where they do. They send this sperm, they do the, the embryo, and now you send the embryo back to the place and anybody can do a number of transfer.

I mean, that could be a potential business model for the future, right? Where you do it. Richard was in one place. You freeze the egg, you freeze the sperm, you send it to a very concentrated laboratory. And you'll create the Ember and you'll send it back. And then you transferred the embryo that is possible.

And now you increase access 

[00:45:48] Griffin Jones: w one point that was given to me, and I want you to apply it on this Dr. Brown Dr. Matt Retzloffemailed me after one of the earlier episodes and says that the only way to really know is to the effectiveness and the safety is and if I'm paraphrasing your point, Dr. Retzloff, you can come on and do your own show.

But he, he was talking about, the only way to really know, is to do a randomized blinded trial of, of outcomes of safety. And because I'm not a clinician because I'm paraphrasing Dr. words, how would that work? How would we, would we really be able to compare the, the outcomes from a board certified.

An ecologist versus the training that's being 

[00:46:31] Dr. Anate Brauer: done, IRB will ever prove that study. And I don't really see patients signing up for that study personally. I wouldn't do that. So, I mean, I think it's, I still am having a hard time wrapping my brain around this conversation, even being a conversation and the word upskilling, which I had never heard that word before a year, 18 months ago, , 

[00:46:55] Griffin Jones: I adopted the word to distinguish it from fellowship training.

[00:46:59] Dr. Anate Brauer: I understand. 

[00:47:01] Dr. Francisco Arredondo: Well,  what happened? What happens in any other country in the world, in Spain, which has been a leader of fertility for years, Spain and France in Eataly in any other place, there's no fellowship, they finished and they go through a certificate or they. And mentoring. I don't know if in Israel there is a fellowship, is there a fellowship in Israel, 

[00:47:28] Dr. Anate Brauer: but they're yes, but they're, they're also required to continue practicing general OB GYN and to take call because it's a, it's a socialized system.

So they see their patients after hours. They do new patient consults, like at 11:00 PM. 

[00:47:43] Dr. Francisco Arredondo: But in order to do an REI, do you have to go through a 

[00:47:45] Dr. Anate Brauer: fellowship? The practice? Yeah. I don't know if it's an official fellowship. You're definitely certified in fertility, all these things that you're mentioning.

They're still training programs and they're not six week training programs. I mean it's years of training. So, but at the end of the day, it's not a new fellowship program. Right. Did you believe that a really good general OBGYN should be take to be cutting out cancer. 

[00:48:10] Dr. Francisco Arredondo: But I would not compare, I would not compare an egg retrieval with the level of complexity of, of a surgery of cancer.

[00:48:18] Dr. Anate Brauer: The liability is similar. I mean, don't feel like our field has the highest liability pretty much at any field. 

[00:48:27] Dr. Francisco Arredondo: I don't think so. I disagree with that. The the premiums of REI are very low compared 

[00:48:33] Dr. Anate Brauer: to the 

[00:48:35] Dr. Francisco Arredondo: liability. That's how it's based. The liability. The liability is based on how likely are you to be sued.

And, and the premiums are fertility. They are very low, very low. I mean, compared to high risk OB, those are high. 

[00:48:49] Dr. Anate Brauer: I feel like what we do and the counseling we offer and the potential issues in the lab are extremely high liability. And so I personally would want to manage those liabilities myself rather than managing someone else's life.

[00:49:06] Griffin Jones: We can bring Dr. Katz on for a liability episode to examine that. But Paco, I want to put something on you because a lot of this conversation might be overlooking second and third order consequences with regard to access to care that come from training. OB GYN is like, I don't know what their overall workload and wait lists look like right now, but I don't think most OB-GYNs are sitting around waiting for new patients.

I think they have case loads and workloads that are pretty full, full. I could that it could be an assumption that needs to be tested, but either way I think it's one we were overlooking here. So if we solve for access to care with regard to fertility treatment, by bringing more OB GYN in to do some of the purview of the REI, then aren't we creating a shortage of care somewhere else in the OB GYN sphere?

[00:49:58] Dr. Francisco Arredondo: I, I don't know. The numbers on the OB GYN, how many are needed? I think that overall, if you look at the statistics by 2045, we are going to have like 70,000 a shortage of physicians in the United States. No matter what specialty you're talking about, because again, we're not producing enough. The, the medical schools are not producing enough physicians.

But I don't specifically to your Western. I, I don't know. We may. But the, the point here is that basically the big disagreement that we have is if an aria, if a OB GYN, after doing 50 or 100 supervised egg retrievals, if it is not capable of doing ed retrievals for an IVF clinic, my answer is yes, if that person and I don't know what the number is, 20 5100.

Which in certain clinics, that person can be trained two months after doing that, it can, that person do equity troubles for you. Absolutely. Absolutely can. In fact, they're are doing it right now. 

[00:51:09] Dr. Anate Brauer: Yeah, I guess my, my question goes back to Griffin. The point he just made, which I still don't see how this specific concept of upskilling solves our issues, because who's going to who we're going to take these jobs.

And we already see that happening. Our residents who GRA, who wanted to do REI, who didn't match for whatever reason. And now this is what they do. And then they get to put on Google that they're a fertility specialist and market themselves in that way. And now you're going to run into a shortage of generalists, which there's already a shortage of generalist generalists, definitely in this area.

I can barely get a patient in to see an OB GYN. Larger problem personally, I would rather train ABPs to do ultrasounds and help me with monitoring and make mission so that I can say my lane and do what I need to do and not take away from any other specialties who, who have their own issues with, with access.

And the other big concern I have is creating a two tier system of care, which we already have in this country clearly. Right. And we see it with cancer, for example, right? The main cancer centers. If you have cancer, you want to go to the best place flown, , you want to go to Texas MD Anderson, there's several big centers in the country you want to go to, you're not going to find it in small town USA.

I mean, I grew up in Memphis, Tennessee, so it's not like I grew up with, , so, so much access around me. Right. And so I do worry about. Giving one part of the population, kind of a water down version of what we do. And one part of a population, an elevated version of what we do the argument against that is, well, you're giving one part of the population, no option and other populations, the best option, but there's something to me just wrong about just because someone lives in a certain place or doesn't have enough money to afford the bad that, that you're potentially giving them a less safe experience.

And 

[00:53:17] Dr. Francisco Arredondo: we don't know if he's let's save. And I would say, we don't know if it let's save. And I would say that if we take a risk, we may fail, but if we don't take any risk, for sure, we will fail 

[00:53:28] Dr. Anate Brauer: to cover everybody. I'm happy to take risks, but I'd rather do it not with upselling of doing.

Well, what I mentioned before, I'm happy to send that set up satellite monitoring clinics, and 

[00:53:42] Dr. Francisco Arredondo: we have proven that that works and delivers the same 

[00:53:47] Dr. Anate Brauer: actual care, so that can work, but I still don't want to solve our problems. They 

[00:53:53] Dr. Francisco Arredondo: are randomized controlled trials where nurse practitioners do embryo transfers versus REI in England, randomized control trials.

Exactly the same pregnancy rate. Exactly the same pregnancy rate nurse practitioners in, in, in in England doing embryo transfers versus 

[00:54:14] Dr. Anate Brauer: res so, okay. So do you feel like we should even have any fellowship programs at all? I mean, everyone could be trained then what's the point of fellowship programs with everything can be, everyone can be trained to do.

Exactly the same thing. If you have any degree or any letter behind your, behind your name? Well, when 

[00:54:31] Dr. Francisco Arredondo: you go now, you're talking about medical education. That's a very important point. So the traditional medical education is based on pedagogy, which is training kids, the dietary pediatry, that's pregnant kids.

The new in, we don't learn like kids will learn by adults, which is unprovoked. And that is by doing things. And you can go and look at medical education. And the best way now is not to saturate people with theory and books and stuff, but it's to give a minimal basis and do things and do things and do things.

So that's why I would say that I will feel very comfortable if I give good basis to an OB GYN and I will train that OB GYN with supervision. To do 50 ed retrievals. It's an experienced surgeon already. I will feel as comfortable as a fellow that sometimes just finished 10 or 20 Avery Tribbles. He has a lot of information, but it does not have the experience or rather the ability to solve a problem.

I am talking specifically about this task. I'm not saying handling all the things I'm talking about. This. I feel very comfortable doing 

[00:55:54] Griffin Jones: it. So I want to let each of you conclude how you want it to, before we do them, I'm going to give you each an open thought to conclude on, but let's hit the embryologist question for a second, which I'm, this is completely anecdotal, but we have strategies based on clinics, different needs and capacities.

And I'm talking about my firm is a creative and biz-dev firm and it seems to me like clinicians hit their capacity first and then embryologist hits their capacity. It seems to me, this is very anecdotal that across the board is generally speaking as possible. The embryologist really, we hit that lab capacity some time after the COVID reopening sometime in September of 20 in the fall of 2020.

And so, but it, it seems to me like they're pretty neck and neck. Maybe the REI bottleneck is tighter, but they're, they're probably equal now, but why not solve the. Problem first Pacoor is, is this, is the embryologist, how is it not more pressing than the REI issue? 

[00:56:58] Dr. Francisco Arredondo: Well, I think that you have to also look at AI, , not that umbrella just will be replaced, but there is a lot, there is the pipeline three to four companies looking at doing the umbrella in a box.

So, and the other thing is not only producing embryologist, but producing umbrella in a way that is lean managed. For example, right now everybody's checking their embryos and they want, and they three, and then they find who you really need to do that. 

[00:57:28] Dr. Anate Brauer: But when we 

[00:57:29] Dr. Francisco Arredondo: used to write one, three and five, now there's people not even checking them until day five or do put them in the editor scope and they just look at it that is working efficiently without changing the effectiveness.

So , one of the things here on, on, on lean management is that you have those two levels. And you have a cost. So how can we produce the same outcome with less cost or how can we remain with the same cost and improve the outcome? And here on the embryology question, you may pray, but actually they might not need as much in five years because AI may catch up with us.

Now you have a lot of people sitting there.

[00:58:16] Dr. Anate Brauer: I don't think I will catch up that bad. I mean, I think it's moving fast, but I still think we'll also always need embryology. Not for us in New York. I'll tell you that we are bottleneck has always been the lab. And so we really had to hire me. Now we have seven embryologists here, but. You really had to staff up and it's, and it's tough.

And so that was always our bottleneck and that was the bottleneck it for now. And that was the bottom line at NYU. I mean, everywhere I've been, that's been the bottleneck because in REI I can always add another new patient slot. I don't mind working hard and I don't mind, , seeing the patients and adding onto my schedule.

I have no issue with that, but the lab I, , in the lab is safety. It's I want my lab to be happy obviously, and feel like everything's being done safely. So I do think a lab is almost a better book, bigger, if not the same bottleneck 

[00:59:04] Griffin Jones: Anecdotally, I don't see REIs leaving REI. I'm seeing embryologist leave the lab, which is crazy to me because they're so in demand, we have embryologists applying for jobs at my firm.

I'm a biz dev and marketing firm because they just don't physically 

[00:59:18] Dr. Anate Brauer: want to be. I said, you send, send me their CV. 

[00:59:22] Griffin Jones: They don't want to be in the lab. They don't want to, they, these are 20 somethings that don't want to, they don't want to work long hours, one and two. They don't want to be in a physical location.

That's a 10 by 12 room for, for however long I'm going to let each, I'm going to let each of you conclude Dr. Arredondo, let's start with you. And then we'll go to Dr. Brower. How would you like to conclude your points? 

[00:59:47] Dr. Francisco Arredondo: Yeah, we'll start with your PaCo. Okay. Now, I mean, just basically I, we believe in, in democratization of IVF, we believe that every single human has the right to be reproduce.

And that is. International and universal human, right. We believe that we are falling short in the United States and that we have to think out of the box to rethink and reshape the model of how we practice medicine without ever compromising quality and without ever compromising safety. And we believe that we've been practicing fertility the same way for 40 years, and it is time to rethink how we do it.

We believe that part of that is to consider training physician assistants and nurse practitioners to do some of the tasks. And if we want to meet that demand of 3 million IVF cycles, we all to train other people to do egg retrievals. And we believe that OB GYN are a good candidate to do that.

[01:00:54] Griffin Jones: Now, how would you like to conclude? 

[01:00:56] Dr. Anate Brauer: So I agree with most of what Dr. Arrendondo has said today. I do think we have a major access problem. I also believe that repositioning is a human right, and everyone should have access to it. I don't think that the problem can be distilled and easily solved by one issue of training.

Would you answer, did you  do retrievals? I think as I mentioned before, the issues of access involve cost. Providers and embryologist, and the only way we're going to solve those problems is by increasing training programs, which is the long game. And in the short term, becoming more efficient through advanced practice providers and artificial intelligence and technology.

[01:01:35] Griffin Jones: You're both very good sports for coming on. You're both also advancing this discussion in the field by being able to do so in good faith. And so I appreciate both of you doing that and that hopefully we can use this as leverage to get somebody we're bringing ABOG to come in and do an episode about what it would be to accredit a REI fellowship program from soup to nuts.

Thank you, Dr. Arredondo. Thank you, Dr. Brauer for coming on Inside Reproductive Health.

138: Retirement and AI coming head to head in the IVF Lab with Dr. Carol Curchoe

Dr. Carol Curchoe on Inside Reproductive Health

Dr. Carol Curchoe, ART Compass director and reproductive physiologist and embryologist, speaks with Griffin Jones about the future of artificial intelligence in the IVF lab, shares her thoughts on how it could be the solution to the ever-present threat of embryologist burnout, and what technologies could take the place of old school, antiquated monitoring systems. 


Listen to the full episode to hear:

  • What will happen when the big names in IVF labs retire (soon), and who will be (or won’t be) replacing them.

  • Why the idea that technology hasn't advanced in the IVF lab is a myth

  • What solutions AI presents for IVF lab quality control, and how we universally implement them. 

  • How the tech gaps in IVF lab management are overburdening embryologists everywhere, and how this can, and should, be solved.



Dr. Carol Curchoe’s Information: 

Linkedin: https://www.linkedin.com/in/carol-lynn-curchoe/

Website: https://artcompass.io/


Inside Reproductive Health is sponsored by EngagedMD. For technology that educates your patients with true informed consent, visit engagedmd.com/IRH for 25% off your implementation fee.


Transcript

[00:01:00] Griffin Jones: There's a massive wave of retirement coming from IVF lab directors and different techniques in the lab are helping or harming IVF success rates. And we often don't know which is which, or by how much, because we need artificial intelligence to integrate into a single system.

This is at least according to my guests, Dr. Carol Curchoe we talk about these concepts as well as the idea that technology hasn't the idea that technology has an advanced in the IVF lab is. The tech needs to be adopted to light and workload because embryologists are burning out and they're leaving the lab and even trying to work for people like me.

And we also talk about venture capital and the lack of funding in the IVF space and, and especially for female founders. And we talk about all of these points and I hope you enjoy this because I am doing more content about the lab. Like I promised you that I would please enjoy today's episode of inside reproductive health Dr. Carol Curchoe. 

Dr. Curchoe Carol welcome to Inside Reproductive hHealth. 

[00:02:04] Dr. Carol Curchoe: Thank you so much for having me. 

[00:02:06] Griffin Jones: You've been up to a lot recently. I saw you at PCRs recently, you had some data about things going on with lab staff and quality testing. And maybe even before we get into that, maybe give us just a little State of The Union of, of how you're seeing the IVF lab nowadays.

And what do you really want to talk about? 

[00:02:30] Dr. Carol Curchoe: Yeah, so my main focus in life is on brain new technologies to the IVF lab. So we are at a pivotal moment in IVF technology where we have. The first generation of embryologists slated to retire. And this is what I call the great gray rhino in the room. So this is the threat that is lurking in the room, that is mostly going by unnoticed. Although I think now this is what everybody's talking about. So the brain drain that's coming to the IVF industry is imminent. And one of the ways that we bridge the gap between first generation embryologists and second or third generation now, maybe fourth generation embryologists, we're getting on 40 years in IVF, right?

And each decade sort of brings us a new wave of fresh graduates and fresh people. Who've trained up under different methodologies and protocols and ideas and ways of thinking in the IVF lab. The best way to bridge this and to really translate the knowledge from the first generation of embryologists all the way to the brand new generation is through the use of technology.

So that is my main focus these days, other than making expensive science babies for infertile couples. 

[00:03:53] Griffin Jones: I was just bragging to you before we started recording that I've included more embryologist lab staff lab topics this year, I think, than in the previous three years of doing the show combined. And then I realized, as you're talking about this brain drain, like I haven't thought about.

Second about, I just did an entire generational grid. That was part of my talk at PCRs about the changing of, I talk about the donors, the patients, the retiring partners, the fellows. I didn't say anything about the lab. So here I am being like, oh yeah, I got way more lab stuff than I ever did before. And then meanwhile, totally neglecting.

[00:04:33] Dr. Carol Curchoe: Yeah. 

[00:04:33] Griffin Jones: Thinking about the lab on either side of this coin that apparently you and I are both thinking about. So let's talk a little bit about the, the brain drain. And do you have like any kind of numbers or when is this waterfall gonna start hitting? Like, is it already hitting, are we seeing the embryologist retire now?

Or are they about to retire as, are we going to see a peak? What's that like? 

[00:04:53] Dr. Carol Curchoe: Yeah. Yeah. So the peak retirement is coming, but what we're seeing now is that they're anywhere from five to 10% of baby boomer generation embryologists are already past the retirement age and they're hanging in the industry either because of lack of somebody to take over their lab or the multiple successive economic failures that the us has had over the past 15 years, which has drained everybody's retirement savings, maybe they're not capable of retiring yet, but the people who are retiring direct multiple IVF labs, and I can think of several big name, IVF lab directors who are directing at least five labs piece who are going to be retiring. So it's not just a sheer numbers game of people who are directly retiring, but each one of those people are going to be directing multiple IVF labs. So if you can think of five big name IVF lab directors who will be retiring in the next five years, they are each directing five IVF labs. So that is going to be 25 openings that are coming onto the market.

And when I see the numbers of people who are getting new HCLDs, which is the certificate that you would need to direct an IVF lab, right? I'm not seeing the same number of HCLD lab directors being produced each year as what we will need to fill the market. 

[00:06:34] Griffin Jones: So if nothing changes, if there's no intervention than what's going to happen, if there's no intervention to increase the number HCLDs then what are we looking at happening in the next five or so years?

[00:06:48] Dr. Carol Curchoe: Yeah, so I think what we're seeing is in the industry in general is kind of a tendency to become more corporate and for bespoke IVF lab practices to be all gathered under one sort of corporate umbrella. And then I think from what I'm seeing is there are brand new IVF lab directors who go to work for these large corporate networks.

And then as brand new IVF lab directors, they're being asked to oversee more than one lab in the network. And so I think that can kind of be a problem for brand new IVF lab directors who don't really have the experience of many years of, of IVF lab directing. And then the other possibility that I'm seeing a lot is the, the rise in offsite lab directorship.

And when we're talking about quality in the IVF lab, a certain amount of oversight that is necessary for the quality to remain high across the industry, or even increase if we're talking about quality improvement and doing even better than we've done before. And I believe we are going to need to do that because of the rise in demand for IVF and the number of IVF cycles is increasing incredibly.

[00:08:13] Griffin Jones: Yeah. Are you worried about the quality from one, either someone who's not experienced enough overseeing too many IVF labs or from one like somebody having to do it remotely from so many different sites, what are the quality implications? 

[00:08:34] Dr. Carol Curchoe: Yeah. And I think that you can open the news, almost any day of the week, it seems like now, and to see some kind of horrific news story coming out of the IVF lab at PCRs, there was actually a talk. 

[00:08:46] Griffin Jones: One a week?

[00:08:47] Dr. Carol Curchoe: Once I hear it, it seems like it's happening so frequently nowadays, right?

[00:08:53] Griffin Jones: That maybe I'm not reading the right news sources that once a week seems like a lot, but what you were about to say an example. 

[00:09:00] Dr. Carol Curchoe: That's an exaggeration, but PCRs there was that amazing talk about risk management and the IVF lab. And this speaker was very careful to point out that the majority of the risk in the practice is actually coming from the IVF lab.

So four times the amount of risk is coming from the IVF lab than anywhere else in, into the practice. And IVF it's one of those things that you really, there is no room for error. You really do have to always get it right of every single time. And so when we're talking about scaling the number of cycles in the US one of my favorite people who has some very compelling, logic and numbers around how many cycles we are doing and how many we're going to do is David Sable.

And he talks for example, a lot about how you could come up with different name combinations in various states, all over the country, name and birthday combinations, and then how they could be the same. And when we're talking about embryos and eggs that are shipping all over the country, just for example, having a unified system of patient identification where each patient has an established unique identifier that everybody else agrees to, kind of like a car driver's license, right? Like when I cross state lines, that license is going to be my identification, no matter what state I'm in, and it's going to be respected and unique and uniquely identify me in a bigger system that someday, I hope I never make it into that system of them being able to tell if I have a ticket in a various state, but.

[00:10:45] Griffin Jones: We are a couple of short analogy. They're going to know all the crap about you and me and everybody listening and going to be in a credit score and you'll all want it. Everybody, you'll all want it because it will be traded for something that's valuable to you.

Either being able to purchase things more quickly or get services tailored more accustomed to you, or whatever it might be be appearing to be a better citizen. You'll all get that we're digressing. This is like the second time in two months that I've got that I've gone on this, this like futuristic time I did it on Dr. Bruno Gaston’s episode, too. But you are talking about something like, so you're in my understanding correctly, you're proposing a kind of solution that helps identify quality across the field.. 

[00:11:35] Dr. Carol Curchoe: Right. And so that there and there are many people proposing different solutions. So there's the IVF open group proposing the patient ID identification solution.

There's the Tomorrow Robot who is proposing the cryo storage solution of the future. And there are many people, many different groups working in artificial intelligence and within my role in artificial intelligence. So we have a lot of very loosely structured data and IVF, and mostly it's all sitting in on paper documents in binders, hundreds of binders in every different IVF lab.

And, my platform, our compass was created to basically have data, stop going onto paper and start going into the computer where it's structured and can be interacted with by artificial intelligence systems. So my platform does a lot of different things along the quality assurance spectrum, including an embryo embryologist training competency and staff related quality assurance.

It's also very helpful for brand new IVF lab directors, because it's bridging that knowledge gap between the baby boomer generation and brand new lab directors or brand new embryologists. 

[00:12:57] Griffin Jones: So I'll ask some questions, which is either born from being devil's advocate or ignorance. And the audience might not know the difference between the two.

I don't know the difference between the two half the time I'm asking you something because I want to poke at it, or because I really don't understand it in this case. It's probably a little bit of both. Why not the EMR in this instance, what is insufficient about the EMR for storing that data there?

[00:13:21] Dr. Carol Curchoe: Yeah and it's a really good question. So EMR, generally electronic medical record system most of the EMR on the market were created 30 or more years ago, and they have been kind of tasked with keeping up with this ever changing landscape of the IVF lab. And they have mainly been created to manage the clinical side of an IVF practice. So they do things like handle insurance and patient calendaring and appointments, the physicians appointments with the patients, so that, physician and staff will have a calendar of what is going on that day with the patients. And also the medication ordering from the pharmacy.

So none of those things have to do with the IVF lab. So on top of the IVF lab cycle management at the heart of every IVF lab practice really is the quality control and quality assurance. It's sort of what elevated IVF from being an art to being more of a science that we know exactly what's going to happen if we do exactly these defined things in the IVF lab, and we can make it predictable, reliable, robust, and effective for the patients. So there's a whole suite of quality management items that overlay everything that happens in the IVF lab. And that's going to be everything from training and competency.

To what happens with your instrumentation or your environment on any given day? We know a lot more now than we know in the beginning of IVF. So we know for example, that using alcohol based hand sanitizers are not good for embryos in the lab. We have to remove those VOCs from the air in the lab.

And so tracking things like how many times our IVF lab door opens and closes and how the pressure in the IVF lab changed and how many times the incubators were open and closed. All of those environmental parameters add up to impacts various impacts on IVF cycles. 

And then it goes all the way through.

[00:15:31] Griffin Jones: How do you track all of those? 

[00:15:32] Dr. Carol Curchoe: Exactly.

[00:15:33] Griffin Jones: I could see like the alcohol sanitizers on the hands it's. How would you even know to hypothesize about that? To look for something like that? And so I'm like, how do you decide what to track to? How do you track it? 

[00:15:49] Dr. Carol Curchoe: Yeah. And it's really, really difficult because there are as many different ways and things to track in an IVF lab as there are embryologists in the United States or in the world.

And so if you compare what any two labs are tracking, and there was a really nice publication a couple of years ago that did this, they looked at 36 different labs and the instruments that were being quality controlled, and it was highly variable. Nobody knows what to track or if it's significant or how many times a day, for example, do you monitor it? So whenever you can go into the lab and you do quality control, you might do it once a day, or maybe every time you walk by an instrument, you might glance at the sensor and see that it's within range. But a lot of these things could be done much, much better if we take the power of computer science and artificial intelligence, I can see a web of smart sensors throughout the IVF lab that are collecting data all the time. Then you combine that with the inputs from the embryo incubators and the , for example, the cryo storage tanks that the tomorrow robot is creating with many, many thousands of data points of continuous monitoring.

So all of that is going to be much, much better than what an embryologist can do. And honestly, embryologists are overburdened with the amount of work that we have. We really need computers and sensors and AI to start taking some of the workload and actually doing it much better than we ever could. So there's no way we can continuously monitor what's happening in the embryo incubator at most, that can only be done a few times a day.

[00:17:32] Griffin Jones: What's impeding technology taking over that workload right now. Is it the technology itself? It's not there yet. Is it regulation? Is it like adoption? What's stopping it from happening now?

[00:17:47] Dr. Carol Curchoe: Yeah, and I think there are solutions that are coming out onto the market where we've seen a really great innovation has been in the electronic witnessing space.

And like different electronic witnessing systems that are watching every step of the process and making sure that, for example, we're not mixing eggs and sperm from two different couples that don't go together or that when we thought the embryo from this patient, we're putting it into that same patient's dish before it gets transferred to the, that patient.

So that whole process now is starting to be electronically witnessed, but these technologies are definitely maturing. I wouldn't say that there are all the way in maturity yet. There are kind of gaps with each one of them. And then I really think one of the biggest things is how does everything integrate together into a single system right now, most manufacturers don't want to play well with each other.

So you might have alarm systems for your tanks. You might have alarm systems for your incubators. And all kinds of various other monitoring systems, but they're all separate logins and they don't talk to each other and they don't share the data. So one of the things that I like to think about is when you log into your Gmail and you click in the upper right-hand corner, you get all of the apps that Google has, you get your drive, you get your calendar, you get any apps that you yourself have, have integrated into that little platform and really that's what IVF labs need. So the EMR is just one small part of the data management in an IVF lab. And then particularly you have technologies that go all the way through the patient management side.

So managing the patient journey, the patient consents the patient calendars patient education and how do you deliver the results of your IVF lab cycle to the patient.

[00:19:51] Griffin Jones: Well, that analogy that you used is also self descriptive of why so many of these companies don't want to integrate with each other because they all want to be the Google in this instance that you used, Google is the perfect example to use because it's Google maps, Google drive, Google docs, Gmail, all of these things that Google assistant, all of these different apps that are within the Google ecosystem.

And, and so people are like, well, we, we want to, we want to be the Google. So before we talk about how to integrate into a single system, I want to ask you more about like the gaps. So you were saying that witnessing is something that has advanced a lot, and the technology is a little bit more mature there than maybe in some of the other w where are the gaps.

[00:20:43] Dr. Carol Curchoe: Yeah. So I think from my perspective, a lot of the gaps are coming from the management of IVF cycle data. It is mostly still done on paper. And for example, when the PGT company gives the genetic testing results to you, that will come to you in a PDF. And so when data is generated, it tends to be static.

It can't be interacted with, and it's very sloppy and unstructured. The thing I like to talk about is for example, like when I want to order something off of Amazon, I just opened my app. And I know that like paper towels in my house are running low because I have this subscribe and save feature and the Amazon app, and then it's, one-click ordering right. Or it's set up to automatically be delivered.

So that's another experience in the IVF lab that is being mainly handled manually. You have an IVF lab supervisor who kind of calculates in their head, how many cycles we're doing, how many cycles we're going to do this month? And then the volume and the amount of reagents that will be needed to not run out of anything.

And that's a process that is very time-consuming. It creates a lot of friction and it could be as simple as one-click ordering an inventory. If there were some smart products that could step in and fill that gap. 

[00:22:16] Griffin Jones: So, how do you envision all of this being integrated? Tell us Larry Page, how does, how does the Google drive and the Google docs and the Google calendar and Gmail and everything else from the lab world integrate in one single system?

[00:22:34] Dr. Carol Curchoe: So I think google didn't, I'm not sure they really developed all of that, or if they went out and bought a best in class solution and then slotted. 

[00:22:42] Griffin Jones: Did plenty of both Carol. 

[00:22:44] Dr. Carol Curchoe: Plenty of both. Right? 

[00:22:45] Griffin Jones: Plenty of both. 

[00:22:46] Dr. Carol Curchoe: So we could be just waiting for that one person to take the vision and really execute it. But one of the other things that I find compelling when David Sable talks about what is IVF going to look like in the next 20 years? He talks a lot about building the IVF super highway. And so right now, the number of IVF clinics that there are they kind of liken it to the old system of country roads, right, where now we have all these country roads and they need to connect into what is really the IVF super highway.

And it's a brand new system that is built for high volume and high capacity in with these best in class solutions. And so, I know that there has been a tendency in the industry right now to be attracting a lot of private equity and building these new sort of forward-thinking networks.

Right. IVF labs that are brand new. So obviously kind body is a good example here and then her fertility and in the UK. So it's definitely going to be very interesting to see, like ultimately what happened with the super highway project is you had a president who put together a, a package at the federal level to build it because it's bigger than what one state could do by itself.

And so how this Federation of IVF labs and the industry of IVF itself is going to continue to be pushed forward without a federal level project or federal level support. I'm not sure, but. 

[00:24:32] Griffin Jones: Well, let's stick with it. I love sticking with people's metaphors. I love using people's own metaphors to like, tweak in and ask these questions.

So, one president that president being Dwight D Eisenhower coming up with the interstate program, late forties, early fifties connected the United States together, advanced mobility, like we had never seen before on the planet. Some cons that came from that, including demolishing entire cities and neighborhoods, including those, like in places where I came from.

And so what are some of the, the doubt? What are some of the risks and dangers that could come from this? 

[00:25:10] Dr. Carol Curchoe: Yeah, and I absolutely hear that. I think so one of the risks and dangers is that the IVF process could actually stagnate because you have these, this sort of way that things are done. And then maybe from it because there are investors and everybody needs to make money and it has to happen this specific way. So it can kind of curtail your scientific freedom, right. To be in these, in these large corporate networks. And that's an argument that I've, I've heard a lot that embryologists nowadays are very much just kind of like technologists, right?

They're given the protocol and they're told what to do and they have to come in and do it the same way every day. And that can be seen in a negative way, or it can be seen in a positive way, right? On the patient side. The patient is assured of what they're getting because the corporate network does things in a certain way.

You're not going to get experimentation directly on humans in many IVF labs. Now. And I think everyone would agree. That's probably a good thing. In the early days of IVF, we were literally experimenting directly on people and embryos for what could happen. And so things are different now. And I think everybody agrees that that, that aspect of it is probably good.

I think there's just in the management of people, that aspect can kind of get lost when you do a huge corporate network. It becomes very difficult to manage staff the further away from the nucleus of the company that you get. And I think you start to get the communication is a little unclear and the path to your career path.

For example, it can be a little unclear in a big network like that where you might have a lot of potential in a very small clinic to rise very quickly and become the lab director and maybe even become a partner in the clinic. And that kind of thing is not going to happen in a corporate setting. Right?

[00:27:24] Griffin Jones: You might be making some decisions about what you want to implement for your practice. And I'll give something for you to consider. You may have been thinking about EngagedMD for a while. You may now be among the minority of practices that are not using EngagedMD. But think about losing even one of your linchpins on your staff, even just one of them, because they've had it, they're too burnt out.

That's what I'm seeing as a hiring manager in this marketplace, people from your clinics, embryologists nurses, mid-level providers, even. Are applying to companies like mine because they want to get the heck out of the clinic and they want to get the heck out of the lab. They're burnt out. There's only so much that you can do.

You're trying everything to hire more people. You're also, you want to lower their workload, but you have such a high patient. All we can do is implement technological solutions. In many cases, to lighten the workload. And some technological solutions are really, really proven. One that's really, really proven is EngagedMD, ask anybody that uses EngagedMD.

You don't have to take my word for it. Ask anyone that uses EngagedMD, and that's probably going to influence your decision, but still mention that you heard it on the. Well, you heard it from Griffin Jones because you'll get 25% off of your implementation fee. If you do go to engagemd.com/irh, but in any event, don't do it for me do, it because we're all in danger of losing the linchpins on our staff right now.

And if there's something that you could have done about it, you're going to be kicking yourself. And one thing that you can do about it, if you haven't done already is to look into EngagedMD. EngagedMD.com/irh. Now back to the show.

One of the things that you got my attention with when we were emailing about this episode was that I do hear people say a lot that technology hasn't advanced and some in one breath, I hear people say technology has advanced incredibly. And then another routes I hear people say, we've been doing the same thing for 40 years.

And so when something is reduced to one sentence, it can become a platitude that could be used for, to support one point or another. Right. You don't actually know what it means until, until you describe it. But I do hear people say it on the side of technology has not advanced. And you feel like, it doesn't have where else is it going to go?

And you said like it's advancing a ton and so can you talk a little bit. 

[00:30:09] Dr. Carol Curchoe: So I think one of the things is like in the early days of IVF, right, we didn't know how to make cultural media. We didn't know humongous things. We didn't know how to incubate embryos. There were these like really big buckets that got figured out early.

And since then, it's been a process of refining all of these steps and there have been huge step changes in the field of IVF where seemingly everything changed overnight. I mean, of course that that's not actually how it went. It was a lot of small discoveries and small labs putting it into practice and people slowly doing it.

And then it seemed like the industry changed overnight. So the couple of things I can think of where that happened, where cultured a blastocyst which is sort of it's been adopted, I think by most IVF labs. Now you might still get ahold out few hold outs here and there that are only culturing to day three. 

[00:31:07] Griffin Jones: Seems like everybody is doing that so.

[00:31:07] Dr. Carol Curchoe: Everyone's doing, yeah, they, at least they have five, six, and now the newest thing is day seven embryo culture. So that has been hotly debated. And it's been, the body of literature has been growing over the past five years to other day seven culture is valuable for patients. I think now we're all starting to agree that it is, you can get normal embryos that implant on day seven.

And so that is a change that like when you talk about experimenting directly on people with no oversight, Right. The decision to go from culturing today, six to extending the culture one more day to day seven, that's kind of an easier decision to make. And there are a lot of things like that that have happened in the IVF lab.

So for example, one of the things that I can think of is the decision of when to hatch an embryo. We're getting all kinds of new technologies like Embryoscope and single-step media, and we're taking the embryos added incubator much less. And so people are starting to get rid of hatching on day three, which was kind of the industry standard for the last however many years since we stopped doing biopsy on day three and shifted it to day five and the wind started hatching on day three and doing biopsy on day five.

But what we've seen with success rates for embryos that are fully hatched is that by and large. They're a little bit lower than embryos that are frozen with Arizona. And so what people have started to do is leave the embryo totally alone and hatchet on day five when they do the biopsy. And so that entails them actually breaching the zona with the whole biopsy pipette and pulling the embryo across to the opening that you've made.

And none of those interventions are, have been properly tested. Right. We just decided to start doing that with patient embryos. And so we have no idea what the effect of tugging on the embryo that much or creating a larger hole in the zona is. But I think everybody sort of agrees that. We want there to be less fully hatched embryos on day six.

And the way to do that is not to hatch it on day three. When you make a hatch on day three, the embryo likes to grow out of that and it fully hatch out by day six. So maybe by doing that overall, we can increase the efficiency rates of IVF by five or 10%. If the whole field stops doing hatching on day three and starts doing it at the time of the biopsy.

And so IVF success rates are pretty good, , and then if we. Increasing them slowly by five or 10% through the use of these kind of lab developed techniques that spread from lab to lab. It's very hard to do any kind of a control trial for these lab developed techniques, any sort of a randomization or a control trial.

So RCTs in the US are extremely expensive. And so being able to test whether this intervention is more effective or less effective, it's very, very difficult. And so I think also one of the best tools we have at our disposal are these longitudinal databases, like the SART CORSdatabase. So everybody loves to hate on the SART CORSdatabase, but it actually acts as a very good post-market surveillance tool for the entire industry.

For these interventions that are, we can kind of point to a time period and say, okay, around this time, almost everybody adopted blastocyst culture around this time, almost everybody started hatching on day three for PGT. And so in a much larger sense, larger than any clinical trial could ever give us.

We can sort of monitor the success of the industry through these longitudinal databases. 

[00:35:17] Griffin Jones: And so this is about the growth of the umbrella, right? So it's not like I'm trying to think of how you would do an RCT like this and you wouldn't. I was thinking, well, this could be something for like this could be something that you use with embryos that you're going to discard, but we're talking about making the umbrella.

So that's not an option. And so what, what needs to happen in order for this to be something that can be standardized across the field. 

[00:35:44] Dr. Carol Curchoe: Yeah. So I think that's why there, there is no mechanism like that that exists. The CLIA regulations basically give us leeway to make and validate a lab developed test in our own labs.

So we will verify and validate that the test is working. And we do that in kind of a step wise procedure, but then what happens is we publish those results at a scientific meeting. And then the lab next to us says, I also want to implement this lab developed test or procedure in my lab. And so then they also go through a process of verifying it and validating it in their own lab.

And so there's a whole bunch of other different innovations that I can think of that fall under that category. Like everybody's doing the flick biopsy now. And that's a method of breaking the cells off of the embryo that obviously can't go through a randomized clinical trial.

There are ultra fast ultra fast thought and freezing protocols that are being developed. And we saw a jaw dropping talk at the recent PCRs meeting about an ultra fast thought protocol that had been developed in a lab. And I personally know, 10 embryologists who are going back to their own lab and trying to verify that work. And then way that the presenter presented it. And so yeah, I think that lake basically, embryo hatching, embryo biopsy technique, even the ICSI needle technique, itself. Has gone through some evolution. So there are some people who insert the ICSI needle and pierce the Oolemma very slowly and very carefully. And there are some people who scrape the Oolemma and stretch it until it breaks.

And then most recently I saw a pipette that sort of sucks back on the Oolemma membrane and makes it taut so that when you puncture it, there's no invagination of the Oolemma into the OS site. And so if you think about what's happening inside the egg, the egg has a cytoskeleton and a structure of its own. And when we pierce it with the ICSI needle and suck the cytoplasm out, we are doing some disruption of the egg membrane and the cytoplasm and the cytoskeletal structure inside the egg.

And so, again, those are all things that are very difficult to do any kind of an RCT on and where we always have to be asking ourselves the question, is our intervention helping? Or is it harming? Is it causing it? 

[00:38:20] Griffin Jones: And we don't know the answer to that is what you're saying right now. We don't know the answer to how much, that you're saying, if it is damaging, we don't know how much it is.

And so that's why we need the artificial intelligence for, to collect all of the data points 

[00:38:36] Dr. Carol Curchoe: And so many other things too, right? Like that just the existence of these longitudinal databases themselves are very important for the industry. But yeah, AI analysis of all of that data especially because humans, aren't very good at synthesizing large amounts of data and analyzing it.

Computers are better suited to that task than we are. So just giving, like tons of parameters different things that you think may or may not be helping or impacting, or even having a negative effect on an IVF cycle, right? AI, a computers are going to do that much better, but getting the data into a database where it's usable and accessible is the most important part of that.

So how do you collect all this data and not rely on people to do it? 

[00:39:25] Griffin Jones: Yeah. What will the role of experiments be, once we have data points for everything? I wonder about that. Like, when you have an artificial intelligence, when, when you have data points for everything, and eventually we will, as you, every breath that we take, everything that we purchase, everything we've made will, will be tracked.

And so what is the role of experiments once you have every possible variable accountable, because the entire point of an experiment is to control for variables. Right and so. 

[00:39:58] Dr. Carol Curchoe: Yeah and really defends the hypothesis, right. 

[00:40:02] Griffin Jones: But do you need the experiment to test the hypothesis if you have every data point from forever?

[00:40:08] Dr. Carol Curchoe: Yeah. 

Yeah. You definitely do. Because the, what you can do is, you can make a prediction. Based on all of those data points. So for example, what is your genetic background? Where did your grandparents grow up? Did they go through a famine and the country that they were living in before they migrated to the U S has there been, incredible stress in your life?

Are the sensors outside at your street light detecting a lot of pollution? Like you live in a heavily polluted area with a lot of car traffic. And so we're using environmental sensors in, in a much broader sense. But the role of experimentation, I think, after you collect all that data and have a data point for everything is then you're constantly testing interventions.

So by intervention, I mean, for example, like a treatment, a drug for endometriosis, for PCOS, for, let's say you have childhood cancers. And so there are different treatments that are impacting fertility later on down the line. There are a lot of STDs that directly cause infertility or STI that directly cause infertility.

So being able to intervene on these different aspects in a much larger way could be very helpful for people. It could be helpful to direct policy can be helpful to direct like public health policy, basically. But yeah, I think the role of experimentation will always be relevant. We're never going to solve all these problems.

[00:41:47] Griffin Jones: Okay, where does our compass figure into this IVF superhighway? 

[00:41:57] Dr. Carol Curchoe: Yeah. So we are just basically a new way to have a database that structures data in order for artificial intelligence to interact with it. So we're just a new way of, of storing and accessing data for AI systems and then providing the forward-looking statement on this, right?

All the AI technologies are in development. The first step is collecting the data. The second step is creating the AI validating it. So developing it, validating it, and then actually making predictions or prognosis. The low-hanging fruit we like to say is whether an embryo is viable or not. So just using embryo images instead of performing an invasive perfected or biopsy, and then waiting two to three weeks for the genetic testing results to come back, we could look at an embryo image and give a score right away for whether that embryo will be viable or not.

So those kinds of advances will be very good for patients. They'll cut down on like an entire cycle time between the time of the retrieval. And then the time you get the genetic testing results back and prepare the uterus for transfer of one of those embryos, it'll also be really good for patients because I think we are going to sort of solve one of the dilemmas of PGTA, which is that.

It really decreases the number of embryos that are available for transfer. And we probably are discarding some embryos that would have been viable. So patients are probably going to get more embryos in the end, more chances to try with those embryos that they've made. And yeah, so it's eventually it becomes diagnosis, prognosis and making predictions.

So business intelligence, even for running your clinic. 

[00:43:50] Griffin Jones: Do you want to share a little bit of what your abstract was about at PCRs because that I've found so interesting of that, of talking about of grading embryologists or their responses. Do you want to talk a little bit about that? 

[00:44:05] Dr. Carol Curchoe: Yeah. 

So if you ask 10 different embryologists ,the same question. You're probably going to get it back. At least 60% of the responses will vary. So a lot of what we do in embryology is, is very subjective. And it's based on your experience and what you have seen. It's not objective and it can be a challenge because so many other things are based on what the embryologist looks at and sees in the dish.

And then what they say about those embryos. So whether an embryo gets biopsied that day, whether it gets frozen that day, whether it gets frozen in the cycle at all of those things have an impact on the number of blastocysts that the patient has at the end of an IVF cycle. And so for embryologist, we need to be really consistent in our judgment and our grading of the embryos.

And it's just, the variability is just completely wild. And so the abstract that I presented at PCRs we basically just did a small survey to see whether the terminology that embryologists were using for early blastocyst development was consistent. It wasn't, and whether we could kind of trick embryologist into picking a fake term, that's not actually in use.

And that term was picked many times. 

So it just.

[00:45:33] Griffin Jones: What was it again? I don't remember the name of it.

[00:45:36] Dr. Carol Curchoe: It was cleaving morchella which is not a real embryo grade. And so it was just kind of interesting, but we've had a couple of surveys that we've published at ASRM and ESHREand shows what we know all along that the consistency and objectivity of embryologist is low.

I mean, we are human. It could vary depending on whether you've just eaten lunch or whether you've already graded 10 patients before this patient. And you're running out of time to do your body. I've seen freezing for the day. And so just being able to rely more on computers, to take some of that routine, manual subjective and highly variable labor off of our plates is probably a good idea.

[00:46:21] Griffin Jones: So once we do, then what is the embryologist going to do once that is off the plates? What are they going to do? 

[00:46:28] Dr. Carol Curchoe: The important work, right? Making sure the embryos get frozen correctly and that your patient doesn't end up having a boy when they asked for a girl, which was a news article that just came out last week.

There is so much more that embryologists needed to do. And some of the most important work that often gets, not a lot of time for is the quality assurance and the training of the next generation of embryologists. So just being able to invest more, even in the, the people and their techniques and it's there's plenty of work to be done outside of embryo grading.

[00:47:08] Griffin Jones: So before we close, I want to go on a little bit of a tangential topic, but it's related to how we opened the show, which is about the soon to be mass Exodus of senior embryologist and HCLDs is, and how there are fewer HCLD candidates in the pipeline right now. And this is totally anecdotal, Carol, but I wonder if you're seeing it too, is I'm seeing a lot of younger embryologists trying to get the hell out of the lab at a time were they've never been more desired. They've never been more in demand. And like everybody's trying to get their hands on embryologists and, and I'm seeing, so I've got a couple open positions for my business development and creative firm, nothing to do with the lab. And embryologists are applying for jobs at my firm.

I get at least once a week, at least one a week, and then I'll talk to them and it typically comes down to, they don't physically want to be in the lab all day. They hate that. And then they don't like the burning the midnight oil been burning the midnight hour, that whatever hours. Yeah.

And so I don't have any data on younger people trying to get out of the lab, but Canary in the coal mine. That's what I'm seeing. What do you see? 

[00:48:31] Dr. Carol Curchoe: Yeah. 

So I can think of that is partially accurate there the profession itself is very difficult. A lot of times so you have a very high pressure situation where you can't make any mistakes.

 It's highly likely that the other people you work with in lab have a certain amount of a certain level of OCD, and that they're going to be correcting you nonstop all the time for your first five years until you become a senior embryologist. Even among senior embryologist, they're going to be correcting each other and picking out each other all day to do things the right way and to document all of these little small details.

And you have high pressure situation long work hours, a lot of times weekends and holidays are required. Because the IVF lab they say it can never stop. And so a lot of those things are management decisions that what it comes down to is you are choosing to run this many cycles with this number of staff and have your clinic be open on all these days and to do retrievals every day of the week.

And on holidays, you could choose a different way to manage your practice. But what I think is the most compelling part is we have to get to an agreement where the number of cycles can scale and really treat the number of patients that need IVF in the country, which we're only treating a fraction of, but that the management of the cycles within the clinic has to somehow get more better for people, more family friendly, more friendly for the embryologists. And so again, I think a lot of that is going to have to do with technology. A lot of healthcare burnout comes from continuous documentation of, of items is that you don't even know why are we doing this?

It has no, it's never going to have any impact on any cycle. It just gets filed away in a binder and put it in the closet for the next 10 years. And so there are just, I think there are just different things that every step of the way that kind of need to be looked at. I also think training more male embryologists in the field would be very helpful.

But I think what happens now is, is maybe a lot of male embryologists start off in embryology. And then they're like, I'm not going to take this. I'm going to go find a better job for better pay and less stress. And I think if we were to do that and get more male embryologists, maybe that can help to actually raise the standard for all embryologists.

And it could also smooth out some of those real big dips that happen when with a lot of maternity leaves and different things that happen in different practices. But for the female embryologist, I know many of them have been asked to return to work within four weeks of having their baby or less, because they're the only embryologist who knows what they're doing in the lab or in that area and. 

[00:51:52] Griffin Jones: Technology is really, it has to be a part of it though, because right now we're in a chicken and egg, and this is all across the marketplace. It's not just the fertility field. It's not just an IVF lab. It's happening everywhere. That tension I'm talking about is between employee needs, wants customer needs wants.

And in our case, staff member, provider embryologist needs wants versus the patient needs, want, patients wanting to get pregnant and they want to be seen, and they don't want to wait eight and a half weeks, 10 weeks, 12 weeks for any IVF cycle. And so I can empathize with both sides here, which is like, we're trying to help these patients here.

And so we're trying to put more people through on the other hand, we're burning people out and then, so they're quitting and then that puts the, makes the burden even heavier for those that remain. And so. We have to have technology. We have to adapt what ever technology that we can to be able to reduce this burden, because otherwise we're just going to be stuck on until, until some other economic force, like a recession or something comes in and makes one side of the teeter-totter go up in one go down.

But until that happens, like we're all. And even then it will be temporary. Like we need this technology in order to break that chicken in the egg. 

[00:53:21] Dr. Carol Curchoe: Yeah, 

absolutely. And I just think, we need to responsibly scale cycles so that it, so that it doesn't break the backs of the workers, but it also, we scale the industry to serve as many patients as possible because people really need this life altering life saving, really technology that we have that.

We need to be able to make it available to everyone who needs it. 

[00:53:46] Griffin Jones: I'm going to selfishly give a little plug for something that I want to see., and then I want you to conclude with the way that you want to conclude. But what I selfishly want to see is a story to tell the importance of the different parts of the lab and the, and the clinic like meet like the hero's journey of the embryologist, the hero's journey of the fertility nurse, because everybody's going through burnout.

People like yourself and others are doing what they can to bring technological solutions as quickly as possible. In the meantime, for being able to carry the burden, it really helps to know to tie into. This greater purpose, this story that you see, or this drama playing out that you see yourself as a part of and creative really helps to do that.

So when I came into the field seven or eight years ago, Carol, it was about new patient acquisition. That was my value prop. And then for a few years, it's still was that most clinics don't need that right now don't need new patients, a couple profiles do then there, it was about converting more to treatment of, okay, you're bringing enough new patients in the door, but you need to help converting them to treatment.

Even now, most people are like, well, it doesn't matter if we convert more because we're at capacity at the lab. And so what we're trying to use creative for is like, use it in such a way that get your people and your patients to be able to understand go through and be a part of like, what's really important for getting this done on the patient side.

It's very often about resetting expectations and on the staff side, nurses, embryologist, it's about seeing like how like really important this is. And you might, you might say like, oh, well, like of course we see it. We see it every day because we're living it. No, there's something about the story allows you to see how you play into it.

I used to volunteer at an orphanage of, of a network of orphanages called new Esther spontaneous or miles. And I was there and I did it like every, I lived there. I did it every day. I'm telling you Carol, that when I watched the YouTube videos of like, of like the family at large and would see like how we played into the bigger.

I was like, yes, this is what I'm doing it for. So I want to see that. I want to see it for the embryologist. I want to see it for fertility nurses. And there's so many different ways to tell this story. And if you're listening, talk to me about that because I'm not talking about just getting new patients in the door, I'm talking about, about using creative to solve challenges, like best, but I'm going to let you conclude that was, that was selfishly for what I want to see.

What do you want to see happen in the field? How would you like to conclude with our audience about the future of, of the lab as you see it? 

[00:56:55] Dr. Carol Curchoe: Yeah, so I think we need funding to make these innovations happen. So I'm in a very small group. A very small segment of the population who ever becomes an embryologist and then creates a technology and makes a startup.

I'm a female founder. And I didn't go to Stanford. I don't have a pedigree. And so the funding, I think for a person like me and the avenues to funding are it's extremely difficult, less than 2% of all female founders nationwide ever get funded. Right? So its ambition, a small market, and we need just more funding.

I know everyone's talking about fem tech nowadays and getting more funding into these technologies. And so that's great. I think that that just needs to go rise more and more and more, but if you're an average everyday embryologist and you have a good idea that needs to be commercialized, and you're the one who's working with these technologies every day and what could make your life better and easier?

How would you commercialize? How would you even go about how would you, what would be your first step to commercialize the technology? And I think it's just not talked about a lot ever. And so having just like the education, the startup education and the mindset of being able to drop a blueprint with an engineer, get a patent together try to raise funding and build a company.

 How to do that should be a little bit clearer and a little bit easier for people to do so that we can continue to innovate basically 

[00:58:44] Griffin Jones: Dr. Carol Curchoe of art compass and CCRM Orange County. Thank you so much for coming onto the show. 

[00:58:51] Dr. Carol Curchoe: Thanks for having me.

137: Private Equity: Genghis Khan of the Fertility World? with Laura Olson

This week, Griffin speaks with Laura Olson, long-time political science professor at Lehigh University and author, about what private equity has done to other healthcare sectors, and what Olson believes it has the potential to do to the fertility space. Should it be banned, or is it the key to correcting the supply vs. demand struggle in fertility care accessibility.

Listen to the full episode to hear:.

  • Laura Olson’s take on the private equity playbook.

  • How private equity has negatively impacted other areas of healthcare, and what that might mean for fertility care’s future.

  • Why new docs and retiring docs make the decision to get into bed with private equity- or not.

  • Griffin push back on the lack of data to praise or condemn private equity controlled networks 

Laura Olson’s Information: 

Linkedin: https://www.linkedin.com/in/laura-katz-olson-a7706034/

Website: https://wordpress.lehigh.edu/ethicallychallenged


Transcript

[00:01:01] Griffin Jones: Which side are you on which side are you on in private equity and healthcare, or I don't know. That's why I keep having guests on either side of the position on the show today. I have an author for you. I brought an author named Dr. Laura Katz Olson. She is a professor of political science at Lehigh university.

She's been there since 1974, and she has a book called “Ethically Challenged; Private Equity Storms US Healthcare”. And she, even at the end of the show, she mentioned, and she says, it sounds like you're not sure. Well, you probably heard me say that on the show of what is the categorical net benefit of outside money in our field buying practices.

And I have people from different perspectives on the show. I don't know guys, like I told you, I'm a communication. Major bachelor graduate from Oswego, NY in upstate New York. I'm not the scientist, but I do appreciate scientific thinking and what I'm still lacking. What I still haven't gotten from other side is.

Really good data to help me say what I think is category categorically better or categorically worse one. I don't even totally know which metric that I would judge on. Would it be patient satisfaction? Would it be clinical success rates? Even if it were like how many other variables take that.

But I suspect you'd probably have three to six key performance indicators. Right? Because if you just had one, you can always maximize one outcome and it could be at the detriment of other things. So you'd probably want various KPIs to balance each other out to say, okay, is this, is this having a net benefit or a net negative?

And I haven't heard that yet. So I asked a little bit for it in the. Interview, it may be in the book and I still haven't gotten my copy yet, so I hope to be able to dig more in but I haven't totally heard it from the, the network groups either. I just hear a bunch of case studies on either side and I seek case studies on either side  manifesting themselves in real life of-this is an example where we've improved efficiency and raise the standard of care.

This is an example where we're reducing costs and reduce the standard of care. And so I would love to hear about how we would really measure this. If we're seeking the truth, I'm seeking the truth guys. I own a privately held business development and creative firm. That's my normal pay grade. And I'm punching up to give you more education and information, as it relates to building your businesses, starting your careers, advancing in your careers. And I would love your thoughts on how we would pursue private equity and venture capital who have both very different impact in healthcare, specifically the fertility field.

But today, I let Dr. Olson give her perspective. She wrote a book about it. She feels very strongly about it, and she does have really good examples to include in her arguments. So you let me know which side do you fall on this, but in the meantime, enjoy today's Inside Reproductive Health with Dr. Laura Katz Olson.

Dr. Olson, Laura, welcome to Inside Reproductive Health. 

[00:04:24] Dr. Laura Olson: My pleasure to be here.

[00:04:26] Griffin Jones: You are coming from an area that is a little bit broader than just reproductive health, justice assisted reproductive technology.

You've recently written a book about private equity in healthcare, and it's called ethically challenged. So there might be an angle where we're pursuing in today's combo is it's called “Ethically Challenged: Private Equity Storms US Healthcare.” Why this book Laura? 

[00:04:52] Dr. Laura Olson: Well, I've been studying actually aging and healthcare now for about 50 years.

And private equity just kept cropping up by when I was looking at nursing homes on healthcare. But I couldn't find anything about it. And then when I was looking at comparisons between let's say, a home health care that's commercially owned and those that are non-profit, they never differentiate the commercially owned from regular commercial to private equity.

And I found that very strange. So I started looking into it. I went to a private equity and one of the reasons I've discovered is because of the secrecy. They, private equity firms have what they call a pension for secrecy. I bought a private equity data from PitchBook, which cost I had a razor for my university, but a plus 22 thousand dollarspacks a year.

And I went to a couple of private equity conferences. One of the incidences that I discovered, which was really a kind of interesting is there were about 350 people at this conference, one of them, and at every session they reminded us that everything that went on there was confidential. And of course, as my father once taught me when I was a young girl and more than one people, one person knows about something it's not confidential.

So the secrecy thing really got to me and got me really more and more curious, and I dug deeper and deeper into how it affected health care and eventually decided this is a story that has to be told. 

[00:06:33] Griffin Jones: So, when did you start noticing it? You said you started noticing it in senior care and other areas of medicine more or less.

What ballpark of years did you start seeing this trend happen? 

[00:06:46] Dr. Laura Olson: I started noticing it in the late 1990s with nursing homes. And then it kept cropping up later on, I would say, oh, about 20 10, 20, 15, a lot of the niches, especially fertility didn't really take off, take off until about 2015.

 So the earliest ones that I noticed were the nursing homes and then more and more of the niches, it started coming. 

[00:07:19] Griffin Jones: Okay. Do you have any idea why that 2015 mark is, is happens to be that because we've noticed that in fertility, that it was about 2015, it wasn't to say that there was no one before 2015, but really that's when you started seeing.

[00:07:36] Dr. Laura Olson: I think that was the first 1, 20 15, if I'm correct. 

[00:07:39] Griffin Jones: Well, so there was IntegraMed , which had gone public and they did own equity of practices and they were, they were early. My listeners will correct me, but I want to say that started in the late nineties. And then they went public at some point in the two thousands, if I'm correct, when my timeline and then were bought off of the market listings by a private equity firm called Sagar Holdings.

But, and that may have been in 2012, I'm making up the year. So I'm hoping one of my, at least one of my listeners will send me an email and, and correct me on it but. 

[00:08:14] Dr. Laura Olson: So Ovation Fertility was clearly one of the first in 2015, which was bought by Windrose. 

[00:08:22] Griffin Jones: And so why is that? Does your book uncover some of this of why halfway through the last decade, did we start seeing this in our niche and others?

[00:08:32] Dr. Laura Olson: Well, I think that there's a number of reasons. And each niche really has its own reasons. There's a general number of reasons that a private equity firm would be interested in a sector. And as these reasons come to the forefront, the private equity go into, for example with fertility, which obviously came later than some of the others.

You get the idea that there's more and more children, people are having babies later. So there's more need for fertility treatment. You have about 15 states now mandate that insurance companies include fertility in their package of offerings more employers are offering a fertility treatment.

The veterans administration now pays for fertility treatments and it's big money. One of the things that I found that was interesting is I spoke to a number of owners of fertility, people who sold to well private equity. They were the most generous with their willingness to talk to me, fertility treatment the owners was interesting. 

[00:09:47] Griffin Jones: On or off the record? 

[00:09:49] Dr. Laura Olson: On the record. And I had the trouble getting anybody else to do them, but they seem to be the most willing. 

[00:09:55] Griffin Jones: What did they tell you? 

[00:09:56] Dr. Laura Olson: Well, let me just give some of the reasons, you have rising single parenthood, but even more important. That I think is we should know is that there's a growing amount of dry powder in private equity.

What that means is they have more and more money this year. They made a record in 2021, a record of something like $330 billion. And they have to spend it somewhere. 

[00:10:23] Griffin Jones: This is just in healthcare is private equity healthcare who made. 

[00:10:26] Dr. Laura Olson: No, this is just private equity money to spend, to buy, buyout funds, to buy.

And they're running out of Toys R Us places, retail places, and they had to find something and healthcare, but particularly fertility care is very lucrative. One of the people I talked to told me that after they put it together and they were ready to sell. He got offers from 40 private equity firms.

So fertility is a hot market right now. 

[00:11:00] Griffin Jones: That makes sense to me. And 40 of those 40 it's like how many of them were good, but sure I bet, people are kicking tires all the time. Some to often people think, oh, I got a call from such and such a firm. Maybe I got a call from Canar or somebody.

And it's often a junior account executive whose job it is just to touch up with everybody and keep your name accurate and in the file. But sure, there are also a number of people that are already within fertility networks that, that are a part of this. So I'm writing down my questions that I have for you, as you say, things that I want to go deeper into, one of which was the $300 billion. And you said that that's a record that was a record in 2021 that private equity firms have to spend. Do we have it? I suspect some of that is just because when inflation goes up, stop people, buy stocks and equities. And so high net worth individuals are putting more of their money into behind these private equity firms.

But did you, do you have any more of the research of where the money is coming from causing the surge? 

[00:12:06] Dr. Laura Olson: No a huge, huge percentage of the funding for private equity acquisitions comes from pension funds. It comes from a state and local pension funds and they of course have been underfunded for decades.

And so they see private equity is a way to get a quick book and make up for the. Pension deficiencies. So most items have the statistics right in front of me, but most of them have increased their private equity investments 2% over the last several years. And they intend to increase it even more, so more and more of their money is not going into the stock market, but it's going into private equity, even though private equity is risky.

[00:12:58] Griffin Jones: Why did you say that? 

[00:13:00] Dr. Laura Olson: Well, that's why they have to make outsize profits because the money you put into, first of all, they keep him money for a long period of time. It's not liquid. And you can go bankrupt. There's all kinds of risk in private equity that you don't. That's a, of course you have risk in the stock market, but that's a far less.

[00:13:21] Griffin Jones: It's not the S and P 500 that's for you. You're not looking for an average 8% return. 

[00:13:27] Dr. Laura Olson: No, you're looking for what they call outsized profits. And they don't really care what they invest in. They can invest in hospice. They can invest in infertility. They can invest in Roto-Rooter. It doesn't matter to them.

They're only like Willie Sutton looking for where the money is, you know, who Willie Sutton is right. 

[00:13:50] Griffin Jones: You're going to have to refresh me. 

[00:13:52] Dr. Laura Olson: He's a bank robber. And when they asked Willie Sutton boy, he robbed banks, he said. 

[00:13:59] Griffin Jones: Oh, that's where the money is. 

[00:14:00] Dr. Laura Olson: That is where the money is. 

[00:14:01] Griffin Jones: So that's who gets that quote. I should know that I really liked field.

I don't know if it was he the Deringer, Bonnie and Clyde era or prior to that. 

[00:14:09] Dr. Laura Olson: Probably around there. I think it's later. 

[00:14:12] Griffin Jones: Well, I'll have to watch something on him and Babyface Nelson and the others and get reacquainted with my old timey bank robbers sounds like a good theme for the show, but so you're talking to fertility practice owners as you're writing the book.

And I'm curious did anything stand out to you as being distinct within the fertility and within the field of fertility? You mentioned that it was a private equity firms are seeking outside profits. They could be talking to plumbers. They can be talking to electricians and, or dry cleaners or anyone and they do.

But did anything stick out to you as different?? What's happening in the fertility field then in other areas or even other areas healthcare? 

[00:14:56] Dr. Laura Olson: Actually, the private equity playbook is pretty static. And one of the differences I think with fertility is that it's new. And as with all the new niches, the relatively the argument that I hear from a lot of physicians and a lot of people in the government and and so on is it's too early to tell.

And if you understand the private equity playbook, and if you understand the history, it's inevitable that certain issues and problems are gonna come up. As far as I can tell, you have to be a magician. I don't know how much your listeners know anything about the private equity playbook. 

[00:15:44] Griffin Jones: Tell us a little bit.

[00:15:45] Dr. Laura Olson: Okay. The private equity playbook begins with the idea that you have to get outsized profits. And again, you can't just make ordinary profits. Well, people will put the money in the stock market, so you really have to give them a lot more than that. They take these profits and buy a flourishing company.

Let's say a flourishing fertility company. They don't want a distressed company. They want something, one that's really well-established and one that's doing really well. And the reason is because they're buying the company with borrowed money today over 60% of all the money is borrowed. Your private equity firm puts in about 2% in equity and they're limited partners.

Usually the pension funds put in about 38%. So you have to pay off this debt. And in addition to the debt, you have to pay off enormous fees. For example, they have transaction fees, monitoring fees, management fees, advisory fees, servicing fees. And I just discovered the other day, there's an other, that's now becoming very contentious and that's the food and travel of the PE manages.

Then you have the dividend recaps, which is where the private equity firm borrows more money from the lays, the debt on the company and pockets it. And these are being bought with what they call junk funds, junk rated loans.

And this has increased enormously this year, also that at 330 billion. So they're pocketing more and more of this money. So what I say, you need enormous cash flow to pay off this debt, to pay these fees, to pay these dividend recaps. And how do you get enormous revenue increased revenue. And that has to come from the operating costs and shrinking operating costs.

And I have an analogy. I see the private equity firms, like the old time doctors in the 18 hundreds. Remember they used to bleed patients and the patient either got really weak or died and that's what they do. And they used to use the 18 hundreds. Sometimes they use leeches, which I think is an ophthalmology for the private equity firm.

So the way I see it, you have to be a magician to be able to pay off all those debts, pay off all those views and keep quality of care. So that's the general outline of private equity and healthcare. 

[00:18:44] Griffin Jones: So you mentioned that part of the private equity playbook is buying a flourishing company.

And very often when we see a new network coming to the field, usually they're starting with, they're saying, can I grab at least one big center, , a group that has. At least 10 docs and is in a pretty sizable market and then use that to use them as the flagship of the new partnership or network.

And and then use that to be able to court other perspective practices to, to sell into my network. So when you say buying a flourishing company, is it, is it, is it that is it just for that, that flagship group or. And then the rest of the portfolio, they're okay with having a distressed asset in here or there, if they can get a good deal on it, or these are all really, really profitable companies that they generally want.

[00:19:36] Dr. Laura Olson: Well, in healthcare, in the old days, they used to buy a conglomerates and then break them up and sell them because the parts were worth more than the hole now with healthcare and fertility centers, but other health care what they do is they buy this platform that you were talking about, but then they add onto it because the idea is to get a local, a regional, or even a national monopoly.

And then they only have four or five years and they have to sell. They generally don't keep it more than four or five years. And it seems to me that it's been lowering the average today is four point, I think it's 4.5 years, but many of them are being flipped in two years. So three years, and then the next private equity adds more and makes bigger.

And so what this does is it makes one prices higher for treatments because they're the only game in town. Once they get a monopoly and choice for consumers is far less. So it has that effect as well. 

[00:20:40] Griffin Jones: So why then are we still seeing more new network backed private equity firms come in as opposed to the current ones being able to consolidate more?

So if everybody has, if they're on this timeline of three to five years, we're still seeing, I think now this. Six to 12 months, we saw three new networks come into the field and there's already a handful here. Then each of those networks are backed by different private equity firms. And so what's going on with this timeline?

Why aren't we starting to see some of the folks that have been around since 2015 or 2017 sell? Well, I guess we have, we have somewhat but why wouldn't you, why wouldn't these new private equity firms be trying to like buy into these firms, buy into these networks or these networks trying to, why haven't they been successful in gobbling up the clinics that these new networks who who've only been here a year or less have been able to do?

[00:21:44] Dr. Laura Olson: I'm not sure they're not successful. I mean, it takes time. And we're talking about very recently. So what would I see for the future is these new networks, increasing in different areas, like, immediate immediately jumped to a national, a monopoly. They spot in cities, they start in different cities.

So you'll have one start. I don't know about, about fertility, but I have seen the history of these. They start in a certain area in Florida or a certain area in Kansas and they slowly build themselves up until four or five years and they sell and then the next one comes in and build itself up. So you have simultaneous in hospice and home care and all these other natures, you have simultaneous platforms building each other up, building up.

They're usually from what I can remember, they usually start in different areas. Somewhere in the south may aim for the south. Some in the Northeast, they aim for them with these. They don't immediately jump in volume, like every year they might buy three and they have to integrate them, which is, which is a big problem.

[00:22:57] Griffin Jones: The integration is a big problem and we can probably, I'm making a note of that. So we can talk a little bit about that. As far as the timeline goes, are there other categories that are more mature? You said that in a lot of the niches that started in 2015 or so, and as you mentioned, relative to other fields of healthcare and other fields of business, fertility is still pretty new. Are there other areas, especially areas of healthcare that are more mature where we've seen it become a, a two horse race or, two companies control everything and other areas of, of healthcare. What's that like in more mature sub-segments? 

[00:23:36] Dr. Laura Olson: Scene where it's become a two person race. But certainly you have one of the early ones is dermatology.

And you see a number of the dermatology companies that have grown and is still throwing themselves off to the next one and not, and not looking to become they're not like a regular corporation. They're only looking to build the value for four or five years, and then they take their money and they run and they either put it up for an IPO.

But more likely these days they're selling to each other. So it's very different than a corporation. So you don't see two major corporations running against each other, but dentistry has had a long history. Dermatology has had a long history. Ophthalmology has had a relatively long history. And what we see is disaster both in terms of the patient care, the quality of care and in terms of bankruptcy.

[00:24:46] Griffin Jones: So I want to talk about the bankruptcy part because that's less self-evident. If, if people are continuing to come in and. why are they doing that? If they're risking being the one, holding the hot potato at the end, and I don't know enough about the IntegreMed deal, but it could have been the case.

That's the guard was holding the hot potato at that point that they had something that they were losing money. And then whoever bought what those properties came into, perhaps got got a better deal on it. But so if it's leading to bankruptcy, what is the incentive for firms to continue doing it?

 It's not my job to tell you what you should do. Should you sell the private equity? Should you fight as an independent practice owner and independent fertility business owner forever. That isn't my job. You started a business or a practice for your reasons. My job is to help you, get to where you want to go, whether it's selling to them or competing against them that's what my firm does. We help you pull out competitive advantages and we are not operations consultants. I will never promise you true operational efficiency as a deliverable. That's not us, but all of those areas where sales and marketing overlap with operations to help for a better patient experience.

Those are the things that we help with. So as you're recruiting staff and you're recruiting doctors and you need the messaging, the brand and the customer service systems that allow you to be relevant. That's what Fertility Bridge helps with. And the only thing that I really ever try to sell people is that initial diagnostic that we do because it's less than $600.

It's $597 to have a consult with us, to have my team do a snapshot and tell you what you need at a high level and go through that with you through the patient journey and then recap everything in a 30 minute follow up it's $597 to get you some of these answers that you're thinking about now, as you think about the future of your group at a high level, go to fertilitybridge.com, sign up for the gold diagnostic.

And I look forward to doing it with you.

 But so if it's leading to bankruptcy, what is the incentive for firms to continue doing it?

[00:27:06] Dr. Laura Olson: Well, a number of reasons, I'll just give you one example, and then I'll tell you some of the reasons U S dermatology partners, which is the third largest dermatology organization in the United States. And I remember when it first started and when I wrote my book, it was still going strong. And then I read in 2020, they defaulted on their loan and wanting to the third largest dermatology company in the country went into the hands of its creditors. So what I would argue is that it probably over stepped itself in terms of loans. if you very greedy, like Bain Capital was with Toys R Us they took dividend recap after dividend recap, and each time that they put these millions and millions into their pockets, they got loans and they can overstep in terms of they get just too many loans.

They can buy too many companies too fast. Which leads to, as you said, integration problems, but also they couldn't pay the loans that just too high. There's all kinds of reasons that at one point they may go into a default and bankruptcy. But one thing I want to make clear is that the private equity companies take out a lot of money before they go bankrupt.

And many of them lose nothing. They also don't have a lot at stake because they've only put 2% equity. So it's not like the private equity firms are going bankrupt. It's the company. 

[00:28:43] Griffin Jones: Well, the very least they have to make good for their LPs. Don't they, even if the firm itself put in a minimal amount, they have to, they have to at least cover their LPs.

[00:28:54] Dr. Laura Olson: Well, they don't have to make up for a bankruptcy, but you gotta be, they have about they have a fund. The LP are really putting money into this fund. Let's say fund number five, they number their funds and fund number five has 12 to 13 companies. And if one goes bankrupt, it doesn't mean that the LPs are losing money because the other 14 or 12 firms could be just doing fine.

I mean, the only real loss is to that one company, its workers and the communities in which they live. 

[00:29:33] Griffin Jones: Hence the risk.

[00:29:34] Dr. Laura Olson: I've never seen a private equity firm suffer because one of their firms went bankrupt 

[00:29:39] Griffin Jones: Do you have any data on the number of healthcare networks funded by private equity that have gone bankrupt between years, whatever, and between years three and 10 or whatever it might be? 

[00:29:57] Dr. Laura Olson: No, no I've seen some data. I just don't have it at hand. 

[00:30:01] Griffin Jones: Because I'm curious where I think we're all curious as to is that as to how frequently the IntegreMed situation happens.

And there is a intermediary here, which is the network themselves. Right. And so you have a US Dermatology Partners, I'm assuming was not the private equity firm. They were the operating network. Am I right in that? Sometimes they call themselves a partnership, but let's just use the word.

[00:30:27] Dr. Laura Olson: No, no, no. The US Dermatology Partners was the conglomerate or not the conglomerate, the platform and the ad-ons. And I forget how many locations they had something like 40, 50 locations and across 30 states, something like that. So the private equity firm was the owner of the whole.

[00:30:49] Griffin Jones: Sure. But where, and within the US Dermatology Partners where they were each of the practices called something different. Dr. Patel's dermatology here, San Diego Dermatology etc. 

[00:31:01] Dr. Laura Olson: Well, that's a very good question. I'm not sure for us dermatology, but a number of private equity firms that buy these companies and build them up into huge state or national monopolies, use something that one of my personally had interviewed, he calls it stealth branding.

What it means is that when you go to the company, it has John's Dermatology, as opposed to a US Partner's Dermatology. So you don't really know that you go into a private equity firm. So some of them do that. Some of them use the name of the US Dermatology and others. Each practice will have a different name.

[00:31:43] Griffin Jones: The reason that I ask is because in our field, we were still one degree removed from the actual private equity firm in many cases, which means that we're then two degrees at that position from of separation from the limited partner. So IntegraMed was the network. It was the conglomerate, as you say, and then behind them was the safeguard.

And that's the case for most of the networks are doing the purchasing. And so again, sometimes they call them partnerships, but then there's a private equity firm behind that funds that conglomerate to that, that network. And so and, and so I think an important distinction for people is that you still might want to find out who's behind those folks.

[00:32:26] Dr. Laura Olson: Yeah, but I want to, I'm going to make clear that regardless of what the private equity firms say, And the mantra to the doctors is that we're going to take the back office burdens off of you. We're going to let you practice medicine. We're going to do regardless. They get from control. All you have to do is look at the board of directors.

Talk to people, see what goes on, but they maintain from control. So the doctors can't just go out and buy anything. They want the fertility places that I write, talk to the owners who sold them, said this strict control. Even one who was, felt positive about it said, I can't just replace some material anymore.

I can't upgrade my equipment. We get rid of nurses and taken less trained people. We do less training all kinds of, I guess, less benefits to our personnel. There was like a list of, from the three or four people I spoke to of negative things that have happened, the patient care and the practice.

So it's not like it just goes on as if nothing had happened, they have to squeeze. 

[00:33:44] Griffin Jones: Well, then that brings us to the title of your book, which is which is ethically challenged. And so let's talk a little bit about this and then maybe I'll steal-man, their arguments at some points. But it seems like you feel that they're not creating the efficiency they have to squeeze. And so what are the ethical implement implications that led you to this conclusion that this is a. Ethically negative thing happening in healthcare? 

[00:34:11] Dr. Laura Olson: Well, because it's affecting quality of care. If you go through the niches where there's some sectors that have a longer history not fertility or some of the newer ones, but if you go through the LP dentistry, if you go through some of the others, there's a long, long history of private equity taking over companies.

And what you see is neglect, you see abuse you see poor quality care in 2012, the. The US Senate did a whole investigation on dentistry and they found that they were putting children on a, what they call papoose boards, so they could extract teeth and do things faster.

They found amazing amounts of abuse. Even today you'll get some, not even today. Yes. Including today you get places like Aspen dental which has a long, long history of abuse, poor treatments. If you look on the any kind of a place that shows what clients and staff think of these places, they'll get a one out of five and a whole bunch of really terrible criticism on.

And you get places like the what's the other one, I just picked out some forefront, dermatology, great expectations, which in 2019, the better business bureau said that they get an F in terms of quality of care. But you can go through all of them.

I picked out some from various niche. 

[00:35:39] Griffin Jones: Well, that's my concern, Laura, is that people are picking out on either side. And I want to know how do we measure these things categorically, because the private equity firms are picking out cases of look at this for this practice that they couldn't invest because the doctor was overworked and, and halfway out the door and didn't have an operations infrastructure.

Didn't have a business background, whatever it might've been. And I see poor rate ratings from, practices sometimes I also see really poor ratings from independently owned practices that talk about how they have such a good standard of care. I see both a lot. I see you're using the camp, the example of dental.

I think I went to, inspire dental, one of those similar ones. And I liked it. I go in, they all know my name. They have a great infrastructure. They've got a great booking system. Just hang my coat up. I'm not, I'm barely seen by the dentist. The dental hygienist does what a dentist is probably doing it.

Many other practices where the dentist comes in at the end and checks and say, okay, this is good. And it's a very easy experience for me. It's lower cost than, or at least equal cost is, is an independent dental firm. And so everyone's pointing including myself, which is why I can't make a categorical judgment on how positive or negative this is for the field.

Because people are pointing to these examples here and those examples there, how do we judge this? What measures can we use categorically across the board?

[00:37:06] Dr. Laura Olson: Well, first of all, I picked out cases because I couldn't go through all of them. It's not like I picked out the worst cases. I just picked out two out of a hundred kind of thing.

Second of all, yes, I agree with you. One of the reasons I studied nursing homes for many, many years, and one of the reasons I didn't put nursing homes in my book is because nursing homes tend to have very poor care. Every government study will tell you that to differentiate between private equity and normal profit-making companies is really difficult.

But I think when you look at some of these niches like dentistry and fertility well, not fertility. I mean, ones that have been there a long time and talk to experts in the field, they will say that this is not good before the healthcare system, because it has to affect negatively quality of care.

Now, I suspect that you have pretty good teeth.

[00:38:10] Griffin Jones: Invested a lot in those over the years, braces, twice surgery on my upper maxillary. 

[00:38:17] Dr. Laura Olson: But you haven't, experienced what happens if you have some real serious issue. Is that going to be done by a nurse practitioner or is it going to be done by a surgeon? I mean, and I don't want to comment on one place.

All I know is that if you truly understand the private equity playbook took me a long time to figure it out. If I truly understand it, it is impossible to have high quality. And take out all that money to pay off debt, all that money to pay private equity. Well, there's nothing left for quality care. And as I said, the few fertility doctors and people that I talked to pretty a scan at what has gone on in the few places that they have seen. 

[00:39:03] Griffin Jones: So you're making a case of why it has to be why it has to affect quality of care negatively because of the debt what's required to service the debt because of what's required to return the investment to the limited partners, especially if the, they went bankrupt on something else, then the burden of returning a multiple.

An outsized profit is even more necessary for the limited partners. So you're making a case of why this is part of inherent in the model. Why have they failed it at delivering on, on the economies of scale that they shoot, that they're promising in your view. And so if they're telling the doctors, look, you can just focus on medicine, let us take care of the EMR and the payroll and marketing and construction and everything else.

Why are they failing on delivering a benefit to economies of scale that as opposed to them just having to take out they're improving efficiencies. 

 Why have private equity firms failed to be able to deliver on the promise of improving economies of scale?

[00:40:07] Dr. Laura Olson: They can definitely do economies of scale. But the problem is that affects the quality of care. No, this is like, if you have, for example one of the fertility doctors that I talked to say that private equity owned places look to get more and more patients and they do it on an assembly line.

So they don't give the same kind of care to each patient. They just sort of go through them fast, that efficient, but that's not necessarily quality care. So efficiency and efficiency in retail may hurt. So the number of workers you may go into a store and somebody doesn't jump at you today.

You find what you're looking for? It's annoying, but in healthcare, efficiency can mean less care, faster care. And certainly less quality. 

[00:40:58] Griffin Jones: W w what if it means, , a center that has been on paper charts in, yes, there are still a couple that are on paper charts, even in the year 20, 22. And for whatever reason, they didn't switch to any, they didn't want to go through the costs.

They didn't want to, take team members off. And a network comes in and says, well, we have a, a cheaper per provider license or whatever per unit licenses is for the EMR. So we can introduce that, that economy of scale, we can bring in our team to train your team. So that won't be an additional expense.

Oh, you. You can't treat enough patients because you don't have any embryologists. We have a team of per diem embryologists, and we can send them to your clinic on the weeks where we're not batching at other or whatever it might be. Why does it, why does it always have to lead to a poor quality of care instead of in those examples, those are the arguments they make.

It seems to me like it would improve quality of care. 

[00:41:58] Dr. Laura Olson: Well, first of all, what I have seen in many of the niches is that they use lessquality materials. Many of the people I talked to said that they got rid of the regular suppliers and they get cheaper suppliers, but that has come with cheaper materials.

They stint on the use of materials, according to what I have heard they Don't train their people as much as they should. They often get rid of physicians to put in less trained physician extenders. If you look at dialysis, for example, model only is it egregious conditions in the owned by dialysis, but the studies show that more people die than anywhere in the world. In, in our dialysis centers they try to keep their patients rather than put them on a transplant list.

Studies have shown there's all kinds of things that they can do to affect the quality of care. Now they're not looking to have negative quality of care. They're just looking to squeeze operations. So they could have as much money coming out and they can hand themselves of dividends. So I, I think in certain places where you can get real efficient it's not good for healthcare.

[00:43:20] Griffin Jones: What about, what does this mean for the younger doctors in the field that they haven't built equity into their own practices yet. They're now buying in or want to possibly buy in. What have you seen from other fields, of the path that this creates for younger doctors?

[00:43:40] Dr. Laura Olson: A lot of physicians are worried about this. They think that private equity is changing the whole nature of opportunities, certainly younger doctors who have huge. Greater than ever can't afford to buy the practices of retiring doctors. So they end up working for places, whether it's private equity or healthcare systems.

So I think the whole nature of being a physician has changed. And I think that what do we have today over 50% of all physicians are now employees and that's increasing and they're going to be working under the, if they work under the conditions of the private equity, they will be basically told what they can and can't do to try to we as operations, they can say, for example, one of the fertility doctors told me that what he likes to do is have flexibility and he decided he would never go into private equity because he really needs this flexibility.

One of the flexibilities that he likes is that if a woman needs another, a second round of fertility treatment for her, , what is it, the in-vitro fertilization IVF, if she needs another round of that he'll give a re a really reduced amount and even more reduced, does she need to third amount?

And he said private equity would not allow that. So there's also a lot less, he argued, there was so much less flexibility to do what you think is right and you practice. 

[00:45:16] Griffin Jones: I do hear many physicians say that many physicians do do that. They're just nice people. They have a relationship with a patient and they want to help out in some way.

I've imagined private private equity backed partnership group might say well, but that's well, that's ad hoc. It's dependent on the doctor, his relationship with this individual. And they're doing that because they don't have a financing program in, in place. It's more equitable and scalable across the board.

I could see that being something where they say, well, that's an example of one of the inefficiencies of private practice that we're able to scale across by having more providers and more resources.

[00:45:59] Dr. Laura Olson: Is that a question? 

[00:46:00] Griffin Jones: I guess it wasn't a question. It's just what they say. I find myself on either side. I constantly Laura and I was recently on the other side of asking the younger physician question to an REI who I really respect that I've done business with, know the person who and believe this person to be a very genuine person who feels that it actually benefits the younger physician more.

And I can't really get my head around it. And because well, one is what you're, when you're cashing out, you're cashing out on future earnings. And so I would want to be more in control. Of my future earnings, I suppose. That's the argument. And for those of you taking that side of the argument, you can tell me if I'm not doing it justice, but you're saying if the, if the private equity firm backed from the network is able to create something that is worth more than then I'm, I'm getting the chance to buy in to something that's going to be work worth a lot more.

But the way I see it as if, when you're selling you're cashing out on you're exchanging that sale price for future earnings and I'd like to be able to affect that if I'm a younger doc and two is the multiple is often dependent on what you've been able , to build up, like the multiple is coming from your sweat equity.

And if you don't have a chance to build that up. So somebody can tell me where I'm wrong, but that that's where I go back and forth. Laura's I'm looking for I guess we don't have those case studies yet for, for younger versus older docs, but it seems to me that many of the older docs, that it seems to me that many people are doing this for an exit that they can't sell it to the new REI fellow, because that REI fellow has $400,000 of debt.

And because the price has gone up and all right, well, now I'm able to sell this for 6, 10, 12, whatever the, the there's trapped equity, at least it's trapped to the potential partner doc. They can't, they can't buy it at that price. And so private equity comes in and so how much. What did you come across with this being an exit strategy for older doctors?

[00:48:13] Dr. Laura Olson: Well, I think, one of the things we're talking about was the quality of care for patients and clients and the conditions for working conditions for physicians. When it comes to finances, doctors make money on this. What they do is they get a piece of the equity. They get lower salary, usually they lower the salary, but they get a piece of the equity when it's sold. They get a piece of the sell price. And when they buy, they stay with the firm and they sell it to a new private equity, they can get yet another piece of the sell price. So for young doctors, it could be financially. But the price they're paying is losing their freedom to be a doctor and do the two the procedures, the way they want use the equipment that they want get updated equipment to have trained personnel have long relationships with clients.

I mean, they pay a price for that, but I never said it wasn't lucrative. They could make good money. As far as the older physicians, they will tell me, this is the only exit strategy I have, because as you said, the young doctors can't afford to buy my practice. Now they could also sell in some niches to a hospital health systems.

I'm not sure my guess would be, and this is purely educated guests that they make more money in private equity, but they have more control, but the health systems. So I guess what physicians have to do is make decisions about whether they want long-term gain from selling at the price of losing their freedom, to be a physician the way they want.

[00:50:05] Griffin Jones: Well, how would hospitals be any different? The hospitals is having every bit, a little as free freedom as a oh, there's two questions that I have with hospitals is one is I see them as having every bit of little as freedom as not being in private practice, because you're not the boss you have, you've got a division chief and then a dean of a department.

And then there's folks above that that are tied and they have procurement and purchase orders. And so a lot of decisions are, are made ahead of time. So I see one hospitals having even less freedom or perhaps the same as, as a potential and two, we're starting to see hospitals sell off the IVF centers of their REI divisions to private equity-backed networks as well.

So wouldn't you just be back in square one? 

[00:50:56] Dr. Laura Olson: Yeah. And that case you would be something I, I grappled with I talked to people about Ithought, a lot of that. One I lament the demise of the independent physician. I think it's a really negative thing for this country that we have lost, we're losing that at a steady rate.

But at least in a hospital system, it is headed by a medical personnel in private equity. It's headed by finances and I find it more troubling to have healthcare, like the whole corporate control of medicine which is basically not allowed. But here you have Financiers, the people that I talked to in fertility, for example they were two friends, one that met in the Wharton school.

One went into private equity and the other decided the buyer fertility fertility com company, and they got together and put together a fertility company. There was no medical personnel involved in that. And I find that with hospitals systems, at least, and I could be wrong on this. And the doctors that I've talked to that belong to a hospital systems don't seem as unhappy as the ones that are controlled by private equity, but at least they have medical experience.

They care about the health care, even with all the bureaucracy, all the problems and.

I can say, it's great thing that the hospital system, excuse me, a buying of docs. But at least they're in medicine that care about health care. 

[00:52:32] Griffin Jones: I also worry about just consolidation in general, limiting competition, limiting. I think that's w that's one thing that's really good about a free society and free markets in a society is that you have on one end democracy bends towards chaos.

We give everybody a voice and everybody ends up voting in their self interest and everything is diluted. And on the other end authority bends toward tyranny and the point of having a system where different people can compete. Is that okay? They're all tiny little authorities and the ones with the better ideas and better systems are able to grow and advance. But if they do that to the point where they're just consolidating and introducing financial systems that aren't necessarily aligned with the rewards for productivity in that system, then they bend too far the other way.

So I'm going to let you conclude how you want Laura, if you want to conclude the way, the same way you concluded the, the book or if there's something else that you feel you didn't get a chance to, to cover in this conversation that you feel is really important. How do you want to conclude about this topic of private equity consolidating and purchasing more of the provider groups in healthcare?

[00:53:52] Dr. Laura Olson: Well, I go a little further. I work with a lot of groups that are interested in this issue. They're very excited about the new Chair of the SEC, where the he's trying to put more accountability to the private equity firms. Warren's Stop Wall Street Looting Act, I think is an important piece of legislation that also tries to give workers account accountability  for workers that tries to get more transparency.

Clearly the secrecy has to stop. Because not even the limited partners with their public, pension funds know what's going on. But I go even further. And this is not in my book. This is something that I came to a year and a half later after spending more and more time on looking at the health care niches and what's going on.

I think that the private equity should be prohibited from health care. I don't think it's a place given their playbook and what they need to do these are billionaires. These are people who have really sucked down from our healthcare system. One of the big problems that we have in healthcare overall is it's 21% of our GDP.

I teach healthcare in class and the last time I looked at was 19% about a year or two ago when I decided to update and I was shocked, it's now 21%. So private equity is increasing the cost of healthcare by the monopolies that you were talking about. I would eliminate all the advantages that they have, the financial advantages such as a carried interest loophole,their ability to take off the taxes the interest on the step and things like that.

I would strongly limit any debt that they can have at least on healthcare. I don't think they should be allowed to have 67%, 80% of dead owner fertility clinic. Oh, and I would also, one of the things they're hungering after is 401k money, billions and billions of dollars in of savings which looks like they may have access to more and more.

I would have prohibit that. And I also gets one of the things you were talking about. I would prohibit stealth branding that when I go into a dentist, I should know it's a private equity owned dental practice. So those are the kinds of things that I think are really necessary, at least in the healthcare area.

Because you, you seem, like you're not sure, and I'll tell you, there's so many people that I deal with that are not sure. But the more and more I study what has gone on and what continues to go on I've concluded that private equity is just detrimental to health. 

[00:56:38] Griffin Jones: Her name is Dr. Laura Katz Olson.

She's the author of Ethically Challenged Private Equity Storms US Healthcare. We will link to the book in the show notes, Dr. Olson, Laura, thanks for coming on the show. 

[00:56:49] Dr. Laura Olson: Must it been a pleasure and thanks for having me.

136: 6 Pillars for your IVF Center’s Killer First Impression

Episode 136 IRH cover photo

This week on Inside Reproductive Health, Griffin shares the 6 pillars to generating the best first impression for new patients, and how that can directly impact both your bottom line, and the patient experience. Listen to hear how you can build a successful New Fertility Patient Concierge Team. 

Listen to hear:

  •  How (and why) to put the right people in charge of your patient’s first impression 

  • Griffin explain how to emotionally incentivize your Concierge team.

  • How to measure the Team’s impact on your practice’s bottom line.

135: The only way to keep fertility staff from quitting when you can’t replace them fast enough? with Steve Rooks

Steve Rooks on Inside Reproductive Health

This week, Steve Rooks, COO of The Fertility Partners, and Griffin discuss how entities like EngagedMD and the Lean system work to reduce employee burnout and improve the patient experience. But can programs like Lean fit into the fertility space? Is the EngagedMD approach of automation helpful to the patient, or does it cut down on valuable patient face-to-face interaction? Listen to learn more.


Listen to hear:

  • Griffin question the one-size-fits-all approach to Lean’s operations solution, and whether or not it works in the fertility space.

  • Steve Rooks explain how it is possible to add patient value and reduce operational volume at the same time through automation with programs like EngagedMD.

  • Griffin question the viability of pre-packaged patient education in a virtual format vs. face-to-face physician conversation.

  • Griffin and Steve discuss the importance of patient engagement during their (long) initial waiting period.


Steve Rooks:

Company name: The Fertility Partners

LinkedIn Handle: https://www.linkedin.com/in/stephenrooks/

Website URL: https://www.thefertilitypartners.com/


Inside Reproductive Health is sponsored by EngagedMD. For technology that educates your patients with true informed consent, visit engagedmd.com/IRH for 25% off your implementation fee.



Transcript

[00:00:55] Griffin Jones: Legal liability nightmares, losing nurses because of burnout really disappointing patients because of how long they have to be seen. These are some things we try to talk about avoiding in today's episode with Steve Rooks. He's the chief operating officer of The Fertility Partners in Canada and now in the United States as well.

And it's an EngagedMD sponsor episode. I brought Steve on to talk from that lens because there's a lot of business people coming into the fertility field. You don't trust a lot of them. You don't like a lot of them and maybe you like some people that I don't and vice versa, but I want to present Steve to you because he has the heart of a teacher.

And whenever I'm assessing, can I trust someone? What are they like? I look to see if they have the heart of a teacher. I hope I do, but I think Steve does definitely does because he also has the heart of a student. He started at IBM, his career decades ago. He has a mechanical engineering degree. And then he later he got his MBA.

He's worked for places like Verizon in Bell Canada and private equity portfolio that has served a lot of funds in their portfolio. And he comes to the fertility with the lean method of management to add value, to increase efficiency, to reduce the burnout and the burden on staff. And we talk about how he used EnagedMD as a part of that.

And we've had so many people on the podcast talk about EnagedMD long before they were ever a sponsor. And I wanted to unpack more of why, like, why is this so resoundingly positive. Why is it sort of disproportionately positive? And so I thought Steve was a good person for that, as well as educating you on a lot of different ways of looking at your practice to improve systems and avoid losing any more staff than you have to and avoid taking off any more patients than you have to.

I hope you enjoy this episode with Steve Rooks, from the fertility partners.

Mr. Rooks, Steve, welcome to Inside Reproductive Health.

[00:03:03] Steve Rooks: Thanks very much Griffin really excited to be here. As I mentioned before, I've learned so much from your podcasts, that my being on here is a real pleasure. 

[00:03:12] Griffin Jones: I was saying to Stephanie from EnagedMD at I think it was PCRS. I got to have Steve on the podcast because he's been such a sponge in the fertility field.

I don't know if it's been about a year or so for you have just been these sponge. I see you in all places, just really learning a lot of people come into the field and they're like, oh yeah, I want to learn. And, but often they're just coming with their own agenda and just kind of tailoring it to that and you really seem to be learning everything.

So tell us a bit about your background. What are you coming into the field with?

[00:03:46] Steve Rooks: Sure. It's been a background that as I've been more about learning a lot, being challenged, but more importantly, supporting the success of others starting, as an engineer, by education and then going on to do my MBA and then working as a management consultant where I worked across multiple industries, helping executives improve their business in a wide range of situations, both top line and bottom line.

And then taking that experience into the corporate world doing some work that had a very customer focused transforming the customer journey and the equivalent of Verizon in Canada called Bell Canada. And then from there going into private equity. So I spent real last 15 years working on the portfolio side of private equity for the likes of TPG capital, sun capital, Ontario teachers' pension plan and a number of others.

And from that, it was about working with the, the portfolio executive management and helping them again, really improve the, their business with a focus on value creation on improving customer value prop, but for me as a person going in there, I had to learn very quickly , a wide range of industries and get up to speed, to establish credibility, to help them.

So that's kind of in the basis. And that's why Dr. Andrew Michael our CEO and founder of Fertility Partners. I had a recommendation of the private equity company that invested in this. Called me up and said, Hey, would you like to try something different? So I was at that time at a private equity company and he laid out the opportunity to come to the fertility partners and really scale a platform to support the clinics, be that much better.

And to me, looking for my last gig, as I would say, my last real role before I look to semi-retirement, this was a fantastic opportunity. And got me excited was as part of that process, I spent some time talking with three of the REI's at our leading clinic, all the fertility in Vancouver and their passion and their excitement and their desire actually to improve further, even though they're already that the best one of the best clinics in Canada really motivated me to want to come on board and support them in becoming even better.

[00:06:05] Griffin Jones: And that's why they want a systems thinker. And you're clearly a systems thinker from your engineering first, then managerial consulting. And then getting your MBA. You're very much, a lot of people have the chief operating officer title because it's the title that was maybe available to some kind of senior executive.

It seems to me that actually a chief operating officer, you really an operator. And so at what point did you come across the Lean Method and will you give lean management an intro for the audience that might not be familiar with it?

[00:06:37] Steve Rooks: Sure. My very first exposure in, in a, in a really serious way, was it drew my first exposure to private equity at TPG capital. TPG is a big believer in lean, and we initially were using it in was in an orthopedic manufacturing environment.

And in the course of seeing how hips and joints knees were made, I also saw how it was applied in orthopedic surgery environment with one of the orthopedic surgeons would use Lean in his offering Belgium and I was really amazed. And then I was asked by TPG surprised me to implement lean at the Caesars and Harrah's casino operations, post global financial crisis, where all of a sudden they had to , look at ways to reduce costs.

But the beauty of Lean is it's not as hard. It's not really a cost reduction exercise. It's about starting with a view of what's value-add to the customer or in our case, it's here in fertility, the patients. And those steps in a process that aren't adding value for the patient in terms of their willingness to pay that is creating value for them are just steps that are adding time and costs to their journey.

And therefore the lean toolkit is about taking out those non-value-added steps and finding ways of working with the team so that I had to implement lean working with a team across 22 properties over nine months. And we applied Lean in every single process in the casinos and the beauty of that as I could see the impact across a wide range of processes, more important.

The other aspect of Lean that I really like is the bottoms-up process. That is you actually engage the people who work and work with the patients, work with the customers. They're the ones actually stepping back and, and with support from facilitator, looking at the process, looking at the wastes, non-value-added steps and finding ways to take it out. And then by the end of the week, cause it's typically a week long exercise, they then have a very clear action plan of what needs to be improved. They've established at least five KPIs that will measure their success and their progress. And then they have an approach going forward that will drive continuous improvement.

Most important, I can't tell you the number of times at the end of one of those weeks, hearing people so motivated where they said, look, this is the first time I felt like I was a part of the process to improve my area. I had real ownership and a stake in it, and that was really gratifying. So that was my, since that moment, literally 15 years ago, I've been a big believer in Lean and seen it have impact across a wide range of industries, service, manufacturing, distribution, et cetera.

[00:09:20] Griffin Jones: So how does that translate into a field where there's emotions, where there's a standard of patient care? I could see it, working on a Toyota manufacturing line, but when you have so many variables of one, there's just so many different kinds of cases to treat and different kinds of patient populations.

And then you have the human element, emotions, relations, human. And how does this Lean method translate to fertility? 

[00:09:49] Steve Rooks: Great, great question. And again, it starts with the view of let's really focus on what's value at patients and how can we enhance that value add? So whether you apply it to the intake process to cycle monitoring, even in the lab, for example it is stepping back and saying, okay, we mapped out this journey from a patient perspective.

Let's map out all the times that they wait, let's map out all the times that they are dealing with issues from a payment standpoint, from a testing standpoint, et cetera. And let's find ways to speed up that journey and remove any constraints or irritants that they experience in a way that again, adds value while still ensuring quality and more effective outcomes, et cetera.

So we hadn't in the clinics that we've applied this, now we've done it in at least two, but we have another three lining up to do it. And we did it in the best clinic and we did it in one plant that needs a little more improvement. And in both cases, it starts with mapping out the entire value stream in this case the IVF journey for a patient. And he actually starts at learning that they're pregnant and moving back through the journey to the intake point from the referral point. And in that process, we identify all the areas that are constraints or issues or bottlenecks. Or pain points for the patient and for the participants that add value in the process, and you bring together a team of REI, of nurses, of an admin of lab, a tax, et cetera.

So that they're all aware wanted the great strengths is just understanding that where the constraints are from end-to-end. And so we'd have REI saying, wow, I didn't realize that my asking for this caused this issue downstream. And through that process, then we identify all the years to improve. And as an example, an intake from referral to first consult, we, the lean exercise on that really focused on how we could improve our capture information and to get to the patient, to the consult earlier, more fully educated with all the testing done, et cetera.

So they can have a much more effective first console. So through that process, I think everybody involved from the REI, two nurses through the intake coordinators, et cetera, they all realize the value of doing this. And they all end up at a, at an endpoint design of a new process that they all feel really good about, that they feel is gonna be more value add for the patient.

And we've established the KPIs and how do we measure success going forward? So that's that, that kind of outcome really drives a desire to apply it to the next area that could be improved, like cycle monitoring or the lab, et cetera. 

[00:12:30] Griffin Jones: Then how did EnagedMD pass this value test for you? Because it seems like this type of system would be, and I'll say that EnagedMD is, this is a sponsored episode for EnagedMD, but you were at the association of reproductive man, where you at, you were at the RM meeting. 

[00:12:46] Steve Rooks: Yes.

[00:12:46] Griffin Jones: Right. And it, like people just started getting up and it was like, oh, you are going to be sponsoring me or is he sponsoring all of these guys? Because it was, it turned into like an EnagedMD commercial from everybody just standing up and talking about the value, but I see a system like this is often like about eliminating things and you go through we don't need that software.

We don't need that bell or whistle. And and with this process, it seems like you added in EnagedMD. So how did they pass this value test?

[00:13:16] Steve Rooks: Well, I hate to sound like a commercial, but the first time I heard about EnagedMD was on one of your podcasts. And I immediately thought, wow, that makes a lot of sense.

And as part of the process, we're in particular, we looked at intake and saw that for some clinics the education process. So the value-add for the patient of really understand their journey, understanding their options, and being able to have a very good discussion with the REI in the first consult about their options.

That to me was an area that was it a challenge to do well for most clinics that weren't, didn't have a, a more effective approach. And in addition, the informed consent component as, as my good friend, Dr. Steven Katz would tell us many times is not typically done well. And so when I saw EnagedMD, I saw it as a big end.

Both really did a phenomenal job in educating the patient, tee them up for the consult, ensuring effective, true informed consent. And it added productivity because it reduced the amount of time that the conditions had to spend with the patient because the patient can now do it themselves at their own pace.

And we can ensure they understand it going into the first consult with the REI or after if that's the process flow. So to me, EnagedMD was a clear value add for the patient, but it also helped improve productivity and effectiveness of that task of educating the patient patient, ensure that you have proper informed consent from them.

[00:14:48] Griffin Jones: Well, , let's talk about that clinician piece for a second. That piece of them having to spend less time with the patient on a particular topic. Some people are concerned about that. They're like, well, I want to spend my time with my patient or our patients are coming to me for a reason.

And I want to give them that time with me as opposed to a module. How has that played out for you all? 

[00:15:12] Steve Rooks: Well, the beauty of this approach is that those steps that are very common for all patients. So in this case, educating about the basics of the fertility journey or even the details around PGT or other value added services within the journey those are common steps for all patients.

 So how do you EnagedMD where you can offload that common engagement with but then spend your time on the specialized, personalized engagement with the patient. So you can focus on their particular issues that frees up your time. And that's the same thing with the REI consult or the nurse coordinator engaging with the patient.

The common stuff is handled offline with the patient via the EnagedMD module, but then the personalized discussion about what does this mean for you? What do we have to do for your specific that gives the REI and the clinicians more time to really focus on the personalized aspect of each patient's journey and less on the common aspects?

[00:16:17] Griffin Jones: Yeah. Because otherwise the clinician is doing the job of the module, right? Like the clinician is simply a replicable recording. If they're doing the, A, B, C, D E checklist. But if the module is doing that, then the clinician said, oh, you didn't really understand. See, let me talk to you a little bit more. Oh, there's a bit more of D in your case.

Why don't we spend some time talking about that?

[00:16:41] Steve Rooks: That's the beauty of EngagedMD with their knowledge checkpoints through the education modules, the commissions have an opportunity to understand where a patient was having issues and therefore just focus on those areas. Whether that's, again, it's in PGT or in stimulation, et cetera.

It allows them to focus on where the patient themselves have had some challenges and understanding the journey. So it really allows that focus in that value, and where it's needed. 

[00:17:08] Griffin Jones: I can't stress it. I do it in our own sales process and how much it helps. I don't do it as efficiently, is in EnagedMD where they've got like a whole module.

But I do have, we have a system for when people come in through the goal diagnostic, I have some articles and some pages on my site that I send them. So that by the time I talk to them and they're, they're filling out some information for me. So by the time I talked to them, it is not just that, what do you do? Who else have you guys work with? What, like, what are the types of strategies you work on? We're focusing on, this is what you all need to do. And so it's like, they're still getting my time, but it's far more tailored to them. It's far more valuable than me serving something that a webpage could do. And it seems to me like EnagedMD does that for patients really well, especially. 

[00:17:58] Steve Rooks: And actually we started the process of really innovating in our intake process that, and this came out of Lean as well as some additional work that I was doing with Dr. Dan and Gary Tokuda at all, it was really trying to make the intake process more efficient, where we're doing initial triage with GPs as an example, we're nearing on a digital platform to help really improve the process for the patient. But the key thing is in that initial triage, before they hit the first consult, we have the ability to understand at least to some degree what their journey may entail though. The REI will confirm it in the first consult, but what we can do that is where we have some unique challenges for a given patient.

We can tee up the EnagedMD module. That's most pertinent to them. Many clinics are using EnagedMD might wait until after the first console to do the education. We feel it's important to tee up those unique aspects ahead of time so that when they have the conversation with the REI they're ready had some pre-education. So it's a much, again, it's a much more fluid. Value-added conversation rather than the REI having to do the education aspect first. So that's an important distinction that, many clinics haven't necessarily optimized, EnagedMD. Cause they look at the costs and say, well, we should do it after when we know that they're definitely a patient as part of the conversion process, we feel though it's me and more value-add head of the first console.

If you have a sense that, okay, this patient may need PGT as an example, and we can provide that ahead of time. 

[00:19:31] Griffin Jones: I wonder if some guys are thinking, well, I have a contrarian point of view on many things. I think if you have a contrarian point of view, it's even more important to have a baseline because otherwise, if the patient's just deer in headlights, they don't even know what you're being concerned about it.

And they don't even know like other than, like, oh, that sounds good. And then they Google something else anyway. But if there's a baseline and you can say, what, on this specific point. I take this approach and I feel like if you're a contrarian, it's all the more important.

And I've just heard, at that our meeting, you started sounding off on EnagedMD and everybody else just kind of started doing the same thing that I know I'm biased because they're a sponsor for us. So everybody knows my bias. They're a sponsor for us though, because I've known them for seven years and I've talked to them about being a sponsor way before I talked to anybody else, because I just keep hearing positive things. And I'm not saying that there's nobody with negative things to say about EnagedMD I'm just saying I haven't heard it yet. So if you actually have negative things to say about EnagedMD email me. Email me.

No, not you. I mean, the listener like email me because if you exist, let me know you exist. Otherwise I don't have any evidence that they exist. I just keep hearing these really good things, but. 

[00:20:51] Steve Rooks: If I can add something there, one great thing that they've done for us as a true partner, because they definitely have a mission for properly educating patients as a true partner, we needed, of course in Canada to also have Quebec, French versions of the module done. And that could have been a very expensive proposition, but they partnered with us and they were very transparent and basically just past. The pure cost of having it done properly by a third party, with a French, with a French Canadian group that helped us get these, these modules up and running for our Quebec patients.

And that made a huge difference. Furthermore for some of the more unique languages that we have in Canada, like Punjabi or say Mandarin, et cetera they have been very quick to say, Hey, the fastest track is to put subtype. For those languages and all our videos, and they've been very supportive to do that quickly in a very inexpensive way.

So I'd say now in Canada, in our clinics, we have the ability to support all of our patient base, irrespective of their language with this, these education modules, which makes a huge difference for them.

[00:21:59] Griffin Jones: We've been talking about the value-add for the patient, but I think the real. Golden, the, the silver lining or the golden bonus, whatever you want to call it is what it does for the staff right now.

Because if you're listening, like how many of your nurses are just sitting on their hands? Like not one of you and not one person listening has a nurse that's just got excess capacity and And nurses are leaving and they're burnt out and they're going per diem other places. And they're going to other parts of women's health or other parts of health care.

Some of them are leaving healthcare altogether and you can't replace them fast enough. You're already trying, I'm talking to you, being the, everyone, all of us are trying to recruit as fast as we possibly can that to exceed retention, we're all in this boat across the marketplace in the workforce, especially with nursing and healthcare.

And you can't replace them fast enough anyway, and you need to get stuff off of their plate that they shouldn't be doing. Can you talk about like that at all? Like with the reduction of burden to the staff? 

[00:23:09] Steve Rooks: Exactly. I mean, that's part of our mission on our innovation that we're trying to bring to the platform.

So looking at as we look at the workflows through the Lean exercises and looking at opportunity again, if it's, non-value add a it's not patient facing, then we're looking at ways where we could automate steps and really improve the flow. So it's not just nurses, even the admin. A lot of our admin still are faced with the issue, for example, of transcribing fax referrals the EMR and that's a huge pain because of lack of integration. So, we're looking at an EMR that that would allow us, for example, to take he faxes and leverage some of the online services that can transcribe. With a strong focus on, on medical faxes transcribed and put them into the EMR.

So that's a step that typically takes 20 to 30 minutes of MOS time, medical office assistants time and typically results in errors. So our goal is to automate a lot of those things, reduce the errors and ensure that all of that is fully captured. On the backend many of our EMRs aren't properly integrated with our billing and, and accounts payable system.

So again, that's a lot of manual work that we are targeting to handle with our EMR. So throughout the value stream we're finding ways to augment all of the players in, in the, the value stream in terms of their roles. So they can focus on patient facing value added steps, for example. And I want to refer, for example, to another thing I heard that Dr. Sable once mentioned, and I think Eduardo as well around, the future of AI. So looking at our new EMR system as a way, for example, of across our clinic network being able to augment the REI by saying, Hey, for this type of patient, with these hormone levels, here are the top five protocols that have resulted in the best results. Now that's still up to the REI to make a decision about what needs to be done. But it's a way of augmenting their capability and bringing value to help speed up the decision-making around a given patient for example. 

[00:25:15] Griffin Jones: So you mentioned informed consent as one of these areas that patients are getting true informed consent.

Yeah. I'm not leaving counsel, neither Steve. So we have to give that obligatory, disclaimer, that always talk with legal counsel, but when you're looking at informed consent, it's like, okay, did this person really have informed consent? If it's a stack of papers, maybe they don't speak the language that, well, maybe it was rushed.

Versus they had an online module where they watched every single one, they took a quiz, they had it in their language. What holds up as, as better as informed consent and Dr. Katz says, it's obviously the video obvious and so but that kind of talks to the effectiveness, but is there any efficiencies?

And if there isn't then talk about that, but is there any efficiency saved with EnagedMD the, in the video module or excuse me, in the informed consent part of well now you're not tracking down people for, if did they. 

[00:26:15] Steve Rooks: Oh yeah, I can tell you that before EnagedMD to do it properly at least to the level that, Dr. Katz would bless us. Okay. That's sufficient informed consent. We would have nurses spend 45 minutes to an hour sitting down and working through the informed consent forms, ensuring that the patient was fully understood each clause, et cetera. And then to get them to sign. And so, again, when I stepped back, you would say the informed consent is important, but it's not necessarily value add per se for the patient in terms of getting pregnant.

It's an important legal requirement to ensure that they understand what they're going through, but that's a step where if you can have something in place, like EnagedMD, be that ensures that the patient went through has the knowledge check points and then ties it into the specific portion of the informed consent form in their language, because that's the other great thing about a EnagedMD, not only the modules, but the actual forms themselves can be there, their language.

Then you truly know you have informed consent and you have an audit trail that you can demonstrate if a bad case scenario happens and the patient comes back and tries to claim, lack of informed consent, you have that audit trail to be able to prove otherwise, now you hope that never happens, but that stuff does happen every now and then.

And you want to be able to have that audit trail. But not spend the time that was required before yet something to EnagedMD to do. 

[00:27:47] Griffin Jones: So that's so much time for the nurses saved. I just like anything that we can get off. The nurses, the mid-levels the providers plates. I want to get off their plate.

If you just look at, when you think of like the cost, say like when you compare the cost of like how much time you're saving for your providers, how much you'd be saving on recruitment by not having to hire recruiters or how much are you saving on retention to me? Like the cost benefit seems there now I think more than half of clinics in north America are using EnagedMD. So we're beyond the tipping point for those that, that aren't yet. I suspect that it's just because like, it's just one more thing that we want to think about. And so for, for them, They might be at a point where it's like, okay, is the juice worth the squeeze?

Is it like how much implementation is going to be there? So can you talk about how many clinics did you unroll EnagedMD for and how did you go about enrolling at?

[00:28:48] Steve Rooks: Oh, as soon as I learned about EnagedMD, I literally teed this up within a month, now of course, as with the fertility part, we can't tell a clinic what to implement.

We have to sell it to them. So I became Jeff and Stephanie's best sales rep working with all our clinics. I liked the value now fortunately, we already had our largest clinic, all of using it for a while and they were able to point to the value in terms of true informed consent. All the savings from a nursing time standpoint, admin time standpoint, but also just having a better patient experience with the modules.

So I was able to sell all our clinics very quickly with the only final hurdle being the French language requirement for the Quebec clinics. But we worked through that. And so we literally had EnagedMD rolled out in multiple waves over, I'd say a four month period at the most eight clinics right away.

And then the other three Quebec clinics we're. Now we finally have the translations and they're implementing now. And they're very excited about that. So it's basically all of our clinics and the impact has been huge, as I say, from a education, patient experience and ensuring true informed consent.

Cause we all know. We've all faced those forms online, where it says scroll through everything and inside the bottom, everybody just scrolls all the way through and then sign. So the time that the nurse would spend having to ensure that they went through properly, it was very painful and time consuming.

And now we know that the patients are doing it properly. 

[00:30:19] Griffin Jones: It's not the Apple consent. You can't just do that. Hit the long thing that who knows how many firstborns we've all agreed to give away because none of us read those disclaimers, so, okay. So you have to sell it to the clinics you got them to buy on in about four months, you were able to unroll it. How does it start? Like, let's pretend we're one of those clinics, like, and maybe, they're not working with the Fertility Partners. So they call Jeff and Stephanie sales team and EnagedMD. Then what happens from there?

How does it get into the practice?

[00:30:52] Steve Rooks: Well, basically first, I mean the very first thing is for the, the actual clinic to review the modules as they stand today, to understand what's in them and make recommendations. Well, not just make recommendations to require some modifications. So for example, here in Canada, there's a slight different way we practice, some of our approaches in protocols, et cetera.

So all of our clinics had the opportunity to say, okay, I want this language changed a little bit. We need to change that there and EnagedMD is very accommodating, they will make the necessary changes on a reasonable basis without any extra charge that's part of the process. The French language one was a whole new step, which did require some additional costs.

And we all agreed to that very transparently. So the first is to modify the modules as they see fit. And it indicated how. And then the team in parallel works on the informed consent form. So digitizes their existing informed consent forms provides necessary translations. If you needed to say English and Spanish or French, et cetera, and tee those up and work with the team to then decide on the workflow.

So helping the nurses understand how to push it out, how to designate the particular modules for a given patient, et cetera, and how to access it. So the total at a given clinic, the, the implementation time really is no more than two to four weeks max, in terms of making the changes on the modules as needed.

Digitizing the informed consent or taking the clinics are informed consent forms, digitizing it, and setting up on the platform and then doing all the training. So those nurses who are engaging with the, the patients that need to assign the modules to the patients, they go through the training process too.

So it can take less than, than four weeks for you to get at a given clinic it up and running and having an impact with your visions. 

[00:32:48] Griffin Jones: What are some of the hiccups that can happen like in, that's, that's pretty quick, like are there any hiccups that people should know about? 

[00:32:57] Steve Rooks: We didn't experience any real, I mean, the only area would be just ensuring that the content was in sync with the way that the clinic practice fertility treatment though, again, then that was, I think a little bit of a Canadian US type of change, but I imagine within the US in particular, there'd be very little hiccups there per se.

Because they were constantly ensuring that their modules are reflect the latest and greatest day of the. When it comes to treatment and approaches, et cetera. And we did, though, they're very good ,on LGBTQ in terms of representing that we did make some suggestions about adding on some additional representations. So we could have support our LGBTQ patient base a little bit better with the educational modules. 

[00:33:44] Griffin Jones: And that's all part of the beginning, part of the process where you're making, you're modifying it to your center's standard of treatment, and that's all part of the standard process.

[00:33:59] Steve Rooks: Exactly. 

And the other thing too, and the thing I like about EnagedMD they do allow you also, if you bought some very good, very specific modules, like an introduction to the clinic and other things they can also host those modules to be able to push out to the patient. I forgot to mention too, they completely white label everything so that the videos all have the branding, the logos, et cetera. As well as of course the informed consent, sir, are identical to what you would have on paper at the clinic. So that's the other key thing is that ability to add in additional video modules that may be produced.

We have one clinic. I'd say more than half of its videos are its own. While the key ones for informed consent standpoint are EnagedMDs. So that's another flexibility that's quite good. 

[00:34:48] Griffin Jones: Was there anything, cause I had to go, I'd go catch a flight at from the RM meeting this. But was there anything that people said that other people didn't really know that they, oh, I didn't know, you could use it that way or we're using it. Like, was everyone using it the same way? Or was there any diamonds in the rough that people fake, oh, I didn't know. I could do that. 

[00:35:09] Steve Rooks: Well, I think it's things like position is when you position the modules so that you can tee up a patient to be prepared for a discussion.

Ahead of time rather than post consult so that it's a much more informed one. The other thing that's great about EnagedMD is that you're alert. You can easily for use with, for training. So as we bring on in particular medical office assistance, admin, et cetera we can leverage the EnagedMD modules to quickly get them up to speed on fertility treatment.

And that's another great thing, especially with the knowledge checkpoints, et cetera. We're not going to get them to do the informed consent, but the training aspect of those modules are fantastic. That have been really helpful as we brought people on into the clinics. 

[00:35:54] Griffin Jones: Well, let's talk a little bit about that pre-consult use because also we have to do something to keep patients engaged for these gigantic wait lists that most people have right now. So the Fertility Bridge position is that the sweet spot of waitlist is between two to five weeks. And everybody's not everybody, most people are past that right now.

And under two weeks, it's just like, what are you doing? You're in big trouble. But over, over four weeks and people, oh I'm an expert, I want to be, I want to have an eight week wait list. It's like, okay, fine. But in a millennial world that four weeks is a ton. And so to have like six week, eight week, 10 week wait-lists, which many of the people listening do?

Like, we need something for the patient in that time. We create materials and things but they also. Yeah, they also need stuff for their treatment. And if, if they can get this education that is white labeled through the practice, then it's like, oh, I'm still participating with the prac. I'm still moving towards my treatment.

I'm still moving towards the answer. I'd get in a consult, even if I'm not going to be seen for another three weeks. 

[00:37:03] Steve Rooks: Exactly, Yeah. And that's the great thing that EnagedMD is now wanted recently, but developed when we implemented was they have two tiers of modules in terms of details.

So there's kind of like the foundational modules, which are very low cost for patients. So to me, those ones are a must ahead of the concept. So it's like fertility, one of for example, and that tees up the preliminary aspects of fertility ahead of the console. Now we've gone one step further. So in addition to those foundational modules, which are very inexpensive to put in front of all patients whether or not, you're going to convert them to IVF or not.

We also, as part of our triage are trying to determine some of the likely added treatments that are necessary, whether it's exi or potentially PGT or other aspects. We can then look to tee those up as well, too, if we're confident, as opposed to doing it after the consult to do it ahead of the concept to help ensure that the patient's well-educated ahead of that, the other things may be modules around some of the value-added services about how nutrition and mindfulness and , wellness, et cetera, can really help on the journey.

And we're using that as a way to teach. As you've certainly highlighted and some of your conversion podcasts that notion of attaching the value-add services ahead of the console to engage them in the process ahead of time. So that could be teed up by some of the modules, and then we can offer that as you're waiting for that first consult as a way to initiate the engagement around wellness, mindfulness, nutrition.

[00:38:41] Griffin Jones: Yeah, that way they're not only are they informed, but they also feel like they're being served. Like I'm not just waiting in line for me to pop into this office. And in eight weeks that I'm working towards something on a journey, it's a really good, it's a really good thing to be able to offer right now.

So we talked about the, the necessary burden relief for the staff. We talk about the value, add to the. I want to do a little free consulting for Jeff and Taylor on air right now. I don't know what have you got any NDAs in place or whatever? And I don't know what their product roadmap looks like either, but just in terms of either what you'd like to see from them or what you want to see, somebody in the, in the field produce to offer a lean solution, what would you like to see come out as a technological solution in the next year to three years?

[00:39:33] Steve Rooks: Around EnagedMD as a platform? 

[00:39:35] Griffin Jones: If you can think of something and if not, then in general. 

[00:39:38] Steve Rooks: Yes. Yes. As I say are our key things is around the language, so that was one they really addressed well, and just enhancing, of the modules in terms of knowledge, checkpoints, more and more knowledge checkpoints that again, going back to what Dr. Katz said by having those knowledge checkpoints and the ability to add more. So I, for example, would love the ability to easily tailor and customize the knowledge checkpoints given are some of the things that we're highlighting in the informed consent, so that I can be very certain that the patient understands some of these key points.

So to me, enhancing that true informed consent through those knowledge checks. It's really critical. So I'd want to really, to add more customization and flexibility around those. I haven't really pushed them on that, but that's definitely an area. I would add and oh yes, I do recall now I remember having a good session and is the ability as the patient is going through the modules to create a scratch.

So that those issues that the patients not really sure about, they can enter in that questions and the things they're unsure that can be captured and shared with the their nurse coordinator, their IVF coordinators and the REI. So those areas, so that goes beyond just having a set note checkpoint.

It's actually allowing the patient to interact. With the material and say, Hey, here's where I'm not sure about here's where I want more information. And that could be, that's actually a great way to further enhance engagement ahead of the first consult by enabling them to have Lira in those questions through the watching the EnagedMD modules, that's something I did highlight to them. And the other key thing is in tying that into the EMR. What's one thing we're working on them is to improve the, the integration of EnagedMD with the EMR to capture some of these notes and, and questions and pull them into the patient history as well, too.

So that would be a, another area as well, but I can see that value add is really enabling better engagement and insight for for the patients and being able to respond. That the IVF coordinator could see those messages ahead of the first consult and even provide responses back in a two-way engagement ahead of time.

[00:41:57] Griffin Jones: Oh, let's talk about th this concept of EMR is being able to talk to other software because I think this is absolutely was that I think that the concept that people are talking about. And the broader lexicon is a digital wallet and a data wallet, really not a digital wallet, like apple wallet that has money in it, but, or even not even at like a cryptocurrency wallet, but a data that those things would likely integrate, but like a data wallet.

And I'm willing to give some of my access to some parts of my data wallet in order to have a better customized experience. And what I want to see in the field is a CMR that integrates with all EMR psych and because everyone wants attribution. I've got a point of view on attribution that it will never be perfect, even if we have what I'm describing here.

But what I'm describing here will, we'll be closer, which is CRM, customer, relationship management, think HubSpot, Salesforce, SharpSpring, things like those, and integrating with EMR and what, what I'd like to see is that because otherwise it's like, it's just one more damn thing for the clinic that they don't want to have to deal with. So are there other things that you think like need to be able to talk to each other? And I think for those softwares that don't talk to each other, at least have the ability to in 10 years, I think they're going to be obsolete. I maybe that's wishful thinking but I think it's part of the reason I just had Gina on from kind body and they're talking about, they've got everything, like it's end to end they've got their own EMR, they've got their own scheduling software and it's like, well, that's might be part of the reason why, because in the meantime, if people aren't going to talk to each other, it's like, all right, well then we'll just create everything and it will talk to each other.

And so what do you think really needs to be able to talk to each other? 

[00:43:48] Steve Rooks: Well, I do your point. some of the sort of external interactions with patients have say within support groups, the ability of through CMR integrated EMR, the ability to understand and be able to to monitor the kinds of questions.

That are being discussed on, on social media group chats around fertility, for example, to, to provide greater insight around some of the issues that the REI is. And the clinicians may not be aware are. Issues for the patients, unless the patients specifically talk about it. So having that kind of awareness, that external awareness of what are some of the, the questions that are being asked, what I want to do in a way that doesn't feel too big Brother-y.

But I see it more as if it's done in an anonymous way to at least allow the clinics to understand that. What are some of the issues that are not being addressed properly in today's patient journey that can be addressed through things like EnagedMD through the, the education of the patient, the engagement with the REI is engagement with the clinicians.

So it's a kind of, I'm trying to think of the right word, but it's, it's having that knowledge of what's not being addressed today. And the typical journey that the patient experiences within the clinic walls, that they need to look externally to patient support groups, et cetera. And it can be done.

There's no reason that you couldn't be able to not honestly review what's going on in those jackets, but that would provide you greater insight on things that aren't being properly. 

[00:45:27] Griffin Jones: I want to go back to, to the point about staff and recruitment and retention. Is this at, is this happening as much in Canada as it is the United States with nurses being burnt out and going to others and going per diem and going other segments is the great resignation or what the great reshuffle it's now being called.

Is that happening in Canada as much as it is in the US? 

[00:45:52] Steve Rooks: I would say, yes, it's likewise happening here as well as, embryologists are also another group of class of, of of staff that are very difficult to find. But yes, there is that, that burnout with the nursing staff, et cetera. And that's one of our key focuses again, is to help through things like lean and tools to make their day-to-day lives much easier to manage with reduced stress, less firefighting, better information flow. ‘Cause that's part of their challenge is getting the information in a timely manner, communicating it to the patient, working with the REI, to support them on adjusting the patient's medications, for example.

So the more that you can do to reduce that stress and the time constraints that they have. Again, the better it is for them. So yeah, absolutely not. That comes in with the proper integration with, with EMR. For example, one of the key things that we're ensuring is a very thorough integration between our say our testing end points, whether that's in clinic or it's external that the test requisitioning and results immediately flow in an ideally you would have that kind of augmented AI that could say, okay, given this test results, here's the recommended adjustment, the idea of 40 and you can look at it and say, yeah, that makes sense, get the okay from the REI and bang it's done. So you can have a lot more that decision-making that goes on. Be augmented and not fully automated, but at least augmented to speed up the process. 

[00:47:23] Griffin Jones: Maybe we'll get there in the cup in the next couple, in the next decade or so I want to give you the thought to conclude about however you want about lean and in the fertility field.

And what you want to see happen in the next couple of years, but we've been talking about EnagedMD for those of you that our managers and, and nursing managers, this is something to bring to your superiors. This is something that. It's worth a little bit of political capital from you. And you can use this episode to do that.

If you say that you heard it on the show or heard it from me or heard it from Steve on the show, then they can get 25% off their implementation fee. But it's really for making sure that you're not losing any more nurses, making sure that you're not having patients lights you up on online reviews because you're just so slammed with capacity and providing some relief at a time where it is. It is hard to relieve the workload that your mid-levels and nurses and other staff are, are dealing with. And if you're a practice owner, it's more likely than not that you're already using EnagedMD and maybe we're preaching to the choir, but if you're not, then now really is the time. And so Steve, I'll let you conclude on how, whether it's EnagedMD whether it's Lean whether it's just what you want to see your vision for the field for the next couple of years. 

[00:48:46] Steve Rooks: Thanks, Grif. I mean, for me, the key thing is finding ways to innovate that bring value to the patient that really improves their understanding and their feeling of control over the process and doing it in a way that helps also realize productivity gains across the value stream. And to me, EnagedMD is a great example of that where it provides much greater education and to the patients. So they understand better.

They're more in control of understanding the decisions that they need to be that ties into the informed consent. And more importantly, we easily justified implementing EnagedMD from just the savings of the nursing time for the education and for walking through the informed consent forms and signing off, it was, it was one to me, it was one of those, no brainer decisions.

The savings alone easily covered the cost of implementation, but more importantly, it was an ant situation where we were really adding value to the patient journey through the better education, through the better understanding for the benefit of a much more effective first consult and I'm follow on and engagements with the, with the REI.

So to me the kind of tools that we're looking to implement are things like EnagedMD, other examples, another source of challenges for patients is really understanding and setting the proper expectation that IVF in particular could easily be a multi-sectoral journey for them.

And I would, I can't tell you the meaningful percent of patients that don't quite understand that despite the REI attempt to explain that given their circumstances IVF could be a multi-sectoral journey. And we're investing in tools that helps visually explain that better. So the REI can using the visuals, help them better understand that for them IVF could be a two or three cycle journey as opposed to getting pregnant the very first embryo transfer, which can happen, but it's very rare. So those are getting the examples of having tools that really add value for the patients, but help improve the REI, his ability to explain and help them make the right decisions for their benefit.

[00:51:04] Griffin Jones: Steve Rooks, you are a true chief operating officer. You are a true systems-thinker. It is the way that your brain is wired. Thank you so much for sharing some of that brain on Inside Reproductive Health. 

[00:51:17] Steve Rooks: Thanks very much Griffin and I really appreciate it. It's been an honor to actually be on your podcast.

I really appreciate it. 

[00:51:24]Griffin Jones: My pleasure.

134: What the Heck is Kindbody Up to Next? with Gina Bartasi

Gina Bartasi on Inside Reproductive Health

This week, Griffin chats with Gina Bartasi, founder and chair of Kindbody about the development and success of the first-ever consumer fertility services brand. Griffin posits that their latest acquisition of Vios will not be their last, Bartasi disagrees and instead has her sights on global scaling. Bartasi believes that the end-to-end care model of Kindbody is most beneficial to the patient, and everything is better, and more efficient, under one umbrella.

Listen to hear:

  • How Kindbody developed their brand, and how it influences their culture for employees and patients alike.

  • Griffin press Bartasi on future multi-site multi-practice acquisitions, and how that may influence global growth.

  • Where Kindbody stands on utilizing extended care practitioners for retrievals and transfers.

  • Bartasi argue that Kindbody’s end-to-end business model improves (and controls) the patient care experience.

  • Bartasi use stats to back the clinical success of the Kindbody model, despite the 25-30% price cut.


Gina’s information:

LinkedIn:https://www.linkedin.com/in/gina-bartasi/

Twitter:https://twitter.com/WeAreKindbody

Facebook:https://www.facebook.com/kindbody/

Website:https://kindbody.com/


[00:01:08] Griffin Jones: The first global brand in the reproductive health space. And if you think there's been global brands before listen to this episode, because I'm talking about consumer brand, this is the first global consumer brand in the reproductive health space. It's Kindbody. I've got CEO, Gina Bartasi back on.

After a couple of years, we talk about what Kindbody has been up to in all the markets they're in and where they're going, talking about the history of their acquisition with Vios, they've raised tens of millions of dollars in venture capital funding. There's a couple of things that I pushed back on Gina about talking about this concept of this Jeff Bezos, Amazon Sam Walton, Walmart type of end to end channel domination. They Kindbody is going after. There's a lot that I'm not qualified to examine. I'm not qualified to examine on a lot of their business model and certainly not the clinical side. And I know that a couple of you are going to think that I'm kissing rear end when I'm, when I talk about brand, when I go into that part of the I will fight you. I am not kissing any, but I am telling you the things that I've been telling you for years, and I'm seeing somebody do in practice and now people are starting to feel, oh, this isn't just about bringing new patients in the door. This is what it means. To have a brand that is not window dressing.

If you think that Kindbody’s brand is, oh, that's just good marketing. That's just pretty stuff. It isn't, it's the foundation of everything that they've been able to put together. And it is an extreme, competitive advantage in recruitment and retention of employees among other things. So if you'd like some help with that guest who does that for us?

The firm that sponsors this podcast, of course, Fertility Bridge. And we are helping a lot of different practices across the country to up their brand, regardless of whether they have a patient acquisition challenge or not many of you don't, but there are reasons why this branding and creative messaging really, really benefits groups.

And we talk about that today. So you can tell me if you feel that I was kissing her. If you feel that I was too tough, you let me know, enjoy this episode with Gina Bartasi.

Ms. Bartasi Gina, welcome back to Inside Reproductive Health. 

[00:03:40] Gina Bartasi: Thank you. Thanks Griffin. Nice to be with you. 

[00:03:43] Griffin Jones: What is it Kindbody been up to in the last two and a half years since we spoke, nothing right?

[00:03:48] Gina Bartasi: Nothing, not anything at all. 

[00:03:50] Griffin Jones: Not a damn thing. 

[00:03:52] Gina Bartasi: Sitting, twiddling our thumbs, trying to figure out what we're going to do next.

You know, I've always said the success of any businesses, only about its people. And so we have an extraordinary team. The team has parlayed their knowledge and experience into a tremendous amount of growth. Right? So today we have 26 locations not the least of which is the new virus clinics that will pull into the Kindbody network that acquisition closed February 1st.

And then those Vios locations will be rebranded Kindbody. But Angie Beltsos is one of a kind you know, I know that the audience is aware of all the PE money rolling up practices in the industry. We are not a roll up firm. We have preferred to build de novo, but Angie is unique. She is extraordinarily talented as a physician and she is even more talented as a clinical leader, just as a leader in general, she knows a tremendous amount about business, about productivity, about margin.

And so, yeah, we have 26 locations. We'll be adding another 10 this year for 36 locations by the end of the year. And then we're back in the employer business. So we see quite a bit of interest from the employer business. Certainly our consumer audience that we started with is still a big part of our revenue.

And then we see quite a bit of payments come from the managed care industry.

[00:05:15] Griffin Jones: She  knows the answer to this, but I don't, is Vios the first acquisition that kind of body is done in terms of presence?

[00:05:21] Gina Bartasi: I noticed the first acquisition, I've done quite a few acquisitions in my career, but it may be the first one at Kindbody.

I shouldn't, it should be an easy answer. We haven't bought any other clinics. I'm trying to think if we've bought anything else, I guess not. So Vios is the first, it will be the last multi-site multi-physician practice we acquire again, we prefer to build de novo. We wouldn't rule out some of.

[00:05:45] Griffin Jones: This podcast lives forever Gina, do really want to say that it will be the last. 

[00:05:49] Gina Bartasi: No Griffin, it'll be the last multi-physician multi-site acquisition we make, we may make some tuck-in acquisitions. Right. 

[00:05:58] Griffin Jones: But even that, why rule that out?

[00:06:00] Gina Bartasi: Because I know the multi-site physician groups and they are already owned by one of our peers that are not a lot of multi-physician groups, still standing that are independent, there's probably less than 10 in the entire country and the 10. 

[00:06:16] Griffin Jones: All multi-position and multi-site meaning multi-site meaning more than one lab. Is that what you mean?

[00:06:22] Gina Bartasi: That is exactly right. That is exactly right, because we wouldn't be interested and it's too easy. Thanks to our extraordinary real estate team for us to stand up a clinic with the lab. They've gotten very proficient at it in the last 12 months. So the reason we would make a multi physician, multi location acquisition is to get scale. There is not, again, there's probably less than 10 of those.

So yes, there are multi-physician, but maybe they only have one lab and then one satellite office, which would rule them out. So that's the reason it's an emphatic statement. I think, you know, we're getting a lot of requests now. From the employer market to think about international expansion and so potentially internationally, we wouldn't rule it out, but in the United States you know, and Angie knows everybody as well.

We are looking for physicians that are like-minded, you know, Angie, she's wildly unique. And so she's amazing, and we have so many other amazing physicians, but there's a culture at Kindbody and Angie believes in that culture, the culture was almost identical to what Vios culture wise. I mean, we prioritize patient care.

The patient always comes first. Our employees come first, you know? And so there was this, this real foundation and we are here to serve others. And so that's what makes, it's one of the things that makes Angie and Vios so unique. And it's also the reason. I think we're limited in terms of other potential acquisition targets is rare to.

So, seamlessly be able to put two companies together that agree on so many things. Usually when you're rolling up things or you're putting two things together, there's a lot of friction. The integration is hard. There's a lot of disagreement. There's a lot of debate about, oh, and you just don't have any of that.

You just don't have any of that. We are incredibly like-minded now we've known each other a decade and that probably helps as well. 

[00:08:19] Griffin Jones: Well, I want to ask about how you did that vetting because it sounds, it reminds me a little bit of like the Facebook, Instagram, sorry, where Zuckerberg said you, most of the time, we're not going to do.

Acquisitions most of the time we're going to be building out Facebook property now, meta properties. But at the time they saw something that was perfectly in line with what they were trying to do. They stole Instagram at the time for $2 billion and it totally fit. And so that's what you were describing with the Vios acquisition, but how did you vet it to that point?

[00:08:51] Gina Bartasi: Yeah, again I think knowing Angie and Greg for more than 10 years was extraordinarily beneficial. We had talked on and off for the last several years. Again I've thought Angie was just as unique as I think she is today. I thought that the first time I met her at 10 years ago, I met her at PCRs and she's so articulate.

She listens first, most leaders talk first and listen, second, Angie listens first and talk second. And that's a rare characteristic to be both a leader and an extraordinary listener. A lot of leaders are not as humble as Angie is. Angie is extraordinarily humble. And so I would watch her in meetings.

I would watch her interact. I was like, wow. She is a total bad-ass and I always wanted to work with her. I did work with her. I worked with her at Fertility Authority. I worked with her progeny and as time grew on, the affinity grew more like she, she continued to impress me. And she continued to raise the bar.

I knew her when she was at FCI, I watched her grow Vios she does everything with a tremendous amount of elegance to and class. And that's hard to do. It is really, really hard to scale a business and grow a company that fast and keep your cool and take the high road and work hard and not lose it while you're trying to juggle all these things.

And she just did it, you know, and I watched her. And so anyway. 

[00:10:18] Griffin Jones: She does do that by the way. No, I don't talk about things that happen in business meetings on the air, but Dennis, at a super high level, I think Dr. Beltsos is comfortable with me saying she does that. We'll be quiet and let everybody talk and then she's, and then it's like, all right.

And then she's honest, like she lets people say it and you get to see your processing and then boom she's she's got it. So you described her well, so that got you into the Midwest. So you, you found this really good culture fit for you all you acquiring Vios and then, and now you're in the Midwest.

What cities are on the, the docket that you can tell us about now?

[00:10:54] Gina Bartasi: Yeah. Well we want to be completely transparent, so we don't mind sharing with the audience, but we're opening Seattle. We're opening Dallas, Houston, orange county Miami, Charlotte we're opening in Washington DC next week. Two weeks.

May 4th. Whenever that is. Oh, maybe it's in more than two weeks. Maybe it's in three or four weeks. What am I missing? Should be like, we've opened two already. We opened Denver two weeks ago. We'll open Dallas in three weeks. Excuse me, Denver. What did I say? DC? Dallas. Houston. I'm missing some, but anyway, that's kind of the footprint.

Oh, we're opening Brooklyn, a third location in New York. I should have the map in front of me, but that gives you a general idea. 

[00:11:35] Griffin Jones: It gives me an idea of the near term is, I mean, in a few years time, are we talking about everywhere? Gina? Is that the play? Like, are we going to see Kindbody Cleveland? Are we gonna see Kindbody Buffalo?

Are we going to see? 

[00:11:46] Gina Bartasi: Columbus, we're actually coming to Columbus before we're coming to Cleveland. We are, we're taking and we're adding a location in the east bay. So both New York, San Francisco and LA we'll all have three locations, but I think that's right. Our plan calls for 50 locations within the next two years.

We want to be where our patient population lives and works. The majority of those locations will be retail in nature. We, you know, believe in the consumerism of healthcare and really building a global brand. We talk about a national brand, so our eyes are set on the US over the next 24 months.

But in three to five years, I think you would see con body locations internationally as well. 

[00:12:25] Griffin Jones: I want to talk about that global brand and what Kindbody is done to get to what you have now. I am jotting that down because I want to ask you a little bit more, but I don't know if the employer benefits side was part when we spoke a few years back on this show.

And so what has changed in, in employer benefits from, from when you started Fertility Authority and then, and then progeny that or whatever, what was that? Seven years ago or? 

[00:12:53] Gina Bartasi: Yeah, seven years ago. 

Yeah. 

[00:12:55] Griffin Jones: So what has changed since then that you feel like, okay, we need to be a part of this? 

[00:13:01] Gina Bartasi: Yeah, I think the biggest thing that's changed is employers now recognize that having a fertility benefit has gone from a nice to have to a must have today there is a robust RFP process.

There wasn't any RFP process. There wasn't anybody to RFP the business too. It was kind of progeny. And then I think you had some legacy players whether that was when or arc, but they really weren't in the employer business like project. You had no competition the first four or five years, and then they've got their hands full.

Now in the last couple of years, there are several kinds of other Progeny me toos, whether you, whether you, you know, again, you see Carey C store club, you see Maven coming in and there they do care navigation. We sit independent from those folks because we're in the provision of care. So we can also do care navigation, which we would argue as table stakes, but really only three things matter in healthcare.

Any kind of healthcare, but specifically fertility patient experience, patient outcome, and cost. It's the only thing that matters to the patient,patient experience, patient outcome and cost. And by the way, it's the only thing that matters to the employer. And what I have found after building and running the largest care navigation firm as a care navigation or middleman or an insurance company, you cannot effectuate change in those three areas, an insurance company, or a care navigation firm cannot affect member experience.

They cannot affect outcomes and they cannot affect costs. Only the doctor's going to set his reimbursement rate. He's only going to decide how many embryos to transfer only. He can decide how to give that patient bad news, whether that's a diminished ovarian reserve diagnosis or a failed IVF cycle, but in order to really effectuate change, And really change kind of how patients go through the process.

You have to be in the doctor business. So today the employers are issuing RFPs. I think in the beginning large tech companies on both coasts are really in the valley, kind of started this fertility benefit. But today you see requests coming in from very, very large employers in retail and manufacturing and automotive.

Like it again, it's moved from kind of a nice to have to a must have benefit.

[00:15:13] Griffin Jones: For that reason though. Wouldn't those other companies say that Kindbody is not independent, that they're independent because they're not in the provision of care and that you're able to manipulate the market. If you end up becoming the Jeff Bezos or the Sam Walton. out there. 

[00:15:32] Gina Bartasi: Yeah, well, so we have partner clinics who are very like-minded. We have other clinics that are not like-minded and they don't join our network, but there's a bunch of clinics that prioritize patient care and are very genuine about patient care. And they see a lot of volume from us now, a lot of volume from us.

So I think that concern of okay, if Kindbody sells and directly to the employers, they're going to keep all the business. We have too many other partner clinics willing to attest that that's just not the case. I think in the beginning there was worried, but we've been at this, you know, a year and a half, almost two years now.

And we have clinics again, that would attest to Kindbody treats is fairly, they pay well, they pay on time. Like there's just too many people out there advocating exactly the opposite. Now our job is to continue to improve member experience every step of the way. And so you know, we prioritize patient experience and we do think we hear from patients the way patients experience and go through that Kindbody journey is very different than many of the other primarily legacy practices.

There are some new clinics, again, that I think are again very like-minded in our peer group that we have a lot of respect for it's mutual, but going through. Kindbody utilizing our proprietary technology is a very different process than a legacy clinic where you fill out a paper chart, the nurse calls, you get your voicemail, you get to call them back.

They get to call you back. They get like all of that waste and inefficiency and telephone tag. That's endemic in the legacy fertility programs, as well as the legacy care navigation from secure navigate. The challenge with the care navigation firms is, you know, once you refer that patient to another clinic, you lose sight of them.

You don't even know if the patient showed for their appointment, much less, whether they had an ultrasound scan and for the employer that they don't even know if they're being double billed, they may have major medical and you could build that for them. You could build the ultrasound scan through major medical.

You could also build the ultrasound scan through your fertility care navigation firm, but there's a lot of waste in healthcare and in the fertility industry that we seek to continue to get rid of and, and operate more efficiently. And I think the employers, and I know the patients see that today, the member experience is significantly different and I use member and patient as the same thing.

Patients are the consumer terminology member is what employers call their consumers or their employees are called members. 

[00:18:02] Griffin Jones: So how do you scale this out at a, at a time when REI is, are a bottleneck with 1100 of them in the entire country, we have far more people that need treatment than we have an infrastructure to be able to treat them.

And so how. Are you able to expand how many people are able to be treated? What's the role of OB GYN is, or physician extenders in your model? 

[00:18:30] Gina Bartasi: Yeah. You know, I think everybody acknowledges today. You have to have a physician extenders. You just do there's, more than demand than supply.

And the number one thing that hurts a patient is having to wait 3, 6, 9 months for treatment. I would tell you that again, Angie Beltsos says, your question is about scale and how we serve up enough REI is to handle all of the demand that is Angie Beltsos's wheelhouse. You look at the physician productivity of her doctors and it's extraordinary.

One of her lead physicians did more than 1000 cases last year. That's extraordinary. Now you have to have the mindset. You have to have the support around you. You have to have the APP's around you. You know, again, I've spent 12 years in the industry and most doctors, not most, a lot of doctors I've talked to are very comfortable doing 150 cases.

And they say that, listen, I do 12 to 10 to 12 cases a month. I sell an IVF cycle for $25,000. And that's my model. I'm like, okay, well here, our success rates and heres, yours, and I just don't think patients, we have one mission and that is to increase accessibility for all. Fertility treatment has been reserved for rich white people on the upper east side of Manhattan.

 And the Bay Area and Beverly Hills, and we think there is something tragically wrong with charging $25,000 for an IVF cycle and insisting on cash pay. We think the model has to change. You have to bring down the cost of care. You can have a premium experience without a premium price tag. Griffin.

The question is, how do you do that? Well, you utilize technology and you use technology to replace everything that's transactional and healthcare scheduling appointment. We are the only fertility clinic that I'm aware of that allows you to schedule an appointment, move an appointment, cancel an appointment.

You can pay your copay. Like everything. That's transactional should not be done by an REI. It should not be done by your front desk manager. It should not be done by your RN. It should not be done by any of those people. It should be done by technology. How do you pay for everything else? You do it online.

Like this industry is incredibly archaic that there's all this telephone tag in doing simple things like paying copays and scheduling an appointment, or even hearing your medication. Like you're walking down the street, you're driving and a nurse calls and says, turn up or down your FSH drug. And you're trying to write and drive and you're, you know, it's incredibly emotional, like all that's bad.

So we own our own patient portal in our EMR. So everything's incredibly transparent. You can pick it up. And by the way, if you forget what the doctor said, you can go right back to your patient portal and remember what the doctor said. So we believe that we can get to scale and extraordinary physician capacity, but we have to have like-minded physicians, the physician that says to us.

I only want to do 10 to 12 cases a month is not the right fit for Kindbody. And if Dr Beltsos says we're on this call, she would say the same thing. And that doesn't mean that we want the physicians working harder. It does simply mean we just want them more efficient instead of taking down the patient's credit card or calling the patient's insurance company to help them understand why same-sex male couple cannot conceive and, and meet the 12 month threshold that your legacy benefits provider has in place.

Like all of that needs to go away so that the REI is doing things only the REI is capable of doing. 

[00:22:05] Griffin Jones: So I've got to decide because I'm not Joe Rogan with a three and a half hour format that I've got to decide, which of these four or five sub topics that I want to go down that you talked about. Let's start with the, you know, talk about like, we agree that we're at a point where we have to use advanced providers.

The debate is to what extent. And I just had the CEO of Mate fertility on debating this topic with Dr. John Storment and I don't know if that episode will drop before or after yours, but th but it's very much a debate of to what extent. And so what is the limit of, in your view of where advanced providers can be used or where trained non REI, OB GYN?

[00:22:50] Gina Bartasi: So you should know that I do not make any clinical decisions. I have never made any clinical decisions. I don't make clinical decisions today. Dr. Angie Beltsos our CEO of clinical. We'll make all of those decisions today. We use REI to do all retrievals in all transfers exclusively. Okay. Now we people know Kindbody and the knock is, oh, you guys have OB GYN.

Well, 20% of our revenue is GYN. We do complex GYN, right? I mean, again, what, what, what we don't-we prioritize the patient. Okay. We just do, and we think when you have an ectopic, the worst thing we can do is send you back to a primary care. Or if you have a miscarriage, the worst thing we can do is send you back to some doctor that doesn't have your medical record to go back and do a surgery that can be done by our OB GYN onsite.

You build an affinity with this brand and this REI doctor, you hear patients talk about autonomy. My fertility doctor, now I have to go back to my primary care doctor to get a D&C, like something's wrong with that? That's archaic healthcare that has all these silos and bifurcation. And no one cares about the patient.

Do my medical records follow me from my primary care, from my OB GYN, to my REI, to my mental health specialists, to my nutrition coach. The answer is no, unless you're at con body at Kindbody. We built the entire company around the patient and we said, okay, we're going to blow everything up. We agree that the current model is broken.

It's not anybody's fault. It's just history, right? That's how it was created. The REI set over here and the primary care it's because of how insurance pays for historically didn't cover fertility, but yes, covered major medical and maternity. But today, again, if you prioritizing the patient, the patient doesn't want to be shuffled to all of these different providers.

They just want a baby. They want it as affordably and as nicely and as kindly and as easily and conveniently as possible. And it's not that hard, but it does mean like breaking some traditional rules that says, okay, your OB GYN and your REI cannot be under the same roof together. We think that's silly and not patient friendly.

[00:25:11] Griffin Jones: Well, you talked about as part of that, that you're not going to make these clinical decisions. That's why Dr. Beltsos says she CEO of clinical. And I have to say I'm incredulous when CEOs say this a bit, because to me, it's not like there's not a perfect divide in everything. There's things overlap a bit.

And an example that I was challenging Dr. Andrew Meikle, on this from the Fertility Partners and how he gave an example of client is kind of like one that you talked about that happy doing 150, 200 cycles, the sweetest, sweetest people that really love their patients are definitely not charging them a lot.

Definitely they are below market rates. This individual sees all of their own you know they eat this individual does the ultrasounds for all of the patients. And like to me, that's where, you know, when you're saying like, you know, we'd get rid of these transactional things that the REI does not need to be doing.

That's something that the REI does not need to be doing in my view business guy, Grif that owns no part of his business, but if I own part of someone's business, I think that I would be making that call. And that's an overlap where the standard of care matches with or overlaps with the transactional, isn't it?

 Is a light bulb starting to go off about what branding really is, what its power is that it's not just a marketing tactic done by your marketing director. It's not just done for patient acquisition.

It involves the binding of the culture of what you're able to do, of how patients perceive you and how they want to come along and how your peers and prospective employees and prospective providers. See you, and are you the one that is in line with the current generation? Can you at least communicate to them or are you seeing as something less relevant, something less?

To want to be a part of, if that's the case, did you know that we have a full creative team? We have a creative director, we have an account manager, we have an operational marketing strategy. We have a digital strategy, all full-time people. Plus our production, people that know the fertility, patient marketing journey of not just the creative messages.

But where it goes and have a system, a fertility brand scale that makes it easy for you to not see, okay. It's just us trying to say we should become more current or more hip, more new, but that can actually say, okay, this is where we are at a 1.75. And this is where we want to be at a three point six. We have that all, we have that all Fertility Bridge and to start with us, we're not going to do everything for you at once, but just to look at what you've got and at least tell you what to do.

That's less than $600. It's the goal diagnostic. It's 90 minutes with myself, us giving you this framework and going through what you have and applying that discussion of positioning and branding with you and your partners go to fertilitybridge.com. Sign up for the goal diagnostic and represent your group in a way that is fitting with the practice that you're really trying to build, because I think you might be starting to see that all this brand thing it goes beyond just getting people in the door.

It's who you are. And if you want some help, we're happy to help you with it fertilitybridge.com goal diagnostic. Meanwhile, enjoy this conversation about branding with Gina Bartasi.

[00:28:46] Gina Bartasi: Well, so again, this has to go, this goes back to why Vios and Kindbody were so meant to be like the way that we were practicing medicine. And we thought about ultra sonographers doing ultrasound scans was that's how we were practicing medicine with Vios and Angie, and decided to come together, like how we practice medicine and how we prioritize the patient, how we have phlebotomist draw blood sonographers, do ultrasound scans.

You know, like what nurses do we was just together. Now I will tell you, Angie has upped the game. She's refined the process and we follow her lead. There is no, like, again, an Angie will be the first to say that. And the business people take a back seat and Angie is a business person, but she is our clinical leader.

So she decides patient flow, a number of nurses to REI. She decides all of that. Now, again, the reason that these companies came together so easily, We believe so many things. We were already practicing medicine. It's not like you had to take the client that you just mentioned that was comfortable doing 150 cases a year.

And you had to put that culture with this culture. The cultures went together just like this easily and seamlessly because we already agreed that truthfully, the REI is a subspecialist. This is a well-educated they've been in medical school a very long time. I have a hard time asking any of our REI's ,can you do an ultrasound scan? They'll they will do it. They're happy to do it. They've done it before. It's just, you know sonographers doing 20 ultrasounds a day and REI might, you know, do two a week to help one out. So it goes back to, you know, again, patient how the what's in the best interest of the patient.

Do you want somebody doing this twice a week or 20 times a day? 

[00:30:43] Griffin Jones: Well, let's talk about the best interest of the patient with regard to what you were talking about. Like you said, you know, what Dr. Beltsos has been able to do with physician productivity is incredible. I was just talking with just recorded a different episode, different topic.

We're talking about embryologist and it was like, these embryologists are burnt out. Like they can't do any more because, but the demand is that, like, we were trying to get everything we possibly can out of these embryologists. And so there is a tension between what the market needs, the patients need that you're trying to address and what the capacity of the workforce is able to deliver.

You said in the very beginning, something that I don't like when CEOs say Gina and I, cause I try to make myself choose, which is employees come first patients come first, which is declines come first or new employees come first. Do the managers come first? Or the customers come first. And so what, what, like when you're trying to meet a demand and meet the market, and we know that the market demands five times more than what the field's putting out, you're trying to meet that.

How do employees possibly come from first? 

[00:31:53] Gina Bartasi: And employees always come first. They have to, because the employees will take care. If you take care of your employees first, they will take care of your customer. They will take care of your patients. And that's when we're talking to doctors, you know, doctors say, well, I used to do that.

You know, we want the doctors to know that we can train and teach nurses and front desk managers and practice managers to be just as kind and just as empathetic to that patient that the doctor can. So again, employees always come first as it relates to the lab. Listen, there's a shortage of labor everywhere.

It's the embryologist, there's a shortage. We know there's a shortage in our eyes. We have to do a better job of training. We've been fortunate, you know, we pay competitively our team members get equity. That's not true for 90% plus of the fertility clinics. And so I do think it was really, really difficult for us to hire the first 12 months, but in the last 12 months there's quite a bit of incoming interest in I've got career opportunities at Kindbody.

[00:33:00] Griffin Jones: So then how, but I used to agree with the employees always come first and I'm trying to like, like actually live that out now. But I used to believe that Mark Spolestra said that we have it wrong, that we put shareholders first, then customer second and employees last, and it should be employees, customers, shareholders, because if you take care of the employees, they'll take care of the customers and now it'll make the shareholders happy.

 And I always did believe that until like, but what about when you get to this point that we're at, which is a bit historic, like this labor shortage that we're seeing, not just in the IVF, like every place in the market, but it's like, all right, I can take care of employees till the cows come home.

Anybody's employees can go someplace else. Right now. You're trying to, you're trying to keep them up. And meanwhile, there's so much money in the marketplace that people are coming to you and there's so much demand. And you're trying to like, how do you do that now? 

[00:33:54] Gina Bartasi: Yeah. I think again, you have to utilize technology, so you have to go through the lab.

Certainly. That's what we're doing in practice management. So our product people, shadow doctors and nurses to see what they do on a daily basis. That's repeated. Okay. What do you do every single day? That's repetitive. That should be moved to our EMR patient portal or somebody else now what needs to happen that we're probably not doing as good.

A job of Griffin is having our product. People shadow the people in the lab and it has to do with the sterile nature of the lab it has to do with I'm not even sure what it has to do with you know, Dr. Beltsos could tell us, or even Dr. Morbeck Dean Morbeck as our chief scientific officer. But we have to get arduous task and any task that can be moved to technology, to technology, and then you free up human labor.

We've been able to do that on the practice side. We have not spent as much time refining that on the lab and embryology side. I'm optimistic that more economies of scale can come. If you just spend time in the lab and say, what are you doing? That's repetitive. That should be moved to technology.

I do know now we've rolled out some new technology platforms to help kind of ease the burden. And then there's this, like, there's a, there's a training and an input of data and an expert and an export of data that is more time consuming for our embryologist than we would like. But you get through this kind of crunch time of about three months, anytime you roll out new technology or implement a new SAS solution, but we are constantly thinking about.

How we can use technology, whether it's our own or whether it's a third-party vendor to free up humans in this case, embryologist. But right now, embryologists are doing a lot of repetitive things that we think that can be moved to technology. Now, right now they're still biopsying, trifecta, derms, like a lot of their stuff.

They're still you know, cryopreserving oh, sites, they're still doing a lot of things that require extraordinary hand-eye coordination. And those things are, are not close to being automated. But there's still a lot of other things on their plate that can be automated. 

[00:36:07] Griffin Jones: Well, let's shift gears a bit and talk about what I really want to talk about, which is this global brand, cause this is the type of stuff that I am interested.

I am interested in brand. I'm interested in creative messaging and I think it is a huge mistake for anybody who thinks is window dressing. That is not looking at it at all correctly. And I want to know if you think that. Maybe exaggerating with this, but I don't think that kind of body could have gone into all of these different angles to the depth that you have without the foundation of the brand that you had built.

Am I overstating it? 

[00:36:48] Gina Bartasi: No, but you're a marketer and a brand guy. You sound like me. Like again, we knew it's not fertility, it's not IVF. It was intentional Kindbody wants us as humans to be kind to our body. It also does not uniquely say IVF. It could be egg freezing. It could be same sex. Like there's a lot of things that go into this name and this brand.

And it doesn't say Seattle, it doesn't say Charlotte, it doesn't say any particular city can be a global brand. But we thought about that from the very beginning, because I felt like healthcare was missing a room. Global brand. It's not blue. It's not pink. It's, you know, yellow, we call it optimistic, yellow, yellow is intentionally gender neutral.

A lot of people, if you do all of these customer surveys, which marketing people do a lot of people, don't they just say, here's what I believe. And I'm like, whoa, did you do any research or did you do any customer surveys? But if you do customer surveys on your thoughts about yellow, lots of people associate yellow with happiness, right?

Hope like there's a lot that goes into this yellow and this name and it's intentional. All of our locations is intentional. Do we don't have any hard edges in any of our clinics? There are no 90 degree desk. Everything is round there's again, a lot of thought that goes around this round desk, softening the edges.

There are no medical degrees on the walls. Our REI are highly educated. We don't need degrees from Brown University or Stanford on the wall. You'd probably as an educated patient, know that I went to Stanford or to I didn't. But so we do, we believe there there's huge power in brand and now, you know, We've been fortunate.

There's a lot of affinity for the brand. And so now we try to, we're always working to extend the brand. And so now we are, you know, we spray paint chalk every time we open a location, it's cool to be kind. Right. ‘Cause we have to remember in this busy world, and this is before the war and now there's a war and there's, you know, there's just a lot of challenge.

And so we have to remind people because it's cool to be kind like lead with kindness because kindness is contagious. It's like our yellow happiness, like, you know, just be kind you know.

[00:39:01] Griffin Jones: Brand driven CEOs have such an advantage that you being a brand driven. Like when you look at like, I think Sara Blakely, Spanx, Walt Disney Richard Branson, like these are brand driven CEOs and to you are Kindbody is the furthest end of the spectrum.

I actually have that spectrum, but the other end of the spectrum is people who think nothing about brand whatsoever and say, oh, we have to, oh, that's like a logo, a yeah. Like colors. Yeah. Like have our marketing director just, just do something like that. And it is everything that you do, and it's enabled you to go to, to all of these different places.

 And so I want to talk a little bit about like, how that. Moving along with the generations, because, so we made a scale, we made a four point spectrum of the fertility brand and decide on a one. This is your advanced reproductive surgical associates of Smithfield like that, the ones. And then the twos is like Patel, Fertility or, you know I'm trying to make up a Smithfield IVF, very on center.

And then a three is like the nicest of your healthcare brands got a familiar messaging and, and kind of body is the, is one of the only, so we ranked every center in the entire us and Canada kind of body is one of maybe like the only force they one or like one to three fours. And so that, like, you're the first kind of consumer brand in this space.

Talk a little bit about. 

[00:40:42] Gina Bartasi: Well, that's intentional. Right? First of all, thank you, Griffin. Second of all, it's intentional. It didn't come after the fact it was we wanted to create a consumer brand, by the way. You know, we also think now, like, and I know Peloton has been beaten up in the public markets, but we think about Peloton instead of soul cycle.

Like, we've talked about how magical Dr. Angie Beltsos says like, how can, how can we get Dr. Angie Beltsos to be Ally Love or Robin Arzon Jess King? Like, how can you, how can you make Dr. Angie Beltsos global, right? And so we are constantly thinking about the brand and about how we protect the brand and how we continue to do right by the brand.

How even in the most difficult, challenging situations, we're kind to each other kind to competitors. We call them peers. Peers is a more friendly term than competitors. So it's in our language, it's in our culture like how we protect each other, how we protect this brand, how we cultivate the brand.

But again, it was very intentional from the beginning when you come to any of our clinics, or even if you go to the patient portal, most patient portals are ugly. Most EMR is, are ugly. Everything when we should, at some point give you a product demo. When you come in to our product through the technology, everything is very elegant.

Everything is yellow. It's on, not everything is yellow because we have neutrals and other colors, but it is aesthetically pleasing, right? And so you can see all these touch points along the way. We predict your likelihood of success. We predict how many eggs we think you're going to get. We predict fertilization rates.

We show your embryos growing. We are completely transparent. And again, when you go into the clinics it's not white, right? There are no white coats. There are no white walls. There's no white paper. 50% of our REI's are BIPOC. I am incredibly proud of that because guess what? Our patients are 43%.

But it goes back between 43 and 50%, but it's intentional. If you really create a mission that says, we want to increase accessibility for all, then you have to have a brand. You have to have visual elements. You have to have clinics that look and speak to accessibility for all. And that's not white walls or white coats or white paper. 

[00:43:08] Griffin Jones: It of corresponds with the generations too.

So on our scale, we laid it across the generation. Like, so you picture the generations is like a news ticker, and it's not that a one was, was like one equals baby boomer. It's just that like the overlay of a one is that it was designed or, or lack of design for the baby boom generation. And a two was that baby boomer bit X and three was mostly acts a little bit millennial. And so the fours, which you're one of very few as is the the first brand that's for millennials and gen Z 

[00:43:49] Gina Bartasi: Yeah. Yeah. Again, a large portion of our new patients come from Instagram, look at Dr. Beltsos or Ruby Jelani or any of our doctors. And, and we encourage them to do that.

Like we are kind, but we're also fun and competitive and we're like, okay, who can, you know, create our competitions? Like could be great. The funniest Tiktok video, like, I don't know, we're having fun, practicing medicine, helping our patients build the families of their dreams and that doesn't have to be white and sterile and old, right.

It can be fresh and it can be fun. And so, you know, when we think about brand, we have competitions of who can create the most fun tick-tock video. The majority of REI is that got your one, two, and maybe even some of your threes are like Tiktok, like, is that tic-tac-toe what is Tiktok? You know? And so, but we are constantly thinking we want to be better than we are today.

All of us do. That's the competition in us. Okay. We have an extraordinary brand today. Like how do we take it up a notch? And we're trying to think about what's happening new on, on Instagram. And do we call our locations like as a con body ATL, is, is it Kindbody Bay Area? Do you start then to segment these markets or is it just one brand?

But we think about brand every single day. We think about culture every single day. 

[00:45:14] Griffin Jones: Talk about how those two are, are together, because I'm trying, I'm just finishing an article called the difference between Brandon and called where they, where they converge and where they diverged. And so I think like so many, I'm finally starting to get people interested in branding and creative messaging for like how they set expectations with their patients and how they get their team to be cohesive around something, as opposed to, they don't care about patient acquisition right now, because everybody's slammed.

That's how I started in this marketing field was marketing patient acquisition, but it's like, no, this is how you get people and like it as a part of something. So I want you to talk about the culture, cause I'm thinking like Gina, before I look at somebody's LinkedIn profile to like, see what they're, I know that they went to work for cause it seemed in the yellow, in the background.

And so talk a bit about how you use the brand for culture. 

[00:46:12] Gina Bartasi: Yeah, I think a lot of it starts with humility, right? The brand is humble. It's not, anybody's last name. It's not, you know and our culture really starts with this humility. Right? So those two things are ingrained. I think that's not just humility too.

It's a vulnerability to it. You know, it's also our brand and our culture. We do embrace risk. You know, we tell our doctors so I can brace risks, do something crazy on TikTok. And you tell a doctor or a scientist embrace risks. They're like, whoa, whoa, whoa, whoa, whoa. I'm a doctor. I don't embrace risk, except that if you teach them, we're not talking about embracing risks.

When it comes to a prognosis of an onco patient, we're talking about taking risks as it relates to the brand, as it relates to culture, allow yourself to have fun. Allow yourself to smile, giving devastating news, another failed pregnancy test is hard. It's hard. And we're so glad you're empathetic to your patient.

But outside of that, how can we make you smile? How can you be cheery and yellow and optimistic? And so we believe that there's a lot of similarities that brand and culture do go together. And I don't think our brand would be as successful if our culture wasn't so strong. And I don't think our culture would be so strong if our brand wasn't so strong.

And I think the other thing that I would say about culture and brand is team, right? I think too often, you know, healthcare, people and doctors in particular may think solo first, like I'm a doctor and at hierarchical and solo, and those are not things that belong in our brand or our culture.

We don't do anything singularly. Not any of us. And Dr. Beltsos would say the same thing and Beth Eschbach Greg Poulos, none of us do anything by ourselves. And that's intentional. We make group collaborative decisions and same thing with our brand. It's we invite feedback. We invite constructive feedback, constructive criticism, because we want to get better every day.

And again, that goes back to our brand and our culture. 

[00:48:15] Griffin Jones: And with recruitment too, I have to believe that that's giving you an edge because just look at, you, look at a one baby boomers. Who's answering your phones. Who's not even the answer who are the docs now who's buying in. And so I have to believe that, you know, it's like in these places that are like, oh, you know, we're busy as can be with.

New patients, but what is it like with people that like, do they want to come work for you? Like are they excited about, are they behind a mission together that they will go and express to their friends of like, this is who IVF and worked for and you better know about them. 

[00:48:53] Gina Bartasi: They are. And they do.

That's recent though. It's just in the last 12 to 18 months. You know, Dr. Lynn Westphal was our first REI and our chief medical officer. And it was hard even with Lynn's reputation and, and she has an extraordinary reputation and is a member of SARC, a legacy member of A\SRM and starting a phenomenal reputation.

But remember doctors I said are notoriously risk-averse. You encourage them to take risks and not like, whoa. And so in the beginning they Kindbody was, you know, another startup and, you know we started in a mobile clinic that was oriented towards the brand and service. We're going to bring care, whoa, Griffin, we're going to bring care to the.

You don't have to come to me. I'm going to come to you and the doctors like, whoa, whoa, whoa, whoa. You have a mobile clinic. You're going to the patient. We don't do that. Patients come see me. They wait months to see me. And I'm like, why are you bragging about patients waiting to see you? Like something's unconscionable, but a doctor would brag that you're you have these long wait lists.

Don't stop bragging, stop bragging. It's not good for the patients so. 

[00:50:01] Griffin Jones: That's thinking like an individual contributor as opposed to an entrepreneur though, because the entrepreneur wants to scale the individual contributor wants. Yeah. It's like, oh, sweet. I'm the best. 

[00:50:12] Gina Bartasi: Yeah, well, and again, I think now we have, if you count all of our providers, the APPS, the REI's the OB GYN, there's 65 or 70 of them.

Now, maybe it's 75 or 80, I'm losing, but there's enough now in the industry that they do call, you know, they do call and say, Hey, it'sKindbody hiring. We have in our slack channel, we have a new hire and there's a big referral network through the doctors in the embryologist. So it's gotten significantly easier in the last 12 to 18 months.

And then again, you look at these extraordinary leaders on the clinical side and again, both our scientific lab site, as well as our practicing. 

[00:50:53] Griffin Jones: I know the criticism that I'm going to get after this episode, which is I've been blowing sunshine for Kindbody for the last 15 minutes. And so no, I'm not because one, I can't evaluate you on a clinical level.

I'm not qualified to do that ever. And and even I'm not qualified to evaluate you all on many of the areas of, of your business model. I don't know. I don't know if they're a good or bad what my wheelhouse is brand and creative messaging. And for those of everybody listening knows that that's what I care about most.

And I'm not making this up, you could look at our scale. If you want, you can look at our spectrum. It's empirical kind of body is a four on that. And I think it is a huge advantage that the other networks don't have. Again, oh, you're blowing sunshine. No, I'm not. This is an advantage.

The other networks have a disadvantage of your there IGA. If anybody remembers the IGA soup or like a True Value, they bought hardware stores. Where kind buddy has the Starbucks advantage. I think it's such a disadvantage for these networks that are, that are going for scale to not have any of the advantages of scale that come from brand, which is not window dressing for all of the reasons that we just talked about the instead of it's we're Joe's coffee in Seattle brought to you by we're we're coffee roasters of Denver brought to you by so-and-so over here versus Starbucks where Starbucks, where Starbucks and that there's something about that, that, that pretty lady in green that you invites the customer to be able to recognize something that unites them, to be able to express it themselves, as opposed to just someplace else and the employees that want to and do work for there.

It's like, this is what we're about. And so when did that, when did you know that that was going to be a thing? Like when did you think about doing it the other way at first? Like, oh, well maybe we'll be a network. 

[00:52:50] Gina Bartasi: No, we were always going to establish a brand. We were always going to have these warm colors.

We had three focus groups, three dinners and three focus groups. So six meetings and we would pull the audience. Do you like yellow? Do you like purple? Do you like warm? Do you like hard edges? Do you like blue? Like. And this brand is where it is because we gave the brand to consumers, to future patients, to existing patients and future patients.

And this was before COVID, you know, we had in-person meetings, we sent out surveys. We still survey patients. We want to know, because I think if you, you establish a brand three and a half years ago, you ought to check in on it every four to six months to say, Hey, am I on the right track?

We do. We measure NPS. We are maniacal. We have a 90 NPS, which is unheard of in the healthcare field. It's definitely unheard of in the fertility field, but we measure every single we want to know from patients how we're doing. We want to know that patients have this affinity for the brand. Doctors and nurses and our front desk team to fill an affinity and a protector of this brand.

So, you know, thank you for the accolades and the kudos. If you were able to measure our clinical success rates, like we have a responsibility to report to the CDC and SART you will see that they are above the national average. Now they're above the national average because we're big proponents of GPTA, but they are in line with our peer group.

And I think that was, you know, everybody said, okay, you can build a brand, but maybe your clinical quality would have to sacrifice, oh, well, you know, how are you able to offer an IVF cycle at 25 to 30% less than everybody else? Like you use technology, you know, Dr. Nicole Noyes just joined Kindbody and New York and you and patients are now going to be able to see Dr. Noyes at 30% less than they were paying at Northwell at NYU. Okay. I am ecstatic about that. I am so happy for a patient because many patients that 30% additional charge would have been out of reach, much less patients that have to go through two or three or four cycles. So we continue to be on a mission to provide more accessibility for all a premium experience, without a premium price tag.

[00:55:15] Griffin Jones: I want to say something about somebody that I've been reluctant to say that about two other companies too. And the reason I haven't said this is either in an article or on the show is because I think that people will either think that I'm insulting them or that I'm propagating them. And I'm really not doing either.

I'm really just saying mucho ojo pay attention, like really pay attention to what they're doing. That I don't feel get enough respect and what, so I've made, like I'm saying, I don't feel like they get enough respect. What I mean is pay attention. And that's you all it's Fertility IQ at CNY Fertility. And and so like where you are in this journey.

I don't remember if it was Nelson Mandela or Desmond Tutu, who that says, you know, first they ignore you, then they laugh at you, who then they fight you, then they join it. Where do you feel you are on that trajectory? 

[00:56:05] Gina Bartasi: It's hard to group everybody in the same bucket, because I think, you know, the end, I think some are still fighting.

Some have already joined and then some are still making fun of us. Despite our clinical success rates. Despite we have 84 clients, they're fortune 50 customers. They're big blue chip customers. You know, we have a sign in every single Kindbody location. And as we have lots of art, because we think art goes back to the quality of the brand, but there's a sign that says underestimate me.

That will be fun. And so, listen, we don't mind, like I I've had a lot of criticism throughout my career. You get tougher at it. You get accustomed to the criticism because you're doing something new. So underestimate me. That'll be fun. 

[00:56:59] Griffin Jones: What is on the horizon for you all? What is Kindbody need to accomplish in the next year or, and more interesting like what's going to happen next with the brand?

[00:57:13] Gina Bartasi: You know, again, we've talked a little bit about it, but I think you'll see the brand globally. And I think you're going to see the brand more and anything Griffin, where we let go of the patient, if you prioritize the patient, but then you send the patient out for genetic testing, or you send the patient out for carrier screening, or you send the patient out for donor egg or donor sperm or surrogacy.

When we let go of our patient, that makes us nervous because we are maniacal about patient care. And we're not sure that all of the other people that we're referring the business to are as patient-centered as we are. Yes. We trust them, are they're our partner today, but I do think you'll see us extend the brand to other ancillary businesses where we may be outsourcing.

Now we're going to pull those services in house. You know, I want us to be a leading brand amongst same-sex men, amongst single moms by choice. We've done a really great job. I was going to say same-sex women, but we have a lot of same-sex women, men that trust this brand, but I just want it. I, again, we're, we're so oriented towards this mission to increase accessibility for all.

[00:58:21] Griffin Jones: Why didn't venture come into this before? So when I have David Sable on this show, we talk about private equity. They're buying clinics, it's their model to buy a clinic. Venture capital is looking for something that will scale. So they're normally looking at like AI or software, you know, other, other kinds of tech because they want that scale.

And many of them don't feel like, oh yeah, clinic model is something that we can scale. What how were you able to pitch this to venture to say, oh yeah, this isn't a private equity play. This is actually something that we can scale. 

[00:58:54] Gina Bartasi: You know, it probably goes back to track record.

I think venture capital people are fearful of CapEx, heavy businesses, like standing up for wall clinics, you know, before we hired a single doctor or stood up a clinic, we own our own technology. We invest in it. We have 55 engineers and engineering and it and dev ops. So there is definitely a tech play.

It's one of the reasons our doctors can be more efficient. They can see more cases because we're not doing all the menial work. I know the VC community, you know, and, and so it was significantly easier this time to raise money than it was five years ago or 10 years ago. So, you know, venture investors, all institutional investors, like pattern recognition and they say, oh, you know, gene has been able to do this before genus, you know, this is Kindbody is my third company and women's health.

It's my fifth startup, which just means I'm crazy. But you know, crazy fun. Like , it does get easier. You're able to build teams easier. You're able to raise money easier. You know, Kindbody has challenges like every other business that's growing has challenges. But today, when we see a challenge versus 10 years ago, in many cases, I know the answer, or I know the person who knows the answer versus when you're just younger or you're a newer entrepreneur.

You spend a lot of time evaluating the answer to that question that was just posed today. Questions and problems come up, but I'm like, oh, I've seen this one before. Here's what we should do. You know, and same thing with Dr. Beltsos and Beth Eschbach or Greg or Lynn or any of our team, like you have an incredibly experienced team with a long depth of knowledge and scaling other organizations.

And that's one of the things that's allowed us to execute this quickly in the short amount of time. This well is a Testament to the experience to this team. If Dr. Beltsos and I tried to do this 12 years ago, when we first met at PCRs and she had all these Christian Louboutin on, like, I am in love with this woman, I don't think we would have been as successful 12 years.

It'd be interesting to ask her that, but 12 years ago, we just didn't have that same level of knowledge of experience. 

[01:00:59] Griffin Jones: That's why my client services firm is completely cash growth because this is my learning speed. Yeah, no like it's my learning speed. I will probably do faster things in the future, but I'm really trying to nail the fundamentals right now.

And cash growth has allowed me to do that. So for those that raise so much money and do it so quickly, it's a. 

[01:01:25] Gina Bartasi: Well, I don't know how old you are Griffin, but let's assume that Dr. Beltsos, so are at least a decade older than you. And that's the experience I'm talking about. So does that help. 

[01:01:36] Griffin Jones: Help there's hope for the rest of us?

I will let you conclude, you know, our audience is REI, is its fellows. It's practice owners. There are a lot of PE and venture people that pop into this podcast when they're doing their, all of their due diligence and studying of the field. So how do you want to conclude to that audit?

[01:01:58] Gina Bartasi: Yeah. We've been incredibly blessed and I just want to thank I think the criticism makes us stronger and makes us better. And then those that have been huge, enormous cheerleaders. Thank you. Thank you, Griffin. It's been great for you to come to the industry as well and really elevate marketing.

I was a marketing CEO, a brand CEO, and so it's good to have other cheerleaders that talk about marketing and brand in the field. So thank you. Thank you. We've been blessed and. 

[01:02:25] Griffin Jones: With the field was crying out for a D student to come in and build a client services firm slowly. 

[01:02:32] Gina Bartasi: Love it. Thank you, Griffin.

[01:02:34]Griffin Jones: Thanks for coming on. I appreciate it. Take care. Bye.